Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
25200.0 | 2018-12-28 00:00:00 UTC | Friday Sector Leaders: Healthcare, Technology & Communications | ABBV | https://www.nasdaq.com/articles/friday-sector-leaders-healthcare-technology-communications-2018-12-28 | nan | nan | Looking at the sectors faring best as of midday Friday, shares of Healthcare companies are outperforming other sectors, up 0.8%. Within the sector, AbbVie Inc (Symbol: ABBV) and Bristol-Myers Squibb Co. (Symbol: BMY) are two large stocks leading the way, showing a gain of 2.5% and 2.4%, respectively. Among healthcare ETFs , one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is up 1.1% on the day, and up 5.72% year-to-date. AbbVie Inc, meanwhile, is down 0.96% year-to-date, and Bristol-Myers Squibb Co., is down 13.17% year-to-date. Combined, ABBV and BMY make up approximately 6.8% of the underlying holdings of XLV.
The next best performing sector is the Technology & Communications sector, up 0.8%. Among large Technology & Communications stocks, Applied Materials, Inc. (Symbol: AMAT) and Advanced Micro Devices Inc (Symbol: AMD) are the most notable, showing a gain of 3.9% and 3.5%, respectively. One ETF closely tracking Technology & Communications stocks is the Technology Select Sector SPDR ETF ( XLK ), which is up 0.8% in midday trading, and down 1.48% on a year-to-date basis. Applied Materials, Inc., meanwhile, is down 34.49% year-to-date, and Advanced Micro Devices Inc is up 76.12% year-to-date. Combined, AMAT and AMD make up approximately 1.1% of the underlying holdings of XLK.
Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom:
Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Friday. As you can see, eight sectors are up on the day, while one sector is down.
25 Dividend Giants Widely Held By ETFs »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Combined, ABBV and BMY make up approximately 6.8% of the underlying holdings of XLV. Within the sector, AbbVie Inc (Symbol: ABBV) and Bristol-Myers Squibb Co. (Symbol: BMY) are two large stocks leading the way, showing a gain of 2.5% and 2.4%, respectively. AbbVie Inc, meanwhile, is down 0.96% year-to-date, and Bristol-Myers Squibb Co., is down 13.17% year-to-date. | Within the sector, AbbVie Inc (Symbol: ABBV) and Bristol-Myers Squibb Co. (Symbol: BMY) are two large stocks leading the way, showing a gain of 2.5% and 2.4%, respectively. AbbVie Inc, meanwhile, is down 0.96% year-to-date, and Bristol-Myers Squibb Co., is down 13.17% year-to-date. Combined, ABBV and BMY make up approximately 6.8% of the underlying holdings of XLV. | Within the sector, AbbVie Inc (Symbol: ABBV) and Bristol-Myers Squibb Co. (Symbol: BMY) are two large stocks leading the way, showing a gain of 2.5% and 2.4%, respectively. AbbVie Inc, meanwhile, is down 0.96% year-to-date, and Bristol-Myers Squibb Co., is down 13.17% year-to-date. Combined, ABBV and BMY make up approximately 6.8% of the underlying holdings of XLV. | Within the sector, AbbVie Inc (Symbol: ABBV) and Bristol-Myers Squibb Co. (Symbol: BMY) are two large stocks leading the way, showing a gain of 2.5% and 2.4%, respectively. AbbVie Inc, meanwhile, is down 0.96% year-to-date, and Bristol-Myers Squibb Co., is down 13.17% year-to-date. Combined, ABBV and BMY make up approximately 6.8% of the underlying holdings of XLV. |
25201.0 | 2018-12-28 00:00:00 UTC | Noteworthy ETF Inflows: SDY, O, NNN, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-inflows-sdy-o-nnn-abbv-2018-12-28 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Dividend ETF (Symbol: SDY) where we have detected an approximate $479.7 million dollar inflow -- that's a 3.1% increase week over week in outstanding units (from 172,650,000 to 178,050,000). Among the largest underlying components of SDY, in trading today Realty Income Corp (Symbol: O) is up about 0.4%, National Retail Properties Inc (Symbol: NNN) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is up by about 0.7%. For a complete list of holdings, visit the SDY Holdings page » The chart below shows the one year price performance of SDY, versus its 200 day moving average:
Looking at the chart above, SDY's low point in its 52 week range is $84.28 per share, with $100.07 as the 52 week high point - that compares with a last trade of $88.92. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SDY, in trading today Realty Income Corp (Symbol: O) is up about 0.4%, National Retail Properties Inc (Symbol: NNN) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is up by about 0.7%. For a complete list of holdings, visit the SDY Holdings page » The chart below shows the one year price performance of SDY, versus its 200 day moving average: Looking at the chart above, SDY's low point in its 52 week range is $84.28 per share, with $100.07 as the 52 week high point - that compares with a last trade of $88.92. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of SDY, in trading today Realty Income Corp (Symbol: O) is up about 0.4%, National Retail Properties Inc (Symbol: NNN) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is up by about 0.7%. For a complete list of holdings, visit the SDY Holdings page » The chart below shows the one year price performance of SDY, versus its 200 day moving average: Looking at the chart above, SDY's low point in its 52 week range is $84.28 per share, with $100.07 as the 52 week high point - that compares with a last trade of $88.92. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SDY, in trading today Realty Income Corp (Symbol: O) is up about 0.4%, National Retail Properties Inc (Symbol: NNN) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is up by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Dividend ETF (Symbol: SDY) where we have detected an approximate $479.7 million dollar inflow -- that's a 3.1% increase week over week in outstanding units (from 172,650,000 to 178,050,000). For a complete list of holdings, visit the SDY Holdings page » The chart below shows the one year price performance of SDY, versus its 200 day moving average: Looking at the chart above, SDY's low point in its 52 week range is $84.28 per share, with $100.07 as the 52 week high point - that compares with a last trade of $88.92. | Among the largest underlying components of SDY, in trading today Realty Income Corp (Symbol: O) is up about 0.4%, National Retail Properties Inc (Symbol: NNN) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is up by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Dividend ETF (Symbol: SDY) where we have detected an approximate $479.7 million dollar inflow -- that's a 3.1% increase week over week in outstanding units (from 172,650,000 to 178,050,000). For a complete list of holdings, visit the SDY Holdings page » The chart below shows the one year price performance of SDY, versus its 200 day moving average: Looking at the chart above, SDY's low point in its 52 week range is $84.28 per share, with $100.07 as the 52 week high point - that compares with a last trade of $88.92. |
25202.0 | 2018-12-28 00:00:00 UTC | Will AbbVie (ABBV) Shares Regain Lost Momentum in 2019? | ABBV | https://www.nasdaq.com/articles/will-abbvie-abbv-shares-regain-lost-momentum-in-2019-2018-12-28 | nan | nan | AbbVie, Inc .'s ABBV stock has declined 7% this year so far against an increase of 2.1% recorded by the industry .
A couple of pipeline setbacks as well as concerns about the impact of EU biosimilar launches on sales of its blockbuster drug Humira hurt the stock this year despite several regulatory approvals and pipeline successes.
In early December, AbbVie stopped enrolment in a late-stage study, TAHOE , evaluating its cancer candidate rovalpituzumab tesirine or Rova-T in second-line small cell lung cancer (SCLC). In March, Rova-T fell short of expectations in a phase II TRINITY study evaluating it in third line or later SCLC.Rova-T was added to AbbVie's portfolio following the $5.8 billion acquisition of Stemcentrx in June 2016. The failure of TRINITY and the clinical hold on TAHOE raised skepticism about Rova-T's potential and has brought into question the viability of the Stemcentrx deal.
Meanwhile, Humira has been performing well based on strong demand trends despite new competition. Though Humira sales continue to be impressive, direct biosimilar competition in Europe can erode Humira revenues in 2019.
Several companies have made biosimilar versions of Humira. Per settlements, Amgen AMGN , Pfizer PFE , Mylan MYL , Fresenius Kabi, Momenta, Sandoz and Samsung Bioepis/Biogen's Humira biosimilars are expected to be launched in the United States in 2023. In the EU, Amgen, Sandoz and Biogen's biosimilars were launched in October this year while others like Momenta, Pfizer and Fresenius Kabi will launch their versions as soon as they get EMA's approval. Direct biosimilar competition in the EU is expected to erode AbbVie's $6 billion international Humira business in 2019. With Humira accounting for around 65% of AbbVie's sales, the entry of biosimilars will have a huge impact on the company's financials.
Nonetheless, AbbVie looks well poised to witness a turnaround in the New Year. In October, AbbVie had said it is confident of delivering double-digit earnings growth in 2019 despite negative impact from EU Humira biosimilar entry, a difficult comparison year (as HCV sales ramped up rapidly in 2018) and significant investments to support product launches.
Humira sales are expected to remain strong as it sees strong prescription volume growth. Meanwhile, AbbVie's oncology/haematology (including Imbruvica and Venclexta) sales should remain strong.
AbbVie has also been successful in expanding approvals for Imbruvica and Venclexta in 2018. Regulatory applications seeking approval for Venclexta plus Rituxan for relapse/refractory CLL (based on MURANO study data) were approved in the United States in June and in the EU in October 2018. Label expansion for this indication has expanded the patient population for Venclexta significantly, which will boost its commercial potential.
Also, in November AbbVie gained FDA approval for Venclexta in first-line AML. Imbruvica was approved by the FDA in combination use with Rituxan for the treatment of Waldenström's macroglobulinemia (WM), a rare form of Non-Hodgkin's lymphoma in August
These line extension approvals can bring in additional sales in 2019.
AbbVie's newest HCV medicine Mavyret gained approval in the United States, EU, Canada and Japan in 2017. Mavyret performed beyond expectations in the first year of launch recording sales of almost $500 million in 2017. The drug recorded sales of $2.6 billion in the first nine months of 2018, commanding a global market share of 50%. Mavyret is expected to keep up the strong performance in 2019.
Meanwhile, AbbVie has a deep pipeline consisting of several interesting late-stage candidates. In 2019, we expect FDA approvals for two key pipeline candidates - risankizumab for plaque psoriasis and upadacitinib for rheumatoid arthritis - both of which are under FDA's review. Meanwhile, these candidates are also being studied for additional indications, which can provide further growth opportunities.
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Mylan N.V. (MYL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In March, Rova-T fell short of expectations in a phase II TRINITY study evaluating it in third line or later SCLC.Rova-T was added to AbbVie's portfolio following the $5.8 billion acquisition of Stemcentrx in June 2016. In October, AbbVie had said it is confident of delivering double-digit earnings growth in 2019 despite negative impact from EU Humira biosimilar entry, a difficult comparison year (as HCV sales ramped up rapidly in 2018) and significant investments to support product launches. AbbVie, Inc . | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, Inc . 's ABBV stock has declined 7% this year so far against an increase of 2.1% recorded by the industry . | In October, AbbVie had said it is confident of delivering double-digit earnings growth in 2019 despite negative impact from EU Humira biosimilar entry, a difficult comparison year (as HCV sales ramped up rapidly in 2018) and significant investments to support product launches. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, Inc . | AbbVie, Inc . 's ABBV stock has declined 7% this year so far against an increase of 2.1% recorded by the industry . In early December, AbbVie stopped enrolment in a late-stage study, TAHOE , evaluating its cancer candidate rovalpituzumab tesirine or Rova-T in second-line small cell lung cancer (SCLC). |
25203.0 | 2018-12-27 00:00:00 UTC | ABBV February 2019 Options Begin Trading | ABBV | https://www.nasdaq.com/articles/abbv-february-2019-options-begin-trading-2018-12-27 | nan | nan | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the February 2019 expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ABBV options chain for the new February 2019 contracts and identified one put and one call contract of particular interest.
The put contract at the $87.00 strike price has a current bid of $2.13. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $87.00, but will also collect the premium, putting the cost basis of the shares at $84.87 (before broker commissions). To an investor already interested in purchasing shares of ABBV, that could represent an attractive alternative to paying $89.12/share today.
Because the $87.00 strike represents an approximate 2% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 59%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 2.45% return on the cash commitment, or 20.78% annualized - at Stock Options Channel we call this the YieldBoost .
Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $87.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $93.00 strike price has a current bid of $1.67. If an investor was to purchase shares of ABBV stock at the current price level of $89.12/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $93.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 6.23% if the stock gets called away at the February 2019 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the $93.00 strike highlighted in red:
Considering the fact that the $93.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 63%. On our website under the contract detail page for this contract , Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 1.87% boost of extra return to the investor, or 15.91% annualized, which we refer to as the YieldBoost .
The implied volatility in the put contract example is 62%, while the implied volatility in the call contract example is 50%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $89.12) to be 35%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the $93.00 strike highlighted in red: Considering the fact that the $93.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the February 2019 expiration. | Below is a chart showing ABBV's trailing twelve month trading history, with the $93.00 strike highlighted in red: Considering the fact that the $93.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the February 2019 expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ABBV options chain for the new February 2019 contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $87.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $93.00 strike price has a current bid of $1.67. Below is a chart showing ABBV's trailing twelve month trading history, with the $93.00 strike highlighted in red: Considering the fact that the $93.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the February 2019 expiration. | At Stock Options Channel , our YieldBoost formula has looked up and down the ABBV options chain for the new February 2019 contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $93.00 strike highlighted in red: Considering the fact that the $93.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the February 2019 expiration. |
25204.0 | 2018-12-27 00:00:00 UTC | AbbVie Stock: 3 Pros and 3 Cons to Consider Before Investing in ABBV | ABBV | https://www.nasdaq.com/articles/abbvie-stock-3-pros-and-3-cons-consider-investing-abbv-2018-12-27 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
When most people think about cannabis stocks, AbbVie (NYSE: ABBV ) doesn't immediately come to mind. But thanks to its cannabis-based drug Marinol, ABBV stock offers indirect exposure to the marijuana industry. Perhaps that's partially why shares jumped over 2% on Dec. 21 after the new farm legislation was signed.
Most of the $867 billion farm bill is aimed at supporting the U.S. agricultural industry, which has been buffeted by commodity price deflation as a trade war escalated this year.
Tucked away, though, in the bill is hemp legalization. Not only does this open opportunities for cannabis firms and independent farmers, it also signals a more-conducive environment for cannabis-based therapies. Unwieldy regulations and protocols presently hamper those therapies. Should that change, AbbVie stock will likely move higher on alternative revenue channels.
Still, in the bigger picture, the company hasn't performed to its usual standard. Despite the ABBV stock price today, shares are down nearly double digits for the year. Against its 52-week closing high, the pharmaceutical giant has pared almost 30% of its value.
10 Stocks That Won Big In 2018
Given its poor market sentiment, should you buy AbbVie stock or wait for additional pullbacks? Here are three pros and three cons to consider:
Pro #1: That Crazy-High Dividend Yield
As a rule, I always question a company that features a high dividend yield. Chances are, they're offering a "generous" payout to sucker in unsuspecting investors towards a fundamentally unsound business.
But every once in a while, you can have your cake and eat it, too. With the ABBV stock price today, the pharma giant pays out 4.81%. Given that the broader exchange-traded fund SPDR S&P 500 ETF (NYSEARCA: SPY ) and the sector-specific iShares U.S. Pharmaceuticals ETF (NYSEARCA: IHE ) are both down sharply for the year, ABBV is undeniably enticing.
What's more, we're probably going to see a continued shift to safety. The trade war may escalate, geopolitical tensions are rising, and the Trump administration is a mess. Which is to say you can easily expect more turbulence in the markets. This makes AbbVie stock a smart choice.
Pro #2: ABBV Stock's Humira Advantage
Rheumatoid arthritis (RA) is a serious problem, affecting about 1.3 million Americans; 41 of every 100,000 people have receive an RA diagnosis.
But because it's so prevalent, the condition represents a goldmine for ABBV stock since AbbVie introduced Humira, which has dominated the pharmaceutical market. Humira was the top-selling drug last year and is expected to retain the top spot this year.
In fact, Humira racked up more than twice the sales of second-place Revlimid, a Celgene (NASDAQ: CELG ) drug. Sector stalwarts like Amgen (NASDAQ: AMGN ), Pfizer (NYSE: PFE ) and Regeneron Pharmaceuticals (NASDAQ: REGN ) have no direct rival to AbbVie's flagship.
Pro #3: Business-first Mentality Boosts AbbVie Stock
A recent Bloomberg article had an interesting take on Gilead Sciences (NASDAQ: GILD ). Despite GILD releasing a groundbreaking hepatitis C drug that actually cured the disease, its share price unintuitively suffered. On the other hand, AbbVie introduced its own hep C therapy, albeit an ineffective one.
While AbbVie clearly had an inferior product, it performed better overall. What gives? The Bloomberg story hinted that ABBV implemented a business and shareholder-friendly structure. Gilead went for the scientific achievement, but got burnt in the markets.
I don't necessarily agree that Gilead made a business mistake, but one thing is clear: ABBV's focus on growth and profitability benefits AbbVie stock.
Now, on to the cons.
Con #1: Tough Competitive Environment
Although AbbVie's leadership team runs a tight ship, the surrounding waters are hardly cooperative. Moving forward, ABBV stock could face longer-term pressures.
For one thing, the pharmaceutical industry has succeeded in delivering unprecedented breakthroughs. As biotechnologies improve over the next several years, innovations like the one Gilead Sciences advance will become more commonplace.
That's good for patients suffering from various diseases and conditions. But it makes it more difficult for pharmaceuticals to thrive. Plus, as therapies improve their efficacy, sector players must invest more in research and development.
That will likely eat into profitability, which explains why pharmaceuticals have suffered so badly this year. To wit, that iShares U.S. Pharmaceuticals ETF mentioned above is down more than 12% while the S&P 500 is off just a hair over 9%.
Con #2: AbbVie Stock has a PR Problem
Humira is a top seller, but that metric alone hasn't prevented AbbVie stock from attracting unwanted attention. Alleged unethical practices give ABBV a black eye at a time when it can do without distractions.
A few months ago, California filed a lawsuit against AbbVie. The Golden State accuses the pharma giant of artificially boosting Humira sales through kickbacks. Furthermore, the pharma company apparently instructed its network of prescribers and nurses to downplay usage risks. AbbVie also requested that prescribers avoid answering questions about adverse effects.
If the allegations are true, ABBV stock has serious problems ahead. But this is not the first time the company has been under scrutiny for shady practices . Like I said earlier, AbbVie is business first, which is a double-edged sword.
Con #3: Sector Weakness Will Hurt ABBV Stock
We're in a bear market . Picking any company right now is a hazardous activity because Wall Street is extremely jittery. People don't tend to think well when they're panicking.
7 Reasons Not to Be Too Worried About the Fed Yet
But the broader healthcare sector is a bear market within a bear market. Whether you're talking about a blue-chip fund like the iShares US Healthcare (NYSEARCA: IYH ) exchange-traded fund, or smaller, individual names, everybody is getting thrashed. ABBV stock is the fifth-largest holding in that particular ETF.
Finally, despite its dividend yield, ABBV stock isn't the greatest safe-haven asset. Legal challenges, competitive threats, or failed drug trials can easily derail valuations.
Bottom Line on ABBV Stock
I'm going to edge slightly bullish on AbbVie stock. Although the company has significant challenges, they're also not unique ones. Lesser organizations have faced far worse and succeeded, so I'm confident that management can rise to the occasion.
Moreover, ABBV has strong financials, which should help in navigating through the storm. Plus, opportunities in medical marijuana align with legislative and electoral trends.
As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities.
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
10 Small-Cap Stocks That Look Like Bargains
7 Stocks to Buy and Hold Through Any Market Selloff
5 Blue-Chip Stocks That Could Break Their Bull Trend
Compare Brokers
The post AbbVie Stock: 3 Pros and 3 Cons to Consider Before Investing in ABBV appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Pro #3: Business-first Mentality Boosts AbbVie Stock A recent Bloomberg article had an interesting take on Gilead Sciences (NASDAQ: GILD ). I don't necessarily agree that Gilead made a business mistake, but one thing is clear: ABBV's focus on growth and profitability benefits AbbVie stock. InvestorPlace - Stock Market News, Stock Advice & Trading Tips When most people think about cannabis stocks, AbbVie (NYSE: ABBV ) doesn't immediately come to mind. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips When most people think about cannabis stocks, AbbVie (NYSE: ABBV ) doesn't immediately come to mind. Despite the ABBV stock price today, shares are down nearly double digits for the year. With the ABBV stock price today, the pharma giant pays out 4.81%. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips When most people think about cannabis stocks, AbbVie (NYSE: ABBV ) doesn't immediately come to mind. Con #2: AbbVie Stock has a PR Problem Humira is a top seller, but that metric alone hasn't prevented AbbVie stock from attracting unwanted attention. More From InvestorPlace 2 Toxic Pot Stocks You Should Avoid 10 Small-Cap Stocks That Look Like Bargains 7 Stocks to Buy and Hold Through Any Market Selloff 5 Blue-Chip Stocks That Could Break Their Bull Trend Compare Brokers The post AbbVie Stock: 3 Pros and 3 Cons to Consider Before Investing in ABBV appeared first on InvestorPlace . | InvestorPlace - Stock Market News, Stock Advice & Trading Tips When most people think about cannabis stocks, AbbVie (NYSE: ABBV ) doesn't immediately come to mind. More From InvestorPlace 2 Toxic Pot Stocks You Should Avoid 10 Small-Cap Stocks That Look Like Bargains 7 Stocks to Buy and Hold Through Any Market Selloff 5 Blue-Chip Stocks That Could Break Their Bull Trend Compare Brokers The post AbbVie Stock: 3 Pros and 3 Cons to Consider Before Investing in ABBV appeared first on InvestorPlace . But thanks to its cannabis-based drug Marinol, ABBV stock offers indirect exposure to the marijuana industry. |
25205.0 | 2018-12-26 00:00:00 UTC | AbbVie Partners Lupin to Boost Hematological Cancer Pipeline | ABBV | https://www.nasdaq.com/articles/abbvie-partners-lupin-to-boost-hematological-cancer-pipeline-2018-12-26 | nan | nan | AbbVie Inc.ABBV and India-based Lupin Limited announced a partnership to develop and commercialize a novel cancer drug for the treatment of hematological cancer. The partnership grants AbbVie exclusive global rights to develop and commercialize Lupin's MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program.
MALT-1, a protein, is involved in T-cell and B-cell lymphocyte activation. AbbVie is planning to develop the MALT1 inhibitors across a range of hematological cancers, the majority of them with limited treatment options.
Per the terms of the agreement, AbbVie will pay $30 million to Lupin in upfront payment and will be liable to pay additional $947 million in future regulatory, development and commercial milestone payments. AbbVie will also pay double-digit royalty on sales, upon successful commercialization, to Lupin. The commercial rights in India for the drug will be held by Lupin.
Shares of AbbVie have plunged 13% year to date against the industry 's increase of 1.2%.
AbbVie believes that oncology will be its major growth driver over the next decade. The company is continuously working on expanding and accelerating its presence in oncology, building upon its growing position in the $30 billion hematological oncology market.
Meanwhile, AbbVie has a few oncology drugs in its marketed portfolio. Imbruvica, which is approved for several indications, has multi-billion dollar potential and AbbVie is exploring the potential to expand Imbruvica's label into solid tumors and autoimmune diseases. AbbVie expects Imbruvica peak sales of more than $7 billion and revenues of about $5 billion in 2020.
Apart from Imbruvica, Venclexta is another cancer drug, which is approved for some lymphoma indications. AbbVie is developing it for other hematologic malignancies.
AbbVie has several collaborations for developing its cancer pipeline, which include one with Roche RHHBY for Venclexta, Johnson & Johnson JNJ for Imbruvica and Bristol-Myers BMY for Empliciti among others.
AbbVie Inc. Price
AbbVie Inc. Price | AbbVie Inc. Quote
Zacks Rank
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The partnership grants AbbVie exclusive global rights to develop and commercialize Lupin's MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program. AbbVie is planning to develop the MALT1 inhibitors across a range of hematological cancers, the majority of them with limited treatment options. AbbVie will also pay double-digit royalty on sales, upon successful commercialization, to Lupin. | AbbVie has several collaborations for developing its cancer pipeline, which include one with Roche RHHBY for Venclexta, Johnson & Johnson JNJ for Imbruvica and Bristol-Myers BMY for Empliciti among others. AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report To read this article on Zacks.com click here. | AbbVie Inc.ABBV and India-based Lupin Limited announced a partnership to develop and commercialize a novel cancer drug for the treatment of hematological cancer. AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report To read this article on Zacks.com click here. | AbbVie Inc.ABBV and India-based Lupin Limited announced a partnership to develop and commercialize a novel cancer drug for the treatment of hematological cancer. Meanwhile, AbbVie has a few oncology drugs in its marketed portfolio. The partnership grants AbbVie exclusive global rights to develop and commercialize Lupin's MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program. |
25206.0 | 2018-12-26 00:00:00 UTC | Health Care Sector Update for 12/26/2018: CAPR,IMMU,ABBV,NEOS,TEVA | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-12262018-caprimmuabbvneosteva-2018-12-26 | nan | nan | Top Health Care Stocks
JNJ +2.51%
PFE +3.63%
ABT +5.58%
MRK +3.56%
AMGN +4.61%
Health care stocks were posting strong gains Wednesday afternoon, including a more than 2.6% rise for the NYSE Health Care Index in late trade. Shares of health care companies in the S&P 500 also were up over 3.7% as a group while the Nasdaq Biotechnology index climbed about 5.3%.
Among health care stocks moving on news:
(-) Capricor Therapeutics ( CAPR ) slid 26% to a record low of 33 cents a share on Wednesday, and later received a downgrade to hold from buy by analysts at Maxim, after saying it was temporarily shelving Phase II testing of its CAP-1002 drug candidate to treat Duchenne muscular dystrophy after a patient with the muscle-wasting disease experienced a severe allergic reaction during infusion of the drug.
In other sector news:
(+) Immunomedics ( IMMU ) rose as much as 13% on Wednesday after the biopharmaceuticals company said it was expanding its long-term master supply agreement with Johnson Matthey, which will continue to ramp up production of its CL2A-SN-38 drug-linker that is a key component of Immunomedics' sacituzumab govitecan treatment for metastatic triple-negative breast cancer. Financial terms were not immediately available.
(+) AbbVie ( ABBV ) was more than 3% higher Wednesday after Standpoint Research began coverage of the drugmaker with a buy investment recommendation.
(-) Neos Therapeutics ( NEOS ) fell 4.4% Wednesday after the specialty drugmaker disclosed a confidential settlement and licensing agreement resolving all patent-related litigation with Teva Pharmaceutical Industries Ltd ( TEVA ) over the larger rival's bid to make a generic version of Neos' Cotempla XR-ODT extended-release orally disintegrating tablets.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (+) AbbVie ( ABBV ) was more than 3% higher Wednesday after Standpoint Research began coverage of the drugmaker with a buy investment recommendation. Among health care stocks moving on news: (-) Capricor Therapeutics ( CAPR ) slid 26% to a record low of 33 cents a share on Wednesday, and later received a downgrade to hold from buy by analysts at Maxim, after saying it was temporarily shelving Phase II testing of its CAP-1002 drug candidate to treat Duchenne muscular dystrophy after a patient with the muscle-wasting disease experienced a severe allergic reaction during infusion of the drug. In other sector news: (+) Immunomedics ( IMMU ) rose as much as 13% on Wednesday after the biopharmaceuticals company said it was expanding its long-term master supply agreement with Johnson Matthey, which will continue to ramp up production of its CL2A-SN-38 drug-linker that is a key component of Immunomedics' sacituzumab govitecan treatment for metastatic triple-negative breast cancer. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (+) AbbVie ( ABBV ) was more than 3% higher Wednesday after Standpoint Research began coverage of the drugmaker with a buy investment recommendation. Shares of health care companies in the S&P 500 also were up over 3.7% as a group while the Nasdaq Biotechnology index climbed about 5.3%. | (+) AbbVie ( ABBV ) was more than 3% higher Wednesday after Standpoint Research began coverage of the drugmaker with a buy investment recommendation. Health care stocks were posting strong gains Wednesday afternoon, including a more than 2.6% rise for the NYSE Health Care Index in late trade. Among health care stocks moving on news: (-) Capricor Therapeutics ( CAPR ) slid 26% to a record low of 33 cents a share on Wednesday, and later received a downgrade to hold from buy by analysts at Maxim, after saying it was temporarily shelving Phase II testing of its CAP-1002 drug candidate to treat Duchenne muscular dystrophy after a patient with the muscle-wasting disease experienced a severe allergic reaction during infusion of the drug. | (+) AbbVie ( ABBV ) was more than 3% higher Wednesday after Standpoint Research began coverage of the drugmaker with a buy investment recommendation. Top Health Care Stocks In other sector news: (+) Immunomedics ( IMMU ) rose as much as 13% on Wednesday after the biopharmaceuticals company said it was expanding its long-term master supply agreement with Johnson Matthey, which will continue to ramp up production of its CL2A-SN-38 drug-linker that is a key component of Immunomedics' sacituzumab govitecan treatment for metastatic triple-negative breast cancer. |
25207.0 | 2018-12-24 00:00:00 UTC | AbbVie (ABBV) Stock Moves -0.89%: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-moves-0.89%3A-what-you-should-know-2018-12-24 | nan | nan | AbbVie (ABBV) closed the most recent trading day at $84.16, moving -0.89% from the previous trading session. This move was narrower than the S&P 500's daily loss of 2.71%. Meanwhile, the Dow lost 2.91%, and the Nasdaq, a tech-heavy index, lost 2.21%.
Prior to today's trading, shares of the drugmaker had lost 1.43% over the past month. This has was narrower than the Medical sector's loss of 8.61% and the S&P 500's loss of 8.68% in that time.
Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. This is expected to be January 25, 2019. The company is expected to report EPS of $1.92, up 29.73% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $8.36 billion, up 8.07% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $7.94 per share and revenue of $32.78 billion, which would represent changes of +41.79% and +16.17%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for ABBV. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. ABBV is currently sporting a Zacks Rank of #3 (Hold).
Digging into valuation, ABBV currently has a Forward P/E ratio of 10.7. This represents a discount compared to its industry's average Forward P/E of 13.83.
Investors should also note that ABBV has a PEG ratio of 0.79 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.84 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 85, putting it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABBV in the coming trading sessions, be sure to utilize Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (ABBV) closed the most recent trading day at $84.16, moving -0.89% from the previous trading session. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. It is also important to note the recent changes to analyst estimates for ABBV. | AbbVie (ABBV) closed the most recent trading day at $84.16, moving -0.89% from the previous trading session. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. It is also important to note the recent changes to analyst estimates for ABBV. | AbbVie (ABBV) closed the most recent trading day at $84.16, moving -0.89% from the previous trading session. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. It is also important to note the recent changes to analyst estimates for ABBV. | AbbVie (ABBV) closed the most recent trading day at $84.16, moving -0.89% from the previous trading session. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. It is also important to note the recent changes to analyst estimates for ABBV. |
25208.0 | 2018-12-22 00:00:00 UTC | Better Buy: AbbVie vs. Merck | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-vs-merck-2018-12-22 | nan | nan | What a difference a year can make. In 2017, shares of AbbVie (NYSE: ABBV) skyrocketed more than 50%, while Merck (NYSE: MRK) stock fell 4%. But so far this year, Merck is a big winner, while AbbVie is down by a double-digit percentage.
And none of that matters very much when it comes to choosing which of these big-pharma stocks is the better buy. What matters are the prospects for the companies' current drugs and pipeline candidates.
Which stock is likely to be the bigger winner over the long run? Here's how AbbVie and Merck stack up against each other.
The case for AbbVie
To understand the case for AbbVie, it's also helpful to know a little about the company's challenges. The primary reason why AbbVie stock hasn't performed very well in 2018 relates to concerns about biosimilar competition for AbbVie's top-selling drug, Humira. It didn't help that AbbVie also experienced a significant pipeline setback this year with disappointing clinical results for experimental cancer drug Rova-T.
But AbbVie's challenges also underscore its strengths. Although Humira now faces biosimilar competition in Europe, biosimilars won't reach the more lucrative U.S. market until 2023. As a result, Humira is likely to remain the world's top-selling drug at least through 2024.
AbbVie had hoped that Rova-T would be successful. Even without the drug, though, the company's pipeline claims several potential blockbusters, notably including immunology drugs risankizumab and upadacitinib. AbbVie thinks that risankizumab and upadacitinib could generate peak annual sales of around $5 billion and $6.5 billion, respectively.
Meanwhile, the pipeline has already produced some big winners in recent years. Cancer drug Imbruvica continues to enjoy strong momentum thanks in part to new approved indications. Hepatitis C virus (HCV) drug Mavyret is off to an impressive start. AbbVie has high hopes for its endometriosis pain drug Orilissa and cancer drug Venclexta as well.
Because of AbbVie's solid current lineup and pipeline, Wall Street analysts project the company will grow earnings by nearly 17% annually on average over the next five years. That level of growth makes AbbVie stock look like a bargain, with shares trading at less than 10 times expected earnings.
In addition, AbbVie boasts one of the best dividends in healthcare. Its dividend currently yields 5%. AbbVie has increased its dividend by a whopping 140% since 2013.
The case for Merck
Since we started with AbbVie's baggage, it's only fair to look at the negatives for Merck as well. Sales continue to decline for several of Merck's older products, including immunology drugs Simponi and Remicade, HCV drug Zepatier, and cardiovascular drugs Zetia and Vytorin.
But Merck has a not-so-secret weapon that has driven the company's success -- Keytruda. The drug is already a huge winner in treating multiple types of cancer. Keytruda seems destined to become the No. 2 best-selling drug in the world within the next six years, trailing only AbbVie's Humira.
Merck also has two other cancer drugs, Lynparza and Lenvima, that it co-markets with partners that are just beginning to pick up momentum. Sales are also resurging for the company's biggest seller other than Keytruda, human papillomavirus (HPV) vaccine Gardasil.
What about Merck's pipeline? The biggest focus, at least in late-stage development, is on obtaining new indications for already-approved drugs, especially Keytruda. However, Merck has eight new candidates in late-stage testing. Probably the most promising of these is pneumoconjugate vaccine V114, which pharmaceutical market researcher EvaluatePharma ranks among the top five vaccines currently in development based on projected 2024 sales.
Wall Street analysts think that Keytruda should largely fuel Merck's growth for a while, with the drugmaker delivering average annual earnings growth of more than 9% over the next five years. Because of Merck's big run this year, though, its stock isn't as attractively valued as AbbVie's. Merck doesn't look too expensive, however, with shares trading at less than 16 times expected earnings.
The big pharma company's dividend yield of 2.88% isn't too shabby, either. Merck recently boosted its dividend by 15%, the largest dividend hike from the company in years.
Better buy
Keytruda is a monster success story for Merck. But I think AbbVie is more likely to be the bigger winner over the long run.
The sell-off in AbbVie stock this year is way overdone, in my view, based on the company's prospects. Sure, Humira's shine will fade. However, AbbVie's other rapidly growing drugs and its strong pipeline should drive sales and earnings higher for years to come.
I think that AbbVie offers a total package for investors -- solid growth prospects, a strong dividend, and an attractive valuation. These factors make it a great stock for investors to buy and hold.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It didn't help that AbbVie also experienced a significant pipeline setback this year with disappointing clinical results for experimental cancer drug Rova-T. Because of AbbVie's solid current lineup and pipeline, Wall Street analysts project the company will grow earnings by nearly 17% annually on average over the next five years. I think that AbbVie offers a total package for investors -- solid growth prospects, a strong dividend, and an attractive valuation. | The primary reason why AbbVie stock hasn't performed very well in 2018 relates to concerns about biosimilar competition for AbbVie's top-selling drug, Humira. Because of AbbVie's solid current lineup and pipeline, Wall Street analysts project the company will grow earnings by nearly 17% annually on average over the next five years. I think that AbbVie offers a total package for investors -- solid growth prospects, a strong dividend, and an attractive valuation. | The primary reason why AbbVie stock hasn't performed very well in 2018 relates to concerns about biosimilar competition for AbbVie's top-selling drug, Humira. Because of Merck's big run this year, though, its stock isn't as attractively valued as AbbVie's. In 2017, shares of AbbVie (NYSE: ABBV) skyrocketed more than 50%, while Merck (NYSE: MRK) stock fell 4%. | That level of growth makes AbbVie stock look like a bargain, with shares trading at less than 10 times expected earnings. Because of Merck's big run this year, though, its stock isn't as attractively valued as AbbVie's. In 2017, shares of AbbVie (NYSE: ABBV) skyrocketed more than 50%, while Merck (NYSE: MRK) stock fell 4%. |
25209.0 | 2018-12-21 00:00:00 UTC | Alector, Gossamer chase Moderna with biotechnology IPOs | ABBV | https://www.nasdaq.com/articles/alector-gossamer-chase-moderna-biotechnology-ipos-2018-12-21 | nan | nan | By Joshua Franklin and Carl O'Donnell
Dec 21 () - U.S. biotechnology startups Alector LLC and Gossamer Bio are preparing for initial public offerings (IPOs) in early 2019, people familiar with the matter said on Friday, after Moderna Inc earlier this month became the sector's biggest company to ever launch an IPO.
Companies have been accelerating their IPO preparations, as a stock market sell-off in the last three months wiped out the gains of most shares for the year and raised the prospect of the window for stock market debuts gradually closing.
The sources asked not to be identified because the IPO plans are confidential. Gossamer declined to comment while Alector did not immediately respond to a request for comment.
Investor demand for high-growth companies and the prospect of consolidation with larger peers helped spur IPO activity for biotechnology firms in 2018, the busiest IPO year for the sector since 2014, according to data provider Dealogic.
Moderna raised $604 million in its IPO on Dec. 6. Its shares have dropped 36 percent since then, much more than Nasdaq Biotechnology Index, which has dropped 14 percent over the same period.
San Francisco-based Alector develops therapies that harness the immune system to cure neurodegenerative diseases, such as dementia, as well as cancer. It has received backing from the likes of Google Ventures and AbbVie Inc and closed its series E funding round earlier this year with a $913 million raise, according to PitchBook.
Gossamer, based in San Diego, focuses on developing drugs in the immunology, inflammation and oncology sectors. It clinched a $650 million valuation in a private fundraising round in July led by Hillhouse Capital.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It has received backing from the likes of Google Ventures and AbbVie Inc and closed its series E funding round earlier this year with a $913 million raise, according to PitchBook. By Joshua Franklin and Carl O'Donnell Dec 21 () - U.S. biotechnology startups Alector LLC and Gossamer Bio are preparing for initial public offerings (IPOs) in early 2019, people familiar with the matter said on Friday, after Moderna Inc earlier this month became the sector's biggest company to ever launch an IPO. San Francisco-based Alector develops therapies that harness the immune system to cure neurodegenerative diseases, such as dementia, as well as cancer. | It has received backing from the likes of Google Ventures and AbbVie Inc and closed its series E funding round earlier this year with a $913 million raise, according to PitchBook. Companies have been accelerating their IPO preparations, as a stock market sell-off in the last three months wiped out the gains of most shares for the year and raised the prospect of the window for stock market debuts gradually closing. Moderna raised $604 million in its IPO on Dec. 6. | It has received backing from the likes of Google Ventures and AbbVie Inc and closed its series E funding round earlier this year with a $913 million raise, according to PitchBook. By Joshua Franklin and Carl O'Donnell Dec 21 () - U.S. biotechnology startups Alector LLC and Gossamer Bio are preparing for initial public offerings (IPOs) in early 2019, people familiar with the matter said on Friday, after Moderna Inc earlier this month became the sector's biggest company to ever launch an IPO. Companies have been accelerating their IPO preparations, as a stock market sell-off in the last three months wiped out the gains of most shares for the year and raised the prospect of the window for stock market debuts gradually closing. | It has received backing from the likes of Google Ventures and AbbVie Inc and closed its series E funding round earlier this year with a $913 million raise, according to PitchBook. Companies have been accelerating their IPO preparations, as a stock market sell-off in the last three months wiped out the gains of most shares for the year and raised the prospect of the window for stock market debuts gradually closing. The sources asked not to be identified because the IPO plans are confidential. |
25210.0 | 2018-12-21 00:00:00 UTC | AbbVie (ABBV) Seeks Approval for RA Candidate Upadacitinib | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-seeks-approval-for-ra-candidate-upadacitinib-2018-12-21 | nan | nan | AbbVie Inc.ABBV announced that it has filed a new drug application ("NDA") to the FDA and a marketing authorization application ("MAA") to the European Medicines Agency ("EMA") for its oral investigational JAK inhibitor, upadacitinib. The company is seeking approval of upadacitinib for the treatment of adult patients with moderate to severe rheumatoid arthritis ("RA").
The regulatory submissions were based on encouraging data from the phase III SELECT study, which evaluated more than 4000 patients across five phase III studies on RA. In all the studies, upadacitinib met all primary and secondary endpoints.
Data from the SELECT study showed that treatment with upadacitinib, both as a monotherapy and in combination with conventional synthetic DMARDs, led to improved symptoms of RA, better physical function and inhibited radiographic progression.
Shares of AbbVie were up 2.2%, following the announcement of the news of Thursday. However, the stock has plunged 11.7% year to date, against the industry's increase of 1.6%.
Humira accounts for around 65% of AbbVie's revenues. The drug generated sales of $15 billion in the first nine months of 2018, an increase of 10.9% year over year. However, biosimilar competition for the drug could hurt sales for the company.
Though biosimilar versions of Humira are already approved by the FDA, per settlements with several companies biosimilar entry in the United States is scheduled for 2023. However, in the EU, Amgen AMGN , Biogen BIIB and Sandoz's biosimilars were launched in October this year, while others like Momenta, Pfizer PFE and Fresenius Kabi will launch their versions as soon as they get EMA's approval.
Notably, other than rheumatoid arthritis, upadacitinib is also being evaluated in a mid-stage study for giant cell arteritis, and late-stage studies for Crohn's disease, psoriatic arthritis, ulcerative colitis and atopic dermatitis.
Zacks Rank
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc.ABBV announced that it has filed a new drug application ("NDA") to the FDA and a marketing authorization application ("MAA") to the European Medicines Agency ("EMA") for its oral investigational JAK inhibitor, upadacitinib. Shares of AbbVie were up 2.2%, following the announcement of the news of Thursday. Humira accounts for around 65% of AbbVie's revenues. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV announced that it has filed a new drug application ("NDA") to the FDA and a marketing authorization application ("MAA") to the European Medicines Agency ("EMA") for its oral investigational JAK inhibitor, upadacitinib. Shares of AbbVie were up 2.2%, following the announcement of the news of Thursday. | AbbVie Inc.ABBV announced that it has filed a new drug application ("NDA") to the FDA and a marketing authorization application ("MAA") to the European Medicines Agency ("EMA") for its oral investigational JAK inhibitor, upadacitinib. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of AbbVie were up 2.2%, following the announcement of the news of Thursday. | AbbVie Inc.ABBV announced that it has filed a new drug application ("NDA") to the FDA and a marketing authorization application ("MAA") to the European Medicines Agency ("EMA") for its oral investigational JAK inhibitor, upadacitinib. Shares of AbbVie were up 2.2%, following the announcement of the news of Thursday. Humira accounts for around 65% of AbbVie's revenues. |
25211.0 | 2018-12-21 00:00:00 UTC | Noteworthy Friday Option Activity: CLVS, ABBV, AAL | ABBV | https://www.nasdaq.com/articles/noteworthy-friday-option-activity-clvs-abbv-aal-2018-12-21 | nan | nan | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Clovis Oncology Inc (Symbol: CLVS), where a total volume of 16,911 contracts has been traded thus far today, a contract volume which is representative of approximately 1.7 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 49.4% of CLVS's average daily trading volume over the past month, of 3.4 million shares. Especially high volume was seen for the $22.50 strike call option expiring January 18, 2019 , with 5,026 contracts trading so far today, representing approximately 502,600 underlying shares of CLVS. Below is a chart showing CLVS's trailing twelve month trading history, with the $22.50 strike highlighted in orange:
AbbVie Inc (Symbol: ABBV) saw options trading volume of 28,094 contracts, representing approximately 2.8 million underlying shares or approximately 48.1% of ABBV's average daily trading volume over the past month, of 5.8 million shares. Particularly high volume was seen for the $95 strike call option expiring January 18, 2019 , with 4,233 contracts trading so far today, representing approximately 423,300 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $95 strike highlighted in orange:
And American Airlines Group Inc (Symbol: AAL) options are showing a volume of 40,148 contracts thus far today. That number of contracts represents approximately 4.0 million underlying shares, working out to a sizeable 46.1% of AAL's average daily trading volume over the past month, of 8.7 million shares. Especially high volume was seen for the $32 strike put option expiring December 21, 2018 , with 11,465 contracts trading so far today, representing approximately 1.1 million underlying shares of AAL. Below is a chart showing AAL's trailing twelve month trading history, with the $32 strike highlighted in orange:
For the various different available expirations for CLVS options , ABBV options , or AAL options , visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Particularly high volume was seen for the $95 strike call option expiring January 18, 2019 , with 4,233 contracts trading so far today, representing approximately 423,300 underlying shares of ABBV. Below is a chart showing CLVS's trailing twelve month trading history, with the $22.50 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 28,094 contracts, representing approximately 2.8 million underlying shares or approximately 48.1% of ABBV's average daily trading volume over the past month, of 5.8 million shares. Below is a chart showing ABBV's trailing twelve month trading history, with the $95 strike highlighted in orange: And American Airlines Group Inc (Symbol: AAL) options are showing a volume of 40,148 contracts thus far today. | Below is a chart showing CLVS's trailing twelve month trading history, with the $22.50 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 28,094 contracts, representing approximately 2.8 million underlying shares or approximately 48.1% of ABBV's average daily trading volume over the past month, of 5.8 million shares. Particularly high volume was seen for the $95 strike call option expiring January 18, 2019 , with 4,233 contracts trading so far today, representing approximately 423,300 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $95 strike highlighted in orange: And American Airlines Group Inc (Symbol: AAL) options are showing a volume of 40,148 contracts thus far today. | Below is a chart showing CLVS's trailing twelve month trading history, with the $22.50 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 28,094 contracts, representing approximately 2.8 million underlying shares or approximately 48.1% of ABBV's average daily trading volume over the past month, of 5.8 million shares. Particularly high volume was seen for the $95 strike call option expiring January 18, 2019 , with 4,233 contracts trading so far today, representing approximately 423,300 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $95 strike highlighted in orange: And American Airlines Group Inc (Symbol: AAL) options are showing a volume of 40,148 contracts thus far today. | Below is a chart showing CLVS's trailing twelve month trading history, with the $22.50 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 28,094 contracts, representing approximately 2.8 million underlying shares or approximately 48.1% of ABBV's average daily trading volume over the past month, of 5.8 million shares. Particularly high volume was seen for the $95 strike call option expiring January 18, 2019 , with 4,233 contracts trading so far today, representing approximately 423,300 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $95 strike highlighted in orange: And American Airlines Group Inc (Symbol: AAL) options are showing a volume of 40,148 contracts thus far today. |
25212.0 | 2018-12-20 00:00:00 UTC | Notable ETF Inflow Detected - XLV, ABBV, ABT, CVS | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-xlv-abbv-abt-cvs-2018-12-20 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $520.3 million dollar inflow -- that's a 2.9% increase week over week in outstanding units (from 209,920,000 to 216,020,000). Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.6%, Abbott Laboratories (Symbol: ABT) is off about 1.4%, and CVS Health Corporation (Symbol: CVS) is lower by about 1.2%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $84.75. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.6%, Abbott Laboratories (Symbol: ABT) is off about 1.4%, and CVS Health Corporation (Symbol: CVS) is lower by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $520.3 million dollar inflow -- that's a 2.9% increase week over week in outstanding units (from 209,920,000 to 216,020,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.6%, Abbott Laboratories (Symbol: ABT) is off about 1.4%, and CVS Health Corporation (Symbol: CVS) is lower by about 1.2%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $84.75. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.6%, Abbott Laboratories (Symbol: ABT) is off about 1.4%, and CVS Health Corporation (Symbol: CVS) is lower by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $520.3 million dollar inflow -- that's a 2.9% increase week over week in outstanding units (from 209,920,000 to 216,020,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $84.75. | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.6%, Abbott Laboratories (Symbol: ABT) is off about 1.4%, and CVS Health Corporation (Symbol: CVS) is lower by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $520.3 million dollar inflow -- that's a 2.9% increase week over week in outstanding units (from 209,920,000 to 216,020,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $84.75. |
25213.0 | 2018-12-20 00:00:00 UTC | 3 Top Healthcare Stocks to Buy in December | ABBV | https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-december-2018-12-20 | nan | nan | The recent market downturn has created lots of bargains for healthcare-focused investors. So which stocks do our team of healthcare contributors think are great buys right now?
We posed that very question to our team, and they called out the SPDR S&P Biotech ETF (NYSEMKT: XBI) , AbbVie (NYSE: ABBV) , and Jazz Pharmaceuticals (NASDAQ: JAZZ) . Here's why.
An easy way to play the biotech boom
Brian Feroldi (SPDR S&P Biotech ETF): Major advances in biotechnology are unfolding before our eyes and promise to change healthcare forever. However, given the high failure rates of new drugs and technologies, it can be exceedingly difficult for investors to pick which companies will go on to be winners. That's why using biotechnology ETFs can be an easy way for investors to gain exposure to the growth in the industry. One of my favorites is the SPDR S&P Biotech ETF.
The SPDR S&P Biotech ETF holds positions in about 122 different biotechnology companies of all different sizes. This includes many of the large-cap biotechnology companies such as Amgen and Gilead Sciences as well as a number of tiny ones like Amicus Therapeutics and Xencor .
What's unique about this ETF is that it follows an equal-weight strategy. This means that it invests the exact same amount of capital in each of its holdings at the outset. The fund's holdings are then rebalanced every quarter to make sure any single holding doesn't get to be too large.
So does this strategy work? Here's a great chart of this fund's performance when compared to the S&P 500.
XBI Total Return Price data by YCharts.
This chart makes me believe that it has created a winning formula that drives long-term success. What's more, the fund's expense ratio is just 0.35%, a completely reasonable price to pay.
The biotechnology sector has been hit hard in the recent market downturn, so investors who buy today can get this ETF at a 27% discount from its recent high. That sounds like a bargain to me.
Hitting the trifecta
Keith Speights (AbbVie): Probably the best equivalent to a trifecta in investing is finding a stock that provides solid income, great growth prospects, and an attractive valuation. There aren't many healthcare stocks that check off all three boxes. But AbbVie does.
The big pharmaceutical company's dividend currently yields more than 4.5%. AbbVie has boosted its dividend by 140% since being spun off from parent Abbott Labs (NYSE: ABT) in 2013.
AbbVie's growth prospects look very good also. Humira should be on course to remain the world's top-selling drug through 2024 . Sure, biosimilar competition for Humira already exists in Europe and will threaten AbbVie's sales in the U.S. beginning in 2023. However, the company also has current big winners with cancer drugs Imbruvica and Venclexta, plus hepatitis C drug Mavyret.
More important, AbbVie's pipeline includes several potential blockbusters that should propel revenue and earnings growth for years to come. Immunology drugs risankizumab and upadacitinib rank at the top of the list.
AbbVie has experienced some pipeline setbacks, though, particularly with experimental cancer drug Rova-T . These have contributed to the stock's pullback in 2018. Shares now trade at less than 10 times expected earnings -- a bargain valuation, especially considering AbbVie's long-term growth opportunities and its rich dividend.
You can find healthcare stocks with a higher yield than AbbVie, better growth prospects, and a lower valuation. But there's probably no other healthcare stock that provides an overall package better than AbbVie's.
Healthcare stocks don't get much cheaper than this
Sean Williams (Jazz Pharmaceuticals): When the stock market is correcting, sometimes the smartest move investors can make is to seek out value -- and there aren't many healthcare stocks offering better value right now than Ireland-based Jazz Pharmaceuticals.
The big worry with Jazz Pharmaceuticals has always been its reliance on narcolepsy drug Xyrem, which comprised $357.3 million of the $469.4 million in sales during the third quarter. Xyrem has faced a number of potential generic challengers in recent years, and yet the company continues to maintain exclusivity over its lead drug. Jazz will go to bat legally, as well as settle with would-be generic entrants , in order to hang onto its cash-cow drug.
Not to mention, Jazz has benefited from label expansion opportunities for Xyrem, as well as exceptionally strong pricing power for its lead therapy. Sales in the third quarter grew a robust 18% from the prior-year period.
However, this could be a company that's about more than just Xyrem, even if it is the drug steering this proverbial ship. Since Vyxeos -- a treatment for certain types of acute myeloid leukemia with a poor prognosis -- was launched last year, this cancer drug has gained significant momentum. Following $9.7 million in sales during the third quarter of last year, Vyxeos racked up $21 million Q3 2018 sales and $75.2 million through the first nine months of the year. At scale, Vyxeos should climb above $200 million in full-year sales, which adds a nice complement to what Jazz is generating from its other high-margin, rare-disease therapies.
Recently, Jazz's board also decided that it wasn't doing nearly enough for its shareholders. Having previously authorized a $640 million share repurchase program, which has been fully utilized by the company, Jazz's board increased its buyback program by another $400 million on Dec. 10. This should help lower the company's outstanding share count and provide a boost to EPS.
Currently valued at just 10 times next year's estimated profit per share, but with projected compound annual EPS growth of 14.6% through 2021, Jazz looks to be quite the bargain for patient investors.
10 stocks we like better than Jazz Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Jazz Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Brian Feroldi has no position in any of the stocks mentioned. Keith Speights owns shares of AbbVie, Gilead Sciences, and SPDR S&P Biotech. Sean Williams has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Amgen. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We posed that very question to our team, and they called out the SPDR S&P Biotech ETF (NYSEMKT: XBI) , AbbVie (NYSE: ABBV) , and Jazz Pharmaceuticals (NASDAQ: JAZZ) . Hitting the trifecta Keith Speights (AbbVie): Probably the best equivalent to a trifecta in investing is finding a stock that provides solid income, great growth prospects, and an attractive valuation. But AbbVie does. | We posed that very question to our team, and they called out the SPDR S&P Biotech ETF (NYSEMKT: XBI) , AbbVie (NYSE: ABBV) , and Jazz Pharmaceuticals (NASDAQ: JAZZ) . Keith Speights owns shares of AbbVie, Gilead Sciences, and SPDR S&P Biotech. Hitting the trifecta Keith Speights (AbbVie): Probably the best equivalent to a trifecta in investing is finding a stock that provides solid income, great growth prospects, and an attractive valuation. | We posed that very question to our team, and they called out the SPDR S&P Biotech ETF (NYSEMKT: XBI) , AbbVie (NYSE: ABBV) , and Jazz Pharmaceuticals (NASDAQ: JAZZ) . Hitting the trifecta Keith Speights (AbbVie): Probably the best equivalent to a trifecta in investing is finding a stock that provides solid income, great growth prospects, and an attractive valuation. But AbbVie does. | But AbbVie does. We posed that very question to our team, and they called out the SPDR S&P Biotech ETF (NYSEMKT: XBI) , AbbVie (NYSE: ABBV) , and Jazz Pharmaceuticals (NASDAQ: JAZZ) . Hitting the trifecta Keith Speights (AbbVie): Probably the best equivalent to a trifecta in investing is finding a stock that provides solid income, great growth prospects, and an attractive valuation. |
25214.0 | 2018-12-19 00:00:00 UTC | Why Eli Lilly Stock Is Still Shining in the Darkness | ABBV | https://www.nasdaq.com/articles/why-eli-lilly-stock-still-shining-darkness-2018-12-19 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
While the average S&P 500 stock has corrected with the market average down 13% in three months, shares in Eli Lilly (NYSE: LLY ) have stood strong, and were due for a nice pop when trade opened Dec. 19. There has been a pronounced turn to big drug stocks amid the tech rout. LLY stock itself is also delivering some welcome good news.
This starts with a 15% hike in the dividend, to 64.5 cents per share, and a prediction from the company it will grow revenues another 5% or so next year, plus earn a profit of about $5.50 per share.
This was enough to send LLY stock up 3% as the market opened, before analysts got a chance to pick apart the announcement and see how realistic those predictions might be.
The Pipeline
First on the list of claims is speeding time to market, said chief scientific officer Daniel Skovronsky in a press release. He hopes to get target molecules into human testing within three years, and cut the time between the start of human trials and market introduction to two years.
10 Small-Cap Stocks That Look Like Bargains
Second, LLY is claiming its new medicines are simply better than the competition. It says its Taltz , an immunosuppressant used against psoriasis, topped AbbVie (NYSE: ABBV ) market leader Humira in a recent study, delivering more symptom improvement. But it should be noted that the study involved just 24 patients, and Lilly will have to follow up with expensive advertising to benefit.
Lilly is also hoping to deliver a new non-opioid pain reliever, buying assets from Hydra Biosciences. Lilly's pipeline includes late-stage drugs against cancer, diabetes and in immunology, as well as against pain, and it expects new medicines like Taltz, Jardiance, Trulicity and Verzenio to represent 45% of revenues next year.
LLY Stock and the Analyst Hype Machine
With tech stocks and bank stocks dropping like stones, analysts are eager to hype the performance of drug-makers like Lilly stock, which is up 30% on the year.
Price targets are being raised and institutional investors are sending out press releases bragging about their purchases of Lilly stock.
Overall, however, the analyst community hasn't rushed to embrace Lilly shares. The number of those suggesting you just "hold" it is up recently, and only 8 of 18 still have it on their buy lists.
Still, Lilly's safety as an investment stands out in the present market. The dividend hike would take its yield to almost 2.4%, at its Dec. 19 price point of $109. Assuming it hits its profit targets for 2019, the new dividend should also be very affordable, at $2.58 per share.
Lilly has about $10 billion in long-term debt, which may cost about $500 million to support in 2019, but in September, the company had about $8 billion in cash and short-term instruments on the balance sheet. The balance sheet is supported by operating cash flows that have nearly doubled in the last three years, and which came to about $4 billion for the first three quarters of 2018.
The Bottom Line on Lilly Stock
The hype around LLY stock is a good indication of the market's current weakness right now.
7 Death Cross Stocks to Ditch Now
While new drugs promise big returns, the sheer number of new drug-discovery approaches and rollouts also assure growing competition, with insurers and international governments focusing on price over the absolute merits of compounds.
This doesn't make Lilly a bad stock to own, especially in a bear market. But it does illustrate that a bear market is indeed what investors are facing right now.
Dana Blankenhorn is a financial and technology journalist. He is the author of a new mystery thriller, The Reluctant Detective Finds Her Family , available now at the Amazon Kindle store. Write him at danablankenhorn@gmail.com or follow him on Twitter at @danablankenhorn . As of this writing, he did not hold a position in any of the aforementioned securities.
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
29 Marijuana Stocks to Buy as the Future Turns Green
15 Stocks Facing Big Political Risk in 2019
15 Winning Stocks to Buy in 2019 (That Were Losers in 2018)
Compare Brokers
The post Why Eli Lilly Stock Is Still Shining in the Darkness appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It says its Taltz , an immunosuppressant used against psoriasis, topped AbbVie (NYSE: ABBV ) market leader Humira in a recent study, delivering more symptom improvement. Lilly's pipeline includes late-stage drugs against cancer, diabetes and in immunology, as well as against pain, and it expects new medicines like Taltz, Jardiance, Trulicity and Verzenio to represent 45% of revenues next year. 7 Death Cross Stocks to Ditch Now While new drugs promise big returns, the sheer number of new drug-discovery approaches and rollouts also assure growing competition, with insurers and international governments focusing on price over the absolute merits of compounds. | It says its Taltz , an immunosuppressant used against psoriasis, topped AbbVie (NYSE: ABBV ) market leader Humira in a recent study, delivering more symptom improvement. InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the average S&P 500 stock has corrected with the market average down 13% in three months, shares in Eli Lilly (NYSE: LLY ) have stood strong, and were due for a nice pop when trade opened Dec. 19. LLY Stock and the Analyst Hype Machine With tech stocks and bank stocks dropping like stones, analysts are eager to hype the performance of drug-makers like Lilly stock, which is up 30% on the year. | It says its Taltz , an immunosuppressant used against psoriasis, topped AbbVie (NYSE: ABBV ) market leader Humira in a recent study, delivering more symptom improvement. InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the average S&P 500 stock has corrected with the market average down 13% in three months, shares in Eli Lilly (NYSE: LLY ) have stood strong, and were due for a nice pop when trade opened Dec. 19. LLY Stock and the Analyst Hype Machine With tech stocks and bank stocks dropping like stones, analysts are eager to hype the performance of drug-makers like Lilly stock, which is up 30% on the year. | It says its Taltz , an immunosuppressant used against psoriasis, topped AbbVie (NYSE: ABBV ) market leader Humira in a recent study, delivering more symptom improvement. LLY stock itself is also delivering some welcome good news. This starts with a 15% hike in the dividend, to 64.5 cents per share, and a prediction from the company it will grow revenues another 5% or so next year, plus earn a profit of about $5.50 per share. |
25215.0 | 2018-12-19 00:00:00 UTC | Eli Lilly sees 2019 profit, revenue above estimates; shares rise | ABBV | https://www.nasdaq.com/articles/eli-lilly-sees-2019-profit-revenue-above-estimates-shares-rise-2018-12-19 | nan | nan | Dec 19 () - Eli Lilly and Co on Wednesday forecast better-than-expected revenue and adjusted profit for 2019, as the drugmaker benefits from higher demand for its newer medicines including diabetes drug Trulicity and psoriasis drug Taltz.
Shares of the company, which raised its quarterly dividend by 15 percent, rose 3.3 percent to $110 in early trading.
Lilly has been banking on 10 new drugs launched since 2014, including Trulicity and the recently approved migraine drug Emgality, to drive growth as some of its older treatments such as erectile dysfunction drug Cialis lose patent exclusivity.
Trulicity, for instance, recently overtook Humalog to become Lilly's top-selling medicine with sales of $816.2 million, and helped power the company's profit beat in the third quarter.
Lilly is also refocusing on high-profit areas such as cancer, as well as building up a strong pipeline.
The company earlier this month said Taltz was found to be more effective in improving symptoms of psoriatic arthritis when compared to AbbVie Inc's Humira, the world's best selling prescription medicine.
Lilly also said it aimed to decrease the time taken from identifying a target to clinical testing to about three years.
The company forecast 2019 adjusted profit of $5.90 to $6 per share, compared with analysts' average estimate of $5.82, according to IBES data from Refinitiv.
Lilly said revenue was expected to be between $25.3 billion and $25.8 billion for the coming year, also above estimate of $24.77 billion.
The Indianapolis-based company reiterated its forecast for 2018 adjusted profit.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company earlier this month said Taltz was found to be more effective in improving symptoms of psoriatic arthritis when compared to AbbVie Inc's Humira, the world's best selling prescription medicine. Trulicity, for instance, recently overtook Humalog to become Lilly's top-selling medicine with sales of $816.2 million, and helped power the company's profit beat in the third quarter. The company forecast 2019 adjusted profit of $5.90 to $6 per share, compared with analysts' average estimate of $5.82, according to IBES data from Refinitiv. | The company earlier this month said Taltz was found to be more effective in improving symptoms of psoriatic arthritis when compared to AbbVie Inc's Humira, the world's best selling prescription medicine. Dec 19 () - Eli Lilly and Co on Wednesday forecast better-than-expected revenue and adjusted profit for 2019, as the drugmaker benefits from higher demand for its newer medicines including diabetes drug Trulicity and psoriasis drug Taltz. The company forecast 2019 adjusted profit of $5.90 to $6 per share, compared with analysts' average estimate of $5.82, according to IBES data from Refinitiv. | The company earlier this month said Taltz was found to be more effective in improving symptoms of psoriatic arthritis when compared to AbbVie Inc's Humira, the world's best selling prescription medicine. Dec 19 () - Eli Lilly and Co on Wednesday forecast better-than-expected revenue and adjusted profit for 2019, as the drugmaker benefits from higher demand for its newer medicines including diabetes drug Trulicity and psoriasis drug Taltz. Lilly has been banking on 10 new drugs launched since 2014, including Trulicity and the recently approved migraine drug Emgality, to drive growth as some of its older treatments such as erectile dysfunction drug Cialis lose patent exclusivity. | The company earlier this month said Taltz was found to be more effective in improving symptoms of psoriatic arthritis when compared to AbbVie Inc's Humira, the world's best selling prescription medicine. Dec 19 () - Eli Lilly and Co on Wednesday forecast better-than-expected revenue and adjusted profit for 2019, as the drugmaker benefits from higher demand for its newer medicines including diabetes drug Trulicity and psoriasis drug Taltz. Shares of the company, which raised its quarterly dividend by 15 percent, rose 3.3 percent to $110 in early trading. |
25216.0 | 2018-12-18 00:00:00 UTC | Lilly's Taltz Outshines Humira in Psoriatic Arthritis Study | ABBV | https://www.nasdaq.com/articles/lillys-taltz-outshines-humira-in-psoriatic-arthritis-study-2018-12-18 | nan | nan | Eli Lilly & Company 's LLY drug Taltz demonstrated superiority in improving the signs and symptoms of active psoriatic arthritis (PsA) while also providing skin clearance in a head-to-head study comparing it with AbbVie, Inc.'s ABBV blockbuster medicine Humira.
The primary endpoint of the phase IIb/IV study - SPIRIT-H2H - was the proportion of patients experiencing improved signs and symptoms of active PsA at week 24. This was measured by the proportion of patients simultaneously achieving at least 50% reduction in disease activity as defined by the American College of Rheumatology (ACR50) as well as the proportion of patients who achieve complete skin clearance - in other words, 100% improvement from their baseline as measured by PASI 100 score.
The study met the primary and all major secondary endpoints, which were demonstrating non-inferiority in ACR50 and superiority in PASI100 in Taltz compared with Humira. Detailed data from the study is expected to be presented at the upcoming scientific meetings.
Lilly's shares have rallied 28.3% this year so far compared with the industry 's increase of 5%.
Taltz was launched for the psoriatic arthritis indication in the United States last December and across some EU countries in 2018. It is also marketed for moderate-to-severe plaque psoriasis in adults, who are candidates for systemic therapy or phototherapy.
Taltz is an important revenue driver for Lilly, recording sales of $630.4 million in the first nine months of 2018, soaring 63% year over year. Data from the SPIRIT-H2H study shows that doctors can comfortably prescribe Taltz as a first-line biologic treatment for patients with active psoriatic arthritis, which may further increase demand for the drug.
Lilly is also conducting a head-to-head study to evaluate superiority of Taltz over J&J's JNJ new drug, Tremfya (guselkumab). The study is likely to be completed by the end of next year.
Lilly currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
A better-ranked large-cap pharma stock is Merck & Co., Inc. MRK with a Zacks Rank #2 (Buy).
Merck's earnings estimates have been revised 1.4% upward for 2018 and 1.3% for 2019 over the past 60 days. The stock has surged 33.7% this year so far.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eli Lilly & Company 's LLY drug Taltz demonstrated superiority in improving the signs and symptoms of active psoriatic arthritis (PsA) while also providing skin clearance in a head-to-head study comparing it with AbbVie, Inc.'s ABBV blockbuster medicine Humira. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. The primary endpoint of the phase IIb/IV study - SPIRIT-H2H - was the proportion of patients experiencing improved signs and symptoms of active PsA at week 24. | Eli Lilly & Company 's LLY drug Taltz demonstrated superiority in improving the signs and symptoms of active psoriatic arthritis (PsA) while also providing skin clearance in a head-to-head study comparing it with AbbVie, Inc.'s ABBV blockbuster medicine Humira. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eli Lilly & Company 's LLY drug Taltz demonstrated superiority in improving the signs and symptoms of active psoriatic arthritis (PsA) while also providing skin clearance in a head-to-head study comparing it with AbbVie, Inc.'s ABBV blockbuster medicine Humira. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eli Lilly & Company 's LLY drug Taltz demonstrated superiority in improving the signs and symptoms of active psoriatic arthritis (PsA) while also providing skin clearance in a head-to-head study comparing it with AbbVie, Inc.'s ABBV blockbuster medicine Humira. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. Data from the SPIRIT-H2H study shows that doctors can comfortably prescribe Taltz as a first-line biologic treatment for patients with active psoriatic arthritis, which may further increase demand for the drug. |
25217.0 | 2018-12-18 00:00:00 UTC | The Zacks Analyst Blog Highlights: McDonald???s, AbbVie, Altria, Wells Fargo and Disney | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-mcdonalds-abbvie-altria-wells-fargo-and-disney-2018-12 | nan | nan | For Immediate Release
Chicago, IL -December 18, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: McDonald's MCD , AbbVie ABBV , Altria MO , Wells Fargo WFC and Disney DIS .
Here are highlights from Monday's Analyst Blog:
Top Stock Reports for McDonald's, AbbVie and Altria
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including McDonald's, AbbVie and Altria. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Buy-ranked McDonald's shares have gained +10.2% in the past six months, outperforming the Zacks Restaurants industry which has gained +4.3% over the same period. The Zacks analyst likes McDonald's impressive earnings surprise history, various sales and digital initiatives as well as positive comparable sales.
Also, the consensus earnings estimate for current quarter has increased over the past month. Increased focus on delivery and accelerated deployment of Experience of the Future restaurants in the United States should boost its performance.
These apart, the company's efforts to drive growth in International Lead & High Growth Markets bode well. In fact, global comps at McDonald's have been positive over the trailing 13 quarters.
Yet high labor costs and currency headwinds remain major concerns. Revenues have been under pressure for quite some time due to strategic refranchising initiatives. Even its heightened focus on refranchising should cut the capital requirements and facilitate EPS growth.
(You can read the full research report on McDonald's here >>> ).
Shares of AbbVie have lost 11.5% year to date, underperforming the Zacks Large-Cap Pharmaceuticals industry's rally of +5%. The Zacks analyst likes the fact that AbbVie's key drug, Humira, has been performing well based on strong demand trends despite new competition. Moreover, Imbruvica has multibillion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. Mavyret's launch has also been stronger than expected.
AbbVie has also been successful in expanding approvals for its cancer drugs, Imbruvica and Venclexta. The company has an impressive late-stage pipeline comprising several products with multibillion-dollar potential expected to be launched in the near term.
AbbVie expects to launch more than 20 new products or line extensions of marketed drugs before Humira biosimilar competition begins in the United States in 2023. Direct biosimilar competition to Humira in Europe from October can erode revenues.
(You can read the full research report on AbbVie here >>> ).
Altria 's shares have underperformed the Zacks Tobacco industry over the past three months (-15.1% vs. -13.2%). Altria has been delivering year-over-year bottom-line growth for quite some time, which continued in third-quarter 2018. The Zacks analyst thinks earnings during the quarter was mainly backed by lower outstanding shares and reduced income tax.
Consistent solid performance propelled management to raise 2018 view. Additionally, Altria has been gaining from the rising popularity of Smokeless products. Pricing also continues to drive the company's revenues in the smokeable and smokeless segments.
On the flip side, stern FDA regulations combined with increased health consciousness has been taking a toll on the cigarette category. Notably, cigarette shipment volumes fell 3.5% year over year during the third quarter, thanks to lower retail share and adverse trade inventory movements. The company's wine category has also been sluggish, due to stiff competition.
(You can read the full research report on Altria here >>> ).
Other noteworthy reports we are featuring today include Wells Fargo and Disney.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss . This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Wells Fargo & Company (WFC): Free Stock Analysis Report
The Walt Disney Company (DIS): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
McDonald's Corporation (MCD): Free Stock Analysis Report
Altria Group, Inc. (MO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include: McDonald's MCD , AbbVie ABBV , Altria MO , Wells Fargo WFC and Disney DIS . The Zacks analyst likes the fact that AbbVie's key drug, Humira, has been performing well based on strong demand trends despite new competition. Here are highlights from Monday's Analyst Blog: Top Stock Reports for McDonald's, AbbVie and Altria The Zacks Research Daily presents the best research output of our analyst team. | Stocks recently featured in the blog include: McDonald's MCD , AbbVie ABBV , Altria MO , Wells Fargo WFC and Disney DIS . Today's Research Daily features new research reports on 16 major stocks, including McDonald's, AbbVie and Altria. Click to get this free report Wells Fargo & Company (WFC): Free Stock Analysis Report The Walt Disney Company (DIS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report McDonald's Corporation (MCD): Free Stock Analysis Report Altria Group, Inc. (MO): Free Stock Analysis Report To read this article on Zacks.com click here. | Here are highlights from Monday's Analyst Blog: Top Stock Reports for McDonald's, AbbVie and Altria The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including McDonald's, AbbVie and Altria. Click to get this free report Wells Fargo & Company (WFC): Free Stock Analysis Report The Walt Disney Company (DIS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report McDonald's Corporation (MCD): Free Stock Analysis Report Altria Group, Inc. (MO): Free Stock Analysis Report To read this article on Zacks.com click here. | Here are highlights from Monday's Analyst Blog: Top Stock Reports for McDonald's, AbbVie and Altria The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including McDonald's, AbbVie and Altria. AbbVie expects to launch more than 20 new products or line extensions of marketed drugs before Humira biosimilar competition begins in the United States in 2023. |
25218.0 | 2018-12-17 00:00:00 UTC | Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial | ABBV | https://www.nasdaq.com/articles/lilly-says-taltz-superior-humira-late-stage-psoriatic-arthritis-trial-2018-12-17 | nan | nan | By Tamara Mathias
Dec 17 () - Eli Lilly and Co said on Monday its psoriatic arthritis drug, Taltz, was found to be more effective than the world's best-selling prescription medicine, AbbVie Inc's Humira, in a late-stage trial.
The trial was the first of its kind to test Taltz and the standard-of-care, Humira, head-to-head in patients with active psoriatic arthritis, a form of arthritis that affects some people who have psoriasis.
However, the drug was found superior to Humira in clearing skin completely in a greater number of patients and achieving both results simultaneously, Lilly said.
"This is a very, very high hurdle to meet and gives doctors confidence that they can prescribe Taltz as a treatment for newly diagnosed patients. It treats joints as well as provides the added value of clearing skin," Lotus Mallbris, vice president of immunology development at Lilly, told .
Lilly's Taltz was first approved in the United States in 2016 for treating plaque psoriasis and had total revenue of about $560 million in 2017. The Indianapolis-based drugmaker said it planned to present detailed data from the study in 2019.
Humira has been the top-earner for AbbVie since the company was spun off from medical device maker Abbott Labs more than five years ago. Last year, the drug brought in worldwide sales of $18 billion, accounting for about two-thirds of AbbVie's net revenue.
However, Humira's sales are expected to come under pressure with a number of biosimilar versions set to hit the market.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Tamara Mathias Dec 17 () - Eli Lilly and Co said on Monday its psoriatic arthritis drug, Taltz, was found to be more effective than the world's best-selling prescription medicine, AbbVie Inc's Humira, in a late-stage trial. Humira has been the top-earner for AbbVie since the company was spun off from medical device maker Abbott Labs more than five years ago. Last year, the drug brought in worldwide sales of $18 billion, accounting for about two-thirds of AbbVie's net revenue. | By Tamara Mathias Dec 17 () - Eli Lilly and Co said on Monday its psoriatic arthritis drug, Taltz, was found to be more effective than the world's best-selling prescription medicine, AbbVie Inc's Humira, in a late-stage trial. Humira has been the top-earner for AbbVie since the company was spun off from medical device maker Abbott Labs more than five years ago. Last year, the drug brought in worldwide sales of $18 billion, accounting for about two-thirds of AbbVie's net revenue. | By Tamara Mathias Dec 17 () - Eli Lilly and Co said on Monday its psoriatic arthritis drug, Taltz, was found to be more effective than the world's best-selling prescription medicine, AbbVie Inc's Humira, in a late-stage trial. Humira has been the top-earner for AbbVie since the company was spun off from medical device maker Abbott Labs more than five years ago. Last year, the drug brought in worldwide sales of $18 billion, accounting for about two-thirds of AbbVie's net revenue. | By Tamara Mathias Dec 17 () - Eli Lilly and Co said on Monday its psoriatic arthritis drug, Taltz, was found to be more effective than the world's best-selling prescription medicine, AbbVie Inc's Humira, in a late-stage trial. Humira has been the top-earner for AbbVie since the company was spun off from medical device maker Abbott Labs more than five years ago. Last year, the drug brought in worldwide sales of $18 billion, accounting for about two-thirds of AbbVie's net revenue. |
25219.0 | 2018-12-17 00:00:00 UTC | AbbVie (ABBV) Stock Moves -0.79%: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-moves-0.79%3A-what-you-should-know-2018-12-17 | nan | nan | In the latest trading session, AbbVie (ABBV) closed at $84.93, marking a -0.79% move from the previous day. This change was narrower than the S&P 500's daily loss of 2.08%. Elsewhere, the Dow lost 2.11%, while the tech-heavy Nasdaq lost 2.27%.
Heading into today, shares of the drugmaker had lost 5.03% over the past month, lagging the Medical sector's loss of 1.48% and the S&P 500's loss of 3.6% in that time.
ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. On that day, ABBV is projected to report earnings of $1.92 per share, which would represent year-over-year growth of 29.73%. Our most recent consensus estimate is calling for quarterly revenue of $8.36 billion, up 8.07% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $7.93 per share and revenue of $32.78 billion. These totals would mark changes of +41.61% and +16.17%, respectively, from last year.
Any recent changes to analyst estimates for ABBV should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. ABBV is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note ABBV's current valuation metrics, including its Forward P/E ratio of 10.79. For comparison, its industry has an average Forward P/E of 14.42, which means ABBV is trading at a discount to the group.
We can also see that ABBV currently has a PEG ratio of 0.8. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.04 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 62, which puts it in the top 24% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the latest trading session, AbbVie (ABBV) closed at $84.93, marking a -0.79% move from the previous day. ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. On that day, ABBV is projected to report earnings of $1.92 per share, which would represent year-over-year growth of 29.73%. | In the latest trading session, AbbVie (ABBV) closed at $84.93, marking a -0.79% move from the previous day. ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. On that day, ABBV is projected to report earnings of $1.92 per share, which would represent year-over-year growth of 29.73%. | In the latest trading session, AbbVie (ABBV) closed at $84.93, marking a -0.79% move from the previous day. ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. On that day, ABBV is projected to report earnings of $1.92 per share, which would represent year-over-year growth of 29.73%. | In the latest trading session, AbbVie (ABBV) closed at $84.93, marking a -0.79% move from the previous day. ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. On that day, ABBV is projected to report earnings of $1.92 per share, which would represent year-over-year growth of 29.73%. |
25220.0 | 2018-12-16 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On John Neff - 12/16/2018 | ABBV | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-john-neff-12162018-2018-12-16 | nan | nan | The following are the top rated Healthcare stocks according to Validea's Low PE Investor model based on the published strategy of John Neff . This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on John Neff is 81% based on the firm's underlying fundamentals and the stock's valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
AMERISOURCEBERGEN CORP. ( ABC ) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on John Neff is 62% based on the firm's underlying fundamentals and the stock's valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: AmerisourceBergen Corporation is a pharmaceutical sourcing and distribution services company. The Company's segments include Pharmaceutical Distribution and Other. The Company provides services to healthcare providers, and pharmaceutical and biotech manufacturers. As of June 30, 2016, the Pharmaceutical Distribution segment consists of two operating segments, including the operations of AmerisourceBergen Drug Corporation ( ABDC ) and AmerisourceBergen Specialty Group (ABSG), which distributes specialty drugs to their customers. Servicing healthcare providers in the pharmaceutical supply channel, the Pharmaceutical Distribution segment's operations provide drug distribution and related services. The Other segment consists of the operations of various segments, including the AmerisourceBergen Consulting Services (ABCS), the World Courier Group, Inc. and the MWI Veterinary Supply, Inc. ABSG operates distribution facilities that focus primarily on complex disease treatment regimens.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
BIOGEN INC ( BIIB ) is a large-cap value stock in the Biotechnology & Drugs industry. The rating according to our strategy based on John Neff is 62% based on the firm's underlying fundamentals and the stock's valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis ( MS ), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
CVS HEALTH CORP (CVS) is a large-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on John Neff is 62% based on the firm's underlying fundamentals and the stock's valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc. (Omnicare) and Omnicare's long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings. It operates through three segments: Pharmacy Services, Retail/LTC and Corporate. The Pharmacy Services Segment provides a range of pharmacy benefit management (PBM) solutions to its clients. As of December 31, 2016, the Retail/LTC Segment included 9,709 retail locations (of which 7,980 were its stores that operated a pharmacy and 1,674 were its pharmacies located within Target Corporation (Target) stores), its online retail pharmacy Websites, CVS.com, Navarro.com and Onofre.com.br, 38 onsite pharmacy stores, its long-term care pharmacy operations and its retail healthcare clinics.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
Since its inception, Validea's strategy based on John Neff has returned 107.89% vs. 133.83% for the S&P 500. For more details on this strategy, click here
About John Neff : While known as the manager with whom many top managers entrusted their own money, Neff was far from the smooth-talking, high-profile Wall Streeter you might expect. He was mild-mannered and low-key, and the same might be said of the Windsor Fund that he managed for more than three decades. In fact, Neff himself described the fund as "relatively prosaic, dull, [and] conservative." There was nothing dull about his results, however. From 1964 to 1995, Neff guided Windsor to a 13.7 percent average annual return, easily outpacing the S&P 500's 10.6 percent return during that time. That 3.1 percentage point difference is huge over time -- a $10,000 investment in Windsor (with dividends reinvested) at the start of Neff's tenure would have ended up as more than $564,000 by the time he retired, more than twice what the same investment in the S&P would have yielded (about $233,000). Considering the length of his tenure, that track record may be the best ever for a manager of such a large fund.
About Validea : Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are the top rated Healthcare stocks according to Validea's Low PE Investor model based on the published strategy of John Neff . | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. For a full detailed analysis using NASDAQ's Guru Analysis tool, click here AMERISOURCEBERGEN CORP. ( ABC ) is a large-cap growth stock in the Biotechnology & Drugs industry. | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab). | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company's segments include Pharmaceutical Distribution and Other. |
25221.0 | 2018-12-12 00:00:00 UTC | Notable ETF Outflow Detected - XLV, ABBV, ABT, CVS | ABBV | https://www.nasdaq.com/articles/notable-etf-outflow-detected-xlv-abbv-abt-cvs-2018-12-12 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $122.7 million dollar outflow -- that's a 0.6% decrease week over week (from 211,265,324 to 209,920,000). Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 2%, Abbott Laboratories (Symbol: ABT) is up about 2.1%, and CVS Health Corporation (Symbol: CVS) is higher by about 1.5%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $92.82. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 2%, Abbott Laboratories (Symbol: ABT) is up about 2.1%, and CVS Health Corporation (Symbol: CVS) is higher by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $122.7 million dollar outflow -- that's a 0.6% decrease week over week (from 211,265,324 to 209,920,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 2%, Abbott Laboratories (Symbol: ABT) is up about 2.1%, and CVS Health Corporation (Symbol: CVS) is higher by about 1.5%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $92.82. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 2%, Abbott Laboratories (Symbol: ABT) is up about 2.1%, and CVS Health Corporation (Symbol: CVS) is higher by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $122.7 million dollar outflow -- that's a 0.6% decrease week over week (from 211,265,324 to 209,920,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $92.82. | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 2%, Abbott Laboratories (Symbol: ABT) is up about 2.1%, and CVS Health Corporation (Symbol: CVS) is higher by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $122.7 million dollar outflow -- that's a 0.6% decrease week over week (from 211,265,324 to 209,920,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $92.82. |
25222.0 | 2018-12-12 00:00:00 UTC | 5 Pharma Stocks That Could Cure Ailing Portfolios in 2019 | ABBV | https://www.nasdaq.com/articles/5-pharma-stocks-that-could-cure-ailing-portfolios-in-2019-2018-12-12 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The pharmaceutical sector delivers two benefits that appeal to investors: reasonable P/E ratios and growth catalysts. Many pharma stocks have suffered as of late. Some have key drugs facing patent expirations. Meanwhile, others have sold off as trade-related fears or regulatory hurdles both domestically and abroad increase uncertainty.
However, some of these companies have responded by developing new drugs. Others trade at attractive valuations due to the uncertainty. Moreover, they benefit from 10,000 baby boomers a day aging into Medicare. This demographic trend increases demand and provides Medicare recipients with a subsidy enabling the purchase of more drugs.
The 10 Best Marijuana Stocks to Buy in 2019
The following five pharma stocks appear particularly well-positioned to benefit from new drugs and demographic tailwinds in 2019:
AbbVie (ABBV)
Source: Shutterstock
AbbVie (NYSE: ABBV ) has sold off in recent months as concerns about losing the patent on Humira and trade-war worries weighed on the stock. However, thanks to the decline, ABBV has become one of the more reasonably-priced pharma stocks. It trades at slightly more than 10 times consensus estimates for this year. Moreover, the company has replaced Humira with new drugs that treat conditions such as cancer and hepatitis C. As a result, investors will enjoy a 42% increase in profits this year and 9% the next.
ABBV stock trades at about $90 per share at the time of this writing. Nobody knows how long it will take to reach and surpass the all-time high of $125.86 per share. However, thanks to its history as part of Abbott Laboratories (NYSE: ABT ), AbbVie holds a 45-year track record of dividend increases, despite the existence of AbbVie itself going back only five years. The current annual payout of $4.28 per share yields about 4.85%. With this kind of profit growth, investors can likely expect an increase next year and in years to come. Hence, even if stock price growth does not return quickly, investors can still profit from a growing dividend.
Still, with the low multiple, the question becomes when and not if stock price growth will return. Once it returns, ABBV stockholders will benefit from not only a healthy income stream but also stock price growth.
Biogen Inc. (BIIB)
Source: Biogen via YouTube
Biogen (NASDAQ: BIIB ) has become one of the biggest success stories for pharma stocks in recent years. BIIB stock traded below $1 per share as late as the mid-1990s. However, in 2003, a merger made BIIB the third largest biotech company in the world . A number of successful drugs have cemented BIIB as the large-cap pharma stock it is today. Multiple sclerosis treatments have served as Biogen's focus from the beginning. And that happens to be the focus of its current best-selling drug Tecfidera. However, most of the current growth surrounds a newer drug, Spinraza. Investors should note that the company produces treatments for other treatments such as leukemia, spinal muscular atrophy and hemophilia.
7 Stocks to Buy Down 10% Last Week
While its almost $330 per share price may show its meteoric rise over time, BIIB stock has fallen about 18% from its July high. As a result, it trades at less than 12.5 times consensus 2018 estimates. Even though consensus profit growth will fall into the single digits next year, Wall Street predicts net income increases averaging just under 8% per year over the next five years. Given the low valuation and the growth coming from Spinraza and other drugs in the pipeline, BIIB stock should recover and resume its long-term march higher.
Celgene Corporation (CELG)
Source: Shutterstock
Celgene (NASDAQ: CELG ) focuses on developing drugs for both cancer and immunological diseases. Otezla and Abraxane constitute some of its better-known drugs. However, Revlimid, a treatment for a type of blood cancer, currently drives the majority of the company's revenues.
Unfortunately for shareholders, the U.S. patent on Revlimid expires in 2022. CELG continues to develop and release new treatments. However, last year they botched a regulatory filing, and investors have not trusted CELG stock since.
As a result, CELG trades at levels first seen in 2013. For the last 14 months, the stock has experienced a steady decline - from $147 to $71.
Despite the negative sentiment, the fundamentals may soon form their own positive catalyst. At a forward P/E ratio around 6.7, CELG stands as one of the cheapest pharma stocks. Analysts also believe profits will grow by 18.1% this year and 17.7% the next. Wall Street predicts these double-digit increases will continue through at least 2021.
Admittedly, losing Revlimid rightly creates high levels of uncertainty. But investors should remember that the company still has four years to replace this lost revenue source. Moreover, the fact that one can buy double-digit profit growth for less than seven times earnings creates a compelling value proposition.
Johnson & Johnson (JNJ)
Source: Shutterstock
The public knows Johnson & Johnson (NYSE: JNJ ) best for its consumer products. However, the company stands out among pharma stocks as it derives just over 50% of its revenues from its pharma division. The majority of JNJ's drugs focus on immunology, neuroscience, infectious diseases and oncology.
From a financial standpoint, JNJ stock remains one of the most highly regarded in the world. It holds the coveted AAA credit rating. Currently, only JNJ and Microsoft (NASDAQ: MSFT ) maintain this designation . This stability allows the stock to trade at a forward multiple of just under 17. Wall Street forecasts 11.8% profit growth this year and 5.6% the next. While this makes JNJ stock somewhat more expensive than some, its valuation remains reasonable. Also, its decades-long history of stability makes a somewhat higher expense worthwhile.
5 High-Value Stocks to Buy While They Start to Rally
Nothing reflects this stability better than the dividend. This year's dividend has paid shareholders $3.60 per share, a yield of just under 2.5%. JNJ has hiked this payout every year since 1963. With the stock's stability and continued growth, stockholders can safely expect the increases to continue. With the rising dividend, the AAA credit rating, and a reasonable valuation, no other equity in the pharma sector tops JNJ stock for both stability and reliable returns.
Pfizer Inc. (PFE)
Source: Kojach Via Flickr
Over the past six months, Pfizer (NYSE: PFE ) stock price has done something it hadn't done in years: move higher. PFE spent years mired in a trading range. Now it has finally broken out of that range, and it could finally deliver the growth which investors have long waited. PFE stock also appears positioned to return to the all-time high achieved 19 years ago.
The equity had suffered as it lost its Viagra patent and faces patent expiration on Lyrica. However, Eliquis, Ibrance, and other treatments appear poised to pick up the slack. As a result, PFE stock has seen its value rise.
That said, new buyers can still benefit. PFE stock trades at a forward P/E ratio of about 14.4. Analysts also expect profits to grow by 13.65% this year. Although that could slow next year, net income should see high-single-digit increases on average.
Pfizer has also built a reputation for its rising dividend. The current dividend yield stands at just over 3%. Moreover, its $1.36 per share annual dividend has increased every year since 2010. Hence, the streak has persisted long enough that investors can expect yearly dividend increases. Also, with new drugs selling well, certainty has returned, and PFE stock has finally begun to move higher. As a result, Pfizer has become one of the pharma stocks that delivers on both growth and income.
As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You canfollow Will on Twitterat @HealyWriting.
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
The 10 Wildest Stock Market Predictions for 2019
7 Stocks to Buy Down 10% Last Week
10 Stocks Defying the Market Selloff, Including Cronos
Compare Brokers
The post 5 Pharma Stocks That Could Cure Ailing Portfolios in 2019 appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The 10 Best Marijuana Stocks to Buy in 2019 The following five pharma stocks appear particularly well-positioned to benefit from new drugs and demographic tailwinds in 2019: AbbVie (ABBV) Source: Shutterstock AbbVie (NYSE: ABBV ) has sold off in recent months as concerns about losing the patent on Humira and trade-war worries weighed on the stock. However, thanks to the decline, ABBV has become one of the more reasonably-priced pharma stocks. ABBV stock trades at about $90 per share at the time of this writing. | The 10 Best Marijuana Stocks to Buy in 2019 The following five pharma stocks appear particularly well-positioned to benefit from new drugs and demographic tailwinds in 2019: AbbVie (ABBV) Source: Shutterstock AbbVie (NYSE: ABBV ) has sold off in recent months as concerns about losing the patent on Humira and trade-war worries weighed on the stock. However, thanks to the decline, ABBV has become one of the more reasonably-priced pharma stocks. ABBV stock trades at about $90 per share at the time of this writing. | The 10 Best Marijuana Stocks to Buy in 2019 The following five pharma stocks appear particularly well-positioned to benefit from new drugs and demographic tailwinds in 2019: AbbVie (ABBV) Source: Shutterstock AbbVie (NYSE: ABBV ) has sold off in recent months as concerns about losing the patent on Humira and trade-war worries weighed on the stock. However, thanks to the decline, ABBV has become one of the more reasonably-priced pharma stocks. ABBV stock trades at about $90 per share at the time of this writing. | The 10 Best Marijuana Stocks to Buy in 2019 The following five pharma stocks appear particularly well-positioned to benefit from new drugs and demographic tailwinds in 2019: AbbVie (ABBV) Source: Shutterstock AbbVie (NYSE: ABBV ) has sold off in recent months as concerns about losing the patent on Humira and trade-war worries weighed on the stock. However, thanks to the decline, ABBV has become one of the more reasonably-priced pharma stocks. ABBV stock trades at about $90 per share at the time of this writing. |
25223.0 | 2018-12-12 00:00:00 UTC | 3 Beaten-Down Biotech Stocks That Could Bounce Back in 2019 | ABBV | https://www.nasdaq.com/articles/3-beaten-down-biotech-stocks-could-bounce-back-2019-2018-12-12 | nan | nan | Developing new drugs is a risky business that hasn't been kind to these three biotechs or their shareholders lately. But despite recent tumbling stock prices, all of these companies have a chance to bounce back in 2019.
Of course, some of these biotech stocks have a better chance than others. Here's what you need to know about potential catalysts on the horizon that could turn these sinking ships around.
Data source: Yahoo! Finance.
1. TG Therapeutics: Tough acts to follow
This biotech stock took a beating when investors expecting response rate data for a leukemia combo in late-stage development were instead told they'd have to wait for a long-term survival benefit to play out. The company expects the Unity trial to produce progression-free survival data in 2019, and results that beat the competition could help this stock bounce back.
Unfortunately for TG Therapeutics, the stock probably won't regain all of its former glory unless results from the Unity study are downright amazing. Chronic lymphocytic leukemia is the type most commonly diagnosed among adults, but it isn't common enough to drive blockbuster sales of a mediocre treatment in a crowded market.
The Unity study will test TG's candidates ublituximab plus umbralisib against Gazyva plus old-school chemotherapy. Ublituximab and Gazyva both target CD20, and TG investors should be nervous about a treatment that AbbVie (NYSE: ABBV) already markets with great success. AbbVie's Venclexta plus Rituxan blew the doors off Rituxan plus chemo for a group of patients similar to those enrolled in the Unity study.
Rituxan is an older CD20 therapy, and low-cost biosimilar versions could make Venclexta plus Rituxan an extremely difficult combination to compete with. TG Therapeutics' market cap has been reduced to ashes, so a positive result could lead to huge gains. Given the strength of the competition, though, it doesn't seem like a risk worth taking.
2. Madrigal Pharmaceuticals: Beta-agonist battle
Madrigal Pharmaceuticals and Viking Pharmaceuticals (NASDAQ: VKTX) are both developing thyroid receptor beta (TRB) agonists for the treatment of nonalcoholic steatohepatitis (NASH). Madrigal stock peaked after its lead candidate, MGL-3196, led to a 42% average liver fat reduction earlier this year. Madrigal's gains were mostly wiped out following surprising results from Viking's TRB agonist, VK2809, which is a few steps behind on the development timeline.
Treatment with Viking's VK2809 led to a whopping 59.7% liver fat reduction for a group of 11 nonalcoholic fatty liver disease (NAFLD) patients compared with those given a placebo. Although MGL-3196 looks washed up, differences between the two patient groups probably improved VK2809's appearance. Patients with NAFLD have high levels of fat in their livers, but they haven't yet started exhibiting signs of inflammation, ballooning, or stiffening.
The NASH patients in Madrigal's much-larger study had livers that were already taking damage, and 36-week biopsy data shows their chances of achieving NASH resolution were 450% better than the placebo group. That's important because the FDA has signaled a willingness to review a drug that helps patients achieve NASH resolution rather than insisting on long-term studies to determine survival outcomes.
The disease currently threatens an estimated 20 million Americans, and there aren't any available treatments yet. Madrigal and Viking are both looking for buyers, and there's a chance a big pharma will jump at the TRB-agonist with the type of NASH data the agency wants to see.
3. Puma Biotechnology: Hey, Glaxo
Puma's breast cancer treatment Nerlynx has been proven to prevent tumors from returning after initial treatments. Unfortunately, the extended adjuvant role isn't providing the sales that investors were expecting when Nerlynx launched last summer.
GlaxoSmithKline recently agreed to acquire Tesaro , another struggling biotech in the middle of a disappointing drug launch. The return of big pharma deals has some investors hopeful that Puma could be next.
During studies leading to Nerlynx's approval, it raised patients' chances of remaining disease-free from 91.9% to 94.2% at two years. That's statistically significant, but third-quarter Nerlynx sales came in at just $53 million. That was only $2 million more than the company recorded during the previous quarter, which suggests the launch has tapered off.
Investors worried Nerlynx sales have stopped growing have hammered Puma's market cap 74% lower since the company launched the drug last summer. At recent prices, some big pharma itching to expand its oncology presence could be tempted to make Puma an offer.
A buyout at a premium could help Puma shareholders recover some recent losses, but hoping for generous offers isn't a sound investing strategy. Moreover, there are more attractive takeout targets available at the moment.
Most likely to succeed
While the odds of bouncing back aren't great for any of these stocks in 2019, Madrigal probably has the best chance to stage a comeback. The company's recent valuation doesn't seem entirely unreasonable for a roll of the dice on one of two drugs that are probably going to make a big difference for the enormous NASH population. That said, it's probably best to watch the show from a safe distance.
10 stocks we like better than Puma Biotechnology
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Puma Biotechnology wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ublituximab and Gazyva both target CD20, and TG investors should be nervous about a treatment that AbbVie (NYSE: ABBV) already markets with great success. AbbVie's Venclexta plus Rituxan blew the doors off Rituxan plus chemo for a group of patients similar to those enrolled in the Unity study. TG Therapeutics: Tough acts to follow This biotech stock took a beating when investors expecting response rate data for a leukemia combo in late-stage development were instead told they'd have to wait for a long-term survival benefit to play out. | Ublituximab and Gazyva both target CD20, and TG investors should be nervous about a treatment that AbbVie (NYSE: ABBV) already markets with great success. AbbVie's Venclexta plus Rituxan blew the doors off Rituxan plus chemo for a group of patients similar to those enrolled in the Unity study. Madrigal Pharmaceuticals: Beta-agonist battle Madrigal Pharmaceuticals and Viking Pharmaceuticals (NASDAQ: VKTX) are both developing thyroid receptor beta (TRB) agonists for the treatment of nonalcoholic steatohepatitis (NASH). | Ublituximab and Gazyva both target CD20, and TG investors should be nervous about a treatment that AbbVie (NYSE: ABBV) already markets with great success. AbbVie's Venclexta plus Rituxan blew the doors off Rituxan plus chemo for a group of patients similar to those enrolled in the Unity study. TG Therapeutics: Tough acts to follow This biotech stock took a beating when investors expecting response rate data for a leukemia combo in late-stage development were instead told they'd have to wait for a long-term survival benefit to play out. | Ublituximab and Gazyva both target CD20, and TG investors should be nervous about a treatment that AbbVie (NYSE: ABBV) already markets with great success. AbbVie's Venclexta plus Rituxan blew the doors off Rituxan plus chemo for a group of patients similar to those enrolled in the Unity study. Of course, some of these biotech stocks have a better chance than others. |
25224.0 | 2018-12-11 00:00:00 UTC | Bristol-Myers to Study Opdivo in Combo With Vedanta's VE800 | ABBV | https://www.nasdaq.com/articles/bristol-myers-to-study-opdivo-in-combo-with-vedantas-ve800-2018-12-11 | nan | nan | Bristol-Myers Squibb CompanyBMY announced that it has signed a collaboration deal with Massachusetts-based, privately held Vedanta Biosciences, Inc. to evaluate its immuno-oncology drug, Opdivo, in combination with Vedanta's lead microbiome-based immuno-oncology candidate, VE800.
The collaboration study will evaluate Bristol-Myers' PD-1 inhibitor, Opdivo, combined with VE800, a rationally-defined human bacterial consortium for the treatment of patients with advanced or metastatic cancers.
The main idea of the study is to check whether the combination of Opdivo plus VE800 can improve outcomes for patients afflicted with advanced cancers.
As part of the transaction, Bristol-Myers plans to make an equity investment in Vedanta Biosciences. The latter will control the VE800 program and retain the global research and development (R&D) plus commercial rights of the same.
Shares of Bristol-Myers have decreased 14.2% year to date against the industry's increase of 6.9%.
Notably, Bristol-Myers has inked collaboration deals with several research institutes, small and large biotech and pharma companies including Johns Hopkins University, Johnson & Johnson JNJ , AbbVie ABBV , Lilly LLY , Celgene, Nektar, Infinity Pharmaceuticals and Seattle Genetics for evaluating Opdivo in combination with respective cancer treatments.
In November 2018, Bristol-Myers signed a collaboration contract with Infinity Pharmaceuticals to evaluate the combination of Opdivo and the latter's investigational immunotherapy, IPI-549, for the treatment of advanced urothelial cancer, a type of bladder cancer. The main idea of the study is to check whether targeting the tumor microenvironment with IPI-549 will increase the activity of Opdivo for subjects suffering urothelial cancer.
We would like to remind investors that in July 2014, Opdivo became the first PD-1 immune checkpoint inhibitor to gain a regulatory approval. It is currently approved in several countries including the United States, the EU and Japan for several cancer indications.
Opdivo generated sales of $4.93 billion in the first nine months of 2018, reflecting a surge of 37% year over year. The drug continues to be a top revenue generator for the company.
Meanwhile, Bristol-Myers is working on expanding the label of Opdivo further. Label expansion into additional indications would provide the product with access to a higher patient population and raise its commercial potential substantially.
Zacks Rank
Bristol-Myers currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Notably, Bristol-Myers has inked collaboration deals with several research institutes, small and large biotech and pharma companies including Johns Hopkins University, Johnson & Johnson JNJ , AbbVie ABBV , Lilly LLY , Celgene, Nektar, Infinity Pharmaceuticals and Seattle Genetics for evaluating Opdivo in combination with respective cancer treatments. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. The collaboration study will evaluate Bristol-Myers' PD-1 inhibitor, Opdivo, combined with VE800, a rationally-defined human bacterial consortium for the treatment of patients with advanced or metastatic cancers. | Notably, Bristol-Myers has inked collaboration deals with several research institutes, small and large biotech and pharma companies including Johns Hopkins University, Johnson & Johnson JNJ , AbbVie ABBV , Lilly LLY , Celgene, Nektar, Infinity Pharmaceuticals and Seattle Genetics for evaluating Opdivo in combination with respective cancer treatments. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. The collaboration study will evaluate Bristol-Myers' PD-1 inhibitor, Opdivo, combined with VE800, a rationally-defined human bacterial consortium for the treatment of patients with advanced or metastatic cancers. | Notably, Bristol-Myers has inked collaboration deals with several research institutes, small and large biotech and pharma companies including Johns Hopkins University, Johnson & Johnson JNJ , AbbVie ABBV , Lilly LLY , Celgene, Nektar, Infinity Pharmaceuticals and Seattle Genetics for evaluating Opdivo in combination with respective cancer treatments. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. In November 2018, Bristol-Myers signed a collaboration contract with Infinity Pharmaceuticals to evaluate the combination of Opdivo and the latter's investigational immunotherapy, IPI-549, for the treatment of advanced urothelial cancer, a type of bladder cancer. | Notably, Bristol-Myers has inked collaboration deals with several research institutes, small and large biotech and pharma companies including Johns Hopkins University, Johnson & Johnson JNJ , AbbVie ABBV , Lilly LLY , Celgene, Nektar, Infinity Pharmaceuticals and Seattle Genetics for evaluating Opdivo in combination with respective cancer treatments. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. In November 2018, Bristol-Myers signed a collaboration contract with Infinity Pharmaceuticals to evaluate the combination of Opdivo and the latter's investigational immunotherapy, IPI-549, for the treatment of advanced urothelial cancer, a type of bladder cancer. |
25225.0 | 2018-12-11 00:00:00 UTC | 4 “Powell-Proof” Stocks Set to Skyrocket in 2019 (and 1 to Sell Now) | ABBV | https://www.nasdaq.com/articles/4-powell-proof-stocks-set-skyrocket-2019-and-1-sell-now-2018-12-11 | nan | nan | By Brett Owens
If youaEURtmre confused about the direction of interest rates, donaEURtmt worryaEUR"Fed Chair Jerome Powell canaEURtmt figure it out either!
And today IaEURtmm going to show you 4 aEURoePowell-proofaEUR stocks set to explode in 2019aEUR"whether rates take off or freeze in place. First, back to Powell.
An Epic Flip-Flop
You may recall October 3, when the Fed chief, momentarily forgetting his words can tank the market, said, aEURoeWeaEURtmre a long way from neutral, probably,aEUR in reference to rates.
HereaEURtms what followed:
Loose Lips aEUR
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Brett Owens If youaEURtmre confused about the direction of interest rates, donaEURtmt worryaEUR"Fed Chair Jerome Powell canaEURtmt figure it out either! And today IaEURtmm going to show you 4 aEURoePowell-proofaEUR stocks set to explode in 2019aEUR"whether rates take off or freeze in place. An Epic Flip-Flop You may recall October 3, when the Fed chief, momentarily forgetting his words can tank the market, said, aEURoeWeaEURtmre a long way from neutral, probably,aEUR in reference to rates. | By Brett Owens If youaEURtmre confused about the direction of interest rates, donaEURtmt worryaEUR"Fed Chair Jerome Powell canaEURtmt figure it out either! HereaEURtms what followed: Loose Lips aEUR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Brett Owens If youaEURtmre confused about the direction of interest rates, donaEURtmt worryaEUR"Fed Chair Jerome Powell canaEURtmt figure it out either! An Epic Flip-Flop You may recall October 3, when the Fed chief, momentarily forgetting his words can tank the market, said, aEURoeWeaEURtmre a long way from neutral, probably,aEUR in reference to rates. HereaEURtms what followed: Loose Lips aEUR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Brett Owens If youaEURtmre confused about the direction of interest rates, donaEURtmt worryaEUR"Fed Chair Jerome Powell canaEURtmt figure it out either! And today IaEURtmm going to show you 4 aEURoePowell-proofaEUR stocks set to explode in 2019aEUR"whether rates take off or freeze in place. First, back to Powell. |
25226.0 | 2018-12-11 00:00:00 UTC | How Worried Should You Be About AbbVie's $5.8 Billion Boondoggle? | ABBV | https://www.nasdaq.com/articles/how-worried-should-you-be-about-abbvies-58-billion-boondoggle-2018-12-11 | nan | nan | What's a 10-letter word that describes a waste of money that at one point had the appearance of adding value? Boondoggle. And the word could now apply to AbbVie 's (NYSE: ABBV) $5.8 billion acquisition of Stemcentrx.
When AbbVie announced the Stemcentrx deal in April 2016, the company expressed excitement and optimism about Stemcentrx's lead candidate and crown jewel, rovalpituzumab tesirine (Rova-T). That excitement and optimism have largely evaporated.
The big investment in Stemcentrx appears to be a big waste of money after disappointing phase 2 results for Rova-T in March, followed by AbbVie halting a phase 3 study of the drug last week. But how worried should you be that AbbVie's multibillion-dollar boondoggle could significantly affect the company's growth prospects?
A big impact
In 2016, AbbVie said that Rova-T "represents a multi-billion dollar peak revenue opportunity with expected commercialization in 2018." The cancer drug definitely won't be commercialized this year. And that multibillion-dollar revenue appears to be a dream that will never come true.
It's a dream that was still quite alive earlier this year, though. At the J.P. Morgan Healthcare Conference in January , AbbVie CEO Rick Gonzalez included Rova-T as one of several drugs that would help the company generate $35 billion in risk-adjusted non-Humira revenue by 2025. AbbVie had targeted peak annual sales of around $5 billion for Rova-T.
Now, though, the phase 3 clinical study of Rova-T as a second-line treatment of advanced small-cell lung cancer has been halted after patients taking the drug had a shorter overall survival rate than did patients taking comparison chemotherapy Hycamtin. AbbVie hasn't thrown in the towel on Rova-T yet. The drug is still being evaluated in other clinical studies. But the outlook isn't good for AbbVie to see a solid return on its investment in Stemcentrx -- if there's any return at all.
What it means for AbbVie's pipeline
There's no question that the big setbacks for Rova-T leave a hole in AbbVie's oncology pipeline. However, the company does have several other promising cancer drugs in development.
Current blockbuster Imbruvica is being evaluated for additional indications including follicular lymphoma and pancreatic cancer. AbbVie hopes to pick up a new indication for another already approved drug, Venclexta, in treating acute myeloid leukemia.
But the potential loss of Rova-T means that AbbVie only has a couple new experimental cancer drugs in late-stage development. One of those drugs, veliparib, has already flopped in phase 3 studies as a treatment for non-small cell lung cancer and triple-negative breast cancer. The other, depatuxizumab mafodotin, targets glioblastoma -- a notoriously difficult-to-treat brain cancer.
However, AbbVie's pipeline appears to be quite strong in other therapeutic areas. Immunology drugs risankizumab and upadacitinib should be big winners, with up to $5 billion and $6.5 billion in peak sales, respectively. Orilissa, which already won approval in managing endometriosis pain, looks to have a good shot at another approval in treating uterine fibroids.
Beyond the boondoggle
Within months of its acquisition of Stemcentrx, some began to question if AbbVie had overpaid for its pickup of Rova-T based on underwhelming clinical data for the drug. After the setbacks for Rova-T this year, those questions have morphed into a statement: Yes, AbbVie paid way too much.
Make no mistake -- the Rova-T failures hurt AbbVie. But while the Stemcentrx deal has turned out to be a boondoggle, AbbVie should be just fine.
The company has successfully negotiated deals to prevent Humira biosimilars from entering the U.S. market until 2023. Sales are strong for Imbruvica and hepatitis C drug Mavyret. Venclexta should gain momentum. Potential megablockbusters risankizumab and upadacitinib are likely on the way.
Thanks to its strong lineup of current products and its pipeline, AbbVie still expects to generate solid growth for years to come. Combined with its attractive dividend yielding 4.7%, the stock should deliver a strong overall return for investors. Rova-T might be a bust. But AbbVie isn't.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A big impact In 2016, AbbVie said that Rova-T "represents a multi-billion dollar peak revenue opportunity with expected commercialization in 2018." At the J.P. Morgan Healthcare Conference in January , AbbVie CEO Rick Gonzalez included Rova-T as one of several drugs that would help the company generate $35 billion in risk-adjusted non-Humira revenue by 2025. Beyond the boondoggle Within months of its acquisition of Stemcentrx, some began to question if AbbVie had overpaid for its pickup of Rova-T based on underwhelming clinical data for the drug. | The big investment in Stemcentrx appears to be a big waste of money after disappointing phase 2 results for Rova-T in March, followed by AbbVie halting a phase 3 study of the drug last week. AbbVie had targeted peak annual sales of around $5 billion for Rova-T. Now, though, the phase 3 clinical study of Rova-T as a second-line treatment of advanced small-cell lung cancer has been halted after patients taking the drug had a shorter overall survival rate than did patients taking comparison chemotherapy Hycamtin. Thanks to its strong lineup of current products and its pipeline, AbbVie still expects to generate solid growth for years to come. | The big investment in Stemcentrx appears to be a big waste of money after disappointing phase 2 results for Rova-T in March, followed by AbbVie halting a phase 3 study of the drug last week. AbbVie had targeted peak annual sales of around $5 billion for Rova-T. Now, though, the phase 3 clinical study of Rova-T as a second-line treatment of advanced small-cell lung cancer has been halted after patients taking the drug had a shorter overall survival rate than did patients taking comparison chemotherapy Hycamtin. What it means for AbbVie's pipeline There's no question that the big setbacks for Rova-T leave a hole in AbbVie's oncology pipeline. | AbbVie hopes to pick up a new indication for another already approved drug, Venclexta, in treating acute myeloid leukemia. And the word could now apply to AbbVie 's (NYSE: ABBV) $5.8 billion acquisition of Stemcentrx. When AbbVie announced the Stemcentrx deal in April 2016, the company expressed excitement and optimism about Stemcentrx's lead candidate and crown jewel, rovalpituzumab tesirine (Rova-T). |
25227.0 | 2018-12-11 00:00:00 UTC | Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO | ABBV | https://www.nasdaq.com/articles/gilead-sciences-gild-appoints-daniel-oday-as-new-ceo-2018-12-11 | nan | nan | Gilead Sciences, Inc.GILD announced that its board of directors has appointed Daniel O'Day as the company's Chairman and Chief Executive Officer (CEO).
O'Day will take over the reins on Mar 1, 2019. Meanwhile, the board appointed Gregg Alton as interim CEO for the period of Jan 1 to Mar 1, 2019.
O'Day is the CEO of the pharmaceutical arm of Roche Holdings RHHBY since 2012. Prior to 2012, O'Day was heading Roche Diagnostics.
The appointment of a veteran leader like O'Day should relieve wary investors as the new CEO will bring leadership experience across multiple therapeutic areas, which is much needed at Gilead.
Gilead has been facing turbulent times lately, and hence O'Day has a tough job in his hands. Gilead's stock has lost 4.4% in the past six months, against the industry' s decline of 12.7%.
Gilead was once a market outperformer, with its strong HCV franchise boasting a number of blockbuster drugs. However, the HCV franchise has been under pressure since the last three-four years due to competitive pressure from the likes of AbbbVie, Inc. ABBV .
Consequently, Gilead had turned focus on its HIV franchise and newer avenues like CAR T therapy. Gilead was the first to bring to market a single-tablet regimen (STR) - Atripla - for the treatment of HIV. Other STRs for HIV in the market include Complera/Eviplera and Stribild. TAF-based products like Genvoya, Odefsey and Descovy are performing well with strong adoption both in the United States and Europe. The company received a major boost when the FDA approved its once-daily STR, Biktarvy.
Due to the dwindling HCV sales, Gilead acquired Kite Pharma in 2017. Kite is a pioneer in cell therapy, having developed engineered cell therapies that express either a CAR or an engineered T cell receptor (TCR) depending on the type of cancer. The approval of lead candidate Yescarta for the treatment of refractory aggressive non-Hodgkin lymphoma and the initial uptake of the therapy have been encouraging.
Nevertheless, Gilead has been trying to revive its portfolio of late, and with a new CEO, we expect a more concrete and focused approach. Gilead has promising late-stage candidates - selonsertib and filgotinib - in the NASH and inflammation markets. The company also has a collaboration agreement with Sangamo Therapeutics, Inc. SGMO to use Sangamo's zinc finger nuclease technology platform for the development of next-generation ex vivo cell therapies in oncology.
Zacks Rank
Gilead currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, the HCV franchise has been under pressure since the last three-four years due to competitive pressure from the likes of AbbbVie, Inc. ABBV . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Gilead Sciences, Inc.GILD announced that its board of directors has appointed Daniel O'Day as the company's Chairman and Chief Executive Officer (CEO). | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. However, the HCV franchise has been under pressure since the last three-four years due to competitive pressure from the likes of AbbbVie, Inc. ABBV . Kite is a pioneer in cell therapy, having developed engineered cell therapies that express either a CAR or an engineered T cell receptor (TCR) depending on the type of cancer. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. However, the HCV franchise has been under pressure since the last three-four years due to competitive pressure from the likes of AbbbVie, Inc. ABBV . Gilead Sciences, Inc.GILD announced that its board of directors has appointed Daniel O'Day as the company's Chairman and Chief Executive Officer (CEO). | However, the HCV franchise has been under pressure since the last three-four years due to competitive pressure from the likes of AbbbVie, Inc. ABBV . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Consequently, Gilead had turned focus on its HIV franchise and newer avenues like CAR T therapy. |
25228.0 | 2018-12-10 00:00:00 UTC | Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend | ABBV | https://www.nasdaq.com/articles/amgen-amgn-continues-to-reward-shareholders-ups-dividend-2018-12-10 | nan | nan | Amgen, Inc.AMGN has announced a 10% hike in its quarterly dividend. Quarterly dividend was increased from $1.32 per share to $1.45 per share. The first increased dividend will be paid on Mar 8, 2019 to shareholders of record as of Feb 15. The new quarterly dividend amounts to an annual dividend of $5.80 per share, which implies a dividend yield of 3%.
Amgen regularly returns cash to shareholders through dividends. The company's target is to return more than 60% of adjusted net income in the form of dividends and share buybacks through 2018. The company started paying dividends in 2011 and has raised it 25% a year on average. Amgen raised its quarterly dividend for 2016 by 27% and for 2017 and 2018 by 15% each. Its free cash flow grew 9% from 2016 to $10.5 billion in 2017, driven by higher profitability. The company also bought back shares worth $3.1 billion in 2017 and $15.7 billion in the first nine months of 2018.
So far this year, Amgen's stock has risen 10.1% against 19% decrease of its industry .
Amgen has done relatively well in 2018 so far, coming up with strong quarterly results and positive pipeline and regulatory updates.
Amgen's newer drugs - Prolia, Xgeva, Blincyto, Repatha, Kyprolis - are performing well. This year, Amgen made rapid progress with its pipeline and line extensions.
The approval of migraine candidate, Aimovig this year was a huge boost. Amgen has developed Aimovig in partnership with Novartis NVS . Aimovig was the first FDA-approved treatment, specifically developed to treat migraine by blocking calcitonin gene-related peptide (CGRP).
Amgen has also delivered on its biosimilars pipeline so far this year, which represents significant growth opportunity. Two of its biosimilars, Kanjinti (a biosimilar of Roche's RHHBY cancer drug Herceptin) and Amjevita (biosimilar of Abbvie's ABBV blockbuster RA drug, Humira) were launched in EU this year and can contribute to sales in the future quarters. Amgen's restructuring plan is making it leaner and more cost efficient. Lower taxes and share buybacks should provide some bottom-line support.
However, Amgen faces challenges related to its more mature products such as launch of competing biosimilar versions of Neulasta and Epogen, further sales erosion of Neupogen and Aranesp and increasing competitive pressure on Enbrel. Meanwhile, uptake of key new drug, Repatha has been slow due to payer restrictions. The recent price cut is expected to hurt Repatha volumes going forward.
Amgen currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Novartis AG (NVS): Free Stock Analysis Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Two of its biosimilars, Kanjinti (a biosimilar of Roche's RHHBY cancer drug Herceptin) and Amjevita (biosimilar of Abbvie's ABBV blockbuster RA drug, Humira) were launched in EU this year and can contribute to sales in the future quarters. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Amgen has done relatively well in 2018 so far, coming up with strong quarterly results and positive pipeline and regulatory updates. | Two of its biosimilars, Kanjinti (a biosimilar of Roche's RHHBY cancer drug Herceptin) and Amjevita (biosimilar of Abbvie's ABBV blockbuster RA drug, Humira) were launched in EU this year and can contribute to sales in the future quarters. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . | Two of its biosimilars, Kanjinti (a biosimilar of Roche's RHHBY cancer drug Herceptin) and Amjevita (biosimilar of Abbvie's ABBV blockbuster RA drug, Humira) were launched in EU this year and can contribute to sales in the future quarters. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The new quarterly dividend amounts to an annual dividend of $5.80 per share, which implies a dividend yield of 3%. | Two of its biosimilars, Kanjinti (a biosimilar of Roche's RHHBY cancer drug Herceptin) and Amjevita (biosimilar of Abbvie's ABBV blockbuster RA drug, Humira) were launched in EU this year and can contribute to sales in the future quarters. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Quarterly dividend was increased from $1.32 per share to $1.45 per share. |
25229.0 | 2018-12-10 00:00:00 UTC | AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-outpaces-stock-market-gains%3A-what-you-should-know-2018-12-10 | nan | nan | In the latest trading session, AbbVie (ABBV) closed at $87.59, marking a +0.72% move from the previous day. This change outpaced the S&P 500's 0.18% gain on the day. Meanwhile, the Dow gained 0.14%, and the Nasdaq, a tech-heavy index, added 0.74%.
Prior to today's trading, shares of the drugmaker had lost 0.88% over the past month. This has was narrower than the Medical sector's loss of 3.85% and the S&P 500's loss of 6.19% in that time.
Investors will be hoping for strength from ABBV as it approaches its next earnings release, which is expected to be January 25, 2019. On that day, ABBV is projected to report earnings of $1.92 per share, which would represent year-over-year growth of 29.73%. Meanwhile, our latest consensus estimate is calling for revenue of $8.36 billion, up 8.07% from the prior-year quarter.
ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.93 per share and revenue of $32.78 billion. These results would represent year-over-year changes of +41.61% and +16.17%, respectively.
Investors might also notice recent changes to analyst estimates for ABBV. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. ABBV is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, ABBV is currently trading at a Forward P/E ratio of 10.96. This valuation marks a discount compared to its industry's average Forward P/E of 14.36.
Also, we should mention that ABBV has a PEG ratio of 0.81. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.95 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 76, which puts it in the top 30% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABBV in the coming trading sessions, be sure to utilize Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the latest trading session, AbbVie (ABBV) closed at $87.59, marking a +0.72% move from the previous day. Investors will be hoping for strength from ABBV as it approaches its next earnings release, which is expected to be January 25, 2019. On that day, ABBV is projected to report earnings of $1.92 per share, which would represent year-over-year growth of 29.73%. | In the latest trading session, AbbVie (ABBV) closed at $87.59, marking a +0.72% move from the previous day. Investors will be hoping for strength from ABBV as it approaches its next earnings release, which is expected to be January 25, 2019. On that day, ABBV is projected to report earnings of $1.92 per share, which would represent year-over-year growth of 29.73%. | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.93 per share and revenue of $32.78 billion. In the latest trading session, AbbVie (ABBV) closed at $87.59, marking a +0.72% move from the previous day. Investors will be hoping for strength from ABBV as it approaches its next earnings release, which is expected to be January 25, 2019. | On that day, ABBV is projected to report earnings of $1.92 per share, which would represent year-over-year growth of 29.73%. In terms of valuation, ABBV is currently trading at a Forward P/E ratio of 10.96. In the latest trading session, AbbVie (ABBV) closed at $87.59, marking a +0.72% move from the previous day. |
25230.0 | 2018-12-09 00:00:00 UTC | Did Gilead Sciences Make an $11 Billion Blunder? | ABBV | https://www.nasdaq.com/articles/did-gilead-sciences-make-11-billion-blunder-2018-12-09 | nan | nan | I read an interesting article recently about Gilead Sciences (NASDAQ: GILD) . Bloomberg Opinion columnist Joe Nocera summarized Gilead's quest to market drugs that cure hepatitis C. The author did a great job explaining the unique challenges for Gilead and the entire biopharmaceutical industry in developing products that cure rather than just treat diseases.
Nocera's points in the article were on target. However, I questioned the sub-headline of the article: "Curing diseases like hepatitis C just doesn't pay."
Gilead Sciences spent $11 billion to acquire Pharmasset in 2011 to get the smaller biotech's hepatitis C virus (HCV) program. The sub-headline of Nocera's article (which, to be fair, could have been written by editors rather than the author) seemingly stated that this investment didn't pay off. But did Gilead really make an $11 billion blunder?
Running the numbers
Gilead has introduced four HCV drugs since late 2013: Sovaldi, Harvoni, Epclusa, and Vosevi. Sovaldi was the first of these drugs to reach the market. All of the others are combinations of Sovaldi and other drugs.
It's pretty easy to determine whether Gilead's acquisition of Pharmasset paid off. The yearly revenue generated by the HCV drugs that Gilead picked up in the deal is readily available. And all of the approved drugs from the Pharmasset acquisition except Vosevi became blockbusters with annual sales of $1 billion or more.
Over the last five years, Gilead Sciences has made a whopping $58.5 billion from its HCV franchise. The actual total is a little higher because Gilead began including Sovaldi sales in its "other" revenue this year. There's no way to know exactly how much of the $285 million in sales the company's other drugs generated in the first three quarters of 2018 stemmed from Sovaldi.
You be the judge: Did Gilead's initial $11 billion to obtain drugs that cure hepatitis C pay off? I think anyone looking at the numbers would readily admit that the investment has paid off quite nicely.
Remember, too, that Gilead's HCV drugs continue to make a lot of money. Although sales have steadily declined over the last three years, Gilead expects HCV revenue to stabilize going forward. The biotech's HCV franchise should generate close to $4 billion annually for years to come.
Granted, we haven't factored in any of Gilead's additional costs in developing and commercializing its HCV drugs. Neither have we calculated a net present value of the company's acquisition cost and HCV revenue to adjust for the time value of money. A dollar spent or made five years ago isn't worth the same amount as a dollar spent or made today. Still, it's pretty clear that curing hepatitis C has definitely paid off for Gilead Sciences in a big way.
What Wall Street wants
The subheading of Nocera's article doesn't, however, reflect the main point of the article. Actually, Nocera didn't state that Gilead's investment in launching a cure for hepatitis C didn't pay off. His main point is best summarized in this statement from the article: "But it turns out that Wall Street much prefers a drug like AbbVie 's (NYSE: ABBV) Humira, which treats -- but doesn't cure -- rheumatoid arthritis, Crohn's disease, and a variety of other illnesses."
That point is correct. And it's totally understandable why Wall Street would like a drug like Humira. After all, it's the top-selling drug in the world and is likely to remain at the top for several more years .
But in 2015, Gilead's HCV drug Harvoni made nearly as much as Humira did. Harvoni and Sovaldi combined made $5 billion more than Humira made that year. It's not that Wall Street only likes top-selling blockbuster drugs; the Street likes top-selling blockbuster drugs that keep on delivering huge sales for a long time.
The problem is that drugs that cure diseases aren't likely to provide the sustained revenues that Wall Street wants. In Gilead's case, the company enjoyed a big surge in revenue during the first couple of years after the launch of its first HCV drugs. But after that, the number of patients needing treatment began to dwindle. Cured patients don't come back for more medications.
A new way of thinking
In August, I wrote an article titled " The Cost of Cures: How Investing in Biotech Stocks Could Soon Be Radically Changed ." My premise was that the world of medicine is changing. Wall Street might want drugs like Humira that rack up billions of dollars in sales every year for over a decade, but that's likely to become less common than it is now.
Several biopharmaceutical companies are developing drugs that hold the promise of curing rather than merely treating diseases. Gilead itself hopes to develop a cure for HIV. Gene editing could dramatically change how genetic diseases are addressed by modifying DNA sequences that correct the genetic mutations that cause these diseases.
If you read Nocera's article -- and I highly recommend that you do -- you might notice that there's an alternate title that shows up in the tab of your web browser and in the URL link for the article. This alternate title is: "Gilead's Cures for Hepatitis C Were Not a Great Business Model."
I think the accuracy of that statement is debatable. Gilead made a huge return on its HCV drugs and continues to do so. But it's definitely true that Gilead's cures for hepatitis C entailed a new business model for the biopharmaceutical industry. And it's a new business model that investors should prepare to see a lot more in the future -- whether Wall Street likes it or not.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Keith Speights owns shares of AbbVie and Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | His main point is best summarized in this statement from the article: "But it turns out that Wall Street much prefers a drug like AbbVie 's (NYSE: ABBV) Humira, which treats -- but doesn't cure -- rheumatoid arthritis, Crohn's disease, and a variety of other illnesses." *Stock Advisor returns as of November 14, 2018 Keith Speights owns shares of AbbVie and Gilead Sciences. Gilead Sciences spent $11 billion to acquire Pharmasset in 2011 to get the smaller biotech's hepatitis C virus (HCV) program. | His main point is best summarized in this statement from the article: "But it turns out that Wall Street much prefers a drug like AbbVie 's (NYSE: ABBV) Humira, which treats -- but doesn't cure -- rheumatoid arthritis, Crohn's disease, and a variety of other illnesses." *Stock Advisor returns as of November 14, 2018 Keith Speights owns shares of AbbVie and Gilead Sciences. Bloomberg Opinion columnist Joe Nocera summarized Gilead's quest to market drugs that cure hepatitis C. The author did a great job explaining the unique challenges for Gilead and the entire biopharmaceutical industry in developing products that cure rather than just treat diseases. | His main point is best summarized in this statement from the article: "But it turns out that Wall Street much prefers a drug like AbbVie 's (NYSE: ABBV) Humira, which treats -- but doesn't cure -- rheumatoid arthritis, Crohn's disease, and a variety of other illnesses." *Stock Advisor returns as of November 14, 2018 Keith Speights owns shares of AbbVie and Gilead Sciences. Bloomberg Opinion columnist Joe Nocera summarized Gilead's quest to market drugs that cure hepatitis C. The author did a great job explaining the unique challenges for Gilead and the entire biopharmaceutical industry in developing products that cure rather than just treat diseases. | His main point is best summarized in this statement from the article: "But it turns out that Wall Street much prefers a drug like AbbVie 's (NYSE: ABBV) Humira, which treats -- but doesn't cure -- rheumatoid arthritis, Crohn's disease, and a variety of other illnesses." *Stock Advisor returns as of November 14, 2018 Keith Speights owns shares of AbbVie and Gilead Sciences. However, I questioned the sub-headline of the article: "Curing diseases like hepatitis C just doesn't pay." |
25231.0 | 2018-12-09 00:00:00 UTC | 3 Top Stocks to Buy in December | ABBV | https://www.nasdaq.com/articles/3-top-stocks-buy-december-2018-12-09 | nan | nan | Oh, the market is certainly frightful. But some stocks still look delightful. So if you want to make your money grow, you've got invest some dough.
My apologies to the composers of "Let It Snow!" However, my revised lyrics are right on target. Despite investors' fear and uncertainty about the stock market's current volatility, there are quite a few stocks that look very attractive right now.
Three that I especially like are AbbVie (NYSE: ABBV) , MongoDB (NASDAQ: MDB) , and PayPal Holdings (NASDAQ: PYPL) . Here's why they're three top stocks to buy in December.
1. AbbVie
Let's start with AbbVie's mouthwatering dividend yield of 4.5%. This stock doesn't have to perform very well at all to provide a solid total return with that kind of dividend payout. But I think AbbVie should deliver significant gains over the next few years.
The company has done a great job of ensuring that its blockbuster drug Humira continues to be a cash cow for years to come. Market research company EvaluatePharma even thinks that Humira will remain the world's best-selling drug through 2024 .
AbbVie also claims a couple of other big winners in its stable. Cancer drug Imbruvica continues to fire on all cylinders. Mavyret has made a big splash in the hepatitis C market. And the big-pharma company should see tremendous growth for a couple of other approved products, endometriosis pain drug Orilissa and cancer drug Venclexta.
Of course, the most important thing to watch with a drugmaker like AbbVie is its pipeline. EvaluatePharma ranked AbbVie's pipeline as the second-best in the industry . Potential blockbuster drugs including risankizumab and upadacitinib could win approval relatively soon and quickly contribute to the company's growth.
2. MongoDB
MongoDB hasn't been immune to the stock market's gyrations. However, the database platform company's stock is still up around 180% so far in 2018.
The main reason behind MongoDB stock's sizzling performance is the company's sizzling growth. In Q3, MongoDB reported year-over-year revenue growth of 57%. Its customer base jumped 69% from the prior-year period to 8,300 customers.
MongoDB isn't profitable yet. And its market cap of around $4 billion might look absurdly expensive for a company that made less than $200 million over the last 12 months. But because of its strong growth prospects, I don't think the stock is overpriced.
CEO Dev Ittycheria noted in his comments during MongoDB's Q3 conference call that the overall database market is projected to grow from $59 billion this year to $84 billion by 2022. Unlike MongoDB's platform, most databases were designed decades ago and don't address the needs of today. The company's technological advantages and popularity among software developers should enable MongoDB to capture a significant chunk of the growing database market.
3. PayPal
Another stock to buy in December also might seem pricey. Shares of digital and mobile payments company PayPal currently trade at nearly 29 times expected earnings. However, like MongoDB, the important thing to look at with PayPal is its growth opportunities.
PayPal's Venmo peer-to-peer payment app enjoys strong popularity with millennials . As CEO Dan Schulman put it, Venmo isn't just a payment transaction, "it's kind of an experience," with features that let users leave comments or emojis after transactions that others can see. And Venmo ranks as one of the top growth drivers for PayPal as the company pursues more ways to monetize the app.
The company has multiple avenues for growth. One is to attract more customers -- as it's doing with Venmo and other products. Another is to get customers to use its products more frequently. PayPal customers currently use their accounts about once every two weeks. The company's goal is to have customers use PayPal twice a week.
Allied Market Research projects that the global mobile-payments market will grow to nearly $4.6 trillion by 2023. I expect PayPal to claim its fair share of that and generate strong returns for investors in the process.
Why now?
You might think that buying these three stocks in December isn't such a great idea in light of the overall stock market choppiness. But there will always be uncertainty about what the market will or will not do.
The key to investing success is a long-term perspective. AbbVie, MongoDB, and PayPal appear to have what it takes to deliver for investors over the long term. The stock market might be frightful, but these stocks look delightful.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Keith Speights owns shares of AbbVie, MongoDB, and PayPal Holdings. The Motley Fool owns shares of and recommends MongoDB and PayPal Holdings. The Motley Fool has the following options: short January 2019 $82 calls on PayPal Holdings. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | *Stock Advisor returns as of November 14, 2018 Keith Speights owns shares of AbbVie, MongoDB, and PayPal Holdings. Three that I especially like are AbbVie (NYSE: ABBV) , MongoDB (NASDAQ: MDB) , and PayPal Holdings (NASDAQ: PYPL) . AbbVie Let's start with AbbVie's mouthwatering dividend yield of 4.5%. | Three that I especially like are AbbVie (NYSE: ABBV) , MongoDB (NASDAQ: MDB) , and PayPal Holdings (NASDAQ: PYPL) . AbbVie Let's start with AbbVie's mouthwatering dividend yield of 4.5%. But I think AbbVie should deliver significant gains over the next few years. | *Stock Advisor returns as of November 14, 2018 Keith Speights owns shares of AbbVie, MongoDB, and PayPal Holdings. Three that I especially like are AbbVie (NYSE: ABBV) , MongoDB (NASDAQ: MDB) , and PayPal Holdings (NASDAQ: PYPL) . AbbVie Let's start with AbbVie's mouthwatering dividend yield of 4.5%. | Three that I especially like are AbbVie (NYSE: ABBV) , MongoDB (NASDAQ: MDB) , and PayPal Holdings (NASDAQ: PYPL) . AbbVie Let's start with AbbVie's mouthwatering dividend yield of 4.5%. But I think AbbVie should deliver significant gains over the next few years. |
25232.0 | 2018-12-09 00:00:00 UTC | Here's Why AbbVie Stock Surged 21.1% in November | ABBV | https://www.nasdaq.com/articles/heres-why-abbvie-stock-surged-211-november-2018-12-09 | nan | nan | What happened
Shares of AbbVie (NYSE: ABBV) , the pharmaceutical company behind all those Humira advertisements, soared 21.1% in November, according to data from S&P Global Market Intelligence . The stock began November near a 52-week low, but impressive results from the company's blood cancer studies helped turn the ship around.
So what
October ended on such a low note that a solid third-quarter report combined with positive news for the company's blood cancer treatments were enough to help AbbVie stock recover. Total third-quarter revenue rose 18% from the previous year, to $8.2 billion, and adjusted earnings jumped 52% higher to $2.14 share.
AbbVie's increased its dividend more than once in the past year, and it looks as if rising sales of blood cancer treatments could make it possible to steadily raise the payout despite the impending loss of Humira sales in the years ahead. Sales of the popular anti-inflammatory injection are on pace to reach $20 billion in 2018, and AbbVie still relies on the flagship treatment for 62% of total revenue.
Now what
Gazyva is a targeted antibody often combined with poorly tolerated chemotherapy to treat newly diagnosed patients with the most common form of leukemia. From now on, it looks as if oncologists will combine it with AbbVie's Imbruvica instead. Patients treated with Gazyva plus Imbruvica were 77% less likely to show signs of disease progression compared to those that received Gazyva plus chemo. AbbVie's share of Imbruvica sales reached $2.6 billion during the first nine months of 2018 and will probably pass $5 billion in 2019 with an extra push from these results.
AbbVie also posted impressive data from the Murano trial with Venclexta plus Rituxan for relapsed leukemia patients. Patients given Rituxan plus Venclexta were 83% less likely to show signs of disease progression than those given Rituxan plus chemo. Replacing Humira in the years ahead won't be easy, but blockbuster blood cancer drug sales on the horizon give AbbVie a fighting chance.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Shares of AbbVie (NYSE: ABBV) , the pharmaceutical company behind all those Humira advertisements, soared 21.1% in November, according to data from S&P Global Market Intelligence . So what October ended on such a low note that a solid third-quarter report combined with positive news for the company's blood cancer treatments were enough to help AbbVie stock recover. Replacing Humira in the years ahead won't be easy, but blockbuster blood cancer drug sales on the horizon give AbbVie a fighting chance. | So what October ended on such a low note that a solid third-quarter report combined with positive news for the company's blood cancer treatments were enough to help AbbVie stock recover. AbbVie's share of Imbruvica sales reached $2.6 billion during the first nine months of 2018 and will probably pass $5 billion in 2019 with an extra push from these results. What happened Shares of AbbVie (NYSE: ABBV) , the pharmaceutical company behind all those Humira advertisements, soared 21.1% in November, according to data from S&P Global Market Intelligence . | So what October ended on such a low note that a solid third-quarter report combined with positive news for the company's blood cancer treatments were enough to help AbbVie stock recover. AbbVie's increased its dividend more than once in the past year, and it looks as if rising sales of blood cancer treatments could make it possible to steadily raise the payout despite the impending loss of Humira sales in the years ahead. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | AbbVie's increased its dividend more than once in the past year, and it looks as if rising sales of blood cancer treatments could make it possible to steadily raise the payout despite the impending loss of Humira sales in the years ahead. What happened Shares of AbbVie (NYSE: ABBV) , the pharmaceutical company behind all those Humira advertisements, soared 21.1% in November, according to data from S&P Global Market Intelligence . So what October ended on such a low note that a solid third-quarter report combined with positive news for the company's blood cancer treatments were enough to help AbbVie stock recover. |
25233.0 | 2018-12-09 00:00:00 UTC | Here's Why BeiGene Stock Rose 21.7% in November | ABBV | https://www.nasdaq.com/articles/heres-why-beigene-stock-rose-217-november-2018-12-09 | nan | nan | What happened
Shares of Beigene (NASDAQ: BGNE) , an oncology-focused biotech out of China, rose 21.7% in November, according to data from S&P Global Market Intelligence . Investors looking forward to sales of two drugs under review in China helped the stock regain some of October's losses.
So what
Beigene markets Celgene 's (NASDAQ: CELG) therapies in China, including Revlimid, which is on pace to generate $9.7 billion in total sales this year. The China Food and Drug Administration (CFDA) is still working through a huge backlog and didn't approve Revlimid to treat newly diagnosed multiple myeloma patients until earlier this year. Beigene reported third-quarter Revlimid revenue that was 22% higher than the previous quarter, suggesting the treatment is gaining steam in the enormous Chinese market.
Last month, investors were also encouraged by priority reviews that the CFDA granted for two new drug applications that Beigene submitted earlier this year. Zanubrutinib is an oral leukemia candidate similar to megablockbuster Imbruvica, and it could become a new treatment option for mantle cell lymphoma patients early next year.
The CFDA is also racing through the review of an application for tislelizumab. This is a PD-1 inhibitor similar to Keytruda that could become a new treatment option for advanced-stage Hodgkin's lymphoma patients.
Now what
If both treatments launch successfully in 2019, Beigene can probably start making ends meet without another capital raise. The company finished September with a whopping $2.1 billion in cash and short-term investments after losing $400 million during the first nine months of the year.
Next year, we'll also find out if zanubrutinib beat Imbruvica during an ongoing head-to-head study with newly diagnosed leukemia patients. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) share rights to Imbruvica, and combined sales of the drug will probably pass $10 billion by 2020. If Beigene's treatment can outperform the market leader, Beigene shares could rocket upward next year.
10 stocks we like better than BeiGene
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and BeiGene wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Cory Renauer owns shares of Celgene and Johnson & Johnson. The Motley Fool owns shares of and recommends Celgene. The Motley Fool owns shares of Johnson & Johnson and has the following options: short January 2019 $140 calls on Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) share rights to Imbruvica, and combined sales of the drug will probably pass $10 billion by 2020. So what Beigene markets Celgene 's (NASDAQ: CELG) therapies in China, including Revlimid, which is on pace to generate $9.7 billion in total sales this year. The China Food and Drug Administration (CFDA) is still working through a huge backlog and didn't approve Revlimid to treat newly diagnosed multiple myeloma patients until earlier this year. | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) share rights to Imbruvica, and combined sales of the drug will probably pass $10 billion by 2020. Next year, we'll also find out if zanubrutinib beat Imbruvica during an ongoing head-to-head study with newly diagnosed leukemia patients. *Stock Advisor returns as of November 14, 2018 Cory Renauer owns shares of Celgene and Johnson & Johnson. | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) share rights to Imbruvica, and combined sales of the drug will probably pass $10 billion by 2020. So what Beigene markets Celgene 's (NASDAQ: CELG) therapies in China, including Revlimid, which is on pace to generate $9.7 billion in total sales this year. If Beigene's treatment can outperform the market leader, Beigene shares could rocket upward next year. | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) share rights to Imbruvica, and combined sales of the drug will probably pass $10 billion by 2020. Last month, investors were also encouraged by priority reviews that the CFDA granted for two new drug applications that Beigene submitted earlier this year. If Beigene's treatment can outperform the market leader, Beigene shares could rocket upward next year. |
25234.0 | 2018-12-06 00:00:00 UTC | AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study | ABBV | https://www.nasdaq.com/articles/abbvie-halts-rova-t-phase-iii-second-line-lung-cancer-study-2018-12-06 | nan | nan | AbbVie, Inc.ABBV announced that it has stopped enrollments in a pivotal phase III study -TAHOE - evaluating its cancer candidate rovalpituzumab tesirine or Rova-T in second-line small cell lung cancer (SCLC).
AbbVie said that the Independent Data Monitoring Committee (IDMC), responsible for ongoing review of data, recommended stoppage of enrollment. The study compared efficacy, safety and tolerability of Rova-T versus topotecan. The IDMC recommendation to halt the study was based on shorter overall survival in the Rova-T arm compared with the topotecan control arm.
AbbVie clarified that IDMC's recommendation is only for the TAHOE study and does not apply to other studies on Rova-T. The company continues to evaluate the candidate as a third-line treatment in SCLC indication. Rova-T is also being evaluated in an early-stage eight-arm "basket study" in neuroendocrine tumors.
AbbVie's stock has declined 6.4% this year so far against an increase of 9.1% recorded by the industry .
We remind investors that Rova-T was added to AbbVie's portfolio following the $5.8 billion acquisition of Stemcentrx in June 2016.
In March this year, Rova-T fell short of expectations in a phase II TRINITY study evaluating it in third line or later SCLC. AbbVie said it will not seek accelerated approval of Rova-T in the third-line setting after consulting with the FDA. Back then, investor concerns about the success of the remaining studies - MERU (first line setting) and TAHOE - had increased after the failure of TRINITY.
AbbVie had significant confidence in Rova-T's potential and believed the candidate had blockbuster potential. AbbVie had in the past guided peak sales for Rova-T of $5 billion. The failure of TRINITY and now the halt on TAHOE has raised skepticism on Rova-T's potential and has brought into question the viability of the Stemcentrx deal.
Rova-T was a key candidate in AbbVie's oncology pipeline. AbbVie believes that oncology will be its major growth driver over the next 10 years. Its key cancer drug, what it calls a "pipeline in a molecule", is Imbruvica. It is currently approved for nine indications across six different cancer types. Imbruvica has multi-billion dollar potential. Several studies on Imbruvica are ongoing to evaluate the drug alone or in combination in different patient segments. AbbVie expects Imbruvica peak sales of more than $7 billion and revenues of about $5 billion in 2020. AbbVie markets Imbruvica in partnership with J&J JNJ .
AbbVie is also studying another key cancer drug, Venclyxto/Venclexta in label expansion studies to address the broader relapsed/refractory chronic lymphocytic leukemia ("CLL") patient population, expand into earlier lines of therapy, and broaden into other hematologic malignancies like multiple myeloma and acute myeloid leukemia ("AML"). Regulatory applications seeking approval for Venclexta plus Roche's RHHBY Rituxan for relapse/refractory CLL (based on MURANO study data) were approved in the United States in June and in the EU in October 2018. Label expansion for this indication has expanded the patient population for Venclexta significantly, which will boost its commercial potential. Also, in July, AbbVie filed U.S. regulatory application for Venclexta in first-line AML while data from the phase III program in multiple myeloma is expected in first half of 2019. AbbVie/Roche also plan to file for approval of Venclexta +Roche's Gazyva in first-line CLL setting soon.
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
A top-ranked large-cap pharma stock is Merck & Co., Inc. MRK , carrying a Zacks Rank #2 (Buy). Merck's earnings estimates have increased 1.4% for 2018 and 0.8% for 2019 over the past 60 days. The company's shares have increased 39% this year so far.
More Stock News: This Is Bigger than the iPhone !
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also, in July, AbbVie filed U.S. regulatory application for Venclexta in first-line AML while data from the phase III program in multiple myeloma is expected in first half of 2019. AbbVie, Inc.ABBV announced that it has stopped enrollments in a pivotal phase III study -TAHOE - evaluating its cancer candidate rovalpituzumab tesirine or Rova-T in second-line small cell lung cancer (SCLC). AbbVie said that the Independent Data Monitoring Committee (IDMC), responsible for ongoing review of data, recommended stoppage of enrollment. | Also, in July, AbbVie filed U.S. regulatory application for Venclexta in first-line AML while data from the phase III program in multiple myeloma is expected in first half of 2019. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, Inc.ABBV announced that it has stopped enrollments in a pivotal phase III study -TAHOE - evaluating its cancer candidate rovalpituzumab tesirine or Rova-T in second-line small cell lung cancer (SCLC). | AbbVie, Inc.ABBV announced that it has stopped enrollments in a pivotal phase III study -TAHOE - evaluating its cancer candidate rovalpituzumab tesirine or Rova-T in second-line small cell lung cancer (SCLC). AbbVie is also studying another key cancer drug, Venclyxto/Venclexta in label expansion studies to address the broader relapsed/refractory chronic lymphocytic leukemia ("CLL") patient population, expand into earlier lines of therapy, and broaden into other hematologic malignancies like multiple myeloma and acute myeloid leukemia ("AML"). Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report To read this article on Zacks.com click here. | AbbVie clarified that IDMC's recommendation is only for the TAHOE study and does not apply to other studies on Rova-T. AbbVie, Inc.ABBV announced that it has stopped enrollments in a pivotal phase III study -TAHOE - evaluating its cancer candidate rovalpituzumab tesirine or Rova-T in second-line small cell lung cancer (SCLC). AbbVie said that the Independent Data Monitoring Committee (IDMC), responsible for ongoing review of data, recommended stoppage of enrollment. |
25235.0 | 2018-12-05 00:00:00 UTC | 7 Dividend Aristocrats to Buy for 2019 | ABBV | https://www.nasdaq.com/articles/7-dividend-aristocrats-buy-2019-2018-12-05 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
We're quickly approaching the end of 2018. That's got most investors reminiscing about the year that was in the markets while also pondering which stocks to buy in the year ahead.
I know I sure am.
This year volatility returned to the markets making the average investor's job picking winners that much more difficult.
Right now, it's hard to say if 2018 will go down as a winning year for the markets or not. Case in point, S&P 500 stocks were up 5.1% year to date through November 30, while this would have been the lowest annual return since 2015, and the second worst over the past seven years, it still would've been positive. Just two sessions later, the S&P 500 is essentially flat on the year - up .16%.
One area that's always going to attract investor interest are dividend stocks . That's especially true when returns are meager like they were in 2018 and investors fear they will be again in 2019.
Dividend Aristocrats, those stocks increasing their annual payment for 25 consecutive years, are the cream of the crop for dividend investors and some of the best stocks to buy for 2019.
10 Defensive Stocks to Protect Your Portfolio in 2019
Currently, there are 53 Dividend Aristocrats in the S&P 500. Here are seven stocks to buy in 2019, all of them yielding at least 3% or more.
Stocks to Buy for 2019: AbbVie (ABBV)
Source: Black Stripe via Wikimedia (Modified)
Current Yield: 4.6%
The great thing about all 53 of the Dividend Aristocrats is that you know they're consistently going to pay a dividend to keep that title - even when their businesses aren't performing at 100%.
AbbVie (NYSE: ABBV ) hasn't had a bad year. Adjusted net revenues are up 17.8% on an operational basis in the first nine months of the year to $24.4 billion. This is mostly due to impressive growth from Humira, its anti-inflammatory drug for treating several types of arthritis as well as Crohn's disease and several other conditions.
On the bottom line, AbbVie earned $9.4 billion, or $6.01 a share in the first nine months of 2018 - 42% higher than a year earlier.
Nothing about that is second rate, yet ABBV stock's is down 8% year-to-date through December 3.
Not to worry.
The company upped its adjusted full-year 2018 EPS guidance November 2 to $7.90 a share on the low end from $7.76 previously, a 41.3% increase over last year.
Regarding free cash flow, AbbVie's generated $9.5 billion through the first three quarters of the year, $2.5 billion higher than in the same period last year.
Also, AbbVie's repurchased 94.1 million of its shares so far in 2018, an outlay of $9.8 billion. In total, AbbVie's returned more than $14 billion to shareholders.
AbbVie's 4.6% yield is very attractive.
Stocks to Buy for 2019: Leggatt & Platt (LEG)
Source: Shutterstock
Current Yield: 3.8%
One of the reasons for a high yield is a lower share price. That's precisely the case for Missouri-based Leggatt & Platt (NYSE: LEG ), a company that got its start by creating a patented bedspring in 1885, going public in 1967 .
LEG stock is down 19.8% year-to-date with most of the damage inflicted in September and October.
On November 7, Leggatt & Platt announced that it would pay $1.25 billion for Elite Comfort Solutions (ECS), a Georgia company specializing in foam bedding. In its latest fiscal year, ECS generated $611 million in revenue from its 16 facilities spread across the U.S.
Leggatt & Platt expects that ECS will generate double-digit sales growth in the next few years with accretive earnings by 2020.
"ECS is uniquely qualified to provide e-commerce, retail and OEM customers the most advanced technology solutions in specialty foams today," stated CEO Karl Glassman. "With our best-in-class manufacturing capabilities and ECS's proprietary and patented technology, we plan to capitalize on current and future trends in the market."
Generating as much as $550 million in annual cash flow as a result of the acquisition, Leggatt & Platt plans to use its increased cash flow to pay down debt quickly.
The online foam mattress market is exploding - I bought one earlier this year. And ECS provides the company with a leadership position in this growing segment of the bedding industry.
Banks vs. Big Tech: 4 to Buy, 4 to Sell
Enjoy the 3.8% yield while you wait for one of the lesser-known Dividend Aristocrats to rebound.
Stocks to Buy for 2019: Chevron (CVX)
Source: swong95765 via Flickr (Modified)
Current Yield: 3.7%
I'm not a fan of oil and gas companies, big or small, but when it delivers a 3.7% yield, I'm willing to make allowances.
Chevron (NYSE: CVX ) is a stock I compared to Exxon Mobil (NYSE: XOM ) a little over a year ago. At the time, I suggested that XOM's dividend was better because of its ability to generate higher free cash flow.
Over the past year, CVX is down 2.3% - 180 basis points less than XOM. Heading into 2019, I'm reversing my opinion of the two companies despite Exxon Mobil's yield of 4.0%, being higher than CVX.
Here's why.
InvestorPlace feature writer James Brumley wrote a piece in mid-November recommending CVX stock as the best of a troubled bunch. Citing several analysts who're bullish on Chevron, it probably never hurts to have an energy company in the mix.
" Credit Suisse's William Featherston largely agrees, upgrading Chevron stock to 'Outperform' in response to the company's third-quarter numbers," Brumley quoted Featherston November 19. "' Chevron continues to execute on its already superior growth outlook, which should translate into better than expected capital efficiencies into 2019 and sets up for continued robust free cash flow.'"
Free cash flow growth is the key to consistently increasing dividends. Although the energy sector continues to take its lumps, I have to agree with my colleague: If you're going to invest in Big Oil, Chevron's the better buy heading into 2019.
Stocks to Buy for 2019: Target (TGT)
Source: Mike Mozart via Flickr (Modified)
Current Yield: 3.5%
Last November, I wrote an article about Target (NYSE: TGT ) entitled Can Target Corporation Stock Get Back to $80? It emphasized how important the holiday season was to regain its position within retail.
" A lot is riding on this holiday season for CEO Brian Cornell. With a good showing, TGT stock is off to the races. With a bad performance, he could be out the door," I wrote November 15, 2017. "If it's the latter, you can forget about TGT stock hitting $80 in 2018. However, the former almost certainly guarantees revisiting $80 or possibly $100 by the end of next year."
Well, it's going to have to sprint if it wants to make $80 by the end of the year - it hit $90 in September before falling back - but long-time shareholders can be thankful Cornell has the company headed in the right direction after a big failure in Canada.
Sure, Target missed its Q3 2018 earnings per share estimate by two pennies - it reported adjusted EPS of $1.09 - but it also had excellent same-store sales growth of 5.1% in the quarter, 30 basis points ahead of its guidance.
In the fourth quarter Target expects same-store sales of 5%, well ahead of analysts, who're expecting 4.4% SSS growth.
10 Aerospace & Defense Stocks to Sell Now
With physical stores growing by 3% a quarter and online sales experiencing growth of 40%-plus, a 3.5% yield is a great way to pay yourself until TGT stock makes its next leg up to $100.
Stocks to Buy for 2019: Kimberly-Clark (KMB)
Source: Shutterstock
Current Yield: 3.4%
Kimberly-Clark (NYSE: KMB ) is not a growth investor's dream stock, I'll grant you, but if you're an income investor, you might want to consider it. Here's why: toilet paper
Toilet paper is one of the world's most useful items. Everybody uses it, and it's available everywhere at a reasonable price. Plumbers especially love it because it clogs up pipes requiring a service call.
Of course, Kimberly-Clark doesn't just sell Kleenex and Cottonelle, it also sells Huggies baby diapers, Depend adult diapers and Kotex feminine care products.
In its third quarter ended September 30, KMB had revenues of $4.6 billion , 2% lower than a year earlier, with adjusted earnings per share of $1.71, 7% higher than a year earlier.
The company's in the middle of a global restructuring that will it see it generate annual savings of at least $500 million by 2021. As part of this restructuring, Kimberly-Clark sought a buyer for its European tissue business. However, the bids received were lower than the $1.2 billion expected, so it's pulled the sale.
Through the first nine months of 2018, KMBs generated $1.5 billion in free cash flow or $2 billion on an annualized basis. It's used a billion of that to pay out dividends and another $596 million to repurchase its shares.
KMB stock might not be a home run, but if you're looking for safe income above a high-interest savings product, this is it.
Stocks to Buy for 2019: Coca-Cola (KO)
Source: Chris Nielsen via Flickr
Current Yield: 3.1%
The Dow Jones Industrial Index is basically flat on the year. Meanwhile, old, stodgy, Coca-Cola (NYSE: KO ) is up 8.9% with less than a month to go in the year. If it holds up, 2018 will be only the second year out of the past five that's outdone the index.
This dividend aristocrat has been through some tough times in recent years as consumers have moved away from soda to other alternatives including coffee.
It's for this reason Coke paid $5.1 billion in August to acquire UK coffee-shop chain Costa Coffee and its 4,000 stores around the world. Previously Coke had no hot-drink offerings to provide customers. And so Costa Coffee is a relatively cheap solution to any growth issues investors might have with the company.
"Hot beverages is one of the few remaining segments of the total beverage landscape where Coca-Cola does not have a global brand," Coca-Cola CEO James Quincey said in a statement about the Costa Coffee acquisition.
Imagine, Coca-Cola products in 4,000 coffee shops around the globe. A strategic acquisition if there ever was one.
Now, it's looking into cannabis-infused drinks and already has an alcoholic drink on the market in Japan. It seems old stodgy Coca-Cola has come alive.
4 Self-Driving Car Stocks Paving the Way for Profits
At a 3.1% yield, you can join Warren Buffett on the ride higher.
Stocks to Buy for 2019: Procter & Gamble (PG)
Source: Mike Mozart via Flickr (Modified)
Current Yield: 3.1%
It seems like forever ago when Procter & Gamble (NYSE: PG ) was considered a powerhouse in the consumer products industry. It's long enough to make investors forget that it's still the world's largest consumer products manufacturer with 21 brands generating $1 billion or more in annual revenue.
As the world continues to grow - in 2007, the global population was 6.1 billion ; in 2028 it's expected to be 7.6 billion - the dividend aristocrat will continue to provide the everyday products we all use and take for granted.
If you've followed P&G in recent years, it's been on a quest for simplification, narrowing the categories it competes in and the number of brands it brings to that competition. If you've seen those Tide Pods commercials, you know what I mean.
As a result, it's generating as much cash as it did in its so-called heydays. In fiscal 2018, its adjusted free cash flow was $11.2 billion. In the first quarter of fiscal 2019, P&G generated adjusted free cash flow of $2.7 billion , 8% higher than a year earlier.
If it keeps up high-single-digit growth, it will generate more than $12 billion in free cash flow in fiscal 2019, its highest level since 2010.
Like Kimberly-Clark, income investors ought to be all over PG stock.
As of this writing Will Ashworth did not hold a position in any of the aforementioned securities.
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
10 Aerospace & Defense Stocks to Sell Now
5 Big Bank Stocks to Sell Now
10 Stocks to Buy With The Trade War on Pause
Compare Brokers
The post 7 Dividend Aristocrats to Buy for 2019 appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks to Buy for 2019: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Current Yield: 4.6% The great thing about all 53 of the Dividend Aristocrats is that you know they're consistently going to pay a dividend to keep that title - even when their businesses aren't performing at 100%. AbbVie (NYSE: ABBV ) hasn't had a bad year. On the bottom line, AbbVie earned $9.4 billion, or $6.01 a share in the first nine months of 2018 - 42% higher than a year earlier. | Stocks to Buy for 2019: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Current Yield: 4.6% The great thing about all 53 of the Dividend Aristocrats is that you know they're consistently going to pay a dividend to keep that title - even when their businesses aren't performing at 100%. AbbVie (NYSE: ABBV ) hasn't had a bad year. On the bottom line, AbbVie earned $9.4 billion, or $6.01 a share in the first nine months of 2018 - 42% higher than a year earlier. | Regarding free cash flow, AbbVie's generated $9.5 billion through the first three quarters of the year, $2.5 billion higher than in the same period last year. Stocks to Buy for 2019: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Current Yield: 4.6% The great thing about all 53 of the Dividend Aristocrats is that you know they're consistently going to pay a dividend to keep that title - even when their businesses aren't performing at 100%. AbbVie (NYSE: ABBV ) hasn't had a bad year. | Stocks to Buy for 2019: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Current Yield: 4.6% The great thing about all 53 of the Dividend Aristocrats is that you know they're consistently going to pay a dividend to keep that title - even when their businesses aren't performing at 100%. AbbVie (NYSE: ABBV ) hasn't had a bad year. On the bottom line, AbbVie earned $9.4 billion, or $6.01 a share in the first nine months of 2018 - 42% higher than a year earlier. |
25236.0 | 2018-12-05 00:00:00 UTC | J&J's Blood Cancer Drugs Succeed in Label Expansion Studies | ABBV | https://www.nasdaq.com/articles/jjs-blood-cancer-drugs-succeed-in-label-expansion-studies-2018-12-05 | nan | nan | Johnson & JohnsonJNJ presented positive data from late-stage label expansion studies evaluating its blood cancer drugs, Imbruvica and Darzalex, in previously untreated patients at the annual meeting of the American Society of Hematology (ASH) held in San Diego, CA.
New findings from a phase III study showed that its key cancer drug, Imbruvica, as a combination therapy, significantly improved survival compared to standard chemo immunotherapy regimen in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients. J&J markets Imbruvica in partnership with AbbVie ABBV .
With nearly three years of follow-up, interim data from the E1912 head-to-head study showed that Imbruvica in combination with Roche's RHHBY Rituxan significantly prolonged progression-free survival (PFS), the primary endpoint of the study, as a first-line treatment for CLL/SLL patients aged 70 or younger compared to fludarabine, cyclophosphamide and rituximab (FCR). The Imbruvica combination therapy resulted in a 65% reduction in the risk of progression or death. Moreover, the combination significantly improved overall survival (OS) compared to FCR. Note that FCR is the most commonly used treatment regimen for younger patients with CLL.
At ASH, J&J also presented data from a phase III study (MAIA) evaluating Darzalex in combination with standard of care treatment regimen - Celgene's CELG Revlimid (lenalidomide) and dexamethasone (Rd) - in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). At a median follow-up of 28 months, the data showed that the addition of Darzalex to Rd significantly reduced the risk of disease progression or death by 44% in such patients compared to treatment with Rd alone. While PFS for patients who received Rd alone was 31.9 months, the median PFS for Darzalex plus Rd arm was not reached. The complete response rates and very good partial response (VGPR) rates were also higher in the patients receiving Darzalex plus Rd versus those receiving Rd alone.
Based on the data from the MAIA study, J&J plans to file supplemental biologics license application (sBLA) for FDA approval of Darzalex in this patient population.
We remind investors that in May, Darzalex was approved in combination with bortezomib, melphalan and prednisone (VMP) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for ASCT.
So far this year, J&J's stock has risen 4.7% compared with an increase of 10.4% recorded by the industry .
Both Darzalex and Imbruvica are key drugs in J&J's oncology portfolio and contribute significantly to the drug giant's top line. Darzalex recorded sales of $1.4 billion in the first nine months of 2018, rising 65.4% on a year-over-year basis. Imbruvica sales in the same period were $1.9 billion, up almost 40%.
Imbruvica is currently approved for nine indications across six different cancer types and the drug is also being evaluated in a number of combination therapies. Darzalex, presently marketed for multiple myeloma in patients who have received at least three prior lines of therapy, is being evaluated in a comprehensive clinical development program across a range of treatment settings in multiple myeloma, such as in front-line and relapsed settings.
J&J currently has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Celgene Corporation (CELG): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | J&J markets Imbruvica in partnership with AbbVie ABBV . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. Johnson & JohnsonJNJ presented positive data from late-stage label expansion studies evaluating its blood cancer drugs, Imbruvica and Darzalex, in previously untreated patients at the annual meeting of the American Society of Hematology (ASH) held in San Diego, CA. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. J&J markets Imbruvica in partnership with AbbVie ABBV . New findings from a phase III study showed that its key cancer drug, Imbruvica, as a combination therapy, significantly improved survival compared to standard chemo immunotherapy regimen in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. J&J markets Imbruvica in partnership with AbbVie ABBV . New findings from a phase III study showed that its key cancer drug, Imbruvica, as a combination therapy, significantly improved survival compared to standard chemo immunotherapy regimen in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients. | J&J markets Imbruvica in partnership with AbbVie ABBV . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. New findings from a phase III study showed that its key cancer drug, Imbruvica, as a combination therapy, significantly improved survival compared to standard chemo immunotherapy regimen in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients. |
25237.0 | 2018-12-05 00:00:00 UTC | Gilead's (GILD) Harvoni and Descovy Get Approval in China | ABBV | https://www.nasdaq.com/articles/gileads-gild-harvoni-and-descovy-get-approval-in-china-2018-12-05 | nan | nan | Gilead Sciences, Inc . GILD announced that the National Medical Products Administration (NMPA) has approved its hepatitis C virus (HCV) drug, Harvoni, in China.
The drug has been approved for the treatment of HCV infection genotype 1-6 infection in adults and adolescents aged 12-18 years.
The approval should boost sales of the dwindling HCV franchise due to competitive pressure from the likes of AbbVie ABBV .
Concurrently, Gilead announced that the NMPA has also approved Descovy (emtricitabine 200 mg/tenofovir alafenamide 10 mg and emtricitabine 200 mg/tenofovir alafenamide 25 mg, F/TAF), a fixed-dose combination for the treatment of HIV. Descovy is approved in combination with other antiretroviral agents for the treatment of HIV-1 in adults and adolescents (aged 12 years or older with at least 35 kg body weight). The therapy is already approved in the United States.
Gilead is a dominant player in the HIV market with an impressive product portfolio. The company was the first to bring to market a single-tablet regimen (STR) - Atripla - for the treatment of HIV. Additional STRs for HIV in the market include Complera/Eviplera and Stribild, among others. TAF-based products like Genvoya, Odefsey and Descovy are performing well with strong adoption both in the United States and Europe.
The company received a major boost when the FDA approved its once-daily STR, Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF) for HIV-1 infection. The approval, which comes ahead of the PDUFA date of Feb 12, 2018, significantly boosts Gilead's HIV franchise. Biktarvy combines the novel, unboosted integrase strand transfer inhibitor ("INSTI") bictegravir, with the demonstrated safety and efficacy profile of Descovy (FTC/TAF). The approval of this new HIV therapy will pose stiff competition to GlaxoSmith's GSK existing therapies, Tivicay and Triumeq.
Gilead's stock has gained 0.9% in the past six months, worse than the industry' s decline of 9.2%.
Given the persistent decline in HCV sales, the company is looking to HIV and newer avenues to help the top line. The initial uptake of Yescarta (from the Kite Pharma acquisition) is slow but encouraging.
Moreover, Gilead has promising late-stage candidates - selonsertib and filgotinib - in the NASH and inflammation markets, respectively. The company also has a collaboration agreement with Sangamo Therapeutics, Inc. SGMO to use Sangamo's zinc finger nuclease technology platform for the development of next-generation ex vivo cell therapies in oncology.
Zacks Rank
Gilead currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GlaxoSmithKline plc (GSK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The approval should boost sales of the dwindling HCV franchise due to competitive pressure from the likes of AbbVie ABBV . Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report To read this article on Zacks.com click here. GILD announced that the National Medical Products Administration (NMPA) has approved its hepatitis C virus (HCV) drug, Harvoni, in China. | Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report To read this article on Zacks.com click here. The approval should boost sales of the dwindling HCV franchise due to competitive pressure from the likes of AbbVie ABBV . Concurrently, Gilead announced that the NMPA has also approved Descovy (emtricitabine 200 mg/tenofovir alafenamide 10 mg and emtricitabine 200 mg/tenofovir alafenamide 25 mg, F/TAF), a fixed-dose combination for the treatment of HIV. | Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report To read this article on Zacks.com click here. The approval should boost sales of the dwindling HCV franchise due to competitive pressure from the likes of AbbVie ABBV . Concurrently, Gilead announced that the NMPA has also approved Descovy (emtricitabine 200 mg/tenofovir alafenamide 10 mg and emtricitabine 200 mg/tenofovir alafenamide 25 mg, F/TAF), a fixed-dose combination for the treatment of HIV. | The approval should boost sales of the dwindling HCV franchise due to competitive pressure from the likes of AbbVie ABBV . Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report To read this article on Zacks.com click here. The therapy is already approved in the United States. |
25238.0 | 2018-12-04 00:00:00 UTC | Wall Street Is Souring on These 7 Stocks to Sell | ABBV | https://www.nasdaq.com/articles/wall-street-souring-these-7-stocks-sell-2018-12-04 | nan | nan | There's a lot of talk about Wall Street's top-rated stocks. As 2018 ends and 2019 nears, everyone - including us - is talking about our favorite stock picks for 2019 , or even the next decade.
But not every stock is a well-loved lunker.
There are numerous stocks with bearish, or at least increasingly bearish, Wall Street sentiment. Stocks where you should look before you leap. And with the market in such a precarious state right now, it makes even more sense to pay attention to those companies that are facing significant challenges ahead.
Here we used TipRanks market data to pinpoint the Street's worst-rated stocks right now. We scanned a database of more than 5,000 stocks to find the following picks - some of which represent stocks to sell, and others of which you may want to hold if you own, but certainly don't want to chase. All stocks, bar one, have an analyst consensus of "Hold" or "Sell." There's one exception, but as you'll see, sentiment is quickly turning against it too.
SEE ALSO: 10 Stocks Warren Buffett Is Buying (And 6 He's Selling)
Market value: $138.2 billion
TipRanks consensus price target: $98.10 (5% upside potential)
TipRanks consensus rating: Hold
AbbVie ( ABBV , $93.66) - a spinoff of Abbott Laboratories ( ABT ) - is the pharmaceutical company known for Humira, one of the greatest blockbuster drugs of all time .
However, AbbVie has entered a period of slower growth, with increased uncertainty about long-term growth prospects. BMO Capital's Alex Arfaei sets out a particularly stark picture of what lies ahead.
"Without strategic change, we believe ABBV should continue to underperform," the analyst told investors on Nov. 4. He has a "Sell" rating on the stock with a $71 price target, implying a pullback in shares of about 24%.
AbbVie's revenue growth should slow until 2022, Arfaei writes, and decline thereafter, pressuring valuations. And as for 2019, he doesn't see any events on the horizon that could meaningfully address fundamental concerns. In contrast to management's guidance, he forecasts declining revenue starting 2023 with Humira's U.S. biosimilar erosion.
"Given the magnitude of probable revenue erosion, we believe BIG strategic action(s) are needed. (We're reminded of Pfizer+Wyeth before Lipitor's patent cliff.) We expect increased pressure on management for strategic change," he concludes. You can get an ABBV Research Report from TipRanks for more information.
SEE ALSO: The 25 Biggest U.S. IPOs of All Time
Market value: $1.3 billion
TipRanks consensus price target: $19.14 (3% downside potential)
TipRanks consensus rating: Moderate Sell
Abercombie & Fitch ( ANF , $19.59) is another struggling retailer to strike off your buy list. In the past three months, not a single analyst has published a buy-equivalent rating on the stock. The last such call was roughly 10 months ago.
Meanwhile, the consensus target indicates that analysts broadly think ANF is heading lower, not higher. So do the two sell calls over the past quarter, meshed with five holds.
Despite return to profitability in 2017, the company's longer-term outlook remains precarious. "With the company facing significant secular headwinds, we see a lack of visibility on ANF's longer-term (earnings before interest and taxes) margin profile," RBC Capital's Brian Tunick writes.
Abercrombie is currently in the midst of a major organizational, product and strategy overhaul to stabilize its top line by boosting sales at both Abercrombie and offshoot Hollister. These updates could not be more necessary, writes the RBC analyst, with the company ending 2016 with productivity and profitability at trough levels.
Tuick has a "Hold" rating and a $24 price target on ANF, and warns that shares are likely to remain volatile. That's in part because the company has 25% short interest, meaning one in every four outstanding shares of Abercrombie & Fitch is being used to short the company. Find out more from the ANF Research Report from TipRanks.
SEE ALSO: What Happens When a Retailer Goes Bankrupt?
Market value: $11.8 billion
TipRanks consensus price target: $35.67 (8% downside potential)
TipRanks consensus rating: Moderate Sell
Steer clear of soupmaker Campbell Soup ( CPB , $38.76), or so says the Street. This stock not only scores a "Moderate Sell" analyst consensus, but Wall Street's brain trust also predicts that shares will drop another 8% or so from current levels - that's in addition to the 19% plunge suffered so far this year.
The reception to news of an agreement between CPB and activist investor Daniel Loeb has been unenthusiastic, to say the least. The company announced on Nov. 26 that Loeb's Third Point fund, which currently holds a 7% stake in Campbell Soup, will receive two seats on the board of directors and a say in the appointment of the next CEO.
But top Tigress Financial analyst Ivan Feinseth says the next company chief will have a firmly uphill battle ahead. The analyst describes this task as trying to unlock "value in a company that in my view has very little intrinsic value to unlock."
Feinseth recommends selling CPB and warns investors that downside potential could bring shares down from current levels to the low $30s. Bank of America's Bryan Spillane agrees, saying that Campbell's stock trades at an unwarranted premium to peers and should drop about 20% to $31 per share. Investors interested in more analyst feedback can find it in this free CPB Research Report from TipRanks .
SEE ALSO: 8 Stocks to Buy for 2019 (and 5 to Sell)
Market value: $18.7 billion
TipRanks consensus price target: $8 (14% downside potential)
TipRanks consensus rating: Moderate Sell
German bank Deutsche Bank ( DB , $9.30) has lost more than half its value in 2018. You can blame multiple factors, from a management shakeup to disappointing earnings and even a ratings downgrade by Moody's back in August.
Now there is a fresh concern plaguing the stock. Police in Germany have raided the company's Frankfurt offices in a money laundering probe. Two employees are being investigated over allegations that they helped clients launder money via offshore accounts.
Sylvie Matherat, the bank's chief regulatory officer, has already admitted that DB needs to improve its money laundering and terror funding control. According to Dow Jones, she is now at risk of being ousted by the firm alongside Deutsche Bank's Americas CEO Tom Patrick.
"We confirm that police are currently investigating our bank at various locations in Germany. The investigation concerns the Panama Papers," Deutsche Bank said in a translated statement.
RBC Capital's Anke Reingen, who rates Deutsche Bank as "Underperform," writes, "DBK continues to focus on cost reduction and is targeting a further (2.1 billion euros) reduction in costs, or 9% over the next two years. There are, however, implications from this for revenues in our view given another round of restructuring and the offset of lower revenues from business disposals." Get the DB Research Report from TipRanks.
SEE ALSO: The 27 Best Mutual Funds in 401(k) Retirement Plans
Market value: $69.2 billion
TipRanks consensus price target: $268.17 (40% upside potential)
TipRanks consensus rating: Moderate Buy
When an analyst downgrades a stock, it's worth paying attention. And in the past couple of weeks, Goldman Sachs ( GS , $191.63) has received two rating downgrades. Both Merrill Lynch's Michael Carrier and Morgan Stanley's Betsy Graseck downgraded GS to "Hold." They also slashed their respective price targets from $280 to $225, and from $291 to $226.
The reason: the multibillion-dollar 1Malaysia Development Berhad (1MDB) bank scandal.
Reports have emerged that the bank's former CEO Lloyd Blankfein attended two meetings with Jho Low, a key figure in the investigation. The financier is accused of bribing officials and stealing billions of dollars from the fund.
"While we view the current valuation as discounting most of the potential negative scenarios related to 1MDB, we only have limited information and the uncertainty could linger for a while and limit the upside potential if markets stabilize," Carrier told clients.
Graseck agreed, writing, "It is unclear how long the issue will take to resolve, what the fines and penalties could be, and what costs Goldman Sachs will subsequently incur to satisfy any demands from regulators."
She explained that these risks, coupled with potential headline risks in the coming months (additional lawsuits, additional regulatory probes, internal reviews), led to her stock downgrade. You can learn more about the brewing troubles in the GS Research Report from TipRanks.
SEE ALSO: 5 Stocks to Sell According to Wall Street Analysts
Market value: $757.5 million
TipRanks consensus price target: $6.69 (28% upside potential)
TipRanks consensus rating: Hold
Action camera maker GoPro ( GPRO , $5.20) is one stock you certainly shouldn't buy on the dip. Shares have lost nearly a third of their value in 2018 and more than 85% over the past five years. Worst of all, the Street remains skeptical about the prospects for a speedy recovery, with analysts calling this a "show me" stock.
Morgan Stanley's Yuuji Anderson sees increased promotional activity as an ominous sign. "Plans to step up promotional activity for the Silver and White highlight our concern over mid- and low-end camera demand heading into the holidays," she said.
This is even more worrying given that performance over the holiday season is so critical for stock performance. "Inventory exiting the year will be a key indicator for GoPro's recovery, and we remain skeptical on the recovery trajectory given the historical pace of functional improvements to the camera ecosystem and consumer receptivity."
As a result, Anderson reiterated her "Sell" rating with a price target of just $5 - somehow more downside risk ahead. Get the GPRO Research Report from TipRanks.
SEE ALSO: 12 Vulnerable Stocks to Watch on Market-Wide Weakness
Market value: $8.9 billion
TipRanks consensus price target: $133 (16% upside potential)
TipRanks consensus rating: Hold
High-end fashion retailer Ralph Lauren ( RL , $114.94) is at a precarious point right now. True, the company has the potential to turn around. But right now the Street believes that 1) it is better to wait and see and 2) expectations are still too high. This is despite shares already losing about 16% of their value in the fourth quarter of 2018.
"We believe it remains to be seen whether RL can continue to deliver the large EPS beats that have been the primary driver of shares over the past year" writes Barclays analyst Chethan Mallela, who has a "Sell" rating and a $124 price target on Ralph Lauren shares.
That's actually more optimistic than UBS analyst Jay Sole, who's also a "Sell" but puts his target at $112 - a little lower than current prices. Hardly an appealing proposition considering the risk involved.
Sole says the brand isn't resonating with customers as well as it once did. And the situation isn't improving. Ralph Lauren faces limited pricing power and a lack of core brand strength. As a result, the UBS analyst believes tougher 2020 comps will prompt downward earnings revisions. Check out TipRanks for an RL Research Report .
Harriet Lefton is head of content at TipRanks, a comprehensive investing tool that tracks more than 4,800 Wall Street analysts as well as hedge funds and insiders. You can find more of their stock insights here .
SEE ALSO: Don't Wish for a Santa Claus Rally. Prepare Instead.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | SEE ALSO: 10 Stocks Warren Buffett Is Buying (And 6 He's Selling) Market value: $138.2 billion TipRanks consensus price target: $98.10 (5% upside potential) TipRanks consensus rating: Hold AbbVie ( ABBV , $93.66) - a spinoff of Abbott Laboratories ( ABT ) - is the pharmaceutical company known for Humira, one of the greatest blockbuster drugs of all time . However, AbbVie has entered a period of slower growth, with increased uncertainty about long-term growth prospects. "Without strategic change, we believe ABBV should continue to underperform," the analyst told investors on Nov. 4. | SEE ALSO: 10 Stocks Warren Buffett Is Buying (And 6 He's Selling) Market value: $138.2 billion TipRanks consensus price target: $98.10 (5% upside potential) TipRanks consensus rating: Hold AbbVie ( ABBV , $93.66) - a spinoff of Abbott Laboratories ( ABT ) - is the pharmaceutical company known for Humira, one of the greatest blockbuster drugs of all time . However, AbbVie has entered a period of slower growth, with increased uncertainty about long-term growth prospects. "Without strategic change, we believe ABBV should continue to underperform," the analyst told investors on Nov. 4. | SEE ALSO: 10 Stocks Warren Buffett Is Buying (And 6 He's Selling) Market value: $138.2 billion TipRanks consensus price target: $98.10 (5% upside potential) TipRanks consensus rating: Hold AbbVie ( ABBV , $93.66) - a spinoff of Abbott Laboratories ( ABT ) - is the pharmaceutical company known for Humira, one of the greatest blockbuster drugs of all time . However, AbbVie has entered a period of slower growth, with increased uncertainty about long-term growth prospects. "Without strategic change, we believe ABBV should continue to underperform," the analyst told investors on Nov. 4. | SEE ALSO: 10 Stocks Warren Buffett Is Buying (And 6 He's Selling) Market value: $138.2 billion TipRanks consensus price target: $98.10 (5% upside potential) TipRanks consensus rating: Hold AbbVie ( ABBV , $93.66) - a spinoff of Abbott Laboratories ( ABT ) - is the pharmaceutical company known for Humira, one of the greatest blockbuster drugs of all time . However, AbbVie has entered a period of slower growth, with increased uncertainty about long-term growth prospects. "Without strategic change, we believe ABBV should continue to underperform," the analyst told investors on Nov. 4. |
25239.0 | 2018-12-04 00:00:00 UTC | Roche Announces Positive Data on Venclexta/Venclyxto at ASH | ABBV | https://www.nasdaq.com/articles/roche-announces-positive-data-on-venclexta-venclyxto-at-ash-2018-12-04 | nan | nan | RocheHolding AGRHHBY announced new data from the phase III MURANO study on Venclexta/Venclyxto (venetoclax) in patients with previously treated chronic lymphocytic leukemia (CLL) at the American Society of Hematology (ASH) 2018 Annual Meeting.
Share price of the company has increased 6.2% year to date compared with the industry 's growth of 13.8%.
An analysis showed that the combination (Venclextaplus MabThera) reduced the risk of disease progression or death by 84% compared to standard of care in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) -Teva Pharmaceutical's TEVA Treanda (bendamustine) plus Rituxan (BR) after a median three-year follow-up. Follow up data from the study showed that the Venclexta combination achieved superior results as 71% of patients achieved progression free survival ("PFS") at 36 months versus 15% of patients in the BR arm.
The patients were treated for a fixed duration of 24 months and treatment was stopped thereafter. The three-year estimated overall survival rate was 87.9% for Venclexta combination and 79.5% for standard of care.
A separate analysis showed higher rates of minimal residual disease (MRD)-negativity observed with Venclexta/Venclyxto plus MabThera/Rituxan compared to BR were sustained after patients completed treatment (62% versus 13%). These results were observed in majority of patients in the Venclexta/Venclyxto arm, including patients in high-risk subgroups and were consistent with the maintained PFS benefit seen with longer follow-up.
The company also announced updated data from two phase Ib/II (phase Ib M14-358 and phase I/II M14-387) studies in people with previously untreated acute myeloid leukaemia (AML) ineligible for intensive chemotherapy due to coexisting medical conditions. These results showed that among patients who were dependent upon blood transfusions at baseline, about half were able to achieve transfusion independence (the absence of transfusions during any consecutive 56 days during the study treatment period).
Based on earlier results from the M14-358 and M14-387 studies, the FDA granted accelerated approval to Venclexta in combination with a hypomethylating agent (azacitidine or decitabine), or low-dose cytarabine (LDAC), for the treatment of people with newly-diagnosed acute myeloid leukaemia (AML), who are age 75 years or older, or for those ineligible for intensive induction chemotherapy due to coexisting medical conditions.
We remind investors that, Venclexta/Venclyxto is being developed by AbbVie ABBV and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the United States, and commercialized by AbbVie outside of the United States.
Roche Holding AG Price
Roche Holding AG Price | Roche Holding AG Quote
Zacks Rank & Stock to Consider
Roche is a Zacks Rank #3 (Hold) stock.
A better-ranked stock worth considering is Bristol-Myers Squibb Company BMY sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Bristol-Myers' earnings per share estimates have increased from $3.63 to $3.87 for 2018 and $3.92 to $4.08 for 2019 over the past 60 days. The company delivered a positive earnings surprise in all the trailing four quarters, with average of 11.99%.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6% and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We remind investors that, Venclexta/Venclyxto is being developed by AbbVie ABBV and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the United States, and commercialized by AbbVie outside of the United States. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that, Venclexta/Venclyxto is being developed by AbbVie ABBV and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the United States, and commercialized by AbbVie outside of the United States. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that, Venclexta/Venclyxto is being developed by AbbVie ABBV and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the United States, and commercialized by AbbVie outside of the United States. | We remind investors that, Venclexta/Venclyxto is being developed by AbbVie ABBV and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the United States, and commercialized by AbbVie outside of the United States. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. |
25240.0 | 2018-12-03 00:00:00 UTC | AbbVie Settles With Pfizer for Humira Biosimilar in U.S. | ABBV | https://www.nasdaq.com/articles/abbvie-settles-with-pfizer-for-humira-biosimilar-in-u.s.-2018-12-03 | nan | nan | AbbVie, Inc.ABBV signed a non-exclusive licensing deal with Pfizer PFE regarding the latter's proposed biosimilar version of its blockbuster rheumatoid arthritis drug, Humira. Per the deal, Pfizer will have a non-exclusive license to launch its biosimilar Humira in the United States on Nov 20, 2023. In the EU, Pfizer can launch Humira biosimilar when it gets approval from the European Medicines Agency.
Per the terms of the settlement, Pfizer will pay royalties to AbbVie once its cheaper version is launched. AbbVie will make no payments to Pfizer.
AbbVie made it clear that Pfizer's U.S. license will not be accelerated by biosimilar launches by other companies, which have similar licensing deals AbbVie.
AbbVie's stock has declined 2.5% this year so far against with the industry 's increase of 11.3%.
Humira is a key driver of AbbVie's revenues, accounting for more than 60% of its total sales. Currently approved for several indications, Humira sales increased 11% in the first nine months of 2018 to $15 billion backed by robust demand trends despite new competition. The product continues to see strong growth in the dermatology and gastroenterology markets. The company expects Humira sales to approach $21 billion in 2020.
With Humira accounting for such a significant amount of AbbVie's total sales, the entry of biosimilars will have a huge impact on the company's financials.
However, AbbVie has successfully struck similar licensing deals with several companies, which have made biosimilar versions of Humira to protect its U.S. revenues from the drug. Per the settlement deals, Amgen AMGN , Mylan MYL , Fresenius Kabi, Momenta, Sandoz and Samsung Bioepis/Biogen's Humira biosimilars are expected to be launched in the United States in 2023.
The settlements give AbbVie more time to strengthen its pipeline with products that are capable of making up for the expected sales decline when Humira biosimilars are launched. AbbVie expects to launch more than 20 new products or line extensions of marketed drugs before Humira biosimilar competition begins in the United States in 2023.
However, in the EU, Amgen, Sandoz and Biogen's biosimilars were launched in October this year while others like Momenta, Fresenius Kabi and Pfizer will launch their versions as soon as they get EMA's approval.
Direct biosimilar competition in the EU is expected to erode AbbVie's $6 billion international Humira business in 2019.
AbbVie currently has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Mylan N.V. (MYL): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie, Inc.ABBV signed a non-exclusive licensing deal with Pfizer PFE regarding the latter's proposed biosimilar version of its blockbuster rheumatoid arthritis drug, Humira. The settlements give AbbVie more time to strengthen its pipeline with products that are capable of making up for the expected sales decline when Humira biosimilars are launched. Per the terms of the settlement, Pfizer will pay royalties to AbbVie once its cheaper version is launched. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, Inc.ABBV signed a non-exclusive licensing deal with Pfizer PFE regarding the latter's proposed biosimilar version of its blockbuster rheumatoid arthritis drug, Humira. Per the terms of the settlement, Pfizer will pay royalties to AbbVie once its cheaper version is launched. | AbbVie made it clear that Pfizer's U.S. license will not be accelerated by biosimilar launches by other companies, which have similar licensing deals AbbVie. The settlements give AbbVie more time to strengthen its pipeline with products that are capable of making up for the expected sales decline when Humira biosimilars are launched. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. | The settlements give AbbVie more time to strengthen its pipeline with products that are capable of making up for the expected sales decline when Humira biosimilars are launched. AbbVie, Inc.ABBV signed a non-exclusive licensing deal with Pfizer PFE regarding the latter's proposed biosimilar version of its blockbuster rheumatoid arthritis drug, Humira. Per the terms of the settlement, Pfizer will pay royalties to AbbVie once its cheaper version is launched. |
25241.0 | 2018-12-03 00:00:00 UTC | XLV, PFE, MRK, ABBV: ETF Inflow Alert | ABBV | https://www.nasdaq.com/articles/xlv-pfe-mrk-abbv-etf-inflow-alert-2018-12-03 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $417.9 million dollar inflow -- that's a 2.1% increase week over week in outstanding units (from 205,065,324 to 209,465,324). Among the largest underlying components of XLV, in trading today Pfizer Inc (Symbol: PFE) is off about 0.3%, Merck & Co Inc (Symbol: MRK) is down about 0.8%, and AbbVie Inc (Symbol: ABBV) is up by about 0.4%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $95.57. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today Pfizer Inc (Symbol: PFE) is off about 0.3%, Merck & Co Inc (Symbol: MRK) is down about 0.8%, and AbbVie Inc (Symbol: ABBV) is up by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $417.9 million dollar inflow -- that's a 2.1% increase week over week in outstanding units (from 205,065,324 to 209,465,324). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today Pfizer Inc (Symbol: PFE) is off about 0.3%, Merck & Co Inc (Symbol: MRK) is down about 0.8%, and AbbVie Inc (Symbol: ABBV) is up by about 0.4%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $95.57. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. | Among the largest underlying components of XLV, in trading today Pfizer Inc (Symbol: PFE) is off about 0.3%, Merck & Co Inc (Symbol: MRK) is down about 0.8%, and AbbVie Inc (Symbol: ABBV) is up by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $417.9 million dollar inflow -- that's a 2.1% increase week over week in outstanding units (from 205,065,324 to 209,465,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $95.57. | Among the largest underlying components of XLV, in trading today Pfizer Inc (Symbol: PFE) is off about 0.3%, Merck & Co Inc (Symbol: MRK) is down about 0.8%, and AbbVie Inc (Symbol: ABBV) is up by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $417.9 million dollar inflow -- that's a 2.1% increase week over week in outstanding units (from 205,065,324 to 209,465,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $95.57. |
25242.0 | 2018-12-03 00:00:00 UTC | AbbVie Stock Could Become a New Happy Pill for Investors | ABBV | https://www.nasdaq.com/articles/abbvie-stock-could-become-new-happy-pill-investors-2018-12-03 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
While AbbVie (NYSE: ABBV ) has shown strong profit growth over the last year, ABBV stock has sold off recently over worries about Humira patent expirations in some parts of the world.
Although the concerns may be overblown, losing any patent protection on the widely prescribed drug breeds the type of uncertainty that often leads to stock declines. What gives investors confidence in the shares, though, is a promising drug pipeline should keep AbbVie stock on a growth trajectory even as Humira fades as a significant revenue contributor.
To be sure, AbbVie stock has struggled this year. ABBV peaked at $125.86 a share back in January. By April, it had fallen below $90 per share, and it has found itself stuck in a range since. Like many stocks, the October correction pushed it down further, taking the shares as low as $77.50 a piece.
Competition Aggravates Patent Expirations
Since its split from Abbott Laboratories (NYSE: ABT ) in 2013, AbbVie has built its fortunes on Humira, a treatment for a range of conditions, including rheumatoid arthritis, psoriatic arthritis and Crohn's disease. With its patent beginning to expire in some key markets, Humira is facing increased competition. ABBV stock has sold off as investors wonder where the company will go next.
10 High-Yield Monthly Dividend Stocks
I believe Wall Street may have overreacted. Data analysts at Evaluate Pharma rate AbbVie's pipeline as second-best in the industry for value creation. The company has also gained approval for drugs that treat conditions such as cancer, hepatitis C, and endometriosis. At the same time, AbbVie has managed to slow the loss of its patent on Humira. In the U.S., the patent will remain in place until at least 2022, which should give ABBV stock enough runway to transition into new revenue sources.
Compelling Financials
Despite the stock's struggles, analysts forecast 42% profit growth for this year. Over the next five years, they predict average annual increases of almost 17%.
The current price-to-earnings (PE) ratio stands at about 11.3, which seems remarkable on many levels. ABBV stock has maintained an average PE of about 26.8 over the last five years. Rarely do stocks posting double-digit profit growth fall into single-digit multiples.
Perhaps investors have begun to see its future potential. November has seen the stock turn around, and it again trades at about the $90 per share level. True, AbbVie stock remains range-bound, however these financials indicate it can eventually break out of its range.
Wall Street may need to see better sales numbers from newer drugs before they bid AbbVie shares higher. While they wait, ABBV's dividend will reward them for their patience. As a result of its previous association with Abbott, ABBV stock is considered a "dividend aristocrat" on the coattails of the former parent's 46 consecutive years of dividend increases.
10 Goldman Sachs Top Stock Picks for 2019
Approval of a dividend increase for February brought the annual payout to $4.28 per share. That give the stock a yield of about 4.75%. Among the dividend aristocrats, only AT&T (NYSE: T ) pays a higher cash return. Given company growth prospects and the expectations for increases that come with its aristocrat status, income investors will struggle to find better alternatives than AbbVie stock.
Bottom Line on AbbVie Stock
As Humira begins a slow fade from driving AbbVie revenue, new drugs should keep ABBV stock on a growth trajectory. Without a doubt, losing Humira poses risks for the company. However, despite this uncertainty, analysts still expect AbbVie to maintain its double-digit profit growth. Equally notable is that the decline in the stock price has pushed the PE ratio close to the single digits.
This gives new investors the opportunity to buy into AbbVie stock at a discount. It also serves income investors who can earn a dividend of about 4.75% with annual increases for years to come. Between the cash payouts and the potential for stock price appreciation, both growth and income investors should enjoy a profitable future in ABBV stock.
As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You canfollow Will on Twitterat @HealyWriting.
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
10 Value Stocks to Buy for December
10 Boring Stocks to Buy for Red-Hot Returns
10 Stocks to Buy for a Rate Hike Slowdown
Compare Brokers
The post AbbVie Stock Could Become a New Happy Pill for Investors appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What gives investors confidence in the shares, though, is a promising drug pipeline should keep AbbVie stock on a growth trajectory even as Humira fades as a significant revenue contributor. Given company growth prospects and the expectations for increases that come with its aristocrat status, income investors will struggle to find better alternatives than AbbVie stock. InvestorPlace - Stock Market News, Stock Advice & Trading Tips While AbbVie (NYSE: ABBV ) has shown strong profit growth over the last year, ABBV stock has sold off recently over worries about Humira patent expirations in some parts of the world. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips While AbbVie (NYSE: ABBV ) has shown strong profit growth over the last year, ABBV stock has sold off recently over worries about Humira patent expirations in some parts of the world. Bottom Line on AbbVie Stock As Humira begins a slow fade from driving AbbVie revenue, new drugs should keep ABBV stock on a growth trajectory. Between the cash payouts and the potential for stock price appreciation, both growth and income investors should enjoy a profitable future in ABBV stock. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips While AbbVie (NYSE: ABBV ) has shown strong profit growth over the last year, ABBV stock has sold off recently over worries about Humira patent expirations in some parts of the world. Bottom Line on AbbVie Stock As Humira begins a slow fade from driving AbbVie revenue, new drugs should keep ABBV stock on a growth trajectory. More From InvestorPlace 2 Toxic Pot Stocks You Should Avoid 10 Value Stocks to Buy for December 10 Boring Stocks to Buy for Red-Hot Returns 10 Stocks to Buy for a Rate Hike Slowdown Compare Brokers The post AbbVie Stock Could Become a New Happy Pill for Investors appeared first on InvestorPlace . | InvestorPlace - Stock Market News, Stock Advice & Trading Tips While AbbVie (NYSE: ABBV ) has shown strong profit growth over the last year, ABBV stock has sold off recently over worries about Humira patent expirations in some parts of the world. ABBV stock has sold off as investors wonder where the company will go next. As a result of its previous association with Abbott, ABBV stock is considered a "dividend aristocrat" on the coattails of the former parent's 46 consecutive years of dividend increases. |
25243.0 | 2018-12-02 00:00:00 UTC | Why Is AbbVie (ABBV) Up 17.5% Since Last Earnings Report? | ABBV | https://www.nasdaq.com/articles/why-is-abbvie-abbv-up-17.5-since-last-earnings-report-2018-12-02 | nan | nan | A month has gone by since the last earnings report for AbbVie (ABBV). Shares have added about 17.5% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is AbbVie due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
AbbVie Q3 Earnings Beat Estimates, 2018 EPS View Up
Third-quarter 2018 earnings of $2.14 per share beat the Zacks Consensus Estimate of $2.01. The figure surged 51.8% year over year. Earnings per share also exceeded the guided range of $2.00 and $2.02. Strong sales, operating margins and lower tax rate led to the bottom-line beat.
Revenues of $8.24 billion marginally missed the Zacks Consensus Estimate of $8.26 billion. Sales rose 17.8% on a reported basis. Excluding a 0.7% unfavorable impact from foreign exchange rate fluctuations, operational revenues rose 18.5% backed by continued strong performances by Humira and Imbruvica. Operational revenue growth was better than the expectation of approximately 17%.
Currency tailwinds of 0.7% were in line with management expectation of a negative impact of approximately 1%.
Quarter in Details
Humira sales rose 9% (9.8% on an operational basis) to $5.1 billion. Sales in the United States increased 12.5% to $3.5 billion, better than expectation of 11% growth. The sales growth was driven by strong prescription volume growth and favorable pricing. Humira sales in the ex-U.S. markets were up 4.2% on an operational basis and 1.8% on reported basis to $1.58 billion, almost in-line with the projected figure of $1.6 billion.
In the U.S. market, Humira sales are expected to be approximately $13.7 billion in 2018. Internationally, Humira sales are expected to approach $6.3 billion in 2018 (previously $6.4 billion), which includes the expected impact of biosimilar entrants in Europe in the fourth quarter. In 2019, international Humira sales are expected to decline in the range of 26-27%.
AbbVie's oncology/hematology (including Imbruvica and Venclexta) sales rose 48.1% to $1.07 billion in the quarter. Third-quarter net revenues from Imbruvica were $972 million, up 41.3% year over year primarily driven by market share gains across all lines of therapy in CLL as well as favorable pricing. U.S. sales of Imbruvica grossed $812 million, up 41.5% from the year-ago figure. AbbVie logged $160 million of international profit sharing with J&J, up 40.1% year over year.
In 2018, Imbruvica global revenues are expected to exceed $3.5 billion (previously $3.4 billion) with sales in the United States likely to cross $2.9 billion (previously $2.8 billion).
Venclexta brought in revenues of $96 million, up more than 100% year over year driven by uptake in the second-line plus setting following approval in the broad relapsed/refractory CLL segment (MURANO study) in June.
HCV products, including Viekira and Mavyret, recorded sales of $862 million, up more than 100% year over year, on the back of strong demand for Mavyret, which was launched in the second half of 2017. Though global HCV sales were higher than management's expectation of $850 million, it declined sequentially from the second quarter due to lower international sales as a result of fewer warehoused patients in certain markets.
Mavyret alone accounted for nearly $839 million in the quarter, up more than 100% year over year driven by rapid uptake. On the call, the company said that Mavyret commands roughly 50% market share globally.
In 2018, global HCV sales are expected to be higher than $3.5 billion.
Other products that performed well include Lupron ($214 million, up 7.5% year over year), Creon ($239 million, up 11.3%), Duodopa ($106 million, up 13.3%) and Kaletra ($88 million, up 6%).
Margins Rise
Adjusted gross margin rose 90 bps to 81.7% in the quarter. Adjusted SG&A expenses increased 8.4% to $1.56 billion. However, as a percentage of sales, SG&A expenses declined 170 bps to 19.1% in the quarter, reflecting sales leverage and operational efficiencies. R&D expenses escalated 6% to $1.27 billion in the quarter due to greater investments in the pipeline. Adjusted operating margin was 47.2% of sales in the reported quarter, up 430 bps year over year.
AbbVie's board of directors announced 11.5% increase in its quarterly dividend from $0.96 per share to $1.07 per share. The first increased dividend will be paid on Feb 15, 2019 to shareholders of record as of Jan 15, 2019
2018 Outlook
AbbVie raised its adjusted EPS guidance to the range of $7.90-$7.92 for 2018 from $7.76-$7.86 predicted earlier. The earnings guidance indicates a year-over-year surge of 41.3% at the mid-point.
Revenues are expected to approach $32.7 billion (including currency impact), higher than the previous expectation of $32.5 billion. Total revenues are expected to grow 15% operationally. Currency impact is expected to benefit revenues by less than 1% in 2018.
Adjusted gross margin is expected to be above 80.5% of sales in 2018.
Operating margin is expected to be approximately 45%. Previously, AbbVie expected operating margin to be above 44% of sales.
Fourth-Quarter 2018 Outlook
Fourth-quarter earnings are expected between $1.89 and $1.91 per share, indicating year-over-year growth of more than 28% at the midpoint. Revenues are estimated to grow above 7% on an operational basis. Foreign exchange is expected to have less than 1% unfavorable impact on sales in the fourth quarter.
Preliminary Outlook for 2019
AbbVie said it is confident of delivering double-digit earnings growth in 2019 despite negative impact from EU Humira biosimilar entry, a difficult comparison year (as HCV sales ramped up rapidly in 2018) and significant investments to support product launches.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended downward during the past month.
VGM Scores
At this time, AbbVie has a great Growth Score of A, though it is lagging a bit on the Momentum Score front with a B. Following the exact same course, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, AbbVie has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The first increased dividend will be paid on Feb 15, 2019 to shareholders of record as of Jan 15, 2019 2018 Outlook AbbVie raised its adjusted EPS guidance to the range of $7.90-$7.92 for 2018 from $7.76-$7.86 predicted earlier. Preliminary Outlook for 2019 AbbVie said it is confident of delivering double-digit earnings growth in 2019 despite negative impact from EU Humira biosimilar entry, a difficult comparison year (as HCV sales ramped up rapidly in 2018) and significant investments to support product launches. A month has gone by since the last earnings report for AbbVie (ABBV). | AbbVie Q3 Earnings Beat Estimates, 2018 EPS View Up Third-quarter 2018 earnings of $2.14 per share beat the Zacks Consensus Estimate of $2.01. A month has gone by since the last earnings report for AbbVie (ABBV). Will the recent positive trend continue leading up to its next earnings release, or is AbbVie due for a pullback? | A month has gone by since the last earnings report for AbbVie (ABBV). Will the recent positive trend continue leading up to its next earnings release, or is AbbVie due for a pullback? AbbVie Q3 Earnings Beat Estimates, 2018 EPS View Up Third-quarter 2018 earnings of $2.14 per share beat the Zacks Consensus Estimate of $2.01. | AbbVie Q3 Earnings Beat Estimates, 2018 EPS View Up Third-quarter 2018 earnings of $2.14 per share beat the Zacks Consensus Estimate of $2.01. A month has gone by since the last earnings report for AbbVie (ABBV). Will the recent positive trend continue leading up to its next earnings release, or is AbbVie due for a pullback? |
25244.0 | 2018-11-30 00:00:00 UTC | The New Amazon Blockchain Products Could Be Huge for AMZN | ABBV | https://www.nasdaq.com/articles/new-amazon-blockchain-products-could-be-huge-amzn-2018-11-30 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
There's no doubt that Amazon (NASDAQ: AMZN ) is a destructive force when it enters a new sector. After all, "your margin is my opportunity." Just the thought of AMZN changing healthcare hit many of the sector's stocks incredibly hard. So, when Amazon sets its sights on a new technology or industry, it's time to pay attention. And this time, AMZN is getting ready to change a potentially game-changing sector. We're talking about new Amazon blockchain services.
No, the retailer isn't ready to start accepting bitcoin for purchases. But what is doing could even more important to advancing blockchain and use of digital ledgers. And it comes courtesy of its successful AWS division.
Amazon Gets Blockchain Fever
You can debate all day on whether digital currencies like bitcoin, ethereum or dogecoin have any actual value or will ever achieve their goals of being used as "money" at your local coffee shop. But what you can't argue about is the development of blockchain and its growing importance. The basics are that the technology allows for peer-to-peer transactions without the use of an intermediary. Blockchain provides a public distributed ledger of these transactions and cryptography to encode the ledger. As more transactions move down the ledger, the encryption grows.
The 7 Best ETFs to Avoid the Tech Bloodbath
Digital currencies like bitcoin use blockchain for their transactions. However, the idea is that blockchain could be used for a variety of other industries. From traditional banking and insurance to even food production and medicine, blockchain can be implemented for many back-office processes. For example, Walmart (NYSE: WMT ) adopted a program using blockchain for food safety with its pork suppliers after a major recall. Meanwhile, Starbucks (NASDAQ: SBUX ) recently started a program using blockchain with its coffee suppliers to improve pricing.
So, the potential for blockchain to help transform businesses is there. That's why old tech companies such as IBM (NYSE: IBM ) are looking seriously at the tech. The problem for IBM and others is that Amazon has decided that blockchain is worthy of investment.
To that end, AMZN just announced that it will offer two Amazon Blockchain services through AWS: Amazon Quantum Ledger Database and Amazon Managed Blockchain. The managed blockchain product will allow users to create and manage scalable blockchain networks using the popular open source frameworks Hyperledger Fabric and Ethereum. Incidentally, Hyperledger is what IBM uses for its blockchain operations. The idea is that the new Amazon blockchain product allows end users to set up and manage a scalable blockchain network with just a few clicks of mouse and lines of code.
After you've built that blockchain network, Amazon's other new service will allow you to dig into that data. Amazon's Quantum Ledger Database will allow customers to replicate a copy of their Amazon blockchain network activity and dig into data to analyze it and see the transactions in the digital ledger.
Amazon Blockchain Products Will Be Huge
For Amazon - and AMZN investors - this is all pretty exciting news. And it could send plenty of additional revenues and cash flowing its way.
AWS is already a monster in cloud computing and web hosting. A number of large firms have chosen to use AWS for its various services. Names like AbbVie (NASDAQ: ABBV ), Netflix (NASDAQ: NFLX ) and Airbnb are just some of the firms using AWS services. Tacking on the small and mid-sized enterprises and Amazon boasts more than 1,000,000 active users on its AWS service. According to the company, the Amazon blockchain product launches were designed at the request of existing customers in the "mortgages, health-care records, supply chain tracking and vehicle history records " spaces.
The beauty lies within AWS's simplicity and scalability. If Amazon can demonstrate that a smaller firm can benefit from Amazon blockchain as a service (BasS) and the cost is right, it'll be able to get additional revenues per client. The same could be said for the big fish on its platform.
And since customers are already "locked" into AWS, Amazon will be the go-to name when clients want to explore blockchain. They're not going to call up IBM to develop a ledger if AWS makes it very easy for a firm to add-on services in the platform as needed. Often these services can be had with various levels of hand-holding by Amazon. The same is true with the new Amazon blockchain operations.
Still In The Early Innings For Amazon And Blockchain
Now, it's still very early in the Amazon blockchain process. But given the huge success of AWS and Amazon's ability to get customers to add on services, blockchain has the potential to be big for AMZN. Over the long haul, as more companies begin using these digital ledgers to track transactions, it could be another mega-sized source of revenues at AMZN. Last year alone, revenues at AWS jumped more than 43% to $17.5 billion. Blockchain could be another big leap forward.
Moreover, given the success of the AWS system, it's a major shot across the bow of firms like IBM and Microsoft (NASDAQ: MSFT ) who are currently leading the blockchain game. They could see their leadership positions slip as Amazon's new products build steam with its customers.
10 Stocks to Buy for a Rate Hike Slowdown
All in all, it's another example of why Amazon is so dangerous when it comes into your sector and why AMZN stock is a great long-term buy.
Disclosure: At the time of writing, Aaron Levitt was long ABBV stock.
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
10 Best Stocks Under $10
10 High-Yield Monthly Dividend Stocks
15 Artificial Intelligence Stocks Leading the New Wave
Compare Brokers
The post The New Amazon Blockchain Products Could Be Huge for AMZN appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Names like AbbVie (NASDAQ: ABBV ), Netflix (NASDAQ: NFLX ) and Airbnb are just some of the firms using AWS services. Disclosure: At the time of writing, Aaron Levitt was long ABBV stock. Amazon Gets Blockchain Fever You can debate all day on whether digital currencies like bitcoin, ethereum or dogecoin have any actual value or will ever achieve their goals of being used as "money" at your local coffee shop. | Names like AbbVie (NASDAQ: ABBV ), Netflix (NASDAQ: NFLX ) and Airbnb are just some of the firms using AWS services. Disclosure: At the time of writing, Aaron Levitt was long ABBV stock. To that end, AMZN just announced that it will offer two Amazon Blockchain services through AWS: Amazon Quantum Ledger Database and Amazon Managed Blockchain. | Names like AbbVie (NASDAQ: ABBV ), Netflix (NASDAQ: NFLX ) and Airbnb are just some of the firms using AWS services. Disclosure: At the time of writing, Aaron Levitt was long ABBV stock. To that end, AMZN just announced that it will offer two Amazon Blockchain services through AWS: Amazon Quantum Ledger Database and Amazon Managed Blockchain. | Names like AbbVie (NASDAQ: ABBV ), Netflix (NASDAQ: NFLX ) and Airbnb are just some of the firms using AWS services. Disclosure: At the time of writing, Aaron Levitt was long ABBV stock. And this time, AMZN is getting ready to change a potentially game-changing sector. |
25245.0 | 2018-11-30 00:00:00 UTC | Key Pharma Players With HIV Focus Ahead of World Aids Day | ABBV | https://www.nasdaq.com/articles/key-pharma-players-hiv-focus-ahead-world-aids-day-2018-11-30 | nan | nan | Acquired Immuno Deficiency Syndrome, popularly known as AIDS, is a pandemic caused due to the infection of human immunodeficiency virus ("HIV"). The virus weakens the immune system by destroying cells that fight diseases and infections, eventually leading to AIDS. Medicines for the treatment of HIV are called antiretroviral therapy ("ART") that slow or put a check on the progression of the disease. The majority of them work either by blocking enzymes needed by HIV virus to multiply or inhibiting its entry into certain immune cells.
Like every year, World AIDS Day will be celebrated on Dec 1 in an effort to unite people in the fight against HIV, show support for HIV affected people and in memory of people who have lost their lives to AIDS-related illness.
World AIDS Day is one of the eight official global public health campaigns carried out by the World Health Organization ("WHO"). According to WHO, globally, about 36.7 million people are living with the deadly virus. Per an estimate, the disease has taken more than 35 million lives since it was first identified in 1984.
Per a UNAIDS report, more than 9.4 million people are unaware of their HIV-infected status. Thus, the theme of the 30 th anniversary of this campaign is "Know Your Status."
Although there is no cure for the disease yet, there has been significant progress in the field of HIV treatment, which helps to slow disease progression and restrict secondary infections and complications. However, the huge number of HIV-affected patients shows that it is a long road ahead before the disease can be eradicated completely. The lack of knowledge of HIV status is a significant roadblock as it prevents timely and accurate treatment.
Despite improved medical understanding of HIV and significant efforts made by leading government and medical bodies to prevent and treat HIV/AIDS, this disease still has limited treatment options. Based on these statistics, it is not surprising that several healthcare companies are investing a significant amount of their R&D expenditures on developing treatments and devices for HIV and AIDS. There are more than 40 FDA-approved therapies available including 8 new regimens receiving approval this year. Several therapies are under development.
Stocks to Watch Out For
Ahead of World AIDS Day, we present some key pharma companies developing treatments for HIV.
GlaxoSmithKline GSK has a long-standing commitment to HIV and AIDS. The company had developed the widely used antibiotic amoxycillin around 40 years ago, which was the first medicine approved to treat HIV. Though sales of its older HIV products - Epzicom and Selzentry - have been declining due to generic competition, its new products, Triumeq and Tivicay, are among the major drivers of the company's top line. In 2017, it received approval for its first two-drug regimen for HIV - Juluca - which is a combination of Johnson & Johnson's JNJ Edurant and Glaxo's Tivicay. It is also showing strong uptake. The company's HIV portfolio generated sales of $4.6 billion in first nine-months of 2018, representing year-over-year growth of 12% at constant exchange rate.
On its third-quarter conference call, the company stated that it expects the HIV franchise to be an important growth driver for its Pharma business going forward. There were some positive developments in its HIV pipeline recently. It has made regulatory filings in the United States and Europe to get its HIV drug, Tivicay approved as a two-drug regimen (2DR) in combination with lamivudine on the back of the positive GEMINI study data. Glaxo anticipates U.S. approval in the second quarter of 2019.
Glaxo also announced positive data from both the FLAIR and ATLAS studies this year, evaluating cabotegravir plus rilpivirine in a long-acting, once-monthly HIV formulation. Glaxo believes that this long-acting injectable HIV therapy will provide a highly differentiated treatment option for patients seeking a long-lasting therapy for HIV, freeing them of the burden of daily oral therapy. It believes the positive data from these studies will allow it to file for approval in the first half of 2019.
Glaxo currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
GileadGILD is another dominant player in the HIV market with an impressive portfolio. In fact, Gilead's HIV franchise is a major contributor to sales with approved drugs like Genvoya, Truvada, Atripla, Stribild, Descovy, Odefsey and Complera. Sales at this franchise have grown 10% year over year to $10.6 billion in the first nine months of 2018. It also represents more than 65% of total product revenues for the period.
The company is the first to introduce single-tablet regimen ("STR") for treating HIV and has several STR regimens in its portfolio. Gilead's latest STR treatment for HIV is Biktarvy, which was approved earlier this year. The company is developing Biktarvy for treatment-naïve adults in a late-stage study. Meanwhile, Gilead is looking to transition the HIV market to drugs with improved long-term safety profiles.
However, the older drugs are facing generic competition and their sales have slumped significantly year over year.
Gilead currently sports a Zacks Rank #1.
Another company working toward developing HIV drugs is Johnson and Johnson . The company markets Juluca with Glaxo. Further, the company along with The Bill & Melinda Gates Foundation and National Institutes of Health is conducting a clinical study for an investigational mosaic HIV-1 preventive vaccine.
In July, J&J's Symtuza, a darunavir-based once-daily single-tablet regimen for the treatment of HIV, was approved in the United States.
J&J is a Zacks Rank #2 company.
Other Drugs
Some other popular marketed HIV drugs are AbbVie's ABBV , Kaletra and Merck's MRK Isentress. In August 2018, Merck received approval for two new HIV drugs - Pifeltro and Delstrigo. These two were approved in EU this week.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
GlaxoSmithKline plc (GSK): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other Drugs Some other popular marketed HIV drugs are AbbVie's ABBV , Kaletra and Merck's MRK Isentress. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. It has made regulatory filings in the United States and Europe to get its HIV drug, Tivicay approved as a two-drug regimen (2DR) in combination with lamivudine on the back of the positive GEMINI study data. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Other Drugs Some other popular marketed HIV drugs are AbbVie's ABBV , Kaletra and Merck's MRK Isentress. Despite improved medical understanding of HIV and significant efforts made by leading government and medical bodies to prevent and treat HIV/AIDS, this disease still has limited treatment options. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Other Drugs Some other popular marketed HIV drugs are AbbVie's ABBV , Kaletra and Merck's MRK Isentress. Like every year, World AIDS Day will be celebrated on Dec 1 in an effort to unite people in the fight against HIV, show support for HIV affected people and in memory of people who have lost their lives to AIDS-related illness. | Other Drugs Some other popular marketed HIV drugs are AbbVie's ABBV , Kaletra and Merck's MRK Isentress. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. There are more than 40 FDA-approved therapies available including 8 new regimens receiving approval this year. |
25246.0 | 2018-11-30 00:00:00 UTC | 3 Beaten-Down Biotech Stocks to Buy Before the End of 2018 | ABBV | https://www.nasdaq.com/articles/3-beaten-down-biotech-stocks-buy-end-2018-2018-11-30 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Biotech stocks, like the rest of the broader market, have been under heavy pressure in late 2018. The iShares Nasdaq Biotechnology ETF (NASDAQ: IBB ), which includes several of the largest biotechnology stocks, and the SPDR S&P Biotech ETF (NYSEARCA: XBI ), which also includes the sectors sector's mid- and small-cap companies, have been in a free-fall since October, declining over 15% each.
Although many of these biotech stocks, including AbbVie (NYSE: ABBV ), Celgene (NASDAQ: CELG ) and Mylan (NASDAQ: MYL ), are much cheaper than they were at the start of September, investors should not expect the choppiness in individual share prices to be over yet.
Furthermore, the daily volatility of all three of these stocks is high, giving each a broad trading range. As such, investors should expect to see wide daily price swings in these names during the final weeks of 2018.
Most biotech stocks have been darlings of Wall Street until recently, but as we approach the end of the year, many analysts and investors are doubtful as to what is next for these stocks. Going into 2019, I believe investors will have to be more selective regarding which biotech stocks they choose to invest in, as some are likely to do better than others.
10 Value Stocks to Buy for December
With that said, here's why you should consider these three biotechnology stocks to buy for success in 2019.
AbbVie (ABBV)
Source: Shutterstock
Of the three biotech stocks in this article, I am most bullish on ABBV stock.
AbbVie's earnings release on Nov. 2 showed robust top-line growth, a strong pipeline of existing and new drugs and increased guidance for its full year 2018 earnings. Humira , the world's bestselling drug, which has U.S. patent protection through 2023, benefited from rising global sales of almost 10%. Imbruvica , its other flagship product in the lymphoma/leukemia segment, exhibited double-digit growth and exceeded revenue expectations, too.
AbbVie investors welcomed an increase in the company's quarterly cash dividend from 96 cents to $1.07 per share. Since its spin-off from Abbott Laboratories (NYSE: ABT ) - another dividend king - in 2013, ABV has increased dividends every year.
Despite competitive pressures from other healthcare and biotech companies, Abbvie has several potential cancer drugs in the pipeline that would keep the company ahead of the competition by providing a projected earnings growth of 15% per annum in the next few years.
During the rest of the year and in early 2019, I expect ABBV stock to trade between $80 - $95. Furthermore, AbbVie's healthy dividend yield of 5% is likely to provide strong support for the ABBV stock price in the weeks and months ahead.
Celgene (CELG)
Source: Shutterstock
For a year, investors in CELG stock have been let down with the price performance of their shares. Year-to-date, Celgene is down over 30%. The downtrend and negative momentum surrounding the stock have become quite extreme.
In addition to the overall weakness in biotech stocks that has affected investor sentiment, Wall Street has been worried about whether Celgene will be able to continue to increase revenues when its vital blockbuster drug Revlimid , which generates over 60% of the revenues, comes off patent in the U.S. in 2027. Yet analysts want to see if the new management led by CEO Mark Alles will succeed in decreasing the over-concentration risk on Revlimid and if there will be new earnings blockbusters.
I am of the firm opinion that smart money will come back to Celgene as its management grows the company both organically and inorganically through acquisitions, partnerships as well as commercialization as a result of in-house research and development (R&D).
When it reported earnings on Oct. 25, Celgene beat estimates and raised its full-year guidance. With a broad and robust pipeline , CELG stock is at the forefront of biotechnology companies developing profitable drugs that enable the company to grow revenues and increase cash flow with both current and potential drugs.
7 ETFs for the Inevitable Boom in Self-Driving Cars
During the first quarter of 2019, I expect the CELG stock price to form a base between $62.5 - $72.5, after which a new sustained leg up can take hold. Long-term investors may regard any dip in price an opportunity to get long Celgene stock.
Mylan (MYL)
Source: Shutterstock
Mylan, one of the most important global generic pharmaceuticals companies, has also had a difficult 2018 like the other biotech stocks on this list.
Year-to-date, MYL shares are down almost 20%. Developing a generic version of GlaxoSmithKline's (NYSE: GSK ) blockbuster drug Advair has been at the center of Mylan's recent R&D efforts. In October, Mylan management said that the FDA approval is imminent.
Wall Street expects Generic Advair to contribute to MYL's revenue and earnings significantly. In addition to the generic drug development, Mylan management has also been concentrating on improving the company's margins by cost-cutting measures.
Despite the company developing a robust pipeline of generic drugs for Restasis , Revefenacin and Copaxone , MYL stock investors realize that the company operates in a challenging and complex generic environment with a slow uptake of the generic Copaxone , and issues with getting generic Advai r and generic Restasis to market persisting.
In the next few months, I expect the MYL stock price to form a base between $27.5 - $37.5 after which a new sustained leg up can take hold. As such, patient investors who wait to get into MYL stock later in the year are likely to have good returns in 2019.
The Bottom Line on These Three Biotechnology Stocks
Source: Shutterstock
All three biotech stocks, ABBV, CELG and MYL stock, have strong fundamental growth prospects in the long-run, despite having come off significantly from their recent highs. Therefore, investors may start thinking about which shares they would like to see in their portfolio at these lower prices.
If I had to rank them, I would start the buying with ABBV stock, followed by MYL stock and finally CELG stock. November has not been a good time for entry into any of these stocks, but December may be a different story for these Biotechnology stocks as investors may decide to step in from the sidelines.
10 Stocks to Buy for a Rate Hike Slowdown
Ultimately, investors should always base their decisions on individual risk/return profiles and remember that most biotech stocks are not likely to have double-digit returns in 2019 while valuations and expectations become more rational.
As of this writing, Tezcan Gecgil did not hold a position in any of the aforementioned securities.
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
10 Best Stocks Under $10
10 High-Yield Monthly Dividend Stocks
15 Artificial Intelligence Stocks Leading the New Wave
Compare Brokers
The post 3 Beaten-Down Biotech Stocks to Buy Before the End of 2018 appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Furthermore, AbbVie's healthy dividend yield of 5% is likely to provide strong support for the ABBV stock price in the weeks and months ahead. Although many of these biotech stocks, including AbbVie (NYSE: ABBV ), Celgene (NASDAQ: CELG ) and Mylan (NASDAQ: MYL ), are much cheaper than they were at the start of September, investors should not expect the choppiness in individual share prices to be over yet. AbbVie (ABBV) Source: Shutterstock Of the three biotech stocks in this article, I am most bullish on ABBV stock. | Although many of these biotech stocks, including AbbVie (NYSE: ABBV ), Celgene (NASDAQ: CELG ) and Mylan (NASDAQ: MYL ), are much cheaper than they were at the start of September, investors should not expect the choppiness in individual share prices to be over yet. The Bottom Line on These Three Biotechnology Stocks Source: Shutterstock All three biotech stocks, ABBV, CELG and MYL stock, have strong fundamental growth prospects in the long-run, despite having come off significantly from their recent highs. AbbVie (ABBV) Source: Shutterstock Of the three biotech stocks in this article, I am most bullish on ABBV stock. | The Bottom Line on These Three Biotechnology Stocks Source: Shutterstock All three biotech stocks, ABBV, CELG and MYL stock, have strong fundamental growth prospects in the long-run, despite having come off significantly from their recent highs. If I had to rank them, I would start the buying with ABBV stock, followed by MYL stock and finally CELG stock. Although many of these biotech stocks, including AbbVie (NYSE: ABBV ), Celgene (NASDAQ: CELG ) and Mylan (NASDAQ: MYL ), are much cheaper than they were at the start of September, investors should not expect the choppiness in individual share prices to be over yet. | Although many of these biotech stocks, including AbbVie (NYSE: ABBV ), Celgene (NASDAQ: CELG ) and Mylan (NASDAQ: MYL ), are much cheaper than they were at the start of September, investors should not expect the choppiness in individual share prices to be over yet. Furthermore, AbbVie's healthy dividend yield of 5% is likely to provide strong support for the ABBV stock price in the weeks and months ahead. AbbVie (ABBV) Source: Shutterstock Of the three biotech stocks in this article, I am most bullish on ABBV stock. |
25247.0 | 2018-11-29 00:00:00 UTC | Global Dividends Get Richer | ABBV | https://www.nasdaq.com/articles/global-dividends-get-richer-2018-11-29 | nan | nan | Photograph by Adolfo Felix
Global dividends had a strong third quarter, helped by record quarterly payments in the U.S., Canada, Taiwan, and India.
In all, dividends tracked by the Janus Henderson Global Dividend index totaled $354.2 billion, up 5.1% from $337 billion in 2017's third quarter.
In local currency and excluding special dividends and other factors, dividends increased 9.2% in the third quarter.
The quarterly survey emphasizes dividends paid by the 1,200 largest firms by market capitalization at the start of every calendar year.
"In absence of a global recession, which we are not forecasting, the outlook for dividends and income investors remains well underpinned," Jane Shoemake, investment director of global equity income at Janus Henderson Investors, tells Barron's.
"Dividends are flowing through from decent corporate profitability," she adds.
"As has been the case throughout 2018, rising payouts around the world implied continued economic growth and corporate confidence," according to Janus Henderson's quarterly report.
Read more:6 Overseas Stocks With Tempting Yields
The firm is forecasting that $1.36 trillion of dividends will be paid this year, an 8.1% increase from last year and above its previous estimate of a 7.4% jump.
There was also a big uptick in dividends paid by Chinese companies, reversing recent trends. In fact, dividends paid by Chinese companies grew during the quarter for the first time in four years. In local currency, disbursements ticked up by 14.6%. That growth was helped by disbursements paid by banks, insurers and energy firms.
One of the biggest third-quarter dividends was paid by China Construction Bank (ticker: CICHY). In the third quarter, the company paid out about $10.7 billion of dividends, according to Bloomberg.
Others in the top 10 included Apple (AAPL) and Exxon Mobil (XOM).
Looking ahead, Janus Henderson says that some slowing of dividend growth is possible. In its release of the latest survey results, it notes that "the pace of dividend increases could slow as companies come to terms with what is likely in the later stages of an economic cycle."
It adds that "any notable change to the availability or cost of credit could factor largely into companies' decisions about whether to pay down debt, horde cash or raise their dividends."
https://asset.barrons.com/dj-mg/dice/barrons-staffpicks-2d590600-c862-4394-b9d3-66b48c376d60/inset.json
Interest rates have been increasing in the U.S., but they are much lower in Europe. The 10-year U.S. Treasury note was recently yielding 3.02%, compared with 2.33% a year ago-though it was at around 3.25% early this month.
In the U.S., every bank tracked by Janus Henderson for the survey increased its third-quarter payout, distributing $1.2 billion more than they did a year earlier. Banks remain a big source of dividend growth globally.
General Electric (GE) was an outlier, one of the very few large U.S. companies to announce a dividend cut this year.
Health-care companies were big contributors to dividend growth as well. Pharmaceutical giant AbbVie (ABBV), whose biggest-selling drug is Humira, paid a dividend of 96 cents a share in the third quarter, up from 64 cents a year earlier.
Special dividends were lower in the quarter, though an exception occurred when Dr Pepper Snapple Group merged with Keurig Green Mountain earlier this year. The combined company is called Keurig Dr Pepper (KDP).
Dr Pepper Snapple shareholders received a special cash dividend of $103.75 per share in early July.
Write to Lawrence C. Strauss at lawrence.strauss@barrons.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Pharmaceutical giant AbbVie (ABBV), whose biggest-selling drug is Humira, paid a dividend of 96 cents a share in the third quarter, up from 64 cents a year earlier. In its release of the latest survey results, it notes that "the pace of dividend increases could slow as companies come to terms with what is likely in the later stages of an economic cycle." It adds that "any notable change to the availability or cost of credit could factor largely into companies' decisions about whether to pay down debt, horde cash or raise their dividends." | Pharmaceutical giant AbbVie (ABBV), whose biggest-selling drug is Humira, paid a dividend of 96 cents a share in the third quarter, up from 64 cents a year earlier. In all, dividends tracked by the Janus Henderson Global Dividend index totaled $354.2 billion, up 5.1% from $337 billion in 2017's third quarter. In the U.S., every bank tracked by Janus Henderson for the survey increased its third-quarter payout, distributing $1.2 billion more than they did a year earlier. | Pharmaceutical giant AbbVie (ABBV), whose biggest-selling drug is Humira, paid a dividend of 96 cents a share in the third quarter, up from 64 cents a year earlier. In all, dividends tracked by the Janus Henderson Global Dividend index totaled $354.2 billion, up 5.1% from $337 billion in 2017's third quarter. In local currency and excluding special dividends and other factors, dividends increased 9.2% in the third quarter. | Pharmaceutical giant AbbVie (ABBV), whose biggest-selling drug is Humira, paid a dividend of 96 cents a share in the third quarter, up from 64 cents a year earlier. In local currency and excluding special dividends and other factors, dividends increased 9.2% in the third quarter. There was also a big uptick in dividends paid by Chinese companies, reversing recent trends. |
25248.0 | 2018-11-29 00:00:00 UTC | How Google Is Helping Make Advances In Medical Technology | ABBV | https://www.nasdaq.com/articles/how-google-helping-make-advances-medical-technology-2018-11-29 | nan | nan | daizuoxin for Getty images
Over the years, medical science has seen tremendous advancements. However, there is always scope for improvement and this time around, doctors and nurses have access to devices, apps and platforms powered with advanced technologies such as Artificial Intelligence, Cloud, Machine Learning—to enhance their capabilities in many ways. Here’s a look at how technology giant, Alphabet, Inc. (GOOG, GOOGL) efforts in the health and wellness space.
The trillion-dollar healthcare market and its challenges show that there is immense capacity for advanced technologies to be leveraged. The U.S. health spending which is presently around $3.67 trillion, based on the U.S. Centers for Medicare and Medicaid Services (CMS) is estimated to touch $5.69 trillion by 2026. Deloitte estimates that the global health care spending is projected to increase at an annual rate of 4.1% in 2017-2021, up from just 1.3% in 2012-2016. The major factors behind this rise are the increasing population of the elderly, developing market expansion, advances in medical treatments, and rising labor costs.
The World Health Organization (WHO) database reveals that over 45% of its member states report to have less than 1 physician per 1,000 population. While a study shows that primary care physicians spend more than one-half of their workday, interacting with the EHR during and after clinic hours. This further squeezes the time for face-to-face patient interaction.
On the other hand, the fast-rising older population highlights the need of better medical infrastructure and a greater number of doctors and other healthcare workers. According to the United Nations, 13% of the global population was aged 60 or over in the world in 2017. The number of people aged 60 years or over—is expected to more than double by 2050.
Here are some of the projects and initiatives within the healthcare space by Alphabet and its subsidiaries. “Healthcare is increasingly moving to the cloud, and the adoption of machine learning will allow the industry to unlock insights that can lead to significant clinical improvements for patients”, wrote Gregory J. Moore MD, PhD, Vice President of Healthcare, Google Cloud.
To address interoperability challenges in healthcare data, Google launched a new version of its Cloud Healthcare API which provides a robust, scalable infrastructure solution to manage key healthcare data types (including HL7, FHIR and DICOM). While Google’s Apigee Health APIx makes it easy for developers and healthcare enterprises to build new FHIR (Fast Healthcare Interoperability Resources) API-based services on top of their existing health record systems in a secure, compliant manner.
To ensure ease in operations for its customers, Google offers Health Insurance Portability and Accountability Act (HIPAA) compliance for its G Suite and Cloud offerings. “Under HIPAA, certain information about a person’s health or health care services is classified as Protected Health Information (PHI).”
To reduce the time and effort going into data-entry into EHRs, and facilitate more time to doctors for patient interaction, Google is working on tools such as specialized speech recognition for medical transcription to create AI-enabled ‘note-writing models’ that can assist doctors in adding patient notes.
Google Fit, a health tracker app for everyday use. Google has been engaging with the WHO and the American Heart Association (AHA) to understand simple yet effective ways to stay active and healthy. “Move Minutes and Heart Points” are two of its focus areas.
Back in 2014, Calico (earlier known as Google Life Sciences) and AbbVie (ABBV) joined hands to focus on new therapies for patients with age-related diseases such as neuro-degeneration and cancer. In January this year, the companies announced the extension of their collaboration for another three years. The $1.5 billion initial budget will be funded with another $500 million.
In April 2018, Verily (a subsidiary of Alphabet) and Gilead Sciences, Inc. (GILD) partnered to identify and understand the immunological and molecular drivers resulting in inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease and lupus-related diseases. Earlier in December 2017, DeepVariant—a technology that uses deep neutral network to reconstruct the true genome sequence from HTS sequencer data, was released by Verily and Google Brain.
In August this year, DeepMind (acquired in 2014) and Moorfields Eye Hospital announced results of their partnership to explore use of AI technology to clinicians. The result describes how machine learning is applied to identify signs of eye disease using scans; “The AI system can recommend the correct referral decision for over 50 eye diseases with 94% accuracy, matching world-leading eye experts.”
In another project, deep learning is being applied to achieve clinically applicable segmentation of head and neck anatomy for radiotherapy. Further, DeepMind is working with the U.S. Department of Veterans Affairs to work on deaths resulting from deterioration in health of hospitalized patients.
DeepMind’s app Streams is already in use at the Royal Free London NHS Foundation Trust. The app sends immediate alerts to clinicians and directs them to patients who are showing signs of a serious condition called Acute Kidney Injury (AKI). DeepMind’s health team will be joining the newly formed division—Google Health led by Dr. David Feinberg.
Alphabet leads the count with 186 healthcare related patents between 2013-2017 as per a E&Y report. With years of research, investments, current projects and now the newly structured health division, Google is among the leading technology players which is set to establish new revenue streams while unlocking the potential of these cutting-edge technologies for the healthcare industry.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Back in 2014, Calico (earlier known as Google Life Sciences) and AbbVie (ABBV) joined hands to focus on new therapies for patients with age-related diseases such as neuro-degeneration and cancer. However, there is always scope for improvement and this time around, doctors and nurses have access to devices, apps and platforms powered with advanced technologies such as Artificial Intelligence, Cloud, Machine Learning—to enhance their capabilities in many ways. In August this year, DeepMind (acquired in 2014) and Moorfields Eye Hospital announced results of their partnership to explore use of AI technology to clinicians. | Back in 2014, Calico (earlier known as Google Life Sciences) and AbbVie (ABBV) joined hands to focus on new therapies for patients with age-related diseases such as neuro-degeneration and cancer. Deloitte estimates that the global health care spending is projected to increase at an annual rate of 4.1% in 2017-2021, up from just 1.3% in 2012-2016. To address interoperability challenges in healthcare data, Google launched a new version of its Cloud Healthcare API which provides a robust, scalable infrastructure solution to manage key healthcare data types (including HL7, FHIR and DICOM). | Back in 2014, Calico (earlier known as Google Life Sciences) and AbbVie (ABBV) joined hands to focus on new therapies for patients with age-related diseases such as neuro-degeneration and cancer. While Google’s Apigee Health APIx makes it easy for developers and healthcare enterprises to build new FHIR (Fast Healthcare Interoperability Resources) API-based services on top of their existing health record systems in a secure, compliant manner. “Under HIPAA, certain information about a person’s health or health care services is classified as Protected Health Information (PHI).” To reduce the time and effort going into data-entry into EHRs, and facilitate more time to doctors for patient interaction, Google is working on tools such as specialized speech recognition for medical transcription to create AI-enabled ‘note-writing models’ that can assist doctors in adding patient notes. | Back in 2014, Calico (earlier known as Google Life Sciences) and AbbVie (ABBV) joined hands to focus on new therapies for patients with age-related diseases such as neuro-degeneration and cancer. Here are some of the projects and initiatives within the healthcare space by Alphabet and its subsidiaries. “Healthcare is increasingly moving to the cloud, and the adoption of machine learning will allow the industry to unlock insights that can lead to significant clinical improvements for patients”, wrote Gregory J. Moore MD, PhD, Vice President of Healthcare, Google Cloud. |
25249.0 | 2018-11-28 00:00:00 UTC | AbbVie (ABBV) Gains But Lags Market: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-gains-but-lags-market%3A-what-you-should-know-2018-11-28 | nan | nan | AbbVie (ABBV) closed the most recent trading day at $88.93, moving +1.43% from the previous trading session. The stock lagged the S&P 500's daily gain of 2.3%. Meanwhile, the Dow gained 2.5%, and the Nasdaq, a tech-heavy index, added 2.95%.
Coming into today, shares of the drugmaker had gained 7.46% in the past month. In that same time, the Medical sector gained 3.55%, while the S&P 500 gained 1.21%.
ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. In that report, analysts expect ABBV to post earnings of $1.92 per share. This would mark year-over-year growth of 29.73%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $8.36 billion, up 8.07% from the year-ago period.
ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.93 per share and revenue of $32.78 billion. These results would represent year-over-year changes of +41.61% and +16.17%, respectively.
It is also important to note the recent changes to analyst estimates for ABBV. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.95% higher. ABBV is currently a Zacks Rank #3 (Hold).
In terms of valuation, ABBV is currently trading at a Forward P/E ratio of 11.05. This represents a discount compared to its industry's average Forward P/E of 14.58.
We can also see that ABBV currently has a PEG ratio of 0.82. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. ABBV's industry had an average PEG ratio of 2.01 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 78, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.93 per share and revenue of $32.78 billion. AbbVie (ABBV) closed the most recent trading day at $88.93, moving +1.43% from the previous trading session. ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. | AbbVie (ABBV) closed the most recent trading day at $88.93, moving +1.43% from the previous trading session. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.93 per share and revenue of $32.78 billion. AbbVie (ABBV) closed the most recent trading day at $88.93, moving +1.43% from the previous trading session. ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. | In that report, analysts expect ABBV to post earnings of $1.92 per share. AbbVie (ABBV) closed the most recent trading day at $88.93, moving +1.43% from the previous trading session. ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. |
25250.0 | 2018-11-27 00:00:00 UTC | 5 Biotech Stocks to Scoop Up for Big Dividends | ABBV | https://www.nasdaq.com/articles/5-biotech-stocks-scoop-big-dividends-2018-11-27 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
When it comes to biotech stocks, the perception is that the sector is a gamble. Many investors believe that most biotech stocks are clinical-stage lotto tickets that will only succeed on a wish and a prayer. And that is true to a point. There are plenty of those firms out there. However, the sector is also full of ripe and mature firms in the commercial stages of their lifespan. It's here that investors can find stable cash flows, profits, and even dividend stocks .
That's right. There are even biotech stocks that offer you some big yields as well.
Even better, is that while these pharma stocks have steady cash flows and revenues, there's still plenty of growth left in the tank from new drugs in development. These dividend-paying biotech stocks could be the best way to play the sector. Their dividends make them less volatile than the lotto tickets, but there's still plenty of upside potential as well.
And with the overall market down in the dumps, many of these strong dividend-paying biotech stocks are now trading for peanuts. That means investors have plenty of opportunities to score some great deals.
7 Retail Stocks That Won Big This Black Friday
With that, here are five dividend-paying biotech stocks you need to scoop up today.
Amgen, Inc. (AMGN)
Source: Shutterstock
Dividend Yield : 2.74%
There's no denying that Amgen (NASDAQ: AMGN ) is king of biotech stocks.. The firm cut its teeth on a variety of groundbreaking treatments back in the 90's. Since then, AMGN has continued to build out an impressive portfolio of drugs. Key blockbusters like Enbrel and Neulasta are two of the most prescribed drugs in their categories. Meanwhile, new therapies such as Repatha, blood-cancer drug Kyprolis and bone-density drug Prolia have all quickly moved into blockbuster status. Prolia made Amgen more than $3.9 billion in sales during the third quarter alone.
That's a lot of revenue and Amgen has been very successful at turning those sales into profits/free cash flows.
With more than $29 billion still on its balance sheet, Amgen has also been very successful at returning that cash back to investors. The firm has been a buyback king - buying back more than $1.9 billion in stock last quarter. It's also one heck of a dividend-growth stock. Since it initiated a payout in 2011, AMGN has increased its dividend by nearly 375%.
With steady revenues, a big pipeline, plenty of cash on its balance, the odds are still in Amgen's favor to keep the tread going. And at a P/E of around 13, it's one of the biggest bargains for investors in the sector these days.
Gilead Sciences (GILD)
Source: Shutterstock
Dividend Yield : 3.42%
Like Amgen, Gilead Sciences (NASDAQ: GILD ) built its impressive dividend on the back of several key blockbuster drugs. Big cash flows from hepatitis-C and antiviral medications managed to build an impressive cash balance of over $34 billion on GILD's balance sheet. With such immense cash, Gilead has turned to rewarding shareholders with back-to-back annual increases of 10% over the last two years. The firm has also been a buyback champion.
And yet, investors have taken shares to the woodshed - shares are down about 44% since its 2015 peak. Much of that comes from revenue declines in Hep-C medicines and the loss of patient protection.
However, GILD is far from a one-trick pony. The firm is far and away the lead drug company in various HIV medications and revenues here continue to grow rapidly. Secondly, the firm plenty in its pipeline. This includes new treatments for NASH, a rich potential rheumatoid arthritis blockbuster partnership with Galapagos (NASDAQ: GLPG ) as well as several CAR-T cancer treatments in development.
7 Best Stock Charts Going Into 2019
All of these new drugs should help GILD replace its aging hepatitis portfolio with ease. That means, investors buying this biotech stocks' 3.42% dividend can rest easy. That payout isn't going anywhere for a long while.
AbbVie (ABBV)
Source: Black Stripe via Wikimedia (Modified)
Dividend Yield : 5%
A big-time approval can do wonders for your future. Just ask AbbVie Inc. (NASDAQ: ABBV ). The story at ABBV has long been Humira. The autoimmune-disease medication has been an insane blockbuster for the biotech firm. Doctors continue to use the drug for a variety of different indications and as a result, Humira has long been one of the best-selling drugs year in and year out. Last year alone, Humira managed to net AbbVie more than $16 billion in revenues.
Which is also kind of the problem and one of the reasons for ABBV's 5% dividend yield.
As one of the biggest generates of AbbVie's bottom line, the fact that the wonder drug is falling off patent shouldn't be taken lightly. That cliff is a real threat, but it looks like this one biotech stock that is up to the challenge.
For starters, ABBV has managed to kick the can via legal means on Humira's patent until at least 2022. That should limit the cash flow loss. In fact, management expects annual Humira sales to climb to more than $21 billion by 2020. It also gives it time to push through on its impressive pipeline of drugs. And it is seeing success here. Recently, AbbVie and partner Roche scored a big win for its acute myeloid leukemia drug, Venclexta.
With a hefty cash balance and continued clinical wins, ABBV offers a rare opportunity among biotechs: a high yield that is actually safe.
Sanofi (SNY)
Source: Shutterstock
Dividend Yield : 3.99%
At first blush, the next of our dividend stocks, French drug producer Sanofi (NYSE: SNY ), looks more like a traditional pharmaceutical firm. It's long been a leader in the vaccines space as well as being one of the big players in the diabetes arena Its diabetes drug Lantus is a big revenue driver for the firm. But thanks to a series of shrewd buyouts, SNY has quickly morphed from traditional pharma into biotech royalty.
Back in 2011, Sanofi purchased Genzyme. At the time, Genzyme was the fourth-largest biotech firm in the country. With a huge product portfolio, that instantly made SNY one of the biggest biotech stocks around. Since that time, as a subsidiary of Sanofi, Genzyme has cranked out more medications and features over twenty different biotech drugs. Not to mention a rich pipeline of new ones.
But Sanofi wasn't done yet. With Lantus hitting a patent cliff, the drug maker is looking for other long runway therapy sectors to fill its coffers and it's chosen hemophilia drug-specialist Bioverativ. With the market for new hemophilia medications estimated to be about $10 billion annually, SNY now has plenty of potential in the space. Especially, when you consider that Bioverativ managed to see year over year sales jump 27% before they were acquired . The firm more recently struck a deal with Denali Therapeutics (NASDAQ: DNLI ) develop treatments for neurological and inflammatory diseases.
7 Big Tech Stocks to End This Bear Market
All in all, Sanofi has hitched its future towards biotech drugs and those new therapies will help continue powering the firm's profits and its dividend for years to come.
Allergan plc (AGN)
Source: Everjean via Flickr
Dividend Yield : 1.87%
Truth be told, Allergan (NYSE: AGN ) could be the biggest bargain of any stock on this list. It's also the riskiest. The back story to AGN comes from several failed buyout attempts. First, it was courted by Bausch Health Companies Inc (NYSE: BHC ), only to spur their advances before a huge scandal hit BHC. It then merged with generic drug producer Actavis to form the current version of the company. It was later courted by Pfizer (NYSE: PFE ) and then sold its generics business to Teva (NASDAQ: TEVA ).
The point is, Allergan has gone through a lot in only a few short years.
Because of this, investors continue to consider it sort of the black sheep of the biotech stocks world. On the surface, it looks like it doesn't have much focus. But digging deeper, AGN has plenty going for it.
For starters, the firm is behind some huge blockbusters such as Botox, Lizness and Restasis. These drugs plus others still produce plenty of cash flows and profits for AGN. This has allowed the firm to pay a decent and growing dividend - currently 1.87%. The firm has a decent pipeline as well.
Moreover, management has recently launched a strategic review of its operations and is looking to sell/spin-off its women's health and infectious disease units . These sales should raise plenty of cash - about $4 to $5 billion - and help the firm focus in on its core operating areas. Analysts estimate that this cash will go right into investors pockets via buybacks and dividends.
All in all, AGN represents a turnaround play. But at least, investors get a dividend while the wait for that to pan out.
At the time of writing, Aaron Levitt held a long position in AGN, AMGN, ABBV and GLPG
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
10 Cheap Stocks You Won't Regret Buying
7 Best Stock Charts Going Into 2019
5 Best ETFs for Slow and Steady Growth
Compare Brokers
The post 5 Biotech Stocks to Scoop Up for Big Dividends appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | With a hefty cash balance and continued clinical wins, ABBV offers a rare opportunity among biotechs: a high yield that is actually safe. AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Dividend Yield : 5% A big-time approval can do wonders for your future. Just ask AbbVie Inc. (NASDAQ: ABBV ). | AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Dividend Yield : 5% A big-time approval can do wonders for your future. Just ask AbbVie Inc. (NASDAQ: ABBV ). The story at ABBV has long been Humira. | At the time of writing, Aaron Levitt held a long position in AGN, AMGN, ABBV and GLPG More From InvestorPlace 2 Toxic Pot Stocks You Should Avoid 10 Cheap Stocks You Won't Regret Buying 7 Best Stock Charts Going Into 2019 5 Best ETFs for Slow and Steady Growth Compare Brokers The post 5 Biotech Stocks to Scoop Up for Big Dividends appeared first on InvestorPlace . AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Dividend Yield : 5% A big-time approval can do wonders for your future. Just ask AbbVie Inc. (NASDAQ: ABBV ). | Just ask AbbVie Inc. (NASDAQ: ABBV ). AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Dividend Yield : 5% A big-time approval can do wonders for your future. The story at ABBV has long been Humira. |
25251.0 | 2018-11-26 00:00:00 UTC | 2 Dividend Stocks You'll Wish You'd Bought 32 Years From Now | ABBV | https://www.nasdaq.com/articles/2-dividend-stocks-youll-wish-youd-bought-32-years-now-2018-11-26 | nan | nan | The baby boomer generation was much larger than those before or after, and by 2050, all 77 million members will have celebrated their 85th birthdays. They're going to need a lot of healthcare, and it looks as if there'll be plenty of working-age millennials to pay the bills.
American adults under 35 might not fill everyone with confidence, but millennials already outnumber baby boomers, and they'll be contributing payroll taxes for a long time to come. Here's a pair of dividend-paying healthcare stocks that stand to benefit a great deal from this powerful demographic trend.
Data source: Yahoo! Finance.
AbbVie: The right products for tomorrow
Older adults are generally more susceptible to inflammatory conditions and cancer, which are two areas where AbbVie excels and is positioned to continue leading in the years ahead. Sales of the company's anti-inflammatory injection, Humira, are on pace to reach $20 billion this year, and the company's burgeoning oncology program keeps racking up important approvals.
Global Humira sales have probably hit a high-water mark now that the main patents protecting its market exclusivity in the U.S. and EU have expired, but AbbVie's blood cancer program is just getting started. In 2016, Imbruvica tablets became the first chemo-free treatment option for patients newly diagnosed with the most common form of leukemia. This year, Venclexta earned FDA approvals to stabilize leukemia patients following other treatments and is now approved for treating first-line acute myeloid leukemia patients 75 and older.
The company's flagship treatment is expiring, but an increasing number of older adults seeking treatment for autoimmune disorders could continue to drive sales growth for AbbVie in the years ahead. That's because AbbVie has two experimental therapies in late-stage development, one for psoriasis and another for rheumatoid arthritis, and successful launches for both would help investors quit worrying about Humira .
AbbVie's years of blazing fast dividend growth are probably in the past, but steady raises over the long run seem entirely possible. Despite boosting the payout 51% higher in 2018, to an annualized $4.28 per share, management also expects adjusted earnings to reach at least $7.90 per share for the full year. That means the company can probably keep up with quarterly payments even if Humira sales tumble faster than expected.
Omega Healthcare Investors: Nice and steady
Investors who find the business of drug development far too risky will want to consider Omega Healthcare Investors. This is a real estate investment trust, or REIT , that owns, but doesn't operate, skilled nursing facilities across the country.
Being a nursing home landlord isn't an exciting business, but retirees find Omega's steady cash flows thrilling. Nearly all of this REIT's clients sign long-term triple-net leases that leave tenants responsible for all the variable costs that come with building ownership, such as maintenance and taxes.
This REIT offers such a juicy yield now, because Orianna, an operator that had been renting dozens of Omega buildings, can't pay its bills anymore. In January, Omega Healthcare announced the 22nd consecutive increase to its quarterly dividend, but trouble with Orianna will keep the payout from rising any further in 2018.
Once 19 remaining Orianna facilities become unstuck from ongoing bankruptcy proceedings, shareholders can probably look forward to quarterly payout bumps as usual. Omega expects funds from operations to reach $3.03 per share in 2018, more than enough to cover dividend payments currently set at an annualized $2.64 per share.
Nursing home reimbursement rates are expected to rise slightly in the near term, which suggests we won't see any more of Omega's operators sliding into arrears. Government payers will probably adjust the way they reimburse Omega's operators for nursing home services again before 2050, but they can't do much about the ongoing demographic shift that keeps providing more patients.
In for the long haul
While investors might not see a whole lot of excitement from Omega Healthcare shares, that doesn't mean they can't outperform if you hold them long enough. Investors who have held the stock for the past 10 years have seen a 517% total return, which is a whole lot better than the 282% total return the S&P 500 delivered over the same time frame.
AbbVie's going to be on the opposite end of the excitement spectrum in the decades ahead, but investors still holding on to these shares in 2050 will be awfully glad they decided to ride the roller coaster.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Cory Renauer owns shares of Omega Healthcare Investors. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Global Humira sales have probably hit a high-water mark now that the main patents protecting its market exclusivity in the U.S. and EU have expired, but AbbVie's blood cancer program is just getting started. AbbVie's going to be on the opposite end of the excitement spectrum in the decades ahead, but investors still holding on to these shares in 2050 will be awfully glad they decided to ride the roller coaster. AbbVie: The right products for tomorrow Older adults are generally more susceptible to inflammatory conditions and cancer, which are two areas where AbbVie excels and is positioned to continue leading in the years ahead. | AbbVie: The right products for tomorrow Older adults are generally more susceptible to inflammatory conditions and cancer, which are two areas where AbbVie excels and is positioned to continue leading in the years ahead. Global Humira sales have probably hit a high-water mark now that the main patents protecting its market exclusivity in the U.S. and EU have expired, but AbbVie's blood cancer program is just getting started. The company's flagship treatment is expiring, but an increasing number of older adults seeking treatment for autoimmune disorders could continue to drive sales growth for AbbVie in the years ahead. | AbbVie: The right products for tomorrow Older adults are generally more susceptible to inflammatory conditions and cancer, which are two areas where AbbVie excels and is positioned to continue leading in the years ahead. Global Humira sales have probably hit a high-water mark now that the main patents protecting its market exclusivity in the U.S. and EU have expired, but AbbVie's blood cancer program is just getting started. The company's flagship treatment is expiring, but an increasing number of older adults seeking treatment for autoimmune disorders could continue to drive sales growth for AbbVie in the years ahead. | AbbVie: The right products for tomorrow Older adults are generally more susceptible to inflammatory conditions and cancer, which are two areas where AbbVie excels and is positioned to continue leading in the years ahead. Global Humira sales have probably hit a high-water mark now that the main patents protecting its market exclusivity in the U.S. and EU have expired, but AbbVie's blood cancer program is just getting started. The company's flagship treatment is expiring, but an increasing number of older adults seeking treatment for autoimmune disorders could continue to drive sales growth for AbbVie in the years ahead. |
25252.0 | 2018-11-26 00:00:00 UTC | The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-pfizer-abbvie-jj-glaxo-and-astrazeneca-2018-11-26 | nan | nan | For Immediate Release
Chicago, IL -November 26, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: PfizerPFE , AbbVieABBV , J&JJNJ , GlaxoGSK and AstraZenecaAZN .
Here are highlights from Friday's Analyst Blog:
Pharma Stock Roundup: PFE, ABBV & More
This week, the FDA granted approval to Pfizer's Daurismo, the drug giant's fourth new cancer drug in less than three months. It also approved the label expansion of AbbVie/Roche's drug Venclexta. Both the drugs gained approval for the treatment of acute myeloid leukemia (AML), a rare blood cancer in newly diagnosed patients. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) gave positive recommendations for granting marketing approval to several drugs this week.
Recap of the Week's Most Important Stories
Pfizer Gets FDA Nod for Rare Cancer Medicine: The FDA granted approval to Daurismo for a rare blood cancer, Pfizer's fourth cancer medicine in less than three months. Daurismo (glasdegib), a once-daily oral medicine is approved for use in combination with low-dose cytarabine (LDAC) - a kind of chemotherapy treatment - for the treatment of newly-diagnosed acute myeloid leukemia (AML) in patients 75 years or older or who cannot take intensive chemotherapy. However, the approval comes with a boxed warning on the U.S. label for embryo-fetal toxicity
Pfizer's recent new cancer drug approvals include Lorbrena (lorlatinib) for second line non-small-cell lung cancer, Vizimpro (dacomitinib) for advanced NSCLC with EGFR activating mutations and Talzenna (talazoparib), an orally-available PARP inhibitor for advanced breast cancer.
However, Pfizer's late-stage study evaluating its PD-L1 inhibitor Bavencio (avelumab), in patients with platinum-resistant/refractory ovarian cancer, failed to meet the primary endpoints of overall survival (OS) or progression-free survival (PFS).In the study, both PFS and OS did not reach statistical significance. Bavencio is marketed for metastatic Merkel cell carcinoma in the United States, Europe and Japan and for the second-line treatment of locally advanced or metastatic urothelial carcinoma in the United States.
Pfizer was also in news this week as a Wall Street report stated that it plans to increase the list prices of 41 prescription drugs in 2019. The drug giant had put off such increases earlier this year as it faced criticism from President Trump.
AbbVie/Roche Get FDA Nod for Venclexta in First-Line AML : FDA also granted accelerated approval to AbbVie and partner Roche's supplemental new drug application (sNDA) looking for a label expansion of Venclexta (venetoclax) for the first-line treatment of acute myeloid leukemia (AML), one of the most aggressive blood cancers.
Venclexta can now be prescribed in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) in AML patients who are ineligible for intensive chemotherapy. Venclexta is now approved for two different blood cancers in the United States - newly-diagnosed AML and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
CHMP Gives Positive Opinion to Several Drugs : The CHMP gave a positive opinion, recommending approval of J&J's Erleada (apalutamide) for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. Erleada gained FDA approval in the United States in February. The CHMP also gave a nod to Glaxo's filing looking for EU approval of its HIV drug, Tivicay as a two-drug regimen (2DR) in combination with lamivudine.
AstraZeneca Presents Final OS Data From MYSTIC Study: AstraZeneca announced final overall survival data from the pivotal phase III MYSTIC study, evaluating Imfinzi in first-line lung cancer. The MYSTIC study evaluated Imfinzi, both as a monotherapy and in combination with tremelimumab, in treatment-naïve non-small cell lung cancer (NSCLC) patients whose tumors express PD-L1 on 25% or more of their cancer cells.The data from the primary analysis population of patients showed that Imfinzi monotherapy as well as in combination with tremelimumab failed to achieve statistical significance in the primary endpoint of overall survival compared to standard-of-care platinum-based chemotherapy. Per data announced in July last year, the study failed to show improvement in progression-free survival, thereby failing to meet the first primary endpoint.
Novartis Gets FDA Nod for Promacta in First-Line Setting: Novartis gained FDA approval for label expansion of its anemia drug, Promacta as a first-line treatment option for severe aplastic anemia (SAA) in combination with standard immunosuppressive therapy (IST). Promacta is already marketed for SAA for patients who have had an insufficient response to IST. A decision by the European Medicines Agency for a similar label expansion is expected in 2019. Promacta was also granted a Breakthrough Therapy designation by the FDA as a counter measure for hematopoietic sub-syndrome of acute radiation syndrome (H-ARS).
Glaxo Files for Approval of Nucala in Pediatric Patients : Glaxo filed a supplemental Biologics License Application (sBLA) to the FDA, seeking label expansion of its severe eosinophilic asthma drug, Nucala, in pediatric patients (aged six to 11 years) in the United States. The drug is already marketed in the United States and EU for patients aged 12 years or older. In the EU, it received approval for pediatric use (from aged six-17 years) in severe eosinophilic asthma in August. Nucala is a key drug in Galxo's respiratory portfolio, recording sales growth of 81% at constant exchange rate in the first nine months of 2018.
FDA Accepts Allergan's sNDA for Avycaz: The FDA accepted Allergan's sNDA looking for approval of the latter's antibacterial medicine, Avycaz, for the pediatric patient population. The sNDA is seeking approval for Avycaz for the treatment of complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI - in combination with metronidazole) in pediatric patients, aged three months and above. Avycaz is already approved to treat these infections in adult patients.
The NYSE ARCA Pharmaceutical Index declined 0.9% in the last four trading sessions.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss . This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
GlaxoSmithKline plc (GSK): Free Stock Analysis Report
AstraZeneca PLC (AZN): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include: PfizerPFE , AbbVieABBV , J&JJNJ , GlaxoGSK and AstraZenecaAZN . Here are highlights from Friday's Analyst Blog: Pharma Stock Roundup: PFE, ABBV & More This week, the FDA granted approval to Pfizer's Daurismo, the drug giant's fourth new cancer drug in less than three months. It also approved the label expansion of AbbVie/Roche's drug Venclexta. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include: PfizerPFE , AbbVieABBV , J&JJNJ , GlaxoGSK and AstraZenecaAZN . Here are highlights from Friday's Analyst Blog: Pharma Stock Roundup: PFE, ABBV & More This week, the FDA granted approval to Pfizer's Daurismo, the drug giant's fourth new cancer drug in less than three months. | AbbVie/Roche Get FDA Nod for Venclexta in First-Line AML : FDA also granted accelerated approval to AbbVie and partner Roche's supplemental new drug application (sNDA) looking for a label expansion of Venclexta (venetoclax) for the first-line treatment of acute myeloid leukemia (AML), one of the most aggressive blood cancers. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include: PfizerPFE , AbbVieABBV , J&JJNJ , GlaxoGSK and AstraZenecaAZN . | AbbVie/Roche Get FDA Nod for Venclexta in First-Line AML : FDA also granted accelerated approval to AbbVie and partner Roche's supplemental new drug application (sNDA) looking for a label expansion of Venclexta (venetoclax) for the first-line treatment of acute myeloid leukemia (AML), one of the most aggressive blood cancers. Stocks recently featured in the blog include: PfizerPFE , AbbVieABBV , J&JJNJ , GlaxoGSK and AstraZenecaAZN . Here are highlights from Friday's Analyst Blog: Pharma Stock Roundup: PFE, ABBV & More This week, the FDA granted approval to Pfizer's Daurismo, the drug giant's fourth new cancer drug in less than three months. |
25253.0 | 2018-11-26 00:00:00 UTC | Gilead's HIV Franchise, CAR T Therapy Likely to Propel Growth | ABBV | https://www.nasdaq.com/articles/gileads-hiv-franchise-car-t-therapy-likely-to-propel-growth-2018-11-26 | nan | nan | Shares of biotech bigwig Gilead Sciences, Inc . GILD have inched up 0.4% in the past six months, against the industry 's 10.3% decline.
While the legacy HCV business has declined significantly of late due to competitive pressure from the likes of AbbVie ABBV , among others, the company's HIV business has maintained momentum.
Gilead is a dominant player in the HIV market with an impressive product portfolio. The company was the first to bring to market a single-tablet regimen (STR) for the treatment of HIV - Atripla. Additional STRs for HIV in the market include Complera/Eviplera and Stribild, among others. TAF-based products like Genvoya, Odefsey and Descovy are performing well with strong adoption in both the United States and Europe. The company received a major boost when the FDA approved its once-daily single tablet regimen ("STR"), Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF) for HIV-1 infection. The approval, which comes ahead of the PDUFA date of Feb 12, 2018, significantly boosts Gilead's HIV franchise. Biktarvy combines the novel, unboosted integrase strand transfer inhibitor ("INSTI") bictegravir, with the demonstrated safety and efficacy profile of the Descovy, (FTC/TAF). The approval of this new HIV therapy will pose stiff competition to GlaxoSmith's GSK existing therapies, Tivicay and Triumeq. The recent approval in Europe will further strengthen the company's HIV franchise.
Given the persistent decline in HCV sales, the company is looking to HIV and newer avenues to help the top line. The initial uptake of Yescarta (from the Kite Pharma acquisition) is slow but encouraging.
We expect the HIV franchise and CAR-T therapy Yescarta to drive growth for the company.
Gilead has a robust pipeline with several development programs currently underway, ranging from phase I through phase III. The company has quite a few programs targeting non-alcoholic steatohepatitis (NASH) with advanced fibrosis, including selonsertib (ASK-1 inhibitor; phase III), GS-9674 (FXR agonist; phase II) and GS-0976 (ACC inhibitor; phase II). Meanwhile, Gilead has been developing a pipeline targeting inflammatory diseases. Phase III studies on filgotinib for the treatment of RA and Crohn's disease are currently ongoing.
The company also has a collaboration agreement with Sangamo Therapeutics, Inc. SGMO to use Sangamo's zinc finger nuclease technology platform for the development of next-generation ex vivo cell therapies in oncology.
Zacks Rank
Gilead currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
GlaxoSmithKline plc (GSK): Free Stock Analysis Report
Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | While the legacy HCV business has declined significantly of late due to competitive pressure from the likes of AbbVie ABBV , among others, the company's HIV business has maintained momentum. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. TAF-based products like Genvoya, Odefsey and Descovy are performing well with strong adoption in both the United States and Europe. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. While the legacy HCV business has declined significantly of late due to competitive pressure from the likes of AbbVie ABBV , among others, the company's HIV business has maintained momentum. The company has quite a few programs targeting non-alcoholic steatohepatitis (NASH) with advanced fibrosis, including selonsertib (ASK-1 inhibitor; phase III), GS-9674 (FXR agonist; phase II) and GS-0976 (ACC inhibitor; phase II). | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. While the legacy HCV business has declined significantly of late due to competitive pressure from the likes of AbbVie ABBV , among others, the company's HIV business has maintained momentum. The company has quite a few programs targeting non-alcoholic steatohepatitis (NASH) with advanced fibrosis, including selonsertib (ASK-1 inhibitor; phase III), GS-9674 (FXR agonist; phase II) and GS-0976 (ACC inhibitor; phase II). | While the legacy HCV business has declined significantly of late due to competitive pressure from the likes of AbbVie ABBV , among others, the company's HIV business has maintained momentum. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. The company was the first to bring to market a single-tablet regimen (STR) for the treatment of HIV - Atripla. |
25254.0 | 2018-11-25 00:00:00 UTC | 2 Cheap Dividend Stocks You Can Buy Right Now | ABBV | https://www.nasdaq.com/articles/2-cheap-dividend-stocks-you-can-buy-right-now-2018-11-25 | nan | nan | Patient investors who let cash accumulate during the bull market of early 2018 have more than leftover turkey to be thankful for at the moment. After tumbling along with much of the broad market, shares of AbbVie (NYSE: ABBV) and Physicians Realty Trust (NYSE: DOC) offer healthy dividends at attractive yields.
Above-average yields always come with extra risks that investors need to understand. With powerful demographic trends in their favor, though, these two dividend-paying healthcare stocks are poised to outperform over the long run.
Physicians Realty Trust: The doctors will pay you now
Physicians Realty Trust is a real estate investment trust ( REIT ) that makes nearly all its money by collecting rent from medical office buildings that it owns but doesn't operate. Despite a solid performance, the stock has fallen 5% this year and offers a nice 5.4% yield at recent prices.
The first baby boomers began turning 65 in 2011, and are an age group that spends around three times as much on healthcare each year as other groups. This long-running demographic trend and a hands-off approach could allow this REIT to pay a steadily growing dividend throughout your retirement.
Physicians Realty has relationships with large health systems that can keep paying the rent even if conditions in one geographic area stumble. At the end of September, 96% of this REIT's portfolio of 250 properties were leased with an average term of eight years. Four-fifths of leases are of the triple-net variety , which leaves its renters responsible for all the variable costs that come with its properties, including taxes and building maintenance.
Physicians' real estate portfolio has grown at a hair-raising pace from $124 million in 2013 to $4.3 billion at the end of September. The REIT has completed three nine-figure portfolio acquisitions since the beginning of 2015, and funds from operations ( FFO ) per share have risen 198% over the same time frame.
In the years ahead, it looks like we can expect the company to raise its payout at roughly the same pace as its fast-growing bottom line. Physicians Realty's most recent quarterly dividend, when annualized, works out to just 79% of FFO generated over the past 12 months.
AbbVie: A Dividend Aristocrat offering 5%
When AbbVie reported third-quarter earnings recently, management raised its adjusted earnings-per-share outlook to a level that is 41% higher than last year. Despite being a Dividend Aristocrat with screaming-fast earnings growth, AbbVie stock has fallen about 30% from a peak reached in January, when it assured investors that Humira sales would continue rising for at least a few more years despite the expiration of its main U.S. patent.
Global Humira sales reached an annualized run rate of $20.5 billion in the third quarter, which means it still makes up 62% of total revenue for the company. A handful of drugmakers with approved Humira biosimilars likely to launch at competitive prices have agreed to hold off until 2023 in the U.S.
Big pharma hasn't been nearly as successful at holding back biosimilar competition in Europe, where AbbVie books a significant portion of Humira sales. International Humira revenue that reached an annualized $6.3 billion in the third quarter will probably become a high-water mark. Humira biosimilars launched in the EU in October, and AbbVie has already begun offering government payers deep discounts to maintain its share of the market.
To help investors forget about impending Humira losses, AbbVie has already boosted its dividend payout twice in 2018. Despite giving shareholders a 51% raise this year, AbbVie's operations are profitable enough to suffer a big hit and retain its Dividend Aristocrat status. The recently raised payout, when annualized, works out to just 56% of the free cash flow that operations generated over the past 12 months.
Humira is probably near a peak, but AbbVie is trading at just 11.3 times free cash flow right now. That's cheap enough to deliver market-thumping gains over the long run, as long as the company's late-stage pipeline continues to deliver blockbusters that offset Humira losses.
AbbVie's Orilissa recently became the first new treatment to reduce pain and other symptoms of endometriosis, and a study to support an expansion to treat women affected by uterine fibroids recently reported blockbuster results. These conditions affect a majority of women before they reach the age of 50, and available treatment options don't always get the job done.
Something for everyone
Orilissa is just one of several products in position to offset impending Humira losses over the next several years and help AbbVie crank up that dividend even higher. While it's a cheap dividend stock worth buying now, unexpected trouble with drugs in development or swifter-than-expected Humira losses could send the shares into a tailspin.
If you're more interested in steady gains and don't have a stomach for roller-coaster investing, Physicians Realty Trust is probably right up your alley.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Despite being a Dividend Aristocrat with screaming-fast earnings growth, AbbVie stock has fallen about 30% from a peak reached in January, when it assured investors that Humira sales would continue rising for at least a few more years despite the expiration of its main U.S. patent. Humira biosimilars launched in the EU in October, and AbbVie has already begun offering government payers deep discounts to maintain its share of the market. After tumbling along with much of the broad market, shares of AbbVie (NYSE: ABBV) and Physicians Realty Trust (NYSE: DOC) offer healthy dividends at attractive yields. | After tumbling along with much of the broad market, shares of AbbVie (NYSE: ABBV) and Physicians Realty Trust (NYSE: DOC) offer healthy dividends at attractive yields. AbbVie: A Dividend Aristocrat offering 5% When AbbVie reported third-quarter earnings recently, management raised its adjusted earnings-per-share outlook to a level that is 41% higher than last year. Despite being a Dividend Aristocrat with screaming-fast earnings growth, AbbVie stock has fallen about 30% from a peak reached in January, when it assured investors that Humira sales would continue rising for at least a few more years despite the expiration of its main U.S. patent. | AbbVie: A Dividend Aristocrat offering 5% When AbbVie reported third-quarter earnings recently, management raised its adjusted earnings-per-share outlook to a level that is 41% higher than last year. Despite being a Dividend Aristocrat with screaming-fast earnings growth, AbbVie stock has fallen about 30% from a peak reached in January, when it assured investors that Humira sales would continue rising for at least a few more years despite the expiration of its main U.S. patent. After tumbling along with much of the broad market, shares of AbbVie (NYSE: ABBV) and Physicians Realty Trust (NYSE: DOC) offer healthy dividends at attractive yields. | Despite being a Dividend Aristocrat with screaming-fast earnings growth, AbbVie stock has fallen about 30% from a peak reached in January, when it assured investors that Humira sales would continue rising for at least a few more years despite the expiration of its main U.S. patent. After tumbling along with much of the broad market, shares of AbbVie (NYSE: ABBV) and Physicians Realty Trust (NYSE: DOC) offer healthy dividends at attractive yields. AbbVie: A Dividend Aristocrat offering 5% When AbbVie reported third-quarter earnings recently, management raised its adjusted earnings-per-share outlook to a level that is 41% higher than last year. |
25255.0 | 2018-11-23 00:00:00 UTC | Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-cancer-approvals-for-pfe-abbv-chmp-nod-for-several-drugs-2018-11-23 | nan | nan | This week, the FDA granted approval to Pfizer's PFE Daurismo, the drug giant's fourth new cancer drug in less than three months. It also approved the label expansion of AbbVie ABBV /Roche's drug Venclexta. Both the drugs gained approval for the treatment of acute myeloid leukemia (AML), a rare blood cancer in newly diagnosed patients. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) gave positive recommendations for granting marketing approval to several drugs this week.
Recap of the Week's Most Important Stories
Pfizer Gets FDA Nod for Rare Cancer Medicine: The FDA granted approval to Daurismo for a rare blood cancer, Pfizer's fourth cancer medicine in less than three months. Daurismo (glasdegib), a once-daily oral medicine is approved for use in combination with low-dose cytarabine (LDAC) - a kind of chemotherapy treatment - for the treatment of newly-diagnosed acute myeloid leukemia (AML) in patients 75 years or older or who cannot take intensive chemotherapy. However, the approval comes with a boxed warning on the U.S. label for embryo-fetal toxicity
Pfizer's recent new cancer drug approvals include Lorbrena (lorlatinib) for second line non-small-cell lung cancer, Vizimpro (dacomitinib) for advanced NSCLC with EGFR activating mutations and Talzenna (talazoparib), an orally-available PARP inhibitor for advanced breast cancer.
However, Pfizer's late-stage study evaluating its PD-L1 inhibitor Bavencio (avelumab), in patients with platinum-resistant/refractory ovarian cancer, failed to meet the primary endpoints of overall survival (OS) or progression-free survival (PFS).In the study, both PFS and OS did not reach statistical significance. Bavencio is marketed for metastatic Merkel cell carcinoma in the United States, Europe and Japan and for the second-line treatment of locally advanced or metastatic urothelial carcinoma in the United States.
Pfizer was also in news this week as a Wall Street report stated that it plans to increase the list prices of 41 prescription drugs in 2019. The drug giant had put off such increases earlier this year as it faced criticism from President Trump.
AbbVie/Roche Get FDA Nod for Venclexta in First-Line AML : FDA also granted accelerated approval to AbbVie and partner Roche's supplemental new drug application (sNDA) looking for a label expansion of Venclexta (venetoclax) for the first-line treatment of acute myeloid leukemia (AML), one of the most aggressive blood cancers.
Venclexta can now be prescribed in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) in AML patients who are ineligible for intensive chemotherapy. Venclexta is now approved for two different blood cancers in the United States - newly-diagnosed AML and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
CHMP Gives Positive Opinion to Several Drugs : The CHMP gave a positive opinion, recommending approval of J&J's JNJ Erleada (apalutamide) for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. Erleada gained FDA approval in the United States in February. The CHMP also gave a nod to Glaxo's GSK filing looking for EU approval of its HIV drug, Tivicay as a two-drug regimen (2DR) in combination with lamivudine.
The regulatory submission for the update to the Tivicay EU label is based on data from phase III GEMINI 1 & 2 studies. Sanofi SNY also gained positive CHMP opinion for fexinidazole, an oral treatment for human African trypanosomiasis (HAT) or sleeping sickness. Novartis' NVS filing looking for label expansion of its CDK4/6 inhibitor, Kisqali in combination with fulvestrant, as a first or second-line treatment for HR+/HER2- locally advanced or metastatic breast cancer, also received CHMP nod. The final decision by the European Union on these products is expected in the coming months.
AstraZeneca Presents Final OS Data From MYSTIC Study: AstraZeneca AZN announced final overall survival data from the pivotal phase III MYSTIC study, evaluating Imfinzi in first-line lung cancer. The MYSTIC study evaluated Imfinzi, both as a monotherapy and in combination with tremelimumab, in treatment-naïve non-small cell lung cancer (NSCLC) patients whose tumors express PD-L1 on 25% or more of their cancer cells.The data from the primary analysis population of patients showed that Imfinzi monotherapy as well as in combination with tremelimumab failed to achieve statistical significance in the primary endpoint of overall survival compared to standard-of-care platinum-based chemotherapy. Per data announced in July last year, the study failed to show improvement in progression-free survival, thereby failing to meet the first primary endpoint.
Novartis Gets FDA Nod for Promacta in First-Line Setting: Novartis gained FDA approval for label expansion of its anemia drug, Promacta as a first-line treatment option for severe aplastic anemia (SAA) in combination with standard immunosuppressive therapy (IST). Promacta is already marketed for SAA for patients who have had an insufficient response to IST. A decision by the European Medicines Agency for a similar label expansion is expected in 2019. Promacta was also granted a Breakthrough Therapy designation by the FDA as a counter measure for hematopoietic sub-syndrome of acute radiation syndrome (H-ARS).
Glaxo Files for Approval of Nucala in Pediatric Patients : Glaxo filed a supplemental Biologics License Application (sBLA) to the FDA, seeking label expansion of its severe eosinophilic asthma drug, Nucala, in pediatric patients (aged six to 11 years) in the United States. The drug is already marketed in the United States and EU for patients aged 12 years or older. In the EU, it received approval for pediatric use (from aged six-17 years) in severe eosinophilic asthma in August. Nucala is a key drug in Galxo's respiratory portfolio, recording sales growth of 81% at constant exchange rate in the first nine months of 2018.
FDA Accepts Allergan's sNDA for Avycaz: The FDA accepted Allergan's sNDA looking for approval of the latter's antibacterial medicine, Avycaz, for the pediatric patient population. The sNDA is seeking approval for Avycaz for the treatment of complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI - in combination with metronidazole) in pediatric patients, aged three months and above. Avycaz is already approved to treat these infections in adult patients.
The NYSE ARCA Pharmaceutical Index declined 0.9% in the last four trading sessions.
Large Cap Pharmaceuticals Industry 5YR % Return
Large Cap Pharmaceuticals Industry 5YR % Return
Here is how the seven major stocks performed in the last four trading sessions:
None of the stocks recorded any significant increase. Glaxo recorded the highest gain (0.3%) while AstraZeneca declined the most (2.8%) in the last four trading sessions.
In the past six months, Lilly has been the biggest gainer (35.7%) while Glaxo recorded the lowest gain (1.2%).
(See the last pharma stock roundup here: FDA Updates on MRK, AZN's Cancer Drugs, Bayer's Q3 Earnings )
What's Next in the Pharma World?
Watch out for pipeline and regulatory updates next week.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sanofi (SNY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Novartis AG (NVS): Free Stock Analysis Report
AstraZeneca PLC (AZN): Free Stock Analysis Report
GlaxoSmithKline plc (GSK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It also approved the label expansion of AbbVie ABBV /Roche's drug Venclexta. AbbVie/Roche Get FDA Nod for Venclexta in First-Line AML : FDA also granted accelerated approval to AbbVie and partner Roche's supplemental new drug application (sNDA) looking for a label expansion of Venclexta (venetoclax) for the first-line treatment of acute myeloid leukemia (AML), one of the most aggressive blood cancers. Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report To read this article on Zacks.com click here. It also approved the label expansion of AbbVie ABBV /Roche's drug Venclexta. AbbVie/Roche Get FDA Nod for Venclexta in First-Line AML : FDA also granted accelerated approval to AbbVie and partner Roche's supplemental new drug application (sNDA) looking for a label expansion of Venclexta (venetoclax) for the first-line treatment of acute myeloid leukemia (AML), one of the most aggressive blood cancers. | Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report To read this article on Zacks.com click here. It also approved the label expansion of AbbVie ABBV /Roche's drug Venclexta. AbbVie/Roche Get FDA Nod for Venclexta in First-Line AML : FDA also granted accelerated approval to AbbVie and partner Roche's supplemental new drug application (sNDA) looking for a label expansion of Venclexta (venetoclax) for the first-line treatment of acute myeloid leukemia (AML), one of the most aggressive blood cancers. | AbbVie/Roche Get FDA Nod for Venclexta in First-Line AML : FDA also granted accelerated approval to AbbVie and partner Roche's supplemental new drug application (sNDA) looking for a label expansion of Venclexta (venetoclax) for the first-line treatment of acute myeloid leukemia (AML), one of the most aggressive blood cancers. It also approved the label expansion of AbbVie ABBV /Roche's drug Venclexta. Click to get this free report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report To read this article on Zacks.com click here. |
25256.0 | 2018-11-21 00:00:00 UTC | AbbVie (ABBV) Shares Cross 5% Yield Mark | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-shares-cross-5-yield-mark-2018-11-21 | nan | nan | Looking at the universe of stocks we cover at Dividend Channel , in trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 5% mark based on its quarterly dividend (annualized to $4.28), with the stock changing hands as low as $85.37 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return. To illustrate, suppose for example you purchased shares of the S&P 500 ETF ( SPY ) back on 12/31/1999 - you would have paid $146.88 per share. Fast forward to 12/31/2012 and each share was worth $142.41 on that date, a decrease of $4.67/share over all those years. But now consider that you collected a whopping $25.98 per share in dividends over the same period, for a positive total return of 23.36%. Even with dividends reinvested, that only amounts to an average annual total return of about 1.6%; so by comparison collecting a yield above 5% would appear considerably attractive if that yield is sustainable. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index.
In general, dividend amounts are not always predictable and tend to follow the ups and downs of profitability at each company. In the case of AbbVie Inc, looking at the history chart for ABBV below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 5% annual yield.
ABBV has been growing its dividend for more than 20 years consecutively. For more dividend growth stocks view our Dividend Aristocrats List on Dividend Channel.
Click here to find out which 9 other dividend stocks just recently went on sale »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at the universe of stocks we cover at Dividend Channel , in trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 5% mark based on its quarterly dividend (annualized to $4.28), with the stock changing hands as low as $85.37 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of AbbVie Inc, looking at the history chart for ABBV below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 5% annual yield. | Looking at the universe of stocks we cover at Dividend Channel , in trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 5% mark based on its quarterly dividend (annualized to $4.28), with the stock changing hands as low as $85.37 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of AbbVie Inc, looking at the history chart for ABBV below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 5% annual yield. | Looking at the universe of stocks we cover at Dividend Channel , in trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 5% mark based on its quarterly dividend (annualized to $4.28), with the stock changing hands as low as $85.37 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of AbbVie Inc, looking at the history chart for ABBV below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 5% annual yield. | Looking at the universe of stocks we cover at Dividend Channel , in trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) were yielding above the 5% mark based on its quarterly dividend (annualized to $4.28), with the stock changing hands as low as $85.37 on the day. AbbVie Inc (Symbol: ABBV) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of AbbVie Inc, looking at the history chart for ABBV below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 5% annual yield. |
25257.0 | 2018-11-20 00:00:00 UTC | AbbVie (ABBV) Stock Moves -1.55%: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-moves-1.55%3A-what-you-should-know-2018-11-20 | nan | nan | In the latest trading session, AbbVie (ABBV) closed at $88.09, marking a -1.55% move from the previous day. This change was narrower than the S&P 500's 1.82% loss on the day. Elsewhere, the Dow lost 2.21%, while the tech-heavy Nasdaq lost 1.7%.
Heading into today, shares of the drugmaker had gained 6.18% over the past month, outpacing the Medical sector's loss of 1.44% and the S&P 500's loss of 2.57% in that time.
Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. This is expected to be January 25, 2019. The company is expected to report EPS of $1.92, up 29.73% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $8.36 billion, up 8.07% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $7.93 per share and revenue of $32.78 billion. These totals would mark changes of +41.61% and +16.17%, respectively, from last year.
Any recent changes to analyst estimates for ABBV should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.95% higher within the past month. ABBV is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note ABBV's current valuation metrics, including its Forward P/E ratio of 11.28. For comparison, its industry has an average Forward P/E of 17.07, which means ABBV is trading at a discount to the group.
It is also worth noting that ABBV currently has a PEG ratio of 0.83. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.09 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 86, putting it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABBV in the coming trading sessions, be sure to utilize Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the latest trading session, AbbVie (ABBV) closed at $88.09, marking a -1.55% move from the previous day. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. Any recent changes to analyst estimates for ABBV should also be noted by investors. | In the latest trading session, AbbVie (ABBV) closed at $88.09, marking a -1.55% move from the previous day. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. Any recent changes to analyst estimates for ABBV should also be noted by investors. | In the latest trading session, AbbVie (ABBV) closed at $88.09, marking a -1.55% move from the previous day. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. Any recent changes to analyst estimates for ABBV should also be noted by investors. | In the latest trading session, AbbVie (ABBV) closed at $88.09, marking a -1.55% move from the previous day. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. Any recent changes to analyst estimates for ABBV should also be noted by investors. |
25258.0 | 2018-11-20 00:00:00 UTC | 3 Top Large-Cap Stocks to Buy in November | ABBV | https://www.nasdaq.com/articles/3-top-large-cap-stocks-buy-november-2018-11-20 | nan | nan | Large-cap stocks typically provide investors with consistency and stability, two features investors are sorely lacking from the rest of the market these days. While not a guarantee against suffering whipsaws in volatility, large-cap stocks can provide investors with a bit more than a modicum of reassurance that they will be around tomorrow when all is said and done.
Three Motley Fool contributors selected AbbVie (NYSE: ABBV) , 3M (NYSE: MMM) , and Netflix (NASDAQ: NFLX) as large-cap stocks to buy in November.
Buy the fear
George Budwell (AbbVie): AbbVie, the maker of the world's best-selling medicine, Humira, has had a particularly rough year in 2018. Despite strong earnings over the course of the first nine months of the year and management's decision to up the company's top-flight dividend yet again during the most recent quarter, AbbVie's stock has now fallen by nearly 18% this year.
The drugmaker's stock is thus trading at a mere nine times forward-looking earnings. That's a dirt cheap valuation for a company that's both a Dividend Aristocrat and one of the fastest-growing large-cap biopharmas in the industry right now.
Why is AbbVie's stock having such a hard time in 2018? The key issue is the future of Humira's revenue stream. Biosimilar competition is reportedly driving deep price cuts in some European markets, which is obviously a serious issue for investors to keep an eye on. Humira, after all, currently makes up about 60% of AbbVie's total revenues.
The good news, though, is that biosimilar competition won't cut into Humira's all-important U.S. sales until 2023 at the earliest. The company has also made major strides toward diversifying its revenue stream. In the third quarter, for instance, AbbVie's hematology/oncology product sales eclipsed $1 billion for the three-month period, thanks to the strong performance of both Imbruvica and Venclexta. AbbVie is also close to bringing several additional high-value product candidates to market, such as the psoriasis medication risankizumab, among others.
All told, AbbVie still expects its top line to grow by double digits in 2019 -- despite the international headwinds swirling around Humira at the moment. This pronounced sell-off, therefore, might turn out to be an incredible buying opportunity for investors willing to tolerate some near-term volatility.
3M just revealed where it could be 5 years from now
Neha Chamaria(3M): Shares in this industrial conglomerate haven't had a great ride so far this year as broader pressure on industrial stocks in recent months was exacerbated by 3M's third-quarter earnings report that turned out to be a damp squib. Amid the pessimism, 3M's recent Investor Day event, which helped the stock gain some ground, should make investors hopeful.
The Nov. 15 event was critical as 3M was not only expected to preview its outlook for 2019 but also reveal its growth plans and financial goals for the next five years. The company did just that: It laid down clear-cut financial goals through 2023, most of which are in line with its previous five-year plan but address some of the concerns that 3M bears may have. Here's what 3M expects to achieve between 2019 and 2023:
3%-5% organic local currency growth in sales.
8%-11% growth in earnings per share.
20% return on invested capital.
100% conversion of net income to free cash flow (FCF).
If the low- to mid-single-digit sales growth doesn't impress you, let's not forget that 3M isn't the kind of company to grow like gangbusters given its product line and the industry it operates in. Also, management's sales guidance is a tad better than its goals in the previous five-year plan that ran from 2016 to 2020, which suggests that fears of 3M's slowdown might be overblown.
At current prices, income investors, in particular, are in for a treat as 3M is a top Dividend King and should reward shareholders with its 61st dividend hike come January. Beyond that, the company's strong EPS and FCF conversion goals should assure shareholders of bigger dividends year after year.
Ready for the big screen
Rich Duprey (Netflix): Since peaking at around $423 per share this summer, Netflix has lost more than a third of its value despite reporting strong third-quarter earnings and subscriber growth. Much of the fear surrounding the stock is that the easy money has been made and it faces a more uncertain future as competition intensifies.
And that's not just from other streaming services like Amazon.com (NASDAQ: AMZN) but also from those producing their own original content. Chasing more programming means Netflix has to spend more, above even the $13 billion it's already committed to spending. While the service has been lauded for the quality of its original programming, supplanting HBO as the top Emmy nominee, it's going to need to do more to keep the pace going.
Netflix is trying a slightly different tack now by introducing some of its movies first into theaters before offering them on its service. It has allowed some of its movies to be shown on the big screen in the past, but this time is different because it's giving the theaters a window of exclusivity that it didn't before.
This is important because it gives its movies a chance to earn Oscar nominations, something a few Amazon movies have done, but also allows it to attract top-tier talent. For example, one of the movies now playing on Netflix after being shown in theaters for several weeks, The Ballad of Buster Scruggs , is directed by the Coen brothers. Netflix has a movie from Martin Scorsese due out soon.
A-list talent will bring even more people to Netflix, so don't underestimate the company's ability to keep surprising analysts by racking up more award-winning results.
10 stocks we like better than Netflix
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Netflix wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. George Budwell owns shares of AbbVie. Neha Chamaria has no position in any of the stocks mentioned. Rich Duprey has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Amazon and Netflix. The Motley Fool recommends 3M. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the third quarter, for instance, AbbVie's hematology/oncology product sales eclipsed $1 billion for the three-month period, thanks to the strong performance of both Imbruvica and Venclexta. Three Motley Fool contributors selected AbbVie (NYSE: ABBV) , 3M (NYSE: MMM) , and Netflix (NASDAQ: NFLX) as large-cap stocks to buy in November. Buy the fear George Budwell (AbbVie): AbbVie, the maker of the world's best-selling medicine, Humira, has had a particularly rough year in 2018. | Three Motley Fool contributors selected AbbVie (NYSE: ABBV) , 3M (NYSE: MMM) , and Netflix (NASDAQ: NFLX) as large-cap stocks to buy in November. Buy the fear George Budwell (AbbVie): AbbVie, the maker of the world's best-selling medicine, Humira, has had a particularly rough year in 2018. Despite strong earnings over the course of the first nine months of the year and management's decision to up the company's top-flight dividend yet again during the most recent quarter, AbbVie's stock has now fallen by nearly 18% this year. | Three Motley Fool contributors selected AbbVie (NYSE: ABBV) , 3M (NYSE: MMM) , and Netflix (NASDAQ: NFLX) as large-cap stocks to buy in November. Despite strong earnings over the course of the first nine months of the year and management's decision to up the company's top-flight dividend yet again during the most recent quarter, AbbVie's stock has now fallen by nearly 18% this year. Buy the fear George Budwell (AbbVie): AbbVie, the maker of the world's best-selling medicine, Humira, has had a particularly rough year in 2018. | Three Motley Fool contributors selected AbbVie (NYSE: ABBV) , 3M (NYSE: MMM) , and Netflix (NASDAQ: NFLX) as large-cap stocks to buy in November. Buy the fear George Budwell (AbbVie): AbbVie, the maker of the world's best-selling medicine, Humira, has had a particularly rough year in 2018. Despite strong earnings over the course of the first nine months of the year and management's decision to up the company's top-flight dividend yet again during the most recent quarter, AbbVie's stock has now fallen by nearly 18% this year. |
25259.0 | 2018-11-19 00:00:00 UTC | Should Value Investors Consider AbbVie (ABBV) Stock Now? | ABBV | https://www.nasdaq.com/articles/should-value-investors-consider-abbvie-abbv-stock-now-2018-11-19 | nan | nan | Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn't want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let's put AbbVie Inc.ABBV stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:
PE Ratio
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock's current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, AbbVie has a trailing twelve months PE ratio of 12.2, as you can see in the chart below:
This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 17.8. If we focus on the long-term PE trend, AbbVie's current PE level puts it below its midpoint over the past five years. Moreover, the current level is fairly below the highs for this stock, suggesting it might be a good entry point.
Further, the stock's PE also compares favorably with the industry's trailing twelve months PE ratio, which stands at 15.9. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.
We should also point out that AbbVie has a forward PE ratio (price relative to this year's earnings) of just 11.5, so it is fair to say that a slightly more value-oriented path may be ahead for AbbVie stock in the near term too.
P/S Ratio
Another key metric to note is the Price/Sales ratio. This approach compares a given stock's price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.
Right now, AbbVie has a P/S ratio of about 4.3. While this is higher than the S&P 500 average, which comes in at 3.2 right now, as we can see in the chart below, this is well below the highs for this stock in particular over the past few years.
If anything, ABBV is toward the lower end of its range in the time period from a P/S metric, suggesting some level of undervalued trading-at least compared to historical norms.
Broad Value Outlook
In aggregate, AbbVie currently has a Zacks Value Style Score of B, putting it into the top 40% of all stocks we cover from this look. This makes AbbVie a solid choice for value investors, and some of its other key metrics make this pretty clear too.
For example, the PEG ratio for AbbVie is just 0.9, a level that is lower than the industry average of 2.0. The PEG ratio is a modified PE ratio that takes into account the stock's earnings growth rate. Clearly, ABBV is a solid choice on the value front from multiple angles.
What About the Stock Overall?
Though AbbVie might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth grade of A and a Momentum score of D. This gives ABBV a Zacks VGM score-or its overarching fundamental grade-of A. (You can read more about the Zacks Style Scores here >> )
Meanwhile, the company's recent earnings estimates have been mixed at best. The current quarter has seen one estimate go higher in the past sixty days compared to five lower, while the full year estimate has seen nine upward and no downward revisions in the same time period.
As a result, the current quarter consensus estimate has fallen by 3.5% in the past two months, while the full year estimate has inched up by 0.9%. You can see the consensus estimate trend and recent price action for the stock in the chart below:
AbbVie Inc. Price and Consensus
AbbVie Inc. Price and Consensus | AbbVie Inc. Quote
This somewhat mixed trend is why the stock has just a Zacks Rank #3 (Hold) and why we are looking for in-line performance from the company in the near term.
Bottom Line
AbbVie is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Moreover, a strong industry rank (Top 39% out of more than 250 industries) further supports the growth potential of the stock. In fact, over the past one year, the industry has outperformed the broader market, as you can see below:
However, with a Zacks Rank #3, it is hard to get too excited about this company overall. So, value investors might want to wait for estimates and analyst sentiment to turn around in this name first, but once that happens, this stock could be a compelling pick.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | If anything, ABBV is toward the lower end of its range in the time period from a P/S metric, suggesting some level of undervalued trading-at least compared to historical norms. In particular, it is worth noting that the company has a Growth grade of A and a Momentum score of D. This gives ABBV a Zacks VGM score-or its overarching fundamental grade-of A. Let's put AbbVie Inc.ABBV stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks: PE Ratio A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. | If we focus on the long-term PE trend, AbbVie's current PE level puts it below its midpoint over the past five years. You can see the consensus estimate trend and recent price action for the stock in the chart below: AbbVie Inc. Price and Consensus AbbVie Inc. Price and Consensus | AbbVie Inc. Quote This somewhat mixed trend is why the stock has just a Zacks Rank #3 (Hold) and why we are looking for in-line performance from the company in the near term. Let's put AbbVie Inc.ABBV stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks: PE Ratio A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. | Let's put AbbVie Inc.ABBV stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks: PE Ratio A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. You can see the consensus estimate trend and recent price action for the stock in the chart below: AbbVie Inc. Price and Consensus AbbVie Inc. Price and Consensus | AbbVie Inc. Quote This somewhat mixed trend is why the stock has just a Zacks Rank #3 (Hold) and why we are looking for in-line performance from the company in the near term. On this front, AbbVie has a trailing twelve months PE ratio of 12.2, as you can see in the chart below: This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 17.8. | Let's put AbbVie Inc.ABBV stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks: PE Ratio A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. Right now, AbbVie has a P/S ratio of about 4.3. On this front, AbbVie has a trailing twelve months PE ratio of 12.2, as you can see in the chart below: This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 17.8. |
25260.0 | 2018-11-19 00:00:00 UTC | Vertex (VRTX) Gets Positive CHMP Opinion for Orkambi in Kids | ABBV | https://www.nasdaq.com/articles/vertex-vrtx-gets-positive-chmp-opinion-for-orkambi-in-kids-2018-11-19 | nan | nan | Vertex Pharmaceuticals Inc.VRTX announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval for expanded use of Orkambi. The opinion is given for Orkambi (lumacaftor/ivacaftor) to treat children with cystic fibrosis (CF) aged two to five years who have two copies of the F508del mutation.
Approximately 1,500 people in Europe in this age group suffer from this most common form of CF disease, thus making Orkambi eligible to treat expanded patient populations.
Orkambi is already approved in the U.S. and Europe for the treatment of CF in patients aged six or older who have two copies of the F508del mutation. It was approved in the United States for the two to five years age group in August.
The CHMP opinion was based on data from a phase III open-label safety study in 60 patients that showed treatment with Orkambi to be generally well tolerated for 24 weeks, with a safety profile similar to that in patients aged 6 years or older.
The stock has gained 10.2% so far this year, against the 18% decline registered by the industry .
Sales of Orkambi were down 16.1% year over year in the third quarter of 2018 to $282 million due to a switch in patient base to Vertex's third and newest CF medicine, Symdeko from Orkambi, which targets the same population. Orkambi revenues are expected to be hurt by this switch during the third quarter of 2018.
Other than Orkambi and Symdeko, Vertex also has Kalydeco (ivacaftor) in its CF product portfolio. We remind investors that, Symdeko is a combination of tezacaftor and ivacaftor, which was launched in the United States in February 2018 for treating CF patients. The drug has shown strong uptake so far.
The company is developing many new combination regimens with CFTR modulators. The CF correctors could bring in multi-billion dollar sales for Vertex.
Vertex is evaluating two next-generation CFTR correctors (VX-659 and VX-445) in phase III studies as part of a triple combination with tezacaftor and ivacaftor. Vertex is evaluating both the combinations in two separate studies for F508del/Min and F508del homozygous patients.
Both AbbVie ABBV and Galapagos NV's GLPG were jointly developing CF product candidates, which included a triple regimen combination. However, last month, AbbVie announced that it is taking full commercial and development responsibility of all clinical/pre-clinical programs in cystic fibrosis products, which were originally discovered and developed in partnership with Galapagos.
AbbVie will now continue the development of the triple combination therapy for CF. Corbus Pharmaceuticals Holdings, Inc. CRBP is developing a CF candidate, lenabasum, in a mid-stage study.
Vertex Pharmaceuticals Inc. Price
Vertex Pharmaceuticals Incorporated Price | Vertex Pharmaceuticals Incorporated Quote
Zacks Rank
Vertex is a Zacks Rank #3 (Hold) stock. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Galapagos NV (GLPG): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Both AbbVie ABBV and Galapagos NV's GLPG were jointly developing CF product candidates, which included a triple regimen combination. However, last month, AbbVie announced that it is taking full commercial and development responsibility of all clinical/pre-clinical programs in cystic fibrosis products, which were originally discovered and developed in partnership with Galapagos. AbbVie will now continue the development of the triple combination therapy for CF. | Both AbbVie ABBV and Galapagos NV's GLPG were jointly developing CF product candidates, which included a triple regimen combination. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report To read this article on Zacks.com click here. However, last month, AbbVie announced that it is taking full commercial and development responsibility of all clinical/pre-clinical programs in cystic fibrosis products, which were originally discovered and developed in partnership with Galapagos. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report To read this article on Zacks.com click here. Both AbbVie ABBV and Galapagos NV's GLPG were jointly developing CF product candidates, which included a triple regimen combination. However, last month, AbbVie announced that it is taking full commercial and development responsibility of all clinical/pre-clinical programs in cystic fibrosis products, which were originally discovered and developed in partnership with Galapagos. | Both AbbVie ABBV and Galapagos NV's GLPG were jointly developing CF product candidates, which included a triple regimen combination. However, last month, AbbVie announced that it is taking full commercial and development responsibility of all clinical/pre-clinical programs in cystic fibrosis products, which were originally discovered and developed in partnership with Galapagos. AbbVie will now continue the development of the triple combination therapy for CF. |
25261.0 | 2018-11-18 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On John Neff - 11/18/2018 | ABBV | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-john-neff-11182018-2018-11-18 | nan | nan | The following are the top rated Healthcare stocks according to Validea's Low PE Investor model based on the published strategy of John Neff . This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on John Neff is 81% based on the firm's underlying fundamentals and the stock's valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
MEDTRONIC PLC ( MDT ) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on John Neff is 62% based on the firm's underlying fundamentals and the stock's valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company's subsidiaries include Medtronic, Inc. and HeartWare International, Inc.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
LIGAND PHARMACEUTICALS INC. ( LGND ) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on John Neff is 62% based on the firm's underlying fundamentals and the stock's valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
HCA HEALTHCARE INC ( HCA ) is a large-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on John Neff is 62% based on the firm's underlying fundamentals and the stock's valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: HCA Healthcare, Inc., formerly HCA Holdings, Inc., is a holding company. The Company, through its subsidiaries, owns and operates hospitals and related healthcare entities. As of December 31, 2016, the Company operated in two geographically organized groups, including the National and American Groups. As of December 31, 2016, the National Group included 84 hospitals, which were located in Alaska, California, Florida, southern Georgia, Idaho, Indiana, northern Kentucky, Nevada, New Hampshire, South Carolina, Utah and Virginia. As of December 31, 2016, the American Group included 80 hospitals, which were located in Colorado, northern Georgia, Kansas, southern Kentucky, Louisiana, Mississippi, Missouri, Oklahoma, Tennessee and Texas. As of December 31, 2016, the Company operated six hospitals in England. The Company owns, manages or operates hospitals, freestanding surgery centers and freestanding emergency care facilities, walk-in clinics, diagnostic and imaging centers, among others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
BIOGEN INC ( BIIB ) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on John Neff is 62% based on the firm's underlying fundamentals and the stock's valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
Since its inception, Validea's strategy based on John Neff has returned 127.83% vs. 146.09% for the S&P 500. For more details on this strategy, click here
About John Neff : While known as the manager with whom many top managers entrusted their own money, Neff was far from the smooth-talking, high-profile Wall Streeter you might expect. He was mild-mannered and low-key, and the same might be said of the Windsor Fund that he managed for more than three decades. In fact, Neff himself described the fund as "relatively prosaic, dull, [and] conservative." There was nothing dull about his results, however. From 1964 to 1995, Neff guided Windsor to a 13.7 percent average annual return, easily outpacing the S&P 500's 10.6 percent return during that time. That 3.1 percentage point difference is huge over time -- a $10,000 investment in Windsor (with dividends reinvested) at the start of Neff's tenure would have ended up as more than $564,000 by the time he retired, more than twice what the same investment in the S&P would have yielded (about $233,000). Considering the length of his tenure, that track record may be the best ever for a manager of such a large fund.
About Validea : Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. As of December 31, 2016, the National Group included 84 hospitals, which were located in Alaska, California, Florida, southern Georgia, Idaho, Indiana, northern Kentucky, Nevada, New Hampshire, South Carolina, Utah and Virginia. | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Company Description: Medtronic Public Limited Company (Medtronic) is a medical technology and services company. | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Company Description: Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. |
25262.0 | 2018-11-17 00:00:00 UTC | Why Abbvie Is Down 5% in 2018 So Far | ABBV | https://www.nasdaq.com/articles/why-abbvie-down-5-2018-so-far-2018-11-17 | nan | nan | Buying up shares of AbbVie Inc. (NYSE: ABBV) at the beginning of 2018 seemed like a brilliant idea when the stock shot up 27% before the end of January, but that was simply the first leg of a long roller-coaster ride. By Nov. 1, 2018, AbbVie stock had fallen 35% from its peak earlier in the year and at recent prices, it's given up just 5.4% so far in 2018.
Results from AbbVie's clinical-stage pipeline and rising sales of the world's bestselling drug have given investors plenty of reasons to cheer this year. Unfortunately for AbbVie, its megablockbuster also makes investors nervous. Here's what you need to know about the levers that keep pushing this battleground stock up, then down, on a repeat cycle.
The good news
AbbVie began the year with a bang at the J.P. Morgan Healthcare Conference by sharing expectations for annual Humira sales that suggested they'll continue climbing to $21 billion by 2020. This seems entirely possible considering the anti-inflammation injection is on pace to achieve $20 billion in 2018.
The main U.S. patent for Humira has expired, but AbbVie encased the franchise in a fortress of additional patents that appear to be working as planned. Momenta Pharmaceuticals (NASDAQ: MNTA) recently became the sixth drugmaker to delay the U.S. launch of its biosimilar version of Humira until 2023, and Momenta won't even receive payment from AbbVie in return for the favor.
In January, AbbVie also soothed investor concerns with a bold prediction that non-Humira sales would rise from $9.8 billion in 2017 to $35 billion in 2025. To achieve this goal, AbbVie had eight key growth drivers in mind, four of which hadn't launched yet. Although one of these key assets has already imploded, the rest of the company's leading growth prospects have performed better than expected.
During the first nine months of the year, revenue from AbbVie's share of the blood-cancer tablet Imbruvica jumped 39% higher, to $2.5 billion. Venclexta sales are still getting started, but recent data from a study with leukemia patients could send them into blockbuster territory soon. During the Murano study, 53% of those given Venclexta plus standard care were completely disease-free after nine months compared to just 12% of the group given standard care on its own.
A pipeline ready to deliver
Earlier this year, AbbVie launched Orilissa, the first new treatment for endometriosis-associated pain in over a decade, and it recently took another big step. Endometriosis is a large indication, but uterine fibroids are non-cancerous growths that affect roughly three-fourths of women by age 50 and the leading reason to seek a hysterectomy.
AbbVie has been surging lately because of trial results that suggest Orilissa could make a big difference for millions of women in need of new treatment options. During twin pivotal studies that will support an upcoming application, women taking Orilissa were at least six times more likely than the placebo group to achieve a blood-loss reduction of 50% or better.
Earlier this month, AbbVie told analysts the company's on track to launch two new immunology drugs with blockbuster potential in 2019. The Food and Drug Administration (FDA) is currently reviewing an application for psoriasis candidate risankizumab, which is supported by studies that show it helped more than half of patients achieve complete skin clearance.
Before the end of 2018, AbbVie should have another submission ready for the FDA -- this time, for a rheumatoid arthritis treatment that could become a standard first-line treatment down the road. After 24 weeks of treatment, half of the patients in a group given upadacitinib achieved clinical remission compared to just 18% of those given methotrexate.
The bad news
AbbVie's list of eight key assets lost an important member in March, and the loss stung a bit more than usual. Rova-T's phase 3 flop was especially disappointing because AbbVie ignored lackluster early data and spent $5.8 billion to get its hands on the troubled lung cancer candidate a couple of years earlier.
Rova-T caused investors to lose some confidence, and more recently, investors were rudely reminded of what's at stake in the U.S. several years from now. In October, Humira biosimilars priced to compete launched throughout Europe, a region where AbbVie's peers have been losing market share to low-cost biosimilars for years.
International Humira sales reached $4.9 billion during the first nine months of 2018 and comprised 20% of total revenue during the period. Analysts will be surprised if biosimilars don't cut international Humira sales in half over the next couple of years, and a recent White House proposal backed by Pfizer means U.S. Humira sales could be in trouble sooner than expected.
A ride worth the ticket
Although AbbVie's stock price has been on a roller-coaster ride throughout 2018, this Dividend Aristocrat 's payout has steadily risen 168% in five short years. European Humira biosimilars will make similar gains difficult in the years ahead, but it would take multiple catastrophes to derail this company's payout.
AbbVie shares offer a juicy 4.7% yield, but don't wait too long to make up your mind. The next leg of this roller-coaster ride could be around the corner.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Momenta Pharmaceuticals. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The good news AbbVie began the year with a bang at the J.P. Morgan Healthcare Conference by sharing expectations for annual Humira sales that suggested they'll continue climbing to $21 billion by 2020. Rova-T's phase 3 flop was especially disappointing because AbbVie ignored lackluster early data and spent $5.8 billion to get its hands on the troubled lung cancer candidate a couple of years earlier. Buying up shares of AbbVie Inc. (NYSE: ABBV) at the beginning of 2018 seemed like a brilliant idea when the stock shot up 27% before the end of January, but that was simply the first leg of a long roller-coaster ride. | A pipeline ready to deliver Earlier this year, AbbVie launched Orilissa, the first new treatment for endometriosis-associated pain in over a decade, and it recently took another big step. Buying up shares of AbbVie Inc. (NYSE: ABBV) at the beginning of 2018 seemed like a brilliant idea when the stock shot up 27% before the end of January, but that was simply the first leg of a long roller-coaster ride. By Nov. 1, 2018, AbbVie stock had fallen 35% from its peak earlier in the year and at recent prices, it's given up just 5.4% so far in 2018. | The good news AbbVie began the year with a bang at the J.P. Morgan Healthcare Conference by sharing expectations for annual Humira sales that suggested they'll continue climbing to $21 billion by 2020. Momenta Pharmaceuticals (NASDAQ: MNTA) recently became the sixth drugmaker to delay the U.S. launch of its biosimilar version of Humira until 2023, and Momenta won't even receive payment from AbbVie in return for the favor. Buying up shares of AbbVie Inc. (NYSE: ABBV) at the beginning of 2018 seemed like a brilliant idea when the stock shot up 27% before the end of January, but that was simply the first leg of a long roller-coaster ride. | Buying up shares of AbbVie Inc. (NYSE: ABBV) at the beginning of 2018 seemed like a brilliant idea when the stock shot up 27% before the end of January, but that was simply the first leg of a long roller-coaster ride. By Nov. 1, 2018, AbbVie stock had fallen 35% from its peak earlier in the year and at recent prices, it's given up just 5.4% so far in 2018. Results from AbbVie's clinical-stage pipeline and rising sales of the world's bestselling drug have given investors plenty of reasons to cheer this year. |
25263.0 | 2018-11-15 00:00:00 UTC | After Hours Most Active for Nov 15, 2018 : QQQ, T, MSFT, GE, INTC, NVDA, ABBV, DWDP, HAL, FCX, CSCO, AMD | ABBV | https://www.nasdaq.com/articles/after-hours-most-active-nov-15-2018-qqq-t-msft-ge-intc-nvda-abbv-dwdp-hal-fcx-csco-amd | nan | nan | The NASDAQ 100 After Hours Indicator is down -34.04 to 6,856.41. The total After hours volume is currently 51,252,404 shares traded.
The following are the most active stocks for the after hours session :
Invesco QQQ Trust, Series 1 ( QQQ ) is -0.58 at $167.51, with 4,564,939 shares traded. This represents a 11.58% increase from its 52 Week Low.
AT&T Inc. ( T ) is +0.06 at $30.18, with 4,111,601 shares traded. Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2018. The consensus EPS forecast is $0.84. T's current last sale is 83.83% of the target price of $36.
Microsoft Corporation ( MSFT ) is -0.2 at $107.08, with 2,423,803 shares traded. Over the last four weeks they have had 9 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2018. The consensus EPS forecast is $1.09. As reported by Zacks, the current mean recommendation for MSFT is in the "buy range".
General Electric Company ( GE ) is unchanged at $8.17, with 2,206,026 shares traded. GE's current last sale is 62.85% of the target price of $13.
Intel Corporation ( INTC ) is -0.89 at $47.22, with 1,649,175 shares traded. Over the last four weeks they have had 14 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2018. The consensus EPS forecast is $1.22. INTC's current last sale is 85.85% of the target price of $55.
NVIDIA Corporation ( NVDA ) is -30.77 at $171.62, with 1,600,433 shares traded. RTT News Reports: NVIDIA Corporation Q3 adjusted earnings Beat Estimates
AbbVie Inc. ( ABBV ) is +0.01 at $90.15, with 1,589,357 shares traded. ABBV's current last sale is 92.94% of the target price of $97.
DowDuPont Inc. ( DWDP ) is unchanged at $58.73, with 1,506,912 shares traded. As reported by Zacks, the current mean recommendation for DWDP is in the "buy range".
Halliburton Company ( HAL ) is +0.02 at $32.47, with 1,433,908 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2019. The consensus EPS forecast is $0.63. As reported by Zacks, the current mean recommendation for HAL is in the "buy range".
Freeport-McMoran, Inc. ( FCX ) is unchanged at $11.96, with 1,358,089 shares traded. FCX's current last sale is 77.16% of the target price of $15.5.
Cisco Systems, Inc. ( CSCO ) is +0.12 at $46.89, with 1,275,177 shares traded. As reported by Zacks, the current mean recommendation for CSCO is in the "buy range".
Advanced Micro Devices, Inc. ( AMD ) is -1.25 at $20.24, with 1,123,305 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2019. The consensus EPS forecast is $0.18. AMD's current last sale is 72.29% of the target price of $28.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | RTT News Reports: NVIDIA Corporation Q3 adjusted earnings Beat Estimates AbbVie Inc. ( ABBV ) is +0.01 at $90.15, with 1,589,357 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2019. ABBV's current last sale is 92.94% of the target price of $97. | RTT News Reports: NVIDIA Corporation Q3 adjusted earnings Beat Estimates AbbVie Inc. ( ABBV ) is +0.01 at $90.15, with 1,589,357 shares traded. ABBV's current last sale is 92.94% of the target price of $97. Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2018. | RTT News Reports: NVIDIA Corporation Q3 adjusted earnings Beat Estimates AbbVie Inc. ( ABBV ) is +0.01 at $90.15, with 1,589,357 shares traded. ABBV's current last sale is 92.94% of the target price of $97. Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2018. | RTT News Reports: NVIDIA Corporation Q3 adjusted earnings Beat Estimates AbbVie Inc. ( ABBV ) is +0.01 at $90.15, with 1,589,357 shares traded. ABBV's current last sale is 92.94% of the target price of $97. The NASDAQ 100 After Hours Indicator is down -34.04 to 6,856.41. |
25264.0 | 2018-11-14 00:00:00 UTC | IWF, KO, PEP, ABBV: ETF Inflow Alert | ABBV | https://www.nasdaq.com/articles/iwf-ko-pep-abbv-etf-inflow-alert-2018-11-14 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $84.8 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 285,750,000 to 286,350,000). Among the largest underlying components of IWF, in trading today Coca-Cola Co (Symbol: KO) is off about 0.2%, PepsiCo Inc (Symbol: PEP) is trading flat, and AbbVie Inc (Symbol: ABBV) is lower by about 1.7%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price performance of IWF, versus its 200 day moving average:
Looking at the chart above, IWF's low point in its 52 week range is $129.08 per share, with $157.30 as the 52 week high point - that compares with a last trade of $141.59. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWF, in trading today Coca-Cola Co (Symbol: KO) is off about 0.2%, PepsiCo Inc (Symbol: PEP) is trading flat, and AbbVie Inc (Symbol: ABBV) is lower by about 1.7%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price performance of IWF, versus its 200 day moving average: Looking at the chart above, IWF's low point in its 52 week range is $129.08 per share, with $157.30 as the 52 week high point - that compares with a last trade of $141.59. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IWF, in trading today Coca-Cola Co (Symbol: KO) is off about 0.2%, PepsiCo Inc (Symbol: PEP) is trading flat, and AbbVie Inc (Symbol: ABBV) is lower by about 1.7%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price performance of IWF, versus its 200 day moving average: Looking at the chart above, IWF's low point in its 52 week range is $129.08 per share, with $157.30 as the 52 week high point - that compares with a last trade of $141.59. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWF, in trading today Coca-Cola Co (Symbol: KO) is off about 0.2%, PepsiCo Inc (Symbol: PEP) is trading flat, and AbbVie Inc (Symbol: ABBV) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $84.8 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 285,750,000 to 286,350,000). For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price performance of IWF, versus its 200 day moving average: Looking at the chart above, IWF's low point in its 52 week range is $129.08 per share, with $157.30 as the 52 week high point - that compares with a last trade of $141.59. | Among the largest underlying components of IWF, in trading today Coca-Cola Co (Symbol: KO) is off about 0.2%, PepsiCo Inc (Symbol: PEP) is trading flat, and AbbVie Inc (Symbol: ABBV) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $84.8 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 285,750,000 to 286,350,000). For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price performance of IWF, versus its 200 day moving average: Looking at the chart above, IWF's low point in its 52 week range is $129.08 per share, with $157.30 as the 52 week high point - that compares with a last trade of $141.59. |
25265.0 | 2018-11-14 00:00:00 UTC | AbbVie (ABBV) Gains As Market Dips: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-gains-as-market-dips%3A-what-you-should-know-2018-11-14 | nan | nan | AbbVie (ABBV) closed at $88.31 in the latest trading session, marking a +0.1% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.76%. At the same time, the Dow lost 0.82%, and the tech-heavy Nasdaq lost 0.9%.
Coming into today, shares of the drugmaker had lost 4.01% in the past month. In that same time, the Medical sector lost 0.16%, while the S&P 500 lost 1.41%.
ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. On that day, ABBV is projected to report earnings of $1.92 per share, which would represent year-over-year growth of 29.73%. Meanwhile, our latest consensus estimate is calling for revenue of $8.36 billion, up 8.07% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $7.93 per share and revenue of $32.78 billion. These totals would mark changes of +41.61% and +16.17%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for ABBV. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.92% higher. ABBV is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, ABBV is holding a Forward P/E ratio of 11.12. This valuation marks a discount compared to its industry's average Forward P/E of 14.52.
Meanwhile, ABBV's PEG ratio is currently 0.82. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.99 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 87, putting it in the top 34% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (ABBV) closed at $88.31 in the latest trading session, marking a +0.1% move from the prior day. ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. On that day, ABBV is projected to report earnings of $1.92 per share, which would represent year-over-year growth of 29.73%. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie (ABBV) closed at $88.31 in the latest trading session, marking a +0.1% move from the prior day. ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. | AbbVie (ABBV) closed at $88.31 in the latest trading session, marking a +0.1% move from the prior day. ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. On that day, ABBV is projected to report earnings of $1.92 per share, which would represent year-over-year growth of 29.73%. | AbbVie (ABBV) closed at $88.31 in the latest trading session, marking a +0.1% move from the prior day. ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. On that day, ABBV is projected to report earnings of $1.92 per share, which would represent year-over-year growth of 29.73%. |
25266.0 | 2018-11-14 00:00:00 UTC | AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study | ABBV | https://www.nasdaq.com/articles/abbvies-hcv-drug-mavyret-succeeds-in-label-expansion-study-2018-11-14 | nan | nan | AbbVie, Inc.ABBV announced that its successful hepatitis C virus (HCV) medicine, Mavyret demonstrated high virologic cure rates in a study evaluating the 8-week, pan-genotypic, ribavirin-free, once-daily HCV treatment for an expanded patient population.
The phase IIIb EXPEDITION-8 study is evaluating Mavyret in treatment naïve HCV patients with compensated cirrhosis across all major genotypes (GT1-6). Mavyret is presently marketed in the United States for treatment-naïve patients without cirrhosis. For patients with compensated cirrhosis, Mavyret is approved as a 12-week pan-genotypic treatment option.
New data from cohort 1 of the study showed that on eight weeks of treatment with Mavyret, 100% of genotype 1, 2, 4, 5 and 6 treatment-naïve HCV patients with compensated cirrhosis achieved SVR12 per protocol analysis. Cohort two of the study, evaluating treatment-naïve genotype 3 patients without cirrhosis, is ongoing.
The data were presented at the Liver Meeting organized by the American Association for the Study of Liver Diseases (AASLD) in San Francisco, CA.
Mavyret has seen a highly successful launch because of the shorter duration treatment benefit it offers.
Mavyret, a combination of glecaprevir, a potent protease inhibitor and pibrentasvir, a NS5A inhibitor, gained approval in the United States, EU, Canada and Japan in 2017. Mavyret performed beyond expectations in the first year of launch, recording sales of almost $500 million in 2017. The drug recorded sales of $2.6 billion in the first nine months of 2018, commanding aglobal marketshare of 50%.
Mavyret has the potential to rejuvenate growth in the HCV franchise. According to AbbVie, it may be used in up to 95% of HCV patients, depending on the stage of liver disease and prior treatment history.
So far this year, AbbVie's stock has declined 8.8% against the industry 's increase of 8%.
AbbVie currently has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Some better-ranked pharma stocks include Johnson & Johnson JNJ , Merck MRK and Eli Lilly LLY . All are #2 Ranked (Buy) stocks.
J&J's earnings estimates have risen 0.2% for 2018 and 0.5% for 2019 over the past 30 days. The stock has gained 3.6% this year so far.
Lilly's earnings estimates have risen 0.7% for 2018 and 0.2% for 2019 over the past 30 days. The stock has gained 33.1% this year so far.
Merck's earnings estimates have risen 1.4% for 2018 and 1.1% for 2019 over the past 30 days. The stock has gained 32.6% this year so far.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | According to AbbVie, it may be used in up to 95% of HCV patients, depending on the stage of liver disease and prior treatment history. AbbVie, Inc.ABBV announced that its successful hepatitis C virus (HCV) medicine, Mavyret demonstrated high virologic cure rates in a study evaluating the 8-week, pan-genotypic, ribavirin-free, once-daily HCV treatment for an expanded patient population. So far this year, AbbVie's stock has declined 8.8% against the industry 's increase of 8%. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, Inc.ABBV announced that its successful hepatitis C virus (HCV) medicine, Mavyret demonstrated high virologic cure rates in a study evaluating the 8-week, pan-genotypic, ribavirin-free, once-daily HCV treatment for an expanded patient population. According to AbbVie, it may be used in up to 95% of HCV patients, depending on the stage of liver disease and prior treatment history. | AbbVie, Inc.ABBV announced that its successful hepatitis C virus (HCV) medicine, Mavyret demonstrated high virologic cure rates in a study evaluating the 8-week, pan-genotypic, ribavirin-free, once-daily HCV treatment for an expanded patient population. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. According to AbbVie, it may be used in up to 95% of HCV patients, depending on the stage of liver disease and prior treatment history. | AbbVie, Inc.ABBV announced that its successful hepatitis C virus (HCV) medicine, Mavyret demonstrated high virologic cure rates in a study evaluating the 8-week, pan-genotypic, ribavirin-free, once-daily HCV treatment for an expanded patient population. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. According to AbbVie, it may be used in up to 95% of HCV patients, depending on the stage of liver disease and prior treatment history. |
25267.0 | 2018-11-14 00:00:00 UTC | AstraZeneca to Sell US Rights of Lung Infection Drug to Sobi | ABBV | https://www.nasdaq.com/articles/astrazeneca-to-sell-us-rights-of-lung-infection-drug-to-sobi-2018-11-14 | nan | nan | AstraZeneca plcAZN announced an agreement to sell the U.S. rights of its pediatric lung infection medicine, Synagis to Swedish pharma company, Sobi for an upfront consideration of $1.5 billion plus further contingent payments.
About 130 AstraZeneca employees will also shift to Sobi as part of the transaction.
Shares of AstraZeneca were up almost 1.5% on Tuesday in response to the news. This year so far, AstraZeneca's shares have risen 19.5% compared with the industry 's increase of 8%.
Synagis is indicated for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV), the most prevalent cause of LRTI among infants and young children.
In addition, the transaction gives rights to Sobi, officially, Swedish Orphan Biovitrum AB, to participate in the future U.S. profits and losses of AstraZeneca's pipeline candidate, MEDI8897, which it is developing in collaboration with Sanofi's (S NY vaccines unit, Sanofi Pasteur. MEDI8897 is a monoclonal antibody also being developed for the prevention of LRTI caused by RSV.
The upfront consideration comprises $1 billion in cash and $500 million in ordinary shares of Sobi, which equates to a stake of 8% in the company. AstraZeneca will get the stake when the transaction is completed.
In addition, AstraZeneca will also be eligible to receive $470 million in sales-related payments for Synagis and another $375 in milestone payments related to MEDI8897.
In 2018 so far, Synagis sales declined 9% to $414 million with sales in the U.S. declining 27%. AstraZeneca's partner AbbVie, Inc. ABBV markets Synagis in over 80 countries outside the United States. This collaboration will not be impacted by the proposed deal with Sobi.
The Synagis sale is the latest of the several divestiture deals announced this year by AstraZeneca as it streamlines its portfolio
Last week, AstraZeneca announced an agreement to divest ex-U.S. marketing and U.S royalty rights to three older respirator products to a Swiss pharmaceutical group, Covis Pharma. In late-October, AstraZeneca announced an agreement to divest European rights to its acid reflux medicine, Nexium and worldwide rights (excluding the United States and Japan) to arthritis pain reliever, Vimovo to Grünenthal.
In July, AstraZeneca sold its European rights to hypertension medicines Atacand and Atacand Plus to Cheplapharm Arzneimittel. In May, it announced an agreement to sell rights in the UK, China and other international markets to Seroquel and Seroquel XR, a treatment for schizophrenia and bipolar disease, to Luye Pharma Group.
The deals are part of the company's strategy to manage its portfolio through divestments and allow AstraZeneca to focus on its core areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory.
AstraZeneca currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
A better-ranked pharma stock is Merck (MRK), a #2 Ranked (Buy) stock.
Merck's earnings estimates have risen 1.4% for 2018 and 1.1% for 2019 over the past 30 days. The stock has gained 32.6% this year so far.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
AstraZeneca PLC (AZN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AstraZeneca's partner AbbVie, Inc. ABBV markets Synagis in over 80 countries outside the United States. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report To read this article on Zacks.com click here. AstraZeneca plcAZN announced an agreement to sell the U.S. rights of its pediatric lung infection medicine, Synagis to Swedish pharma company, Sobi for an upfront consideration of $1.5 billion plus further contingent payments. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report To read this article on Zacks.com click here. AstraZeneca's partner AbbVie, Inc. ABBV markets Synagis in over 80 countries outside the United States. AstraZeneca plcAZN announced an agreement to sell the U.S. rights of its pediatric lung infection medicine, Synagis to Swedish pharma company, Sobi for an upfront consideration of $1.5 billion plus further contingent payments. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report To read this article on Zacks.com click here. AstraZeneca's partner AbbVie, Inc. ABBV markets Synagis in over 80 countries outside the United States. AstraZeneca plcAZN announced an agreement to sell the U.S. rights of its pediatric lung infection medicine, Synagis to Swedish pharma company, Sobi for an upfront consideration of $1.5 billion plus further contingent payments. | AstraZeneca's partner AbbVie, Inc. ABBV markets Synagis in over 80 countries outside the United States. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report To read this article on Zacks.com click here. The Synagis sale is the latest of the several divestiture deals announced this year by AstraZeneca as it streamlines its portfolio Last week, AstraZeneca announced an agreement to divest ex-U.S. marketing and U.S royalty rights to three older respirator products to a Swiss pharmaceutical group, Covis Pharma. |
25268.0 | 2018-11-13 00:00:00 UTC | Better Buy: AbbVie Inc. vs. GlaxoSmithKline PLC | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-inc-vs-glaxosmithkline-plc-2018-11-13 | nan | nan | The trajectories for AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) stocks have been very different in recent years. While AbbVie generated big gains, GlaxoSmithKline (GSK) languished. The tables have been turned in 2018, though, with GSK outperforming AbbVie so far this year.
Which of these two big pharma stocks is the better pick for long-term investors? Here's how AbbVie and GlaxoSmithKline compare against each other.
The case for AbbVie
Let's start with the biggest reason why not to buy AbbVie stock. The company remains highly dependent on Humira for its revenue. Humira began facing competition in Europe from biosimilars in October 2018, with biosimilars on the way in the U.S. beginning in 2023. Some investors worry about whether AbbVie will be able to replace the billions of dollars in revenue generated by its top-selling drug.
But there are several reasons to be optimistic about AbbVie's chances. For one thing, sales for Humira aren't going to dry up overnight. EvaluatePharma projects that Humira will still rank as the No. 1 best-selling drug in the world at least through 2024 .
More important, AbbVie has several newer drugs stepping up to the plate. Cancer drug Imbruvica continues to enjoy strong momentum. Hepatitis C virus (HCV) treatment Mavyret got off to a roaring start in 2017 and 2018. Leukemia drug Venclexta is really picking up steam as well.
It's still early for endometriosis pain drug Orilissa, which gained Food and Drug Administration approval in July. However, AbbVie expects that it will become another blockbuster in the lineup in the not-too-distant future.
The company's pipeline should also deliver some big winners. AbbVie thinks it can obtain FDA approval for two new immunology drugs next year, risankizumab and upadacitinib. Both drugs could be best-in-class successors to Humira.
In the meantime, AbbVie's dividend yields a very attractive 4.82%. The company has increased its dividend payout by 168% since being spun off from parent Abbott Labs in 2013.
The case for GlaxoSmithKline
GlaxoSmithKline doesn't have to wait on its top product to decline. Sales have been falling for a while for the company's respiratory drug Seretide/Advair. GSK also has a basket of older drugs that generate far less revenue than they did in the past.
However, the drugmaker also has plenty of newer products that are driving overall growth. GSK's Ellipta franchise of respiratory drugs is especially performing well, led by Relvar/Breo Ellipta and Anoro Ellipta. The company is also enjoying strong growth for asthma drug Nucala/Mepolizumab.
GlaxoSmithKline has established itself as a formidable player in the HIV market, too. Sales continue to increase for the company's HIV drugs, Tivicay and Triumeq. GSK's first two-drug HIV regimen, Juluca, is picking up some momentum as well, although perhaps not as much as hoped in the face of a strong launch by Gilead Sciences for its new HIV drug, Biktarvy.
The company's biggest new winner is shingles vaccine Shingrix. This new vaccine appears to be on track to become another blockbuster for GSK . Success for Shingrix so far in 2018 led GSK to boost its full-year earnings guidance in the third quarter.
What about the pipeline? GSK plans to build on its existing HIV and respiratory franchises. Two other two-drug HIV combos are in late-stage testing. The company also has a late-stage study underway for cabotegravir as an HIV pre-exposure prophylactic. In addition, GSK hopes to pick up more approved indications for existing drugs with phase 3 studies evaluating Trelegy Ellipta in treating asthma and Nucala in treating rare-disease hypereosinophilic syndrome and nasal polyposis.
Like AbbVie, GlaxoSmithKline offers an attractive dividend, with its yield currently at 5.1%. However, GSK will begin declaring its dividend on a quarter-by-quarter basis next year, which adds to uncertainty about dividend payouts going forward.
Better buy
Although GlaxoSmithKline appears to be doing quite well right now, I think that AbbVie is the better pick. The company appears to have a good strategy to deliver growth even after Humira's sales begin to decline. Its other products and pipeline candidates give AbbVie a solid foundation to execute on its strategy.
The stock's valuation is also very attractive. AbbVie shares trade at a little over 10 times expected earnings. Its growth prospects over the next few years make the stock a bargain at current share prices. With a great dividend to boot, I think that AbbVie can deliver a market-beating return over the long run.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Keith Speights owns shares of AbbVie and Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has the following options: short November 2018 $78 calls on Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie thinks it can obtain FDA approval for two new immunology drugs next year, risankizumab and upadacitinib. With a great dividend to boot, I think that AbbVie can deliver a market-beating return over the long run. *Stock Advisor returns as of August 6, 2018 Keith Speights owns shares of AbbVie and Gilead Sciences. | The trajectories for AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) stocks have been very different in recent years. While AbbVie generated big gains, GlaxoSmithKline (GSK) languished. The tables have been turned in 2018, though, with GSK outperforming AbbVie so far this year. | The trajectories for AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) stocks have been very different in recent years. The case for AbbVie Let's start with the biggest reason why not to buy AbbVie stock. While AbbVie generated big gains, GlaxoSmithKline (GSK) languished. | Better buy Although GlaxoSmithKline appears to be doing quite well right now, I think that AbbVie is the better pick. The trajectories for AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) stocks have been very different in recent years. While AbbVie generated big gains, GlaxoSmithKline (GSK) languished. |
25269.0 | 2018-11-13 00:00:00 UTC | Health Care Sector Update for 11/13/2018: ABBV,VKTX,CRON,CRON.TO,VLRX | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-11132018-abbvvktxcroncrontovlrx-2018-11-13 | nan | nan | Top Health Care Stocks
JNJ -0.56%
PFE -1.56%
ABT -1.83%
MRK -0.41%
AMGN -0.07%
Health care stocks continue to trend lower today, including a slightly more than 0.6% decline for the NYSE Health Care Index in recent trade. Also, shares of health care companies in the S&P 500 were down just over 0.9% as a group while the Nasdaq Biotechnology index was falling more than 0.5% today.
Among health care stocks moving on news:
(-) AbbVie ( ABBV ) dropped as much as 1.5% on Tuesday despite the drugmaker reported new data demonstrating its Mavyret pan-genotypic chronic hepatitis C virus treatment produced a sustained virologic response 12 weeks after treatment in 100% of the cirrhosis patients with genotypes 1, 2, 4, 5 and 6 during ongoing Phase IIIb testing. The trial has been evaluating the safety and efficacy of Mavyret in treatment-naive chronic HCV patients with compensated cirrhosis across all major genotypes. The study includes two cohorts; cohort one with genotype 1, 2, 4, 5, 6 chronic HCV-infected patients and cohort two with genotype 3 chronic HCV-infected patients.
In other sector news:
(-) Viking Therapeutics ( VKTX ) was nearly 2% lower just before Tuesday's close, giving back all of a 17% increase earlier Tuesday that followed the company saying its liver-selective thyroid receptor beta agonist met all of its primary and secondary endpoints during Phase II testing in patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol. No serious adverse events were reported among patients receiving VK2809 or placebo.
(-) Cronos (CRON,CRON.TO) was nearly 2% lower Tuesday afternoon, trimming a nearly 11% decline previously in the session that followed the Canadian medical marijuana company reporting a wider-than-expected Q3 net loss despite a 186% jump in revenue over the same fiscal period last year. Net loss for the three months ended Sept. 30 was CND0.04 per share, reversing a CND0.01 per share during the year-ago quarter and missing the two-analyst mean expecting a CND0.02 per share net loss. Revenue climbed to $3.8 million from $1.3 million during the year-ago period and topping the lone analyst forecast expecting CND2.71 million in revenue.
(+) Valeritas Holdings ( VLRX ) fell just over 15% on Tuesday despite the company announcing an exclusive distribution agreement with drug manufacturer Julphar for the commercialization of its V-Go Wearable Insulin Delivery device in the Middle East. Under terms of the new contract, Julphar gains the rights to promote, market, and sell V-Go to diabetes clinics and patients in the member countries of the Gulf Cooperation Council. Valeritas will retain responsibility for product development, regulatory approval and manufacturing.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among health care stocks moving on news: (-) AbbVie ( ABBV ) dropped as much as 1.5% on Tuesday despite the drugmaker reported new data demonstrating its Mavyret pan-genotypic chronic hepatitis C virus treatment produced a sustained virologic response 12 weeks after treatment in 100% of the cirrhosis patients with genotypes 1, 2, 4, 5 and 6 during ongoing Phase IIIb testing. (-) Cronos (CRON,CRON.TO) was nearly 2% lower Tuesday afternoon, trimming a nearly 11% decline previously in the session that followed the Canadian medical marijuana company reporting a wider-than-expected Q3 net loss despite a 186% jump in revenue over the same fiscal period last year. (+) Valeritas Holdings ( VLRX ) fell just over 15% on Tuesday despite the company announcing an exclusive distribution agreement with drug manufacturer Julphar for the commercialization of its V-Go Wearable Insulin Delivery device in the Middle East. | Among health care stocks moving on news: (-) AbbVie ( ABBV ) dropped as much as 1.5% on Tuesday despite the drugmaker reported new data demonstrating its Mavyret pan-genotypic chronic hepatitis C virus treatment produced a sustained virologic response 12 weeks after treatment in 100% of the cirrhosis patients with genotypes 1, 2, 4, 5 and 6 during ongoing Phase IIIb testing. Top Health Care Stocks Health care stocks continue to trend lower today, including a slightly more than 0.6% decline for the NYSE Health Care Index in recent trade. | Among health care stocks moving on news: (-) AbbVie ( ABBV ) dropped as much as 1.5% on Tuesday despite the drugmaker reported new data demonstrating its Mavyret pan-genotypic chronic hepatitis C virus treatment produced a sustained virologic response 12 weeks after treatment in 100% of the cirrhosis patients with genotypes 1, 2, 4, 5 and 6 during ongoing Phase IIIb testing. The study includes two cohorts; cohort one with genotype 1, 2, 4, 5, 6 chronic HCV-infected patients and cohort two with genotype 3 chronic HCV-infected patients. In other sector news: (-) Viking Therapeutics ( VKTX ) was nearly 2% lower just before Tuesday's close, giving back all of a 17% increase earlier Tuesday that followed the company saying its liver-selective thyroid receptor beta agonist met all of its primary and secondary endpoints during Phase II testing in patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol. | Among health care stocks moving on news: (-) AbbVie ( ABBV ) dropped as much as 1.5% on Tuesday despite the drugmaker reported new data demonstrating its Mavyret pan-genotypic chronic hepatitis C virus treatment produced a sustained virologic response 12 weeks after treatment in 100% of the cirrhosis patients with genotypes 1, 2, 4, 5 and 6 during ongoing Phase IIIb testing. Top Health Care Stocks Also, shares of health care companies in the S&P 500 were down just over 0.9% as a group while the Nasdaq Biotechnology index was falling more than 0.5% today. |
25270.0 | 2018-11-09 00:00:00 UTC | 6 Pharmaceutical Stocks to Buy After the Midterms | ABBV | https://www.nasdaq.com/articles/6-pharmaceutical-stocks-to-buy-after-the-midterms-2018-11-09 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Despite massive gains for the Democrats in the midterm elections in the House of Representatives and on the state level, the Republicans managed to hold onto the Senate. This is good for big pharmaceutical stocks (if bad for pharmaceutical users ). Had the Democrats won both the House and Senate, scrutiny over drug pricing and the actions of the largest pharmaceutical companies would have resumed. But that is not what happened.
The Republicans took control of the Senate while the Democrats have the House. This also means that the Affordable Care Act won't be repealed anytime soon - so more consumers are insured and able to get healthcare. And with both pharmaceutical stocks and healthcare plan providers both trading higher the day after the elections, markets may correctly anticipate healthy profits ahead in this sector.
The 7 Best Stocks to Buy Now That Jeff Sessions Is Gone
Here are six big pharmaceutical stocks to consider.
Teva Pharmaceutical (TEVA)
Source: Open Grid Scheduler (Modified)
Teva Pharmaceutical (NYSE: TEVA ) reported third-quarter revenue of $4.54 billion. Though it lost $0.27 a share (GAAP), free cash flow was a positive $0.7 billion. Teva is a monster player in the generic drug space, but its big acquisition of Actavis Generics left the company with plenty of debt. But management embarked on a restructuring program, and spending fell by $1.8 billion since the start of the year.
In Q3, Teva earned approval for AJOVY and launched it. The drug is the first and only anti-CGRP treatment for preventing migraine in adults . Austedo , a drug for treating tardive dyskinesia in adults and chorea associated with Huntington's disease, continued growing nicely. Austedo and Ajovy were major growth drivers for Teva's Specialty business. Teva owes the growth in Austedo to the availability of samples for doctors within 24-48 hours after they are ordered through retail and specialty pharmacies.
AJOVY demand grew steadily in the quarter. The convenient quarterly and monthly dosing likely drew a healthy level of prescriptions. Teva also put extra care in providing customers with the best experience, from the moment they are in the physician's office through to the accessing and administrating process for the product.
Financials are looking better this year. Teva ended 2017 with $32.5 billion in gross debt and $1 billion in cash. By Sep. 30 gross debt had fallen to $29.5 while cash rose to $1.9 billion. As debt levels fall and revenue stabilizes, Teva, which rose nearly 20% on the week of its earnings report, could continue moving higher.
AbbVie (ABBV)
Source: Shutterstock
AbbVie Inc. (NYSE: ABBV ) recently hiked its dividend from $0.96 a share to $1.07. The dividend is payable on February 2019. In Q3, adjusted earnings grew 50% Y/Y to $2.14. Adjusted operational sales grew 18.5%, thanks to strong performance of AbbVie's portfolio. This includes Humira, growing 10% and Imbruvica, growing over 40% Y/Y.
Management was so confident in its outlook that it raised its 2018 earnings guidance again - for the fourth time this year! ABBV now expects FY 2018 adjusted earnings coming in at $7.90 to $7.92 a share, which represents annual growth of 41%. This solid outlook lifted the stock higher by around 12% on the week ended Nov. 8. Though this rally in ABBV stock is impressive, it still has a long way to go. Shares are down by over 30% from yearly highs. It trades at a P/E of 20 times, which is low given the drugs in the pipeline. Risankizumab and upadacitinib will both launch in 2019. Again, management is confidence with these two products because they expect them to drive growth. These products also add to the portfolio of drugs having three to four years of a ramp-up phase.
15 Winners and Losers From This Earnings Season
Elagolix is another product whose revenue potential is in the multi-billion-dollar range. Orilissa, which AbbVie recently launched, is meeting expectations. Looking ahead, the firm has plenty of products set for approval. The most immediate product worth mentioning is upadacitinib, a drug treating rheumatoid arthritis. Management is on track to submit a regulatory application for upadacitinib by the end of the year.
Sanofi (SNY)
Source: Mike Mozart via Flickr (Modified)
Sanofi (NYSE: SNY ), whose shares closed recently at yearly highs, reported third-quarter results on Oct. 31 that sent the stock from a $42 low to $45. Investors have good reason to bid shares higher because company sales grew 6.3% year-over-year while EPS rose 11.2% to EUR 1.84. Sanofi's acquisition of Bioverative contributed to the solid quarterly results. Products in the vaccines and rare blood disorders spaces also contributed. Sales in Specialty Care, Vaccines, and CHC rose the most of all units - 14.9%. Sanofi owes the strength in Specialty Care to products like Pompe (up 13.7%) in the rare diseases space and Aubagio (+13%) in the multiple sclerosis space.
In the immunology unit, Dupixent, which treats atopic dermatitis, blew past expectations in Q3 by growing in all possible metrics. Prescriptions grew 16% sequentially, while trade inventory held steady at ~ 4 weeks. Dupixent is now available in 13 countries. Sanofi launched the drug in four countries during the Q3 period. Looking ahead, the TAM - total addressable market - will only get bigger as the drug gets FDA approval for treatment in adolescents.
Amgen (AMGN)
Source: Richard Masoner via Flickr
Amgen's (NASDAQ: AMGN ) Q3 revenue grew 2.3% from last year to $5.904 billion. However, sales for many key products fell. Sales of Neulasta fell 6.4%, Enbrel fell 5.2%, and Sensipar/Mimpara sales fell 10.5% Conversely, Prolia and Repatha sales rose 14.7% and 34.8%, respectively.
Amgen raised its revenue guidance to as high as $23.5 billion and EPS guidance as high as $12.55. The outlook is good despite the company's challenges ahead. While revenue will grow 15% Y/Y, Amgen will adjust for weaker non-GAAP operating income by watching its spending levels in R&D. It will invest just enough in its products and pipeline to drive growth and maximize shareholder value.
Management expected for some time that drug prices will come under pressure in this industry. Similar to other pharmaceutical stocks, Amgen has several products in the pipeline. Prolia sales continue to build momentum globally. The TAM may expand as the drug potentially treats osteoporosis. Repatha sales will improve as Amgen opens up access and improves patient affordability.
Similar to Teva launching a drug for migraine treatment, Amgen has Aimovig, whose launch is already showing positive momentum.
10 Strong Buy Stocks Trading at Killer Entry Points
Amgen is competing other drug firms through its launch of biosimilars in Europe. Eight more biosimilar programs are in development and are important drivers to the company's long-term growth sustainability.
Biogen (BIIB)
Source: Biogen via YouTube
Biogen Inc. (NASDAQ: BIIB ) reported third-quarter earnings on Oct. 23. Non-GAAP EPS came in at $7.40 and revenue rose 11.7% from last year to 3.44 billion. Biogen also introduced a $3.5 billion share repurchase program.
Biogen specializes in neurological diseases. Its strategy involves growing its core Multiple Sclerosis business. Spinraza sales grew in the U.S. and did even better outside of this region. Spinraza added $468 million to revenue as patients on therapy in the U.S. grew 12% sequentially (from Q2). Overall, the MS division delivered $2.3 billion in revenue in Q3. Ocrevus royalties added $137 million but were not enough to offset the 3% drop in MS revenue.
In the area of Alzheimer's Disease and dementia, Biogen presented the data at a CTAD (Clinical Trials and Alzheimer's Disease) meeting. There, it discussed the safety and efficacy of aducanumab, a monoclonal antibody.
Looking ahead, the Humira biosimilar launch in the Q4 will make some contribution to the business. But this takes time. Biogen signed big contracts in Europe; the revenue will not have much impact yet in the fourth quarter. This should not matter to the long-term investors because as the business grows, revenue will grow nicely.
Allergan (AGN)
Source: Everjean via Flickr
Despite reporting lower revenue Allergan (NYSE: AGN ) raised its revenue and EPS guidance for 2018. This suggests Allergan, known for its Botox cosmetics, faced slower activity in Q3 due to seasonality. Revenue fell 3% Y/Y to $3.911 billion. Botox Cosmetic revenues increased by 13.6% to $879.7 million. Alloderm revenue rose 24%, albeit, at around $106 million, this was a small part of the business.
Value investors will find AGN stock more compelling after the share price fell following earnings. Performance suffered in the quarter because of a recall on Ozurdex in certain international markets. This setback will probably prove temporary because Allergan self-identified the issue and addressed it. Unfavorable currency exchange, LOEs, and pressure from payers, which is felt industry-wide, also added to the third-quarter weakness.
Allergan continued to invest in its pipeline by acquiring Bonti. Bonti is a clinical-stage biotech firm that specializes in fast-acting neurotoxin programs. This should complement nicely with the company's Botox business.
7 Safe Dividend Stocks to Buy Now
Looking ahead, with the restructuring complete, Allergan is expected to hold an operating margin of at least 48.7%. The debt reduction of $750 million in the third quarter, plus $450 million in share buyback, should lead to meaningful EPS growth. This assumes the Botox and Vraylar business continues growing.
Disclosure: The author does not own shares in any of the companies mentioned.\
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
The 7 Best Stocks to Buy Now That Jeff Sessions Is Gone
7 Stocks to Buy in 7 Growing Sectors
7 Safe Dividend Stocks to Buy Now
Compare Brokers
The post 6 Pharmaceutical Stocks to Buy After the Midterms appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (ABBV) Source: Shutterstock AbbVie Inc. (NYSE: ABBV ) recently hiked its dividend from $0.96 a share to $1.07. Adjusted operational sales grew 18.5%, thanks to strong performance of AbbVie's portfolio. ABBV now expects FY 2018 adjusted earnings coming in at $7.90 to $7.92 a share, which represents annual growth of 41%. | AbbVie (ABBV) Source: Shutterstock AbbVie Inc. (NYSE: ABBV ) recently hiked its dividend from $0.96 a share to $1.07. Adjusted operational sales grew 18.5%, thanks to strong performance of AbbVie's portfolio. ABBV now expects FY 2018 adjusted earnings coming in at $7.90 to $7.92 a share, which represents annual growth of 41%. | AbbVie (ABBV) Source: Shutterstock AbbVie Inc. (NYSE: ABBV ) recently hiked its dividend from $0.96 a share to $1.07. Adjusted operational sales grew 18.5%, thanks to strong performance of AbbVie's portfolio. ABBV now expects FY 2018 adjusted earnings coming in at $7.90 to $7.92 a share, which represents annual growth of 41%. | Adjusted operational sales grew 18.5%, thanks to strong performance of AbbVie's portfolio. AbbVie (ABBV) Source: Shutterstock AbbVie Inc. (NYSE: ABBV ) recently hiked its dividend from $0.96 a share to $1.07. ABBV now expects FY 2018 adjusted earnings coming in at $7.90 to $7.92 a share, which represents annual growth of 41%. |
25271.0 | 2018-11-09 00:00:00 UTC | Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-lly-azn-report-q3-earnings-pfe-gets-fda-nod-for-cancer-drug-2018-11 | nan | nan | This week Lilly LLY and AstraZeneca AZN released their third-quarter 2018 results. Pfizer PFE gained FDA approval for a new cancer medicine, its third cancer drug approval in less than two months while Bristol-Myers BMY got a nod from the same regulatory body for a triplet cancer combination for multiple myeloma.
Recap of the Week's Most Important Stories
Earnings: Lilly's third-quarter results were mixed as it beat estimates for earnings but missed the same for sales. Lilly, however, raised its previously issued outlook for adjusted earnings while increasing the lower end of the total revenue guidance. Going forward, new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance, Lartruvo, Verzenio and Olumiant are expected to drive revenues.
AstraZeneca beat estimates for both earnings and sales in the third quarter and maintained its previously issued outlook for 2018. AstraZeneca's product sales rose 9% at CER in the quarter to $5.27 billion. Higher sales of newer medicines, particularly cancer drugs, and strong performance in emerging markets, mainly China, offset lower sales of many other legacy medicines to drive product sales. With its product sales returning to growth after a long time, Pascal Soriot, AstraZeneca's chief executive officer, said this marks "the start of a period of sustained growth" for several years.
Pfizer Gets FDA Nod for Another Cancer Medicine: Pfizer gained FDA's accelerated approval for a cancer medicine, lorlatinib, to be marketed by the trade name of Lorbrena. Lorbrena can be prescribed for the treatment of patients with ALK-positive metastatic non-small cell lung cancer ("NSCLC") who have received prior treatment with one or more ALK TKIs.
This is the third cancer medicine approval for Pfizer in less than two months. In late September, it gained FDA approval for Vizimpro (dacomitinib) for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with EGFR activating mutations. In October, the FDA approved Talzenna (talazoparib), an orally-available PARP inhibitor for advanced breast cancer.
Bristol-Myers Cancer Combination Drugs in Focus: Bristol-Myers gained FDA approval for a new immunotherapy combination - a triplet combination of Empliciti (elotuzumab), pomalidomide and dexamethasone for certain previously treated patients with multiple myeloma.
Bristol-Myers signed a collaboration deal with Infinity Pharmaceuticals to evaluate a combination of its PD-1 inhibitor, Opdivo and Infinity's investigational immunotherapy, IPI-549 for the treatment of advanced urothelial cancer. The companies plan to initiate MARIO-275, a randomized, global phase II study to evaluate the combination drugs in the first half of 2019. The combination drugs are already being evaluated in a phase I/Ib study in patients with advanced solid tumors.
Sanofi's Dupixent Gets FDA Nod for Adolescent Patients: Sanofi SNY and partner Regeneron gained priority review for a supplemental Biologics License Application (sBLA) looking for approval of their atopic dermatitis drug, Dupixent for adolescent patients (12 years to 17 years of age). The FDA's decision is expected by Mar 11, 2019. Dupixent is already approved in the United States and Europe for treating adult patients for the same disease. Last month, Dupixent was approved by the FDA as an add-on maintenance treatment in adults and adolescents (12 years of age or older) with moderate-to-severe asthma.
Lilly's Diabetes Drug Succeeds in Reducing Cardiovascular Risk: Lilly announced data from an outcomes study (REWIND) on Trulicity, which showed that the GLP-1 receptor agonist led to superior reduction in cardiovascular events like death, non-fatal myocardial infarction (heart attack) or non-fatal stroke in a broad range of type II diabetes patients. Importantly, only 31% of the participants in the REWIND study had established CV disease compared to other CV outcomes studies, which have a much greater percentage of type II diabetes patients already with a heart disease. The statistically significant heart risk reduction shown by Trulicity in the study demonstrates that the drug may be able to cater to a much broader patient population if the data is approved to be included on the label.
Meanwhile, initial data from a real-world study, EMPRISE, showed that Jardiance was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in type II diabetes patients with and without cardiovascular disease.
Lilly signed a multi-year collaboration deal with small cancer biotech, NextCure, Inc. to develop novel cancer targets utilizing the latter's proprietary discovery platform - FIND-IO. For the deal, Lilly will make an upfront payment of $25 million to NextCure and the latter will also be entitled to receive milestones and royalty payments if Lilly can successfully develop new cancer medicines under the collaboration.
AstraZeneca Sells Rights to Older Asthma & Rhinitis Drugs: AstraZeneca announced an agreement to divest rights to three older respirator products to a Swiss pharmaceutical group, Covis Pharma. Covis Pharma gained ex-U.S. marketing rights as well rights to U.S. royalties for AstraZeneca's three medicines - Alvesco indicated for persistent asthma and Omnaris and Zetonna indicated for nasal symptoms associated with rhinitis. Covis Pharma already has the U.S. rights for Alvesco, Omnaris and Zetonna, which it acquired from AstraZeneca in 2017. Covis Pharma will pay AstraZeneca $350 million for rights to the three drugs plus conditional sales-related payments of up to $21 million over four years from 2019.
AbbVie Settles With Momenta on Humira Biosimilar : AbbVie ABBV signed a non-exclusive licensing deal with Momenta regarding the latter's proposed biosimilar version of Humira. Per the deal, Momenta will have a non-exclusive license to launch its biosimilar Humira in the United States on Nov 20, 2023. In Europe, Momenta can launch Humira biosimilar when it gets approval from the European Medicines Agency.
AbbVie has similar licensing deals with Amgen, Mylan, Sandoz and Biogen/Samsung Bioepis. Amgen, Mylan, Sandoz and Samsung Bioepis/Biogen's Humira biosimilars are expected to be launched in the United States in 2023 while in the EU, Amgen, Sandoz and Biogen's biosimilars were launched in October this year.
While Amgen, Sandoz and Samsung Bioepis' biosimilar versions are already approved by the FDA, Mylan is yet to gain FDA approval.
The NYSE ARCA Pharmaceutical Index rose 2.6% in the last five trading sessions.
Large Cap Pharmaceuticals Industry 5YR % Return
Large Cap Pharmaceuticals Industry 5YR % Return
Here is how the seven major stocks performed in the last five trading sessions:
All stocks were in the green this week except Bristol-Myers and Pfizer. While Bristol-Myers recorded a massive decline of 15%, Merck MRK rose the most (5.5%) in the last five trading sessions.
In the past six months, Lilly has been the biggest gainer (36.2%) while Bristol-Myers recorded the lowest gain (3.3%).
(See the last pharma stock roundup here: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus )
What's Next in the Pharma World?
Watch out for pipeline and regulatory updates next week.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
AstraZeneca PLC (AZN): Free Stock Analysis Report
Sanofi (SNY): Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Settles With Momenta on Humira Biosimilar : AbbVie ABBV signed a non-exclusive licensing deal with Momenta regarding the latter's proposed biosimilar version of Humira. AbbVie has similar licensing deals with Amgen, Mylan, Sandoz and Biogen/Samsung Bioepis. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Settles With Momenta on Humira Biosimilar : AbbVie ABBV signed a non-exclusive licensing deal with Momenta regarding the latter's proposed biosimilar version of Humira. AbbVie has similar licensing deals with Amgen, Mylan, Sandoz and Biogen/Samsung Bioepis. | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Settles With Momenta on Humira Biosimilar : AbbVie ABBV signed a non-exclusive licensing deal with Momenta regarding the latter's proposed biosimilar version of Humira. AbbVie has similar licensing deals with Amgen, Mylan, Sandoz and Biogen/Samsung Bioepis. | AbbVie Settles With Momenta on Humira Biosimilar : AbbVie ABBV signed a non-exclusive licensing deal with Momenta regarding the latter's proposed biosimilar version of Humira. AbbVie has similar licensing deals with Amgen, Mylan, Sandoz and Biogen/Samsung Bioepis. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. |
25272.0 | 2018-11-09 00:00:00 UTC | Momenta (MNTA) Reports Narrower-Than-Expected Loss in Q3 | ABBV | https://www.nasdaq.com/articles/momenta-mnta-reports-narrower-than-expected-loss-in-q3-2018-11-09 | nan | nan | Shares of Momenta Pharmaceuticals Inc. MNTA gained 0.5% after the company reported mixed results for the third quarter.
Momenta's stock has gained 4% in the year so far, against the industry's decline of 14.3%.
The company reported loss per share of 45 cents in the quarter (excluding restructuring charges), narrower than the Zacks Consensus Estimate of 63 cents but wider than the year-ago loss of 44 cents.
Revenues in the quarter came in at $14.9 million, significantly down from $24.1 million in the year-ago quarter and missed the Zacks Consensus Estimate by 13.2%.
Quarter in Detail
Momenta's top line comprises product revenues of $13.6 million earned from Sandoz's sales of Glatopa, a generic version of Copaxone (20 mg), compared with $10.9 million in the year-ago quarter. The increase in product revenues was primarily due to non-recurring deduction of a $5-million contractual amount in 2017, which was offset by lower net sales of Glatopa, driven by Mylan N.V.'s MYL entry into the Copaxone market.
Research and development revenues came in at $1.3 million compared with $13.2 million in the year-ago quarter. The decrease was primarily due to a $10-million milestone achieved in the 2017 period.
Research and development expenses decreased to $30.7 million from $37.9 million in the year-ago quarter due to a decrease in external R&D expenses for M923. General and administrative expenses were roughly flat at $20.4 million.
Pipeline Updates
As a result of its strategic review (results announced in October 2018), Momenta plans to advance its two late-stage biosimilar assets, M923, which is its wholly-owned proposed biosimilar to AbbVie's ABBV Humira, and M710, which is its proposed biosimilar to Regeneron's Eylea being developed in collaboration with Mylan. The company is in discussions with its collaboration partner, Mylan, to exit its participation in the development of its five other biosimilar programs, including M834, a proposed biosimilar to Orencia.
Momenta recently announced that it entered into a settlement with AbbVie Inc., to enable the commercialization of M923. Per the terms of the agreement and subject to approval by health regulatory authorities, Momenta may launch M923 in the United States on Nov 20, 2023 and in Europe upon approval by the European Medicines Agency.
The company intends to submit a biologics license application for M923 to the FDA in the fourth quarter of 2018 and a marketing authorization application in the European Union in the first half of 2019.
Momenta is now seeking commercialization partners for M923.
In August 2018, Mylan initiated a clinical trial in patients with diabetic macular edema to compare safety, efficacy and immunogenicity of M710 with Eylea.
Momenta's novel auto-immune portfolio includes M230, a Selective Immunomodulator of Fc receptors (SIF3); M281, an anti-FcRn monoclonal antibody; and M254.
In October 2018, Momenta announced additional data from its phase I study of M281 in healthy volunteers.
The company announced that it plans to commence two phase II proof of concept clinical trials, one in generalized myasthenia gravis (gMG) and one in hemolytic disease of the fetus and newborn (HDFN), in the fourth quarter of 2018.
The company intends to initiate a phase I/II proof of concept study in immune thrombocytopenic purpura (ITP) in early 2019, pending regulatory feedback.
Our Take
Momenta's third-quarter results were pretty ho-hum with loss coming in narrower than expected, while revenues lagging estimates. While the FDA approval of Glatopa 40 mg should relieve Momenta, competition will limit market share gains for the company as Mylan has already won the FDA's approval for a generic version of Teva Pharmaceuticals' TEVA Copaxone 40 mg. The company continues to face fierce competition due to growing pricing pressure from Mylan and Teva.
The completion of the strategic review has narrowed the company's focus on its biosimilar portfolio.
Zacks Rank
Momenta currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Momenta Pharmaceuticals, Inc. (MNTA): Free Stock Analysis Report
Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report
Mylan N.V. (MYL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Pipeline Updates As a result of its strategic review (results announced in October 2018), Momenta plans to advance its two late-stage biosimilar assets, M923, which is its wholly-owned proposed biosimilar to AbbVie's ABBV Humira, and M710, which is its proposed biosimilar to Regeneron's Eylea being developed in collaboration with Mylan. Momenta recently announced that it entered into a settlement with AbbVie Inc., to enable the commercialization of M923. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Momenta Pharmaceuticals, Inc. (MNTA): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Momenta Pharmaceuticals, Inc. (MNTA): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Pipeline Updates As a result of its strategic review (results announced in October 2018), Momenta plans to advance its two late-stage biosimilar assets, M923, which is its wholly-owned proposed biosimilar to AbbVie's ABBV Humira, and M710, which is its proposed biosimilar to Regeneron's Eylea being developed in collaboration with Mylan. Momenta recently announced that it entered into a settlement with AbbVie Inc., to enable the commercialization of M923. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Momenta Pharmaceuticals, Inc. (MNTA): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Pipeline Updates As a result of its strategic review (results announced in October 2018), Momenta plans to advance its two late-stage biosimilar assets, M923, which is its wholly-owned proposed biosimilar to AbbVie's ABBV Humira, and M710, which is its proposed biosimilar to Regeneron's Eylea being developed in collaboration with Mylan. Momenta recently announced that it entered into a settlement with AbbVie Inc., to enable the commercialization of M923. | Pipeline Updates As a result of its strategic review (results announced in October 2018), Momenta plans to advance its two late-stage biosimilar assets, M923, which is its wholly-owned proposed biosimilar to AbbVie's ABBV Humira, and M710, which is its proposed biosimilar to Regeneron's Eylea being developed in collaboration with Mylan. Momenta recently announced that it entered into a settlement with AbbVie Inc., to enable the commercialization of M923. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Momenta Pharmaceuticals, Inc. (MNTA): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. |
25273.0 | 2018-11-08 00:00:00 UTC | AbbVie (ABBV) Gains As Market Dips: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-gains-as-market-dips%3A-what-you-should-know-2018-11-08 | nan | nan | In the latest trading session, AbbVie (ABBV) closed at $87.73, marking a +0.89% move from the previous day. This move outpaced the S&P 500's daily loss of 0.25%. Meanwhile, the Dow gained 0.04%, and the Nasdaq, a tech-heavy index, lost 0.53%.
Heading into today, shares of the drugmaker had lost 6.58% over the past month, lagging the Medical sector's loss of 1.06% and the S&P 500's loss of 2.35% in that time.
ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. The company is expected to report EPS of $1.91, up 29.05% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $8.36 billion, up 8.07% from the prior-year quarter.
ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.92 per share and revenue of $32.78 billion. These results would represent year-over-year changes of +41.43% and +16.17%, respectively.
Investors might also notice recent changes to analyst estimates for ABBV. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.89% higher within the past month. ABBV currently has a Zacks Rank of #3 (Hold).
In terms of valuation, ABBV is currently trading at a Forward P/E ratio of 10.97. This represents a discount compared to its industry's average Forward P/E of 14.74.
Also, we should mention that ABBV has a PEG ratio of 0.83. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.01 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 75, which puts it in the top 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABBV in the coming trading sessions, be sure to utilize Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the latest trading session, AbbVie (ABBV) closed at $87.73, marking a +0.89% move from the previous day. ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.92 per share and revenue of $32.78 billion. ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. In the latest trading session, AbbVie (ABBV) closed at $87.73, marking a +0.89% move from the previous day. ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.92 per share and revenue of $32.78 billion. In the latest trading session, AbbVie (ABBV) closed at $87.73, marking a +0.89% move from the previous day. ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. | In the latest trading session, AbbVie (ABBV) closed at $87.73, marking a +0.89% move from the previous day. ABBV currently has a Zacks Rank of #3 (Hold). ABBV will be looking to display strength as it nears its next earnings release, which is expected to be January 25, 2019. |
25274.0 | 2018-11-07 00:00:00 UTC | Better Buy: Eli Lilly and Company vs. AbbVie Inc. | ABBV | https://www.nasdaq.com/articles/better-buy-eli-lilly-and-company-vs-abbvie-inc-2018-11-07 | nan | nan | Over the past six months, shares of Eli Lilly and Company (NYSE: LLY) and AbbVie Inc. (NYSE: ABBV) have been traveling in opposite directions that might seem a bit bizarre on the surface. AbbVie has reported much faster growth on the top and bottom lines than Lilly, but AbbVie's stock price fell 13% while Eli Lilly's rocketed 41% higher.
These big pharmaceutical companies generate a lot of cash, and they aren't shy about returning it to their shareholders. Let's stack their operations side by side to see which is positioned to deliver the most gains over the long run.
The case for Eli Lilly and Company
Eli Lilly launched the world's first insulin product in 1923, and the company's still at the forefront of diabetes care. Third-quarter sales of Lilly's next-generation diabetes treatment, Trulicity, surged 55% to an annualized $3.3 billion run rate, and it isn't showing any sign of a slowdown. The company's oral diabetes treatment, Jardiance, is also on the rise after Lilly proved it can lower diabetes patients' risk of heart attacks and other cardiovascular problems.
Jardiance and Trulicity are just two of eight products Lilly has launched since 2014 that are surging right now. Combined sales of the company's young lineup grew 53% year over year to an annualized $7.5 billion in the third quarter.
Unfortunately for Lilly, sales of many established products have already started fading. Cialis began losing ground to generic competition in Europe last year, and more recently in the U.S. The company's fast-acting insulin product, Humalog, began losing ground to competition from a similar drug that launched in the U.S. during the second quarter.
Cialis and Humalog are still responsible for around 19% of total revenue, so their continued losses will create a strong headwind to overcome in the quarters ahead. With a bit of luck, though, Lilly's new migraine program can go a long way toward offsetting the losses. The FDA recently approved Emgality for the prevention of migraine headaches, a condition that affects an estimated 36 million people in the U.S. alone.
Emgality isn't the first new migraine prevention drug to enter the market recently, but Lilly could launch the first new pain reliever for the acute treatment of the vicious headaches we've seen in a long time. The FDA is currently reviewing an application for lasmiditan that's supported by a clinical trial where those treated were 82% more likely to report being migraine pain-free after two hours than those given a placebo.
At recent prices, Eli Lilly shares offer a fairly meager 2.1% dividend yield that probably won't rise very fast in the years ahead. Even though the company has only raised its payout 15% over the past five years, dividend payments ate up 89% of the free cash flow that operations generated over the past 12 months.
The case for AbbVie Inc.
While Lilly's dividend program has limped along over the past five years, AbbVie raised its payout a stunning 168%, and investors can expect the 4.9% yield the stock offers at recent prices to continue rising in the near term. Dividend payments ate up just 44% of free cash flow over the past year.
Sales of AbbVie's mega-blockbuster arthritis drug, Humira, could reach $20 billion this year, but further gains will be difficult. Less-expensive biosimilar versions of Humira became available in the EU this October. Just 69% of Humira sales originate in the U.S., where biosimilar competition has been thwarted until 2023. U.S. sales rose 13% in the third quarter, but it will be hard to offset European losses, which are expected to be swift .
AbbVie markets Imbruvica, an oral leukemia treatment in partnership with Johnson & Johnson (NYSE: JNJ) , that is quickly becoming the standard of care for newly diagnosed patients. AbbVie's share of Imbruvica sales hit an annualized $3.9 billion in the third quarter, a 41% increase over the previous year.
During the third quarter, AbbVie launched the first of a few potential blockbusters in late-stage development. Orilissa is the first new pill for endometriosis pain the FDA has approved in over a decade, and an expansion to reduce uterine fibroids could happen next year. With millions of potential patients in need of new treatment options, Orilissa sales are expected to pass the $1 billion per year threshold by 2020.
The FDA is currently reviewing an experimental psoriasis treatment, risankizumab, which could go much further than Orilissa. During a head-to-head study with a drug that boasts sales on pace to reach $5 billion this year, Stelara, patients treated with risankizumab were twice as likely to report feeling symptom-free after 16 weeks.
The better buy
Eli Lilly has a lot going for it right now, but at 19.8 times forward earnings expectations, it looks like investors are asking a little too much from the company's young lineup. If Lilly's more recently launched drugs can't offset sagging sales of Cialis and decades-old insulin products in the quarters ahead, the stock's recent gains could get wiped out.
At just 10.9 times forward earnings, it looks like a European biosimilar onslaught is already baked into AbbVie's share price. That gives AbbVie a better chance to outperform if its late-stage pipeline delivers, and it makes the company the better buy right now.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Cory Renauer owns shares of Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson and has the following options: short January 2019 $140 calls on Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | While Lilly's dividend program has limped along over the past five years, AbbVie raised its payout a stunning 168%, and investors can expect the 4.9% yield the stock offers at recent prices to continue rising in the near term. Over the past six months, shares of Eli Lilly and Company (NYSE: LLY) and AbbVie Inc. (NYSE: ABBV) have been traveling in opposite directions that might seem a bit bizarre on the surface. AbbVie has reported much faster growth on the top and bottom lines than Lilly, but AbbVie's stock price fell 13% while Eli Lilly's rocketed 41% higher. | While Lilly's dividend program has limped along over the past five years, AbbVie raised its payout a stunning 168%, and investors can expect the 4.9% yield the stock offers at recent prices to continue rising in the near term. Over the past six months, shares of Eli Lilly and Company (NYSE: LLY) and AbbVie Inc. (NYSE: ABBV) have been traveling in opposite directions that might seem a bit bizarre on the surface. AbbVie has reported much faster growth on the top and bottom lines than Lilly, but AbbVie's stock price fell 13% while Eli Lilly's rocketed 41% higher. | AbbVie has reported much faster growth on the top and bottom lines than Lilly, but AbbVie's stock price fell 13% while Eli Lilly's rocketed 41% higher. While Lilly's dividend program has limped along over the past five years, AbbVie raised its payout a stunning 168%, and investors can expect the 4.9% yield the stock offers at recent prices to continue rising in the near term. Over the past six months, shares of Eli Lilly and Company (NYSE: LLY) and AbbVie Inc. (NYSE: ABBV) have been traveling in opposite directions that might seem a bit bizarre on the surface. | Over the past six months, shares of Eli Lilly and Company (NYSE: LLY) and AbbVie Inc. (NYSE: ABBV) have been traveling in opposite directions that might seem a bit bizarre on the surface. AbbVie has reported much faster growth on the top and bottom lines than Lilly, but AbbVie's stock price fell 13% while Eli Lilly's rocketed 41% higher. The case for AbbVie Inc. |
25275.0 | 2018-11-07 00:00:00 UTC | 7 Healthcare Stocks Soaring on Election Results | ABBV | https://www.nasdaq.com/articles/7-healthcare-stocks-soaring-election-results-2018-11-07 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
U.S. equities are surging strongly on Wednesday as the Democrats emerged with a narrow majority in the House of Representatives following a bitter mid-term election contest. The Republicans expanded their majority in the Senate. The outcome should be a mix of gridlock (especially on trade) and possible action on infrastructure, both of which the market seems excited about.
But above all this, the Democrats' ran on the healthcare issue - concerning both their focus on protecting the gains in coverage expansion under Obamacare and also on things like lowering prescription drug prices - something that GOP Senate Majority leader McConnell and President Donald Trump have both voiced support for this morning.
As a result, the Health Care Sector SPDR (NYSEARCA: XLV ) is rallying 2.8% so far today vs. a 1.9% gain for the Dow Jones Industrial Average , returning to the highs seen in the middle of October.
10 Strong Buy Stocks Trading at Killer Entry Points
Here are seven key healthcare stocks powering the move higher on the hope price relief will drive increased unit sales and thus, higher revenues:
Healthcare Stocks to Buy: Merck (MRK)
Merck (NYSE: MRK ) shares are breaking higher on Wednesday, pushing up and out of a three-month consolidation range to set new highs. This marks a gain of more than 44% from the lows set in April. Investors have been excited about higher demand for its GARDASIL 9 HPV vaccine.
The company will next report results on Feb. 1 before the bell. Analysts are looking for earnings of $1.05 per share on revenues of $10.99 billion. When the company last reported on Oct. 25 earnings of $1.19 per share beat estimates by five cents on a 4.5% rise in revenues.
Healthcare Stocks to Buy: Pfizer (PFE)
Pfizer (NYSE: PFE ) shares are pushing up and out of a two-month downtrend in what looks like an attempt at the early October highs after bouncing off of support at its 50-day moving average. Investors have had a lot to consider lately, from reports of a potential sale of its women's health portfolio to a recent downgrade by analysts at BMO Capital Markets.
15 Winners and Losers From This Earnings Season
The company will next report results on Jan. 29 before the bell. Analysts are looking for earnings of 65 cents per share on revenues of $13.9 billion. When the company last reported on Oct. 30 earnings of 78 cents per share beat estimates by three cents on a 1% rise in revenues.
Healthcare Stocks to Buy: Eli Lilly (LLY)
Shares of Eli Lilly (NYSE: LLY ) have pushed back up and over their 50-day moving average, catching support at the lower end of a four-month sideways range. Already up nearly 50% from the lows seen in May, watch for an early 5% gain to test the early October highs.
The company will next report results on Feb. 5 before the market. When the company last reported on Nov. 6, earnings of $1.39 beat estimates by four cents on a 7.1% rise in revenues. The top-line lift was spurred by a 12% increase in volumes which offset a 4% drop in prices.
Healthcare Stocks to Buy: AbbVie (ABBV)
Shares of AbbVie (NYSE: ABBV ) are climbing back up and over their 20-day moving average in what looks like an attempt to return to the trading range that has prevailed for most of the year to date - centered around the $95-a-share level. Management recently raised both the company's dividend and their forward guidance on solid HUMIRA sales.
10 Stocks to Buy for a Midterm Rally
The company will next report results on Jan. 25 before the bell. Analysts are looking for earnings of $1.93 per share on revenues of $8.4 billion. When the company last reported on Nov. 2 earnings of $2.14 per share beat estimates by 13 cents on a 17.7% rise in revenues.
Healthcare Stocks to Buy: Amgen (AMGN)
Amgen (NASDAQ: AMGN ) shares are emerging from a three-month downtrend to close back in on its 200-day moving average after a nice looking tap of its 200-day moving average. Merely a return to its late September high would be worth a 7%-plus gain from here. The company recently reported positive clinical benefits for REPATHA for patients with established cardiovascular disease.
The company will next report results on Jan. 31 after the close. Analysts are looking for earnings of $3.27 per share on revenues of $5.9 billion. When the company last reported on Oct. 30, earnings of $3.69 per share beat estimates by 24 cents on a 2.3% rise in revenues.
Healthcare Stocks to Buy: Biogen (BIIB)
Biogen (NASDAQ: BIIB ) shares have recovered back above their 200-day moving average and are closing in on their 50-day average setting up a possible move back to the upper end of a multi-month trading range near $360. Such a move would be worth a gain of more than 9% from here.
Management recently highlighted that the number of commercial patients receiving SPINRAZA for spinal muscular atrophy increased 11% in the United States and 29% outside the U.S.
7 Dividend Stocks To Consider for Growth
The company will next report results on January 24 before the bell. Analysts are looking for earnings of $6.73 per share on $6.7 billion in revenues. When the company last reported on October 23, earnings of $7.40 beat estimates by 64 cents on an 11.7% rise in revenue.
Healthcare Stocks to Buy: UnitedHealth Group (UNH)
Shares of insurer UnitedHealth (NYSE: UNH ) are surging more than 4% higher on Wednesday to eclipse the highs seen in September and October - marking a rise of nearly 8% from the lows seen in late October. Not only are the Democrat's gain of the House bolstering sentiment here - on their focus on expanding coverage - but solid earnings from competitor Humana (NYSE: HUM ) are helping as well.
The company will next report results on Jan. 15 before the bell. Analysts are looking for earnings of $3.22 per share on revenues of $58.1 billion. When the company last reported on Oct. 16, earnings of $3.41 per share beat estimates by 11 cents on a 12.4% rise in revenues.
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
10 Blue-Chip Stocks to Buy Ahead of Black Friday
7 Dividend Stocks To Consider for Growth
5 Artificial Intelligence Stocks to Consider
Compare Brokers
The post 7 Healthcare Stocks Soaring on Election Results appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Healthcare Stocks to Buy: AbbVie (ABBV) Shares of AbbVie (NYSE: ABBV ) are climbing back up and over their 20-day moving average in what looks like an attempt to return to the trading range that has prevailed for most of the year to date - centered around the $95-a-share level. But above all this, the Democrats' ran on the healthcare issue - concerning both their focus on protecting the gains in coverage expansion under Obamacare and also on things like lowering prescription drug prices - something that GOP Senate Majority leader McConnell and President Donald Trump have both voiced support for this morning. As a result, the Health Care Sector SPDR (NYSEARCA: XLV ) is rallying 2.8% so far today vs. a 1.9% gain for the Dow Jones Industrial Average , returning to the highs seen in the middle of October. | Healthcare Stocks to Buy: AbbVie (ABBV) Shares of AbbVie (NYSE: ABBV ) are climbing back up and over their 20-day moving average in what looks like an attempt to return to the trading range that has prevailed for most of the year to date - centered around the $95-a-share level. 10 Strong Buy Stocks Trading at Killer Entry Points Here are seven key healthcare stocks powering the move higher on the hope price relief will drive increased unit sales and thus, higher revenues: Healthcare Stocks to Buy: Merck (MRK) Merck (NYSE: MRK ) shares are breaking higher on Wednesday, pushing up and out of a three-month consolidation range to set new highs. Healthcare Stocks to Buy: Eli Lilly (LLY) Shares of Eli Lilly (NYSE: LLY ) have pushed back up and over their 50-day moving average, catching support at the lower end of a four-month sideways range. | Healthcare Stocks to Buy: AbbVie (ABBV) Shares of AbbVie (NYSE: ABBV ) are climbing back up and over their 20-day moving average in what looks like an attempt to return to the trading range that has prevailed for most of the year to date - centered around the $95-a-share level. 10 Strong Buy Stocks Trading at Killer Entry Points Here are seven key healthcare stocks powering the move higher on the hope price relief will drive increased unit sales and thus, higher revenues: Healthcare Stocks to Buy: Merck (MRK) Merck (NYSE: MRK ) shares are breaking higher on Wednesday, pushing up and out of a three-month consolidation range to set new highs. When the company last reported on Oct. 25 earnings of $1.19 per share beat estimates by five cents on a 4.5% rise in revenues. | Healthcare Stocks to Buy: AbbVie (ABBV) Shares of AbbVie (NYSE: ABBV ) are climbing back up and over their 20-day moving average in what looks like an attempt to return to the trading range that has prevailed for most of the year to date - centered around the $95-a-share level. 10 Strong Buy Stocks Trading at Killer Entry Points Here are seven key healthcare stocks powering the move higher on the hope price relief will drive increased unit sales and thus, higher revenues: Healthcare Stocks to Buy: Merck (MRK) Merck (NYSE: MRK ) shares are breaking higher on Wednesday, pushing up and out of a three-month consolidation range to set new highs. The company will next report results on Feb. 5 before the market. |
25276.0 | 2018-11-06 00:00:00 UTC | Notable ETF Inflow Detected - DGRO, PFE, ABBV, CMCSA | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-dgro-pfe-abbv-cmcsa-2018-11-06 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core Dividend Growth ETF (Symbol: DGRO) where we have detected an approximate $222.0 million dollar inflow -- that's a 4.9% increase week over week in outstanding units (from 127,850,000 to 134,100,000). Among the largest underlying components of DGRO, in trading today Pfizer Inc (Symbol: PFE) is down about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.8%, and Comcast Corp (Symbol: CMCSA) is lower by about 0.2%. For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price performance of DGRO, versus its 200 day moving average:
Looking at the chart above, DGRO's low point in its 52 week range is $32.82 per share, with $37.93 as the 52 week high point - that compares with a last trade of $35.60. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of DGRO, in trading today Pfizer Inc (Symbol: PFE) is down about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.8%, and Comcast Corp (Symbol: CMCSA) is lower by about 0.2%. For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price performance of DGRO, versus its 200 day moving average: Looking at the chart above, DGRO's low point in its 52 week range is $32.82 per share, with $37.93 as the 52 week high point - that compares with a last trade of $35.60. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of DGRO, in trading today Pfizer Inc (Symbol: PFE) is down about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.8%, and Comcast Corp (Symbol: CMCSA) is lower by about 0.2%. For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price performance of DGRO, versus its 200 day moving average: Looking at the chart above, DGRO's low point in its 52 week range is $32.82 per share, with $37.93 as the 52 week high point - that compares with a last trade of $35.60. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of DGRO, in trading today Pfizer Inc (Symbol: PFE) is down about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.8%, and Comcast Corp (Symbol: CMCSA) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core Dividend Growth ETF (Symbol: DGRO) where we have detected an approximate $222.0 million dollar inflow -- that's a 4.9% increase week over week in outstanding units (from 127,850,000 to 134,100,000). For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price performance of DGRO, versus its 200 day moving average: Looking at the chart above, DGRO's low point in its 52 week range is $32.82 per share, with $37.93 as the 52 week high point - that compares with a last trade of $35.60. | Among the largest underlying components of DGRO, in trading today Pfizer Inc (Symbol: PFE) is down about 0.2%, AbbVie Inc (Symbol: ABBV) is up about 0.8%, and Comcast Corp (Symbol: CMCSA) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core Dividend Growth ETF (Symbol: DGRO) where we have detected an approximate $222.0 million dollar inflow -- that's a 4.9% increase week over week in outstanding units (from 127,850,000 to 134,100,000). For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price performance of DGRO, versus its 200 day moving average: Looking at the chart above, DGRO's low point in its 52 week range is $32.82 per share, with $37.93 as the 52 week high point - that compares with a last trade of $35.60. |
25277.0 | 2018-11-02 00:00:00 UTC | AbbVie's (ABBV) Q3 Earnings Beat Estimates, 2018 EPS View Up | ABBV | https://www.nasdaq.com/articles/abbvies-abbv-q3-earnings-beat-estimates-2018-eps-view-up-2018-11-02 | nan | nan | AbbVie Inc.ABBV posted better-than-expected third-quarter 2018 earnings while its revenues missed estimates by a slight margin. Moreover, the company raised its expectations for 2018 bottom line. Shares rose almost 3.4% in pre-market.
Shares of AbbVie have declined 17.1% in a year's time against the industry 's 5% rise.
The biopharmaceutical company reported earnings of $2.14 per share in the third quarter, beating the Zacks Consensus Estimate of $2.01. The figure surged 51.8% year over year. Earnings per share also exceeded the guided range of $2.00 and $2.02.
The company posted revenues of $8.24 billion in the quarter under review, missing the Zacks Consensus Estimate of $8.26 billion. However, the top line increased 17.8% year over year. Excluding a 0.7% favorable impact from foreign exchange rate fluctuations, operational revenues rose 18.5%. Revenues growth was higher than the projection of approximately 17% on an operational basis.
Quarter in Detail
Key drug Humira recorded sales growth of 9.8% on an operational basis with revenues from the same coming in at $5.1 billion. Sales in the United States increased 12.5% to $3.5 billion, better than expectations. Humira sales in the ex-U.S. markets were up 4.2% on an operational basis and 1.8% on reported basis to $1.58 billion, almost in-line with the projected figure of $1.6 billion.
Third-quarter net revenues from Imbruvica were $972 million, up 41.3% year over year. U.S. sales of Imbruvica grossed $812 million, up 41.5% from the year-ago figure and also higher than the guided figure of $725 million. AbbVie logged $160 million of international profit sharing with Johnson & Johnson JNJ .
The company's leukemia drug, Venclexta, brought in revenues of $96 million, up more than 100% year over year.
Other products that delivered an impressive performance include Duodopa. It recorded revenue growth of 13.3% on operational basis and 12.1% on reported basis. Another product, Creon witnessed an increase of 11.3% in revenues on both operational and reported basis.
HCV (chronic hepatitis C virus) products recorded sales of $862 million, up more than 100% year over year, on the back of strong demand for Mavyret, which was launched in the second half of 2017. The company's expectation for HCV sales was $850 million.
However, sales of two key drugs, Androgel and Sevoflurane, fell 8.3% and 10.4%, respectively, operationally, during the quarter.
Adjusted SG&A expenses increased 8.4% to $1.56 billion while R&D expenses escalated 6% to $1.27 billion in the third quarter. Adjusted operating margin was 47.2% of sales.
Other Updates
In October, a label expansion of cancer drug, Venclyxto (Venclexta), in combination with Roche's RHHBY Rituxan (rituximab) for the treatment of patients with chronic lymphocytic leukemia ("CLL") in second or later-line setting was approved in Europe. Data from a phase III study showed that Venclexta in combination with Roche's Gazyva had superior progression-free survival ("PFS") in first-line CLL compared to standard of care. A label expansion application for the drug is under review in the United States for treating acute myeloid leukemia in first-line setting.
During the quarter, AbbVie entered into a license agreement with Sandoz, a generic arm of Novartis NVS , which will grant non-exclusive license relating to Humira in the United States and other countries. The agreement restricts Sandoz from launching a biosimilar version of the drug till Sep 30, 2023 in the United States. The restriction on the launch of a biosimilar version in Europe expired on Oct 16, 2018.
2018 Outlook Raised
AbbVie raised its adjusted EPS guidance to the range of $7.90-$7.92 for 2018 from $7.76-$7.86 predicted earlier. The earnings guidance reflects a year-over-year surge of 41.3% at the mid-point. The Zacks Consensus Estimate for current-year earnings is pegged at $7.86 per share.
Price, Consensus and EPS Surprise
Price, Consensus and EPS Surprise | Quote
Zacks Rank
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Novartis AG (NVS): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc.ABBV posted better-than-expected third-quarter 2018 earnings while its revenues missed estimates by a slight margin. Shares of AbbVie have declined 17.1% in a year's time against the industry 's 5% rise. AbbVie logged $160 million of international profit sharing with Johnson & Johnson JNJ . | Price, Consensus and EPS Surprise Price, Consensus and EPS Surprise | Quote Zacks Rank AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV posted better-than-expected third-quarter 2018 earnings while its revenues missed estimates by a slight margin. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV posted better-than-expected third-quarter 2018 earnings while its revenues missed estimates by a slight margin. Shares of AbbVie have declined 17.1% in a year's time against the industry 's 5% rise. | AbbVie Inc.ABBV posted better-than-expected third-quarter 2018 earnings while its revenues missed estimates by a slight margin. Shares of AbbVie have declined 17.1% in a year's time against the industry 's 5% rise. AbbVie logged $160 million of international profit sharing with Johnson & Johnson JNJ . |
25278.0 | 2018-11-02 00:00:00 UTC | AbbVie Stock Jumps Higher on Q3 Earnings Beat | ABBV | https://www.nasdaq.com/articles/abbvie-stock-jumps-higher-q3-earnings-beat-2018-11-02 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie stock got a slight boost on Friday following the release of its earnings report for the third quarter of 2018.
Source: Shutterstock
AbbVie (NYSE: ABBV ) reported earnings per share of $2.14 for the third quarter of the year. This is an increase over the company's earnings per share of $1.41 from the same time last year. It is also a boon to AbbVie stock by coming in above Wall Street's earnings per share estimate of $2.02 for the quarter.
Net income reported by AbbVie for the second quarter of 2018 came in at $2.75 billion. This is better than the company's net income of $1.63 billion reported in the third quarter of 2017.
AbbVie's earnings report for the third quarter of the year also includes operating income of $3.16 billion. The biopharmaceutical company's operating income for the same period of the year prior was $2.69 billion.
During the third quarter of 2018, AbbVie reported revenue of $8.24 billion . This is up from the company's revenue of $7.00 billion reported in the third quarter of the previous year. It is also good news for AbbVie stock by just barely beating out analysts' revenue estimate of $8.23 billion for the period.
7 U.S. Marijuana Stocks to Buy for the Midterm Elections
AbbVie's most recent earnings report also sees the company updating its outlook for the full year of 2018. This has it increasing its earnings per share guidance for the year to between $7.90 to $7.92. Its previous guidance range was for earnings per share of $7.76 to $7.86. This is a good sign for AbbVie stock as Wall Street is looking for earnings per share of $7.88 for the year.
ABBV stock was up 1% as of Friday morning, but is down 18% year-to-date.
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
7 Canadian Stocks to Buy Now (And Only 2 Are Pot Stocks)
5 Stocks to Sell In November Amid Elections and Earnings
3 Retail Stocks to Buy Despite All the Fearmongering
As of this writing, William White did not hold a position in any of the aforementioned securities.
Compare Brokers
The post AbbVie Stock Jumps Higher on Q3 Earnings Beat appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It is also good news for AbbVie stock by just barely beating out analysts' revenue estimate of $8.23 billion for the period. Marijuana Stocks to Buy for the Midterm Elections AbbVie's most recent earnings report also sees the company updating its outlook for the full year of 2018. Compare Brokers The post AbbVie Stock Jumps Higher on Q3 Earnings Beat appeared first on InvestorPlace . | AbbVie's earnings report for the third quarter of the year also includes operating income of $3.16 billion. It is also good news for AbbVie stock by just barely beating out analysts' revenue estimate of $8.23 billion for the period. InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie stock got a slight boost on Friday following the release of its earnings report for the third quarter of 2018. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie stock got a slight boost on Friday following the release of its earnings report for the third quarter of 2018. AbbVie's earnings report for the third quarter of the year also includes operating income of $3.16 billion. Source: Shutterstock AbbVie (NYSE: ABBV ) reported earnings per share of $2.14 for the third quarter of the year. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie stock got a slight boost on Friday following the release of its earnings report for the third quarter of 2018. Source: Shutterstock AbbVie (NYSE: ABBV ) reported earnings per share of $2.14 for the third quarter of the year. It is also a boon to AbbVie stock by coming in above Wall Street's earnings per share estimate of $2.02 for the quarter. |
25279.0 | 2018-11-02 00:00:00 UTC | AbbVie (ABBV) Tops Q3 Earnings Estimates | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-tops-q3-earnings-estimates-2018-11-02 | nan | nan | AbbVie (ABBV) came out with quarterly earnings of $2.14 per share, beating the Zacks Consensus Estimate of $2.01 per share. This compares to earnings of $1.41 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 6.47%. A quarter ago, it was expected that this drugmaker would post earnings of $1.98 per share when it actually produced earnings of $2, delivering a surprise of 1.01%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $8.24 billion for the quarter ended September 2018, missing the Zacks Consensus Estimate by 0.28%. This compares to year-ago revenues of $7 billion. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
AbbVie shares have lost about 17.1% since the beginning of the year versus the S&P 500's gain of 2.5%.
What's Next for AbbVie?
While AbbVie has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for AbbVie was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.98 on $8.47 billion in revenues for the coming quarter and $7.86 on $32.89 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Large Cap Pharmaceuticals is currently in the top 16% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (ABBV) came out with quarterly earnings of $2.14 per share, beating the Zacks Consensus Estimate of $2.01 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $8.24 billion for the quarter ended September 2018, missing the Zacks Consensus Estimate by 0.28%. AbbVie shares have lost about 17.1% since the beginning of the year versus the S&P 500's gain of 2.5%. | AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $8.24 billion for the quarter ended September 2018, missing the Zacks Consensus Estimate by 0.28%. AbbVie (ABBV) came out with quarterly earnings of $2.14 per share, beating the Zacks Consensus Estimate of $2.01 per share. AbbVie shares have lost about 17.1% since the beginning of the year versus the S&P 500's gain of 2.5%. | AbbVie (ABBV) came out with quarterly earnings of $2.14 per share, beating the Zacks Consensus Estimate of $2.01 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $8.24 billion for the quarter ended September 2018, missing the Zacks Consensus Estimate by 0.28%. AbbVie shares have lost about 17.1% since the beginning of the year versus the S&P 500's gain of 2.5%. | AbbVie (ABBV) came out with quarterly earnings of $2.14 per share, beating the Zacks Consensus Estimate of $2.01 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $8.24 billion for the quarter ended September 2018, missing the Zacks Consensus Estimate by 0.28%. AbbVie shares have lost about 17.1% since the beginning of the year versus the S&P 500's gain of 2.5%. |
25280.0 | 2018-11-02 00:00:00 UTC | Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-pfe-agn-q3-earnings-lly-nvs-collaboration-deals-in-focus-2018-11-02 | nan | nan | It was another busy week for the pharma sector, marked by earnings of bigwigs like Pfizer PFE , Allergan AGN , Sanofi SNY and Glaxo GSK . Merck MRK and AbbVie ABBV gained regulatory approvals for label expansion of their key cancer drugs. Eli Lilly LLY , Pfizer and Sanofi announced collaboration deals.
Recap of the Week's Most Important Stories
Earnings: Pfizer beat estimates for third-quarter earnings while recording in-line sales. The company narrowed its earnings as well as sales expectations for the full year. Pfizer attributed the lowered sales guidance to weaker-than-expected revenues in the Essential Health segment as a result of continued shortages in the sterile-injections business, and currency headwinds.
Allergan delivered solid performance in the third quarter, beating estimates for both earnings and sales while also raising its full-year expectations. However, revenues declined year over year as some of its key blockbuster drugs lost exclusivity and are facing generic competition.
Sanofi and Glaxo beat estimates for earnings as well as sales in the third quarter. Both the companies raised the lower end of their full-year earnings growth guidance.
Collaboration/Divestiture Announcements: Lilly signed a deal with Dicerna Pharmaceuticals to help develop new medicines for the treatment of cardio-metabolic, neurodegeneration disorders and pain using the latter's proprietary RNAi technology platform. RNAi is an emerging technology for drug discovery attracting the attention of big drugmakers.
Per the deal, Lilly will make an upfront payment of $100 million to Dicerna as well as invest $100 million in the latter's stock. In addition, Dicerna is eligible to receive up to approximately $350 million for each development target and also commercialization milestones and royalties.
Two big drug giants, Pfizer and Novartis, came together to research on combination therapies of their early-stage investigational candidates for the treatment of non-alcoholic steatohepatitis (NASH), a fatty liver disease with no approved treatments at present. Pfizer has three candidates in clinical development with several others in pre-clinical stage for NASH. Per the deal, one or more of Pfizer's three early-stage candidates will be studied in combination with Novartis's tropifexor targeting different pathways in NASH.
Sanofi said it plans to collaborate with Denali Therapeutics to develop multiple molecules, which have the potential to treat neurologic and inflammatory diseases like multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and systemic inflammatory diseases. For the deal, Sanofi will pay $125 million upfront payment and Denali Therapeutics will also be entitled to future milestone payments that could amount to more than $1 billion.
AstraZeneca announced an agreement to divest European rights to its acid reflux medicine, Nexium and worldwide rights (excluding the US and Japan) to arthritis pain reliever, Vimovo to Grünenthal. The divestiture will allow AstraZeneca to focus on its core areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory. For the purchase, Grünenthal will make upfront payments of $700 million and $150 million for Nexium and Vimovo, respectively. AstraZeneca will also be entitled to future milestones and sales-related payments of up to $107 million. AstraZeneca will continue to market Nexium in markets outside EU.
Merck's Keytruda Gets FDA Nod for Difficult Lung Cancer: Merck received FDA approval for the label expansion of its blockbuster PD-1 inhibitor, Keytruda (in combination with chemotherapy) for first-line treatment of metastatic squamous NSCLC - a difficult-to-treat lung cancer patient population. The supplemental biologics license application (sBLA) filing was based on data from the KEYNOTE-407 study.
We remind investors that data presented from this study stole the limelight at the annual meeting of the American Society of Clinical Oncology in June. Data from the study showed that the combination of Keytruda plus chemotherapy led to significant improvement in both overall survival (OS) and progression-free survival regardless of tumor PD-L1 expression status. The approval further strengthens Keytruda's position in the lung cancer market.
AbbVie Gets EU Approval for Venclexta and Rituxan Combo: AbbVie received European Commission's (EC) marketing approval for use of Venclexta in combination with Roche's MabThera (rituximab) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia ("CLL") who have received at least one prior therapy. Regulatory applications seeking approval for the combination use in this broader patient population were approved in the United States in June.
Label expansion for this indication should expand the patient population for Venclexta significantly and boost its commercial potential. The approval was based on positive data from the phase III MURANO study, which showed that the combination led to a profound improvement in progression free survival compared to Treanda plus Rituxan.
AbbVie also announced that a phase III study evaluating a Venclexta combo met the primary endpoint. The study, CLL14, was evaluating a combination of Venclexta plus Roche's Gazyva (obinutuzumab) as a first-line therapy with a fixed duration of treatment in patients with chronic lymphocytic leukemia versus standard of care Gazyva plus chlorambucil. Data from the study demonstrated that patients in the Venclexta arm had superior progression-free survival (PFS) compared to those in the standard of care arm. AbbVie is optimistic that the data may serve as the basis to expand into first-line setting.
District Court Invalidates J&J's Zytiga Patent : A New Jersey district court invalidated J&J's patent (patent '438) related to Zytiga, opening the doors for generic launches. However, the court prohibited commercial launches of generic products before Oct 31. J&J said it will appeal the court's decision. Several generic companies are looking to bring generic versions of 250 mg and/or 500 mg tablets of Zytiga.
In a separate development, J&J received FDA approval for the inclusion of cardiovascular outcomes data from the CANVAS program on the label of its diabetes drug, Invokana. This means the drug can be prescribed to reduce the risk of cardiovascular events like heart attack, stroke or cardiovascular death in adults with type II diabetes and established cardiovascular disease. The filing was based on data from a large CANVAS outcomes program. However, the label will include a warning about an increased risk of amputations. A similar label update was approved in the EU in September.
Glaxo Presents New HIV Data: Glaxo's HIV company, ViiV Healthcare announced 160-week data from the LATTE-2 phase IIb study evaluating the efficacy of a long-lasting HIV injection in ART-naïve HIV patients. Data from the study showed that the long-acting, two-drug, injectable regimen of cabotegravir and rilpivirine led to high rates of virologic response, long-term durability of virologic response and good overall tolerability. In the study, the patients were administered cabotegravir+rilpivirine either every eight weeks or every four weeks.
Glaxo also announced positive headline 48-week results from another study, FLAIR, evaluating the once monthly dose of the long-lasting HIV injection. The study met the primary endpoint, showing similar efficacy of the once-monthly regimen as a daily, oral three-drug HIV pill in virally-suppressed adults.
Glaxo is developing the long-acting injectable dosing regimen to reduce the patients' number of annual doses from 365 to 12.
The NYSE ARCA Pharmaceutical Index rose 2.2 % in the last five trading sessions.
Large Cap Pharmaceuticals Industry 5YR % Return
Large Cap Pharmaceuticals Industry 5YR % Return
Here is how the seven major stocks performed in the last five trading sessions:
All stocks were in the green this week except Lilly, which declined 0.1%. Bristol-Myers rose the most (5.9%) in the last five trading sessions.
In the past six months, Lilly (LLY) has been the biggest gainer (38.2%) while Bristol-Myers recorded the lowest gain (1.3%).
(See the last pharma stock roundup here: MRK, BMY Q3 Earnings, Cancer Data Presentations at ESMO )
What's Next in the Pharma World?
Watch out for pipeline and regulatory updates next week.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Sanofi (SNY): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
GlaxoSmithKline plc (GSK): Free Stock Analysis Report
Allergan plc (AGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Merck MRK and AbbVie ABBV gained regulatory approvals for label expansion of their key cancer drugs. AbbVie Gets EU Approval for Venclexta and Rituxan Combo: AbbVie received European Commission's (EC) marketing approval for use of Venclexta in combination with Roche's MabThera (rituximab) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia ("CLL") who have received at least one prior therapy. AbbVie also announced that a phase III study evaluating a Venclexta combo met the primary endpoint. | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Allergan plc (AGN): Free Stock Analysis Report To read this article on Zacks.com click here. Merck MRK and AbbVie ABBV gained regulatory approvals for label expansion of their key cancer drugs. AbbVie Gets EU Approval for Venclexta and Rituxan Combo: AbbVie received European Commission's (EC) marketing approval for use of Venclexta in combination with Roche's MabThera (rituximab) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia ("CLL") who have received at least one prior therapy. | AbbVie Gets EU Approval for Venclexta and Rituxan Combo: AbbVie received European Commission's (EC) marketing approval for use of Venclexta in combination with Roche's MabThera (rituximab) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia ("CLL") who have received at least one prior therapy. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Allergan plc (AGN): Free Stock Analysis Report To read this article on Zacks.com click here. Merck MRK and AbbVie ABBV gained regulatory approvals for label expansion of their key cancer drugs. | Merck MRK and AbbVie ABBV gained regulatory approvals for label expansion of their key cancer drugs. AbbVie Gets EU Approval for Venclexta and Rituxan Combo: AbbVie received European Commission's (EC) marketing approval for use of Venclexta in combination with Roche's MabThera (rituximab) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia ("CLL") who have received at least one prior therapy. AbbVie also announced that a phase III study evaluating a Venclexta combo met the primary endpoint. |
25281.0 | 2018-11-02 00:00:00 UTC | Earnings Reaction History: AbbVie Inc., 63.6% Follow-Through Indicator, 4.0% Sensitive | ABBV | https://www.nasdaq.com/articles/earnings-reaction-history-abbvie-inc-636-follow-through-indicator-40-sensitive-2018-11-02 | nan | nan | Expected Earnings Release: 11/02/2018, Premarket
Avg. Extended-Hours Dollar Volume: $7,550,687
AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect very active trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in ABBV indicates that the price change in the extended hours is likely to be of significant value in forecasting additional price movement by the following regular session close.
Last 12 Qtrs Positive Only Price Reactions
Percent of time added to extended-hours gains: 83.3%
Average next regular session additional gain: 3.1%
Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 83.3% of the time (5 events) the stock posted additional gains in the following regular session by an average of 3.1%.
Last 12 Qtrs Negative Only Price Reactions
Percent of time added to extended-hours losses: 40%
Average next regular session additional loss: 1.6%
Over that same historical period, when shares of ABBV dropped in the extended-hours in reaction to its earnings announcement, history shows that 40.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 1.6% by the following regular session close.
Data provided by the MT Pro service at MTNewswires.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 83.3% Average next regular session additional gain: 3.1% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 83.3% of the time (5 events) the stock posted additional gains in the following regular session by an average of 3.1%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 40% Average next regular session additional loss: 1.6% Over that same historical period, when shares of ABBV dropped in the extended-hours in reaction to its earnings announcement, history shows that 40.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 1.6% by the following regular session close. Extended-Hours Dollar Volume: $7,550,687 AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Historical earnings event related premarket and after-hours trading activity in ABBV indicates that the price change in the extended hours is likely to be of significant value in forecasting additional price movement by the following regular session close. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 83.3% Average next regular session additional gain: 3.1% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 83.3% of the time (5 events) the stock posted additional gains in the following regular session by an average of 3.1%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 40% Average next regular session additional loss: 1.6% Over that same historical period, when shares of ABBV dropped in the extended-hours in reaction to its earnings announcement, history shows that 40.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 1.6% by the following regular session close. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 83.3% Average next regular session additional gain: 3.1% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 83.3% of the time (5 events) the stock posted additional gains in the following regular session by an average of 3.1%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 40% Average next regular session additional loss: 1.6% Over that same historical period, when shares of ABBV dropped in the extended-hours in reaction to its earnings announcement, history shows that 40.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 1.6% by the following regular session close. Extended-Hours Dollar Volume: $7,550,687 AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Extended-Hours Dollar Volume: $7,550,687 AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Historical earnings event related premarket and after-hours trading activity in ABBV indicates that the price change in the extended hours is likely to be of significant value in forecasting additional price movement by the following regular session close. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 83.3% Average next regular session additional gain: 3.1% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 83.3% of the time (5 events) the stock posted additional gains in the following regular session by an average of 3.1%. |
25282.0 | 2018-11-02 00:00:00 UTC | 5 Income Stocks for Massive Payouts and Steady Growth | ABBV | https://www.nasdaq.com/articles/5-income-stocks-massive-payouts-and-steady-growth-2018-11-02 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Although many investors like to follow equities for potential stock price increases, a large number also choose to focus on income stocks . Some stocks offer cash payouts compelling enough to make dividend stocks the stocks to buy. This is especially true for investors focused on cash flow or retirees who depend on their assets to generate income.
The average S&P 500 stock dividend yield currently stands at just over 1.9%. While that may not impress many investors, that still beats yields one can find at many banks. Also, it allows for the long-term appreciation gained by investing in S&P 500 equities.
Income-focused investors tend to look at two classes of dividend stocks. Some income stocks have earned the designation of "dividend aristocrat." These equities have increased dividend payouts for a minimum of 25 consecutive years. While no stock has to pay a dividend, relinquishing dividend aristocrat status will usually lead to the mass selling of a stock. Hence, dividend stocks which can avoid such an outcome will almost always continue paying and increasing dividends.
Real estate investment trusts (REITs) have also become popular income stocks. These equities stand out for their investments in both real property or the mortgage securities related to real estate investing. They also have become popular because REITs have to pay out 90% of their net income to receive an exemption from federal income tax on their operational income. REITs also pay a higher average dividend. This average payout of 4.36% stands at more than double the yield seen from the average S&P 500 equity.
5 Stocks to Sell In November Amid Elections and Earnings
However, most investors want to beat averages. As such, these five income stocks offer higher than average dividends as well as the potential for stock price growth:
AbbVie, Inc. (ABBV)
Source: Shutterstock
AbbVie (NYSE: ABBV ) spun off from Abbott Laboratories (NYSE: ABT ) in 2013. Best known for the drug Humira, ABBV continues to develop and introduce new drugs as its best sellers begin to lose patent protection.
The stock has lost more than one-third of its value since January. However, this places ABBV stock in a fortuitous position for both income and value investors. Due to the lower stock price, the price-to-earnings P/E ratio has fallen to just 10.2. Moreover, analysts also expect profits to grow by 40.7% this year and at an average annual rate of 15.4% per year for the next five years.
ABBV's status among income stocks remains secure. This year, investors will earn $3.84 per share. This translates to a yield of almost 4.8%. Also, due to its past connection with Abbott, it stands as a dividend aristocrat. As such, these profit increases will likely translate into higher dividends. Hence, even if the stock has not yet finished dropping, investors will earn increasing amounts of cash flow while they wait for a recovery.
In most cases, I recommend not buying into stocks near 52-week lows. But with an almost-single-digit PE ratio, double-digit profit growth, and a large, growing dividend, long-term investors should earn both income and gains by buying into ABBV stock.
AT&T, Inc. (T)
Source: Shutterstock
AT&T (NYSE: T ) has struggled in recent years as investors have cut the cord on its traditional landline and cable TV businesses. Moreover, its wireless segment also suffered as intense competition weighed on profit margins. To stay in that business, T has also had to spend tens of billions of dollars to build a 5G wireless network.
However, that 5G network will now begin to generate revenue. With it offering a minimum of ten times the speed of 4G wireless networks, most tech analysts expect it to spawn new applications not yet imagined.
Its years of struggle have also positioned T stock well for new buyers. AT&T stock now trades at a PE ratio of 8.7. This comes in well below its five-year average P/E of just under 18. Also, its predicted average annual growth rate stands at 5.9% per year for the next five years.
7 Canadian Stocks to Buy Now (And Only 2 Are Pot Stocks)
But what T stock lacks in growth, it will make up for in dividends. The company will pay $2 per share in dividends this year. That takes AT&T to a dividend yield of about 6.5%! Moreover, the stock will probably not want to give up its dividend aristocrat status. Hence, investors will likely see another dividend increase for next year. This high dividend, an unusually low P/E ratio and its 5G network make T stock an excellent investment for long-term growth and income.
Ladder Capital Corporation (LADR)
Source: Anders Jildén via Unsplash
Ladder Capital (NYSE: LADR ) functions as a REIT. While LADR owns commercial real estate, it also provides loans, owns mortgage-backed securities, and holds other investments. The New York-based real estate company was founded in 2008. It began trading as a REIT in 2014. Today, it holds over $6 billion in assets.
Like most income stocks in this category, growth remains slow for the most part. The stock trades near the levels of its 2014 IPO. However, it has rebounded by over 60% from its 2016 lows. Analysts forecast 18.8% growth for the current year. For the next five years, they foresee an average annual growth rate of 5%. Still, what it lacks in growth, it makes up for in valuation, stability, and dividend payments. It currently supports a P/E ratio of about 9.1, well below its five-year average P/E of 16.2.
Also, despite its short history, LADR has provided stability and income by paying a consistent and steadily-growing dividend. In some years, it has paid a substantially larger dividend to meet the 90% minimum payout requirement. This year, it expects to pay dividends of $1.30 per share. This takes the dividend yield to almost 7.8%. Given this high dividend and its below-average multiple, its stable asset base should provide investors with a generous, steady return.
Omega Healthcare Investors (OHI)
Omega Healthcare (NYSE: OHI ) finds itself in a fortuitous position among income stocks. With baby boomers aging into Medicare at a rate of 10,000 per day, nearly all healthcare-related assets appear positioned for growth. This includes the long-term healthcare facilities owned by Omega. Since its founding in 1992, the REIT has acquired over 900 facilities valued at about $9 billion.
Omega trades at a P/E of almost 21, so it does not come as cheap as some income-producing stocks. However, with the demand coming from retiring baby boomers, analysts expect income to grow at an average annual rate of 15.8% over the next five years. It also represents a vast improvement over the 0.6% yearly growth rate it saw in the previous five years.
3 Bank Stocks to Sell on This Bounce
Still, the company's business model has allowed for a slow, steady stream of profits. This has permitted OHI stock to hike its dividend over the years. In 2018, the company paid $2.64 per share in dividends, a yield of about 8%. This comes after the stock rose 33% from its April lows. Given the prospects for profit increases, both the dividend and OHI stock should see steady increases as long as baby boomers continue to become eligible for Medicare.
Sabra Health Care REIT, Inc. (SBRA)
Source: Shutterstock
Like Omega, Sabra (NASDAQ: SBRA ) operates as a healthcare REIT. It owns almost 500 facilities in the U.S. and Canada. More than 70% of its properties operate as skilled nursing facilities. However, specialty hospitals and senior housing also make up a large percentage of its portfolio. All have enjoyed rising demand as more baby boomers age into Medicare.
Analysts predict growth will average at about 6% per year over the next five years. While it may not grow as fast as some healthcare REITs, it also has not reached a high multiple. It maintains a P/E ratio of just over 11, even though SBRA stock has also risen 27% from its lows in the spring.
Sabra has also maintained a steadily growing dividend since 2013. The equity should see a payout of $1.80 per share this year. At current prices, this gives new investors a yield of almost 8.4%, making it one of the better cash-producing income stocks available.
Given its growing customer base and the profit increases that will come with it, I expect the dividend to keep rising for the foreseeable future. Couple that growing dividend with the low P/E ratio, and investors should find themselves well-positioned to profit from both the dividend and a higher SBRA stock price for some time to come.
As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You canfollow Will on Twitterat @HealyWriting.
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
7 Canadian Stocks to Buy Now (And Only 2 Are Pot Stocks)
5 Stocks to Sell In November Amid Elections and Earnings
3 Retail Stocks to Buy Despite All the Fearmongering
Compare Brokers
The post 5 Income Stocks for Massive Payouts and Steady Growth appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | But with an almost-single-digit PE ratio, double-digit profit growth, and a large, growing dividend, long-term investors should earn both income and gains by buying into ABBV stock. As such, these five income stocks offer higher than average dividends as well as the potential for stock price growth: AbbVie, Inc. (ABBV) Source: Shutterstock AbbVie (NYSE: ABBV ) spun off from Abbott Laboratories (NYSE: ABT ) in 2013. Best known for the drug Humira, ABBV continues to develop and introduce new drugs as its best sellers begin to lose patent protection. | As such, these five income stocks offer higher than average dividends as well as the potential for stock price growth: AbbVie, Inc. (ABBV) Source: Shutterstock AbbVie (NYSE: ABBV ) spun off from Abbott Laboratories (NYSE: ABT ) in 2013. But with an almost-single-digit PE ratio, double-digit profit growth, and a large, growing dividend, long-term investors should earn both income and gains by buying into ABBV stock. Best known for the drug Humira, ABBV continues to develop and introduce new drugs as its best sellers begin to lose patent protection. | As such, these five income stocks offer higher than average dividends as well as the potential for stock price growth: AbbVie, Inc. (ABBV) Source: Shutterstock AbbVie (NYSE: ABBV ) spun off from Abbott Laboratories (NYSE: ABT ) in 2013. Best known for the drug Humira, ABBV continues to develop and introduce new drugs as its best sellers begin to lose patent protection. However, this places ABBV stock in a fortuitous position for both income and value investors. | As such, these five income stocks offer higher than average dividends as well as the potential for stock price growth: AbbVie, Inc. (ABBV) Source: Shutterstock AbbVie (NYSE: ABBV ) spun off from Abbott Laboratories (NYSE: ABT ) in 2013. Best known for the drug Humira, ABBV continues to develop and introduce new drugs as its best sellers begin to lose patent protection. However, this places ABBV stock in a fortuitous position for both income and value investors. |
25283.0 | 2018-11-02 00:00:00 UTC | AbbVie's Q3 Update: 3 Things You Need to Know | ABBV | https://www.nasdaq.com/articles/abbvies-q3-update-3-things-you-need-know-2018-11-02 | nan | nan | Investors can be fickle when it comes to AbbVie (NYSE: ABBV) . The big pharma company reported great Q2 results in July, but AbbVie's share price dropped anyway. You might think the company would have to really hit the ball out of the park with its third-quarter results to cause its stock to rise.
AbbVie pretty much did hit the ball out of the park with its Q3 earnings that were announced before the market opened on Friday. And its stock did rise in early trading. What made the difference this time around? Here are three things you need to know from AbbVie's Q3 update.
1. Strong revenue growth -- but Humira wasn't the star
AbbVie's Q3 revenue jumped 17.8% year over year to $8.24 billion. Adjusting for the negative impact of foreign exchange, the company's top-line performance looked even better, increasing 18.5% from the prior-year period.
In nearly every quarter since AbbVie was spun off from Abbott Labs , Humira was the main story. That makes sense considering that Humira has been and still is the world's best-selling drug . Humira was certainly key to AbbVie's third-quarter success with sales growing 9% year over year to $5.1 billion. But it wasn't the star performer this quarter.
That honor belonged to AbbVie's hematology franchise. Sales for Imbruvica soared 41% above the prior-year period to $972 million. Venclexta was included in AbbVie's revenue details for the first time, with solid sales of $96 million. AbbVie CEO Richard Gonzalez said that the company was "particularly pleased" with the franchise's progress, adding that it's "now delivering revenue in excess of $1 billion per quarter and is poised for continued strong growth next year and beyond."
Hepatitis C virus (HCV) drug Mavyret is still performing well. AbbVie reported that the drug generated sales of $839 million in Q3. However, momentum for the company's HCV franchise (which also includes Viekira) appears to be slowing.
2. Uncle Sam helped a lot with the sizzling earnings growth
If you liked AbbVie's revenue numbers, you'll love its earnings results. The drugmaker reported Q3 earnings of $2.75 billion, or $1.81 per diluted share. AbbVie announced adjusted diluted earnings per share (EPS) of $2.14. This reflected a whopping 51.8% increase over the adjusted EPS from the prior-year period. It also easily topped the consensus Wall Street estimate of $2.02.
AbbVie's revenue growth definitely was key in boosting its earnings in the third quarter. But other factors were also important.
The company's net other expenses not associated with operational costs decreased by $244 million from the prior-year period, accounting for over one-fifth of AbbVie's GAAP earnings increase. AbbVie's adjusted EPS improvement was also helped by share buybacks, which lowered the company's weighted-average diluted shares outstanding by 5.5% year over year.
Uncle Sam provided the greatest assistance in making AbbVie's earnings growth outshine its top-line growth. Income tax expense in Q3 fell $450 million from the prior-year period. This lower tax expense accounted for 40% of AbbVie's GAAP earnings year-over-year increase.
3. The year is looking better and better
Thanks to its better-than-expected Q3 performance, AbbVie once again raised its full-year 2018 guidance. The company now expects 2018 adjusted EPS between $7.90 and $7.92, up from its previous outlook of $7.76 to $7.86. The midpoint of this revised guidance range reflects year-over-year growth of 41.3%.
And to add icing to the cake, AbbVie announced that it was increasing its dividend by 11.5%. Since 2013, the company has increased its quarterly dividend by 168%. AbbVie's dividend yield prior to this hike stood at 4.8%.
What's next for AbbVie?
Things will now get tougher for Humira. AbbVie's agreement with Amgensigned last year paved the way for the rival's biosimilar to Humira to launch in Europe in October 2018. AbbVie slashed its prices for Humira. The combination of these price cuts and some market share erosion will no doubt take a toll on international sales for the company's top drug.
However, the outlook for Imbruvica and Venclexta appears to be really good. Imbruvica recently picked up approval for another indication -- Waldenstrom's macroglobulinemia (WM), a rare type of non-Hodgkin's lymphoma (NHL). AbbVie awaits approval for a combination of Imbruvica and Roche 's Gazyva in treating chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). Venclexta also gained approvals recently for new indications in the U.S. and Europe with more potentially on the way.
Expect AbbVie's launch of endometriosis pain drug Orilissa to begin bearing fruit over the next few quarters. And Humira could soon be joined by AbbVie's next generation of autoimmune drugs. Risankizumab currently awaits U.S. and European approval in treating psoriasis. AbbVie also expects to submit for regulatory approval for upadacitinib in treating rheumatoid arthritis in the near future.
Investors might continue to be fickle about AbbVie, though. Many still aren't convinced the company will move out from beneath the shadow of looming U.S. competition for Humira a few years from now. However, AbbVie is doing exactly what it said it would do by building other strong franchises to fuel growth. The Q3 results underscore AbbVie's progress in delivering on its goal.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Keith Speights owns shares of AbbVie. The Motley Fool recommends Amgen. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie CEO Richard Gonzalez said that the company was "particularly pleased" with the franchise's progress, adding that it's "now delivering revenue in excess of $1 billion per quarter and is poised for continued strong growth next year and beyond." The company's net other expenses not associated with operational costs decreased by $244 million from the prior-year period, accounting for over one-fifth of AbbVie's GAAP earnings increase. Investors can be fickle when it comes to AbbVie (NYSE: ABBV) . | Strong revenue growth -- but Humira wasn't the star AbbVie's Q3 revenue jumped 17.8% year over year to $8.24 billion. AbbVie announced adjusted diluted earnings per share (EPS) of $2.14. This lower tax expense accounted for 40% of AbbVie's GAAP earnings year-over-year increase. | Strong revenue growth -- but Humira wasn't the star AbbVie's Q3 revenue jumped 17.8% year over year to $8.24 billion. AbbVie CEO Richard Gonzalez said that the company was "particularly pleased" with the franchise's progress, adding that it's "now delivering revenue in excess of $1 billion per quarter and is poised for continued strong growth next year and beyond." AbbVie's adjusted EPS improvement was also helped by share buybacks, which lowered the company's weighted-average diluted shares outstanding by 5.5% year over year. | Strong revenue growth -- but Humira wasn't the star AbbVie's Q3 revenue jumped 17.8% year over year to $8.24 billion. AbbVie's adjusted EPS improvement was also helped by share buybacks, which lowered the company's weighted-average diluted shares outstanding by 5.5% year over year. Investors can be fickle when it comes to AbbVie (NYSE: ABBV) . |
25284.0 | 2018-11-01 00:00:00 UTC | Interesting ABBV Put And Call Options For December 14th | ABBV | https://www.nasdaq.com/articles/interesting-abbv-put-and-call-options-december-14th-2018-11-01 | nan | nan | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the December 14th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ABBV options chain for the new December 14th contracts and identified one put and one call contract of particular interest.
The put contract at the $78.00 strike price has a current bid of $3.35. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $78.00, but will also collect the premium, putting the cost basis of the shares at $74.65 (before broker commissions). To an investor already interested in purchasing shares of ABBV, that could represent an attractive alternative to paying $78.57/share today.
Because the $78.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 54%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 4.29% return on the cash commitment, or 36.42% annualized - at Stock Options Channel we call this the YieldBoost .
Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $78.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $79.50 strike price has a current bid of $2.78. If an investor was to purchase shares of ABBV stock at the current price level of $78.57/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $79.50. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 4.72% if the stock gets called away at the December 14th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the $79.50 strike highlighted in red:
Considering the fact that the $79.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 53%. On our website under the contract detail page for this contract , Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 3.54% boost of extra return to the investor, or 30.00% annualized, which we refer to as the YieldBoost .
The implied volatility in the put contract example is 44%, while the implied volatility in the call contract example is 47%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $78.57) to be 33%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the $79.50 strike highlighted in red: Considering the fact that the $79.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the December 14th expiration. | Below is a chart showing ABBV's trailing twelve month trading history, with the $79.50 strike highlighted in red: Considering the fact that the $79.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the December 14th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ABBV options chain for the new December 14th contracts and identified one put and one call contract of particular interest. | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $78.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $79.50 strike price has a current bid of $2.78. Below is a chart showing ABBV's trailing twelve month trading history, with the $79.50 strike highlighted in red: Considering the fact that the $79.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the December 14th expiration. | At Stock Options Channel , our YieldBoost formula has looked up and down the ABBV options chain for the new December 14th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $79.50 strike highlighted in red: Considering the fact that the $79.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the December 14th expiration. |
25285.0 | 2018-11-01 00:00:00 UTC | Pre-Market Earnings Report for November 2, 2018 : XOM, CVX, BABA, ABBV, DUK, ENB, IMO, WLTW, FTS, CBOE, VST, STX | ABBV | https://www.nasdaq.com/articles/pre-market-earnings-report-november-2-2018-xom-cvx-baba-abbv-duk-enb-imo-wltw-fts-cboe-vst | nan | nan | The following companies are expected to report earnings prior to market open on 11/02/2018. Visit our Earnings Calendar for a full list of expected earnings releases.
Exxon Mobil Corporation ( XOM ) is reporting for the quarter ending September 30, 2018. The oil company's consensus earnings per share forecast from the 7 analysts that follow the stock is $1.21. This value represents a 30.11% increase compared to the same quarter last year. Zacks Investment Research reports that the 2018 Price to Earnings ratio for XOM is 17.21 vs. an industry ratio of 10.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Chevron Corporation ( CVX ) is reporting for the quarter ending September 30, 2018. The oil company's consensus earnings per share forecast from the 7 analysts that follow the stock is $2.06. This value represents a 100.00% increase compared to the same quarter last year. Zacks Investment Research reports that the 2018 Price to Earnings ratio for CVX is 13.68 vs. an industry ratio of 10.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Alibaba Group Holding Limited ( BABA ) is reporting for the quarter ending September 30, 2018. The internet company's consensus earnings per share forecast from the 6 analysts that follow the stock is $0.82. This value represents a 19.61% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2019 Price to Earnings ratio for BABA is 38.25 vs. an industry ratio of 12.70, implying that they will have a higher earnings growth than their competitors in the same industry.
AbbVie Inc. ( ABBV ) is reporting for the quarter ending September 30, 2018. The large cap pharmaceutical company's consensus earnings per share forecast from the 8 analysts that follow the stock is $2.01. This value represents a 42.55% increase compared to the same quarter last year. In the past year ABBV has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 1.01%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABBV is 9.90 vs. an industry ratio of 15.30.
Duke Energy Corporation ( DUK ) is reporting for the quarter ending September 30, 2018. The electric power utilities company's consensus earnings per share forecast from the 7 analysts that follow the stock is $1.53. This value represents a 3.77% decrease compared to the same quarter last year. DUK missed the consensus earnings per share in the 2nd calendar quarter of 2018 by -9.71%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for DUK is 17.58 vs. an industry ratio of 17.30, implying that they will have a higher earnings growth than their competitors in the same industry.
Enbridge Inc ( ENB ) is reporting for the quarter ending September 30, 2018. The oil (production/pipeline) company's consensus earnings per share forecast from the 5 analysts that follow the stock is $0.42. This value represents a 7.69% increase compared to the same quarter last year. In the past year ENB has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 47.62%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ENB is 14.21 vs. an industry ratio of 27.00.
Imperial Oil Limited ( IMO ) is reporting for the quarter ending September 30, 2018. The consensus earnings per share forecast from the 4 analysts that follow the stock is $0.67. IMO reported earnings of $0.35 per share for the same quarter a year ago; representing a a increase of 91.43%.
Willis Towers Watson Public Limited Company ( WLTW ) is reporting for the quarter ending September 30, 2018. The insurance brokers company's consensus earnings per share forecast from the 12 analysts that follow the stock is $1.11. This value represents a 0.89% decrease compared to the same quarter last year. WLTW missed the consensus earnings per share in the 3rd calendar quarter of 2017 by -0.88%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for WLTW is 14.96 vs. an industry ratio of 17.60.
Fortis Inc. ( FTS ) is reporting for the quarter ending September 30, 2018. The electric power utilities company's consensus earnings per share forecast from the 3 analysts that follow the stock is $0.49. This value represents a no change for the same quarter last year. In the past year FTS has met analyst expectations three times and beat the expectations the other quarter. Zacks Investment Research reports that the 2018 Price to Earnings ratio for FTS is 16.94 vs. an industry ratio of 17.30.
Cboe Global Markets, Inc. ( CBOE ) is reporting for the quarter ending September 30, 2018. The securities exchange company's consensus earnings per share forecast from the 6 analysts that follow the stock is $1.01. This value represents a 13.48% increase compared to the same quarter last year. CBOE missed the consensus earnings per share in the 4th calendar quarter of 2017 by -1.14%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for CBOE is 24.75 vs. an industry ratio of 25.60.
Vistra Energy Corp. ( VST ) is reporting for the quarter ending September 30, 2018. The electric power utilities company's consensus earnings per share forecast from the 2 analysts that follow the stock is $0.70. This value represents a 9.37% increase compared to the same quarter last year. VST missed the consensus earnings per share in the 1st calendar quarter of 2018 by -55.56%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for VST is 16.52 vs. an industry ratio of 17.30.
Seagate Technology PLC ( STX ) is reporting for the quarter ending September 30, 2018. The computer storage company's consensus earnings per share forecast from the 7 analysts that follow the stock is $1.55. This value represents a 61.46% increase compared to the same quarter last year. In the past year STX has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 11.72%. Zacks Investment Research reports that the 2019 Price to Earnings ratio for STX is 6.62 vs. an industry ratio of 6.40, implying that they will have a higher earnings growth than their competitors in the same industry.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc. ( ABBV ) is reporting for the quarter ending September 30, 2018. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABBV is 9.90 vs. an industry ratio of 15.30. | AbbVie Inc. ( ABBV ) is reporting for the quarter ending September 30, 2018. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABBV is 9.90 vs. an industry ratio of 15.30. | AbbVie Inc. ( ABBV ) is reporting for the quarter ending September 30, 2018. In the past year ABBV has beat the expectations every quarter. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABBV is 9.90 vs. an industry ratio of 15.30. | In the past year ABBV has beat the expectations every quarter. AbbVie Inc. ( ABBV ) is reporting for the quarter ending September 30, 2018. Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABBV is 9.90 vs. an industry ratio of 15.30. |
25286.0 | 2018-10-31 00:00:00 UTC | Noteworthy Wednesday Option Activity: DVA, GOGO, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-dva-gogo-abbv-2018-10-31 | nan | nan | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in DaVita Inc (Symbol: DVA), where a total of 6,422 contracts have traded so far, representing approximately 642,200 underlying shares. That amounts to about 41.1% of DVA's average daily trading volume over the past month of 1.6 million shares. Particularly high volume was seen for the $70 strike call option expiring November 16, 2018 , with 2,003 contracts trading so far today, representing approximately 200,300 underlying shares of DVA. Below is a chart showing DVA's trailing twelve month trading history, with the $70 strike highlighted in orange:
Gogo Inc (Symbol: GOGO) options are showing a volume of 7,016 contracts thus far today. That number of contracts represents approximately 701,600 underlying shares, working out to a sizeable 41% of GOGO's average daily trading volume over the past month, of 1.7 million shares. Particularly high volume was seen for the $5 strike put option expiring January 17, 2020 , with 3,762 contracts trading so far today, representing approximately 376,200 underlying shares of GOGO. Below is a chart showing GOGO's trailing twelve month trading history, with the $5 strike highlighted in orange:
And AbbVie Inc (Symbol: ABBV) saw options trading volume of 23,170 contracts, representing approximately 2.3 million underlying shares or approximately 40.8% of ABBV's average daily trading volume over the past month, of 5.7 million shares. Particularly high volume was seen for the $79 strike put option expiring November 02, 2018 , with 3,766 contracts trading so far today, representing approximately 376,600 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $79 strike highlighted in orange:
For the various different available expirations for DVA options , GOGO options , or ABBV options , visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Particularly high volume was seen for the $79 strike put option expiring November 02, 2018 , with 3,766 contracts trading so far today, representing approximately 376,600 underlying shares of ABBV. Below is a chart showing GOGO's trailing twelve month trading history, with the $5 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 23,170 contracts, representing approximately 2.3 million underlying shares or approximately 40.8% of ABBV's average daily trading volume over the past month, of 5.7 million shares. Below is a chart showing ABBV's trailing twelve month trading history, with the $79 strike highlighted in orange: For the various different available expirations for DVA options , GOGO options , or ABBV options , visit StockOptionsChannel.com. | Below is a chart showing GOGO's trailing twelve month trading history, with the $5 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 23,170 contracts, representing approximately 2.3 million underlying shares or approximately 40.8% of ABBV's average daily trading volume over the past month, of 5.7 million shares. Particularly high volume was seen for the $79 strike put option expiring November 02, 2018 , with 3,766 contracts trading so far today, representing approximately 376,600 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $79 strike highlighted in orange: For the various different available expirations for DVA options , GOGO options , or ABBV options , visit StockOptionsChannel.com. | Below is a chart showing GOGO's trailing twelve month trading history, with the $5 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 23,170 contracts, representing approximately 2.3 million underlying shares or approximately 40.8% of ABBV's average daily trading volume over the past month, of 5.7 million shares. Particularly high volume was seen for the $79 strike put option expiring November 02, 2018 , with 3,766 contracts trading so far today, representing approximately 376,600 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $79 strike highlighted in orange: For the various different available expirations for DVA options , GOGO options , or ABBV options , visit StockOptionsChannel.com. | Below is a chart showing GOGO's trailing twelve month trading history, with the $5 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 23,170 contracts, representing approximately 2.3 million underlying shares or approximately 40.8% of ABBV's average daily trading volume over the past month, of 5.7 million shares. Particularly high volume was seen for the $79 strike put option expiring November 02, 2018 , with 3,766 contracts trading so far today, representing approximately 376,600 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $79 strike highlighted in orange: For the various different available expirations for DVA options , GOGO options , or ABBV options , visit StockOptionsChannel.com. |
25287.0 | 2018-10-30 00:00:00 UTC | What's in the Cards for AbbVie (ABBV) This Earnings Season? | ABBV | https://www.nasdaq.com/articles/whats-in-the-cards-for-abbvie-abbv-this-earnings-season-2018-10-30 | nan | nan | AbbVie Inc.ABBV is scheduled to report third-quarter 2018 results on Nov 2, before market open. In the last reported quarter, the company delivered a positive earnings surprise of 1.01%.
Shares of AbbVie have declined 16.4% so far this year against the industry 's increase of 7%.
Notably, AbbVie's earnings history is quite impressive with the pharmaceuticals company outpacing estimates in all the last four quarters with an average beat of 2.28%.
Let's see how things are shaping up for the company ahead of the announcement.
Factors to Consider
AbbVie expects earnings per share for the quarter to be in the range of $2.00 and $2.02. Revenues are expected to be driven by operational growth of 17% but are expected to bear an unfavorable currency impact of 1%.
AbbVie's flagship product, Humira, which is approved for several inflammatory indications, continues to witness strong demand trends despite launch of drugs with new mechanisms of action and competition from indirect biosimilars. The positive sales growth trend is expected to continue in the third quarter. Humira's sales are expected to grow 11% domestically and international sales are estimated to be approximately $1.6 billion. The Zacks Consensus Estimate for Humira is pegged at $5.1 billion.
The company also has a strong oncology portfolio. Imbruvica, which is currently approved for quite a few indications, showed significant growth rate in the first half of 2018 on the back of continued uptake in the front-line chronic lymphocytic leukemia ("CLL") market and steady gains across other indications.
In August, a label expansion of Imbruvica in combination with Roche/Biogen's BIIB Rituxan for treating Waldenström's macroglobulinemia was approved by the FDA. Although the approval will probably not add much to sales this quarter, it has the potential to boost sales in future quarters. AbbVie expects global sales of $725 million. The Zacks Consensus Estimate for the drug is pegged at $889 million.
Other drugs, namely Duodopa and Creon, are also likely to continue their encouraging first half performance in the soon-to-be-reported quarter. The Zacks Consensus Estimate for Duodopa and Creon sales is $113 million and $230 million, respectively.
In September, the FDA approved a label expansion of leukemia drug, Venclexta, to include previously treated CLL patients with minimal residual disease. AbbVie also added a new pain drug to its marketed portfolio as the FDA approved Orilissa (elagolix) for the management of moderate-to-severe pain associated with endometriosis in July. However, these approvals will probably have minimal effect on product sales in the third quarter.
AbbVie's hepatitis C virus ("HCV") segment also showed impressive growth on the back of better-than-expected uptake of Mavyret despite stiff competition. Mavyret has become a major growth driver for AbbVie in a short time following its launch. We expect the positive trend to continue in the third quarter. However, Viekira may continue to see declining sales, affected by intense pricing and competitive pressure in the HCV market. HCV global sales are estimated to be $850 million, representing a sequential decline from the second quarter. The decline in HCV sales will be due to an expectation of reduced patient volume in the U.S. markets and softer demand in Japan.
The company may continue to see higher operating expense due to ongoing clinical studies and launch of new drugs and expanded labels.
Earnings Whispers
Our proven model does not conclusively show that AbbVie is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate ($1.99) and the Zacks Consensus Estimate ($2.01), stands at -1.16%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: . AbbVie's Zacks Rank #3 increases the predictive power of ESP. However, we need to have a positive ESP to be confident about an earnings surprise.
We caution against the Sell-rated stocks (#4 or 5) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
AbbVie Inc. Price and EPS Surprise
AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote
Stocks That Warrant a Look
Here are some biotech stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases.
Regeneron Pharmaceuticals, Inc. REGN has an Earnings ESP of +4.65% and a Zacks Rank #1. The company is scheduled to release third-quarter results on Nov 6. You can see the complete list of today's Zacks #1 Rank stocks here .
Alnylam Pharmaceuticals, Inc. ALNY has an Earnings ESP of +12.54% and a Zacks Rank #3. The company is expected to release third-quarter results on Nov 6.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie's flagship product, Humira, which is approved for several inflammatory indications, continues to witness strong demand trends despite launch of drugs with new mechanisms of action and competition from indirect biosimilars. AbbVie's hepatitis C virus ("HCV") segment also showed impressive growth on the back of better-than-expected uptake of Mavyret despite stiff competition. AbbVie Inc.ABBV is scheduled to report third-quarter 2018 results on Nov 2, before market open. | AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Stocks That Warrant a Look Here are some biotech stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV is scheduled to report third-quarter 2018 results on Nov 2, before market open. | AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Stocks That Warrant a Look Here are some biotech stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV is scheduled to report third-quarter 2018 results on Nov 2, before market open. | AbbVie expects global sales of $725 million. AbbVie Inc.ABBV is scheduled to report third-quarter 2018 results on Nov 2, before market open. Shares of AbbVie have declined 16.4% so far this year against the industry 's increase of 7%. |
25288.0 | 2018-10-30 00:00:00 UTC | Better Buy: Celgene Corporation vs. Gilead Sciences | ABBV | https://www.nasdaq.com/articles/better-buy-celgene-corporation-vs-gilead-sciences-2018-10-30 | nan | nan | It's been a terrifying month for biotech stocks across the board. The Nasdaq Biotechnology index has already tumbled 14% in October. That's brought some already attractive biotech stocks down to prices that are hard to ignore.
Shares of Celgene Corporation (NASDAQ: CELG) and Gilead Sciences Inc. (NASDAQ: GILD) have tumbled along with their industry despite strong growth for key drugs. Which of these knocked-down biotech stocks is poised to deliver bigger gains in the years ahead? Let's stack them side by side to find out.
The case for Celgene Corporation
Celgene's lead product, Revlimid, is one of the world's best-selling drugs, and it's still growing, along with the number of newly diagnosed multiple myeloma patients it's approved to treat. In 2018, Revlimid sales are expected to climb $1.5 billion higher than in 2017, to a stunning $9.7 billion.
Revlimid sales will probably keep climbing until generic competition sets in a few years from now. Luckily, Celgene isn't a one-trick pony. Third-quarter sales of the company's psoriasis tablet, Otezla, surged 40% compared to the previous-year period, and the company raised its full-year outlook for the drug to $1.6 billion.
Further ahead, investors could see five new drugs launch by 2020. Celgene's late-stage pipeline includes ozanimod, an oral multiple sclerosis and inflammatory bowel disease candidate expected to generate blockbuster sales.
Altogether, Celgene expects adjusted earnings to rise from $7.44 per share in 2017 to a range between $8.75 and $8.80 per share this year. The biotech stock doesn't offer a dividend, but the company has been able to lower its outstanding share count by 8% in 2018 with $6.0 billion in buybacks.
The case for Gilead Sciences Inc.
While Celgene's lead product is still growing, Gilead Sciences' shareholders have already watched in horror as the company's top franchise went down in flames. Revenue from Gilead's hepatitis C antiviral drugs peaked at $19.1 billion in 2015 and has since plummeted to an annualized run rate of just $3.8 billion.
With the worst problems in the rear view, Gilead will finally be able to report some top-line sales growth in the quarters ahead, driven by sales of its HIV franchise. Earlier this year, Gilead launched Biktarvy, the first and only single-tablet regimen for new HIV patients and for those with experience on other drugs.
Biktarvy is still cannibalizing sales of Gilead's older treatments, but that didn't stop the company from reporting overall HIV sales that rose 12% in the third quarter. Investors can probably look forward to more growth from the HIV segment in the years ahead. Biktarvy sales aren't expected to top out until they reach around $5 billion annually.
In the quarters ahead, Gilead could also launch a new arthritis drug with "future blockbuster" written all over it. Filgotinib is far behind similar oral rheumatoid arthritis treatments but could become a leading option with several billion in annual sales. That's because Gilead and its development partner Galapagos (NASDAQ: GLPG) recently presented trial results that suggest filgotinib is on par with upadacitinib from AbbVie and Olumiant from Eli Lilly in terms of efficacy. Most importantly, filgotinib scored high marks without any signs of disturbing side effects that have troubled its potential competitors.
Gilead Sciences stock pays a dividend that currently offers an attractive 3.3% yield, and investors can look forward to increased payouts. Over the past year, the company generated a whopping $8.4 billion in free cash flow , just 34% of which was needed to make dividend payments.
The better buy now
Following recent missteps , Celgene shares have been beaten down to just 8.2 times forward earnings estimates. That's awfully low when you consider the average stock in the S&P 500 trades at 16.4 times estimates. While I believe Celgene is attractive at recent prices, Gilead Sciences is trading at the low price of 10.1 times earnings estimates.
Gilead's hepatitis C segment doesn't have much farther to fall, which should make it fairly easy for Biktarvy to move the needle forward at a steady pace. Celgene's putting up impressive sales figures for Revlimid now, but the eventual losses mean we'll probably see more earnings growth from Gilead Sciences over the long run. That makes Gilead the better stock to buy now.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Cory Renauer owns shares of Celgene and Gilead Sciences. The Motley Fool owns shares of and recommends Celgene and Gilead Sciences. The Motley Fool has the following options: short November 2018 $78 calls on Gilead Sciences. The Motley Fool recommends Nasdaq. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | That's because Gilead and its development partner Galapagos (NASDAQ: GLPG) recently presented trial results that suggest filgotinib is on par with upadacitinib from AbbVie and Olumiant from Eli Lilly in terms of efficacy. Celgene's late-stage pipeline includes ozanimod, an oral multiple sclerosis and inflammatory bowel disease candidate expected to generate blockbuster sales. Gilead's hepatitis C segment doesn't have much farther to fall, which should make it fairly easy for Biktarvy to move the needle forward at a steady pace. | That's because Gilead and its development partner Galapagos (NASDAQ: GLPG) recently presented trial results that suggest filgotinib is on par with upadacitinib from AbbVie and Olumiant from Eli Lilly in terms of efficacy. The case for Celgene Corporation Celgene's lead product, Revlimid, is one of the world's best-selling drugs, and it's still growing, along with the number of newly diagnosed multiple myeloma patients it's approved to treat. While I believe Celgene is attractive at recent prices, Gilead Sciences is trading at the low price of 10.1 times earnings estimates. | That's because Gilead and its development partner Galapagos (NASDAQ: GLPG) recently presented trial results that suggest filgotinib is on par with upadacitinib from AbbVie and Olumiant from Eli Lilly in terms of efficacy. Shares of Celgene Corporation (NASDAQ: CELG) and Gilead Sciences Inc. (NASDAQ: GILD) have tumbled along with their industry despite strong growth for key drugs. *Stock Advisor returns as of August 6, 2018 Cory Renauer owns shares of Celgene and Gilead Sciences. | That's because Gilead and its development partner Galapagos (NASDAQ: GLPG) recently presented trial results that suggest filgotinib is on par with upadacitinib from AbbVie and Olumiant from Eli Lilly in terms of efficacy. The biotech stock doesn't offer a dividend, but the company has been able to lower its outstanding share count by 8% in 2018 with $6.0 billion in buybacks. Filgotinib is far behind similar oral rheumatoid arthritis treatments but could become a leading option with several billion in annual sales. |
25289.0 | 2018-10-29 00:00:00 UTC | 5 Dividend Aristocrats Where Analysts See Capital Gains | ABBV | https://www.nasdaq.com/articles/5-dividend-aristocrats-where-analysts-see-capital-gains-2018-10-29 | nan | nan | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention - and furthermore, "tracking" funds that follow the Dividend Aristocrats Index must own them. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets.
But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. Which means, if the analysts are correct, these are five dividend growth stocks that could produce capital gains in addition to their growing dividend payments.
In the first table below, we present the five stocks. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented.
The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential:
Another consideration with dividend growth stocks is just how much the dividend is growing . We looked up the trailing twelve months worth of dividends shareholders of each of the above five companies have collected, and then also looked up the same number for the prior trailing twelve months. This gives us a rough yardstick to see how much the dividend has grown, from one trailing twelve month period to another.
These five stocks are part of our full Dividend Aristocrats List . The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com .
Get the latest Zacks research report on NDSN - FREE
Get the latest Zacks research report on WTR - FREE
Dividend Growth Stocks: 25 Aristocrats »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Another consideration with dividend growth stocks is just how much the dividend is growing . Get the latest Zacks research report on NDSN - FREE Get the latest Zacks research report on WTR - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Get the latest Zacks research report on NDSN - FREE Get the latest Zacks research report on WTR - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Another consideration with dividend growth stocks is just how much the dividend is growing . | But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. Get the latest Zacks research report on NDSN - FREE Get the latest Zacks research report on WTR - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
25290.0 | 2018-10-29 00:00:00 UTC | How The Parts Add Up: RNLC Targets $25 | ABBV | https://www.nasdaq.com/articles/how-parts-add-rnlc-targets-25-2018-10-29 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Large Cap US Equity Select ETF (Symbol: RNLC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $25.23 per unit.
With RNLC trading at a recent price near $20.63 per unit, that means that analysts see 22.30% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of RNLC's underlying holdings with notable upside to their analyst target prices are Aramark (Symbol: ARMK), Nucor Corp. (Symbol: NUE), and AbbVie Inc (Symbol: ABBV). Although ARMK has traded at a recent price of $34.55/share, the average analyst target is 39.29% higher at $48.12/share. Similarly, NUE has 33.62% upside from the recent share price of $56.13 if the average analyst target price of $75.00/share is reached, and analysts on average are expecting ABBV to reach a target price of $107.75/share, which is 33.37% above the recent price of $80.79. Below is a twelve month price history chart comparing the stock performance of ARMK, NUE, and ABBV:
Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a twelve month price history chart comparing the stock performance of ARMK, NUE, and ABBV: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of RNLC's underlying holdings with notable upside to their analyst target prices are Aramark (Symbol: ARMK), Nucor Corp. (Symbol: NUE), and AbbVie Inc (Symbol: ABBV). Similarly, NUE has 33.62% upside from the recent share price of $56.13 if the average analyst target price of $75.00/share is reached, and analysts on average are expecting ABBV to reach a target price of $107.75/share, which is 33.37% above the recent price of $80.79. | Three of RNLC's underlying holdings with notable upside to their analyst target prices are Aramark (Symbol: ARMK), Nucor Corp. (Symbol: NUE), and AbbVie Inc (Symbol: ABBV). Similarly, NUE has 33.62% upside from the recent share price of $56.13 if the average analyst target price of $75.00/share is reached, and analysts on average are expecting ABBV to reach a target price of $107.75/share, which is 33.37% above the recent price of $80.79. Below is a twelve month price history chart comparing the stock performance of ARMK, NUE, and ABBV: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? | Similarly, NUE has 33.62% upside from the recent share price of $56.13 if the average analyst target price of $75.00/share is reached, and analysts on average are expecting ABBV to reach a target price of $107.75/share, which is 33.37% above the recent price of $80.79. Below is a twelve month price history chart comparing the stock performance of ARMK, NUE, and ABBV: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of RNLC's underlying holdings with notable upside to their analyst target prices are Aramark (Symbol: ARMK), Nucor Corp. (Symbol: NUE), and AbbVie Inc (Symbol: ABBV). | Similarly, NUE has 33.62% upside from the recent share price of $56.13 if the average analyst target price of $75.00/share is reached, and analysts on average are expecting ABBV to reach a target price of $107.75/share, which is 33.37% above the recent price of $80.79. Three of RNLC's underlying holdings with notable upside to their analyst target prices are Aramark (Symbol: ARMK), Nucor Corp. (Symbol: NUE), and AbbVie Inc (Symbol: ABBV). Below is a twelve month price history chart comparing the stock performance of ARMK, NUE, and ABBV: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? |
25291.0 | 2018-10-27 00:00:00 UTC | AbbVie Takes Aim at Vertex Pharmaceuticals Incorporated | ABBV | https://www.nasdaq.com/articles/abbvie-takes-aim-vertex-pharmaceuticals-incorporated-2018-10-27 | nan | nan | At the moment, treatment options for cystic fibrosis are limited to drugs marketed by Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) , but a deep-pocketed drugmaker just took a big step toward entering the space. AbbVie, Inc. (NYSE: ABBV) recently acquired full control of a clinical-stage cystic fibrosis program from Galapagos N.V. (NASDAQ: GLPG) .
Should Vertex investors be worried, now that the company's main challenger is a biopharma giant with nearly endless resources for developing competing treatments? Here's what you need to know.
Reasons to stay calm
Galapagos recently reported preliminary results from an early-stage trial with its cystic fibrosis (CF) candidates; they didn't make a strong impression. During part one of the Falcon study, the dual combination of GLPG2451 and GPLG2222 led to a forced expiration volume (FEV) improvement of approximately 3% after two weeks.
We really shouldn't make direct comparisons without a head-to-head study, but Galapagos' two-week data from patients with two copies of the F508del mutation don't appear any better than results that supported approval of Vertex's drug Orkambi in 2015. Vertex's two-drug combination treatment led to a 2.6% FEV improvement at 24 weeks in one trial and a 3% improvement in another. While it looks like GLPG2451 plus GPLG2222 might be able to eventually compete with Orkambi, Vertex also markets Symdeko, which led to a 4% improvement for the same patient group.
Vertex is also miles ahead with two next-generation triplets. Adding VX-659 to tezacaftor plus ivacaftor (two drugs physicians are already familiar with) led to a 9.7% improvement in lung function, and adding VX-445 to the popular pair worked even better. Galapagos attempted a three-drug treatment by adding GLPG2737 to its combo, but investigators didn't notice any improvement compared to GLPG2451 plus GLPG2222 on their own.
The F508del mutation is the most common cause of cystic fibrosis, but hundreds of mutations in the CFTR gene have been shown to cause the disease. In order to speed treatment options to as many different patient groups as possible, Vertex spent $1.3 billion on research and development last year, and it intends to spend another $1.8 billion in 2018.
Vertex won't have any trouble paying the bills. The company recently reported third-quarter cystic fibrosis revenue that jumped 42% higher to an annualized $3.1 billion run rate.
Vertex's attempts at a three-drug CF therapy are miles ahead of AbbVie's phase 1 program. Late-stage results from a triplet containing VX-659 are expected before the end of the year, and we should also have data for a triplet containing VX-445 in the first quarter of 2019.
Reasons to be nervous
Over the past year Vertex has plowed 45% of the revenue its drugs generate right back into research and development, but that doesn't stop insurers from complaining about Orkambi's $272,000-per-year list price.
Vertex's pricing power depends on a lack of viable alternatives, as AbbVie has proven in the past. Gilead Sciences ' (NASDAQ: GILD) sales in its hepatitis C antiviral franchise hit $19 billion in 2015 before AbbVie began fielding competing treatments at deep discounts in 2016. Based on the latest quarter, Gilead is on pace to record just $3.6 billion in annual hepatitis C antiviral sales.
A successful assault on Gilead's franchise taught us that competing drugs don't need to be better in order to take down a monopoly; they just need to be good enough. With this in mind, Vertex investors probably should be nervous about Galapagos' candidates now that they're in AbbVie's hands.
Not Vertex's first rodeo
More seasoned biotech investors remember Vertex's first drug, Incivek, a hepatitis C treatment that achieved blockbuster status briefly before getting knocked out of the lead by Sovaldi from, coincidentally, Gilead Sciences.
By all indications, Vertex has learned a great deal from its first experience with the biotech circle of life, and the company has what it takes to keep its bottom line climbing for many years to come. Operations generated $1 billion in free cash flow over the past year, which Vertex is using to fill its pipeline with tomorrow's potential blockbusters.
Vertex will begin a clinical trial in partnership with CRISPR Therapeutics later this year, and results from a midstage study with a novel, wholly-owned pain-relief candidate are due in 2019.
AbbVie has nearly endless resources, but it's going to be a long time before its CF program moves from phase 1 testing to a position where it could begin to threaten Vertex's franchise. With a growing pipeline of midstage candidates and money to develop them, Vertex probably won't be a one-trick pony when that time comes.
10 stocks we like better than Vertex Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Vertex Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Cory Renauer owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool owns shares of CRSP and has the following options: short November 2018 $78 calls on Gilead Sciences. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie, Inc. (NYSE: ABBV) recently acquired full control of a clinical-stage cystic fibrosis program from Galapagos N.V. (NASDAQ: GLPG) . Vertex's attempts at a three-drug CF therapy are miles ahead of AbbVie's phase 1 program. Vertex's pricing power depends on a lack of viable alternatives, as AbbVie has proven in the past. | Gilead Sciences ' (NASDAQ: GILD) sales in its hepatitis C antiviral franchise hit $19 billion in 2015 before AbbVie began fielding competing treatments at deep discounts in 2016. AbbVie, Inc. (NYSE: ABBV) recently acquired full control of a clinical-stage cystic fibrosis program from Galapagos N.V. (NASDAQ: GLPG) . Vertex's attempts at a three-drug CF therapy are miles ahead of AbbVie's phase 1 program. | AbbVie, Inc. (NYSE: ABBV) recently acquired full control of a clinical-stage cystic fibrosis program from Galapagos N.V. (NASDAQ: GLPG) . Vertex's attempts at a three-drug CF therapy are miles ahead of AbbVie's phase 1 program. Vertex's pricing power depends on a lack of viable alternatives, as AbbVie has proven in the past. | Gilead Sciences ' (NASDAQ: GILD) sales in its hepatitis C antiviral franchise hit $19 billion in 2015 before AbbVie began fielding competing treatments at deep discounts in 2016. AbbVie, Inc. (NYSE: ABBV) recently acquired full control of a clinical-stage cystic fibrosis program from Galapagos N.V. (NASDAQ: GLPG) . Vertex's attempts at a three-drug CF therapy are miles ahead of AbbVie's phase 1 program. |
25292.0 | 2018-10-27 00:00:00 UTC | Where Will Gilead Sciences, Inc. Be in 5 Years? | ABBV | https://www.nasdaq.com/articles/where-will-gilead-sciences-inc-be-5-years-2018-10-27 | nan | nan | Gilead Sciences (NASDAQ: GILD) is in a slump. Over the past three years, the biotech's stock has lost over 35% of its value, thanks to falling hepatitis C sales, generic competition entering the HIV market in key geographies, and a slate of setbacks in hematology/oncology.
To break out of this prolonged downturn, Gilead presently is undergoing a dramatic leadership overhaul -- highlighted by the the upcoming departure of current CEO John Milligan by year-end. Will this executive turnover enable Gilead to reverse course? Let's take a deeper look and consider how this top biotech might evolve over the next five years under new leadership.
Value drivers and obstacles
As things stand now, Gilead is attempting to reinvigorate its growth engine through three key therapeutic markets: hematology/oncology, inflammatory disorders, and nonalcoholic steatohepatitis (NASH). While all three of these therapeutic areas are absolutely enormous in terms of their respective commercial opportunities, Gilead lacks a clear competitive advantage in each case.
In hematology, Gilead burst onto the scene roughly a year ago by paying a whopping $11.9 billion for Kite Pharma and its adoptive cell therapy Yescarta. Although Gilead reported a respectable $75 million in Yescarta sales for the third quarter of 2018, this franchise already is facing a slew of competitive threats.
Atara Biotherapeutics , Celgene , Crispr Therapeutics , Johnson & Johnson , Pfizer , and numerous others all are developing next-generation adoptive cell therapies that likely will eclipse Yescarta in terms of safety and efficacy. Gilead has been working to shore up its Kite investment with additional acquisitions, but there's a growing chance that this sizable investment won't produce a healthy return on capital over the long run. And this harsh reality is probably one of the major drivers behind Gilead's ongoing executive exodus.
On the inflammation front, Gilead and partner Galapagos are angling to grab market share away from AbbVie (NYSE: ABBV) and Pfizer with their experimental JAK1 inhibitor, filgotinib. But this strategy also has obvious problems.
First and foremost, AbbVie decided to hand back the development rights to filgotinib to Galapagos in favor of its own internal candidate, upadacitinib (ABT-494). Since then, filgotinib has produced some truly compelling midstage data that suggests that it might be a safer option than upadacitinib. But AbbVie is likely to grab an all-important first-mover advantage for upadacitinib.
AbbVie also is far more familiar with the anti-inflammatory market than Gilead, which has been proven by the biotech's ability to repel nearly every major competitive threat to its flagship arthritis medication Humira for a sustained period of time. In short, Gilead has its work cut out for it when it comes to promoting filgotinib and challenging entrenched competitors like AbbVie and Pfizer.
Lastly, Gilead is advancing three different compounds in the clinic for NASH. The lowdown is that the NASH space is expected to be the next big thing in biopharma, and Gilead is hoping to be a top player in this potentially $35 billion-a-year market.
Unfortunately, the biotech's NASH pipeline doesn't appear to stack up well to the leaders in the field, namely Intercept Pharmaceuticals (NASDAQ: ICPT) , Madrigal Pharmaceuticals (NASDAQ: MDGL) , and Viking Therapeutics (NASDAQ: VKTX) . Intercept is poised to become the first to market with its drug Ocaliva , and Madrigal and Viking stand an excellent shot at eventually developing the most potent/safest NASH therapies overall.
What's next?
Gilead is presently a cash cow with a middling-to-lower-tier clinical pipeline. As such, the next CEO's first priority is probably going to be to add some star power to the biotech's clinical lineup.
The good news is that the next person to take Gilead's top job will have a mountain of cash to work with in order to accomplish this feat (more than $30 billion). Moreover, this is a target rich mergers and acquisitions environment. In NASH alone, Gilead could gobble up Intercept, Madrigal, and Viking to build out a formidable competitive position -- and still have billions left over to tack on additional assets in hematology.
Gilead's best chance at righting the ship in the next five years is unquestionably NASH. After all, NASH has a more favorable competitive landscape than hematology, more reasonably priced acquisition targets, and a wide-open commercial opportunity that might even rival blood cancer at some point down the road.
That being said, it's obviously impossible to know exactly where this biotech is headed until a new CEO is named, and Gilead may choose to double down on hematology due to its massive investment in adoptive cell therapy. The path of least resistance, though, seems to indicate that Gilead is headed toward building an economic moat in NASH -- a move that would be cemented by hiring a CEO with experience in this novel therapeutic area.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
George Budwell owns shares of AbbVie, Atara Biotherapeutics, Celgene, Johnson & Johnson, Pfizer, and Viking Therapeutics. The Motley Fool owns shares of and recommends Celgene and Gilead Sciences. The Motley Fool owns shares of CRISPR Therapeutics and Johnson & Johnson and has the following options: short November 2018 $78 calls on Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie also is far more familiar with the anti-inflammatory market than Gilead, which has been proven by the biotech's ability to repel nearly every major competitive threat to its flagship arthritis medication Humira for a sustained period of time. On the inflammation front, Gilead and partner Galapagos are angling to grab market share away from AbbVie (NYSE: ABBV) and Pfizer with their experimental JAK1 inhibitor, filgotinib. First and foremost, AbbVie decided to hand back the development rights to filgotinib to Galapagos in favor of its own internal candidate, upadacitinib (ABT-494). | *Stock Advisor returns as of August 6, 2018 George Budwell owns shares of AbbVie, Atara Biotherapeutics, Celgene, Johnson & Johnson, Pfizer, and Viking Therapeutics. On the inflammation front, Gilead and partner Galapagos are angling to grab market share away from AbbVie (NYSE: ABBV) and Pfizer with their experimental JAK1 inhibitor, filgotinib. First and foremost, AbbVie decided to hand back the development rights to filgotinib to Galapagos in favor of its own internal candidate, upadacitinib (ABT-494). | AbbVie also is far more familiar with the anti-inflammatory market than Gilead, which has been proven by the biotech's ability to repel nearly every major competitive threat to its flagship arthritis medication Humira for a sustained period of time. On the inflammation front, Gilead and partner Galapagos are angling to grab market share away from AbbVie (NYSE: ABBV) and Pfizer with their experimental JAK1 inhibitor, filgotinib. First and foremost, AbbVie decided to hand back the development rights to filgotinib to Galapagos in favor of its own internal candidate, upadacitinib (ABT-494). | On the inflammation front, Gilead and partner Galapagos are angling to grab market share away from AbbVie (NYSE: ABBV) and Pfizer with their experimental JAK1 inhibitor, filgotinib. First and foremost, AbbVie decided to hand back the development rights to filgotinib to Galapagos in favor of its own internal candidate, upadacitinib (ABT-494). But AbbVie is likely to grab an all-important first-mover advantage for upadacitinib. |
25293.0 | 2018-10-26 00:00:00 UTC | Pharma Stock Roundup: MRK, BMY Q3 Earnings, Cancer Data Presentations at ESMO | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-mrk-bmy-q3-earnings-cancer-data-presentations-at-esmo-2018-10-26 | nan | nan | This week was a relatively busy one for the pharma sector, marked by earnings of bigwigs like Merck MRK and Bristol Myers BMY . Early this week, several drug giants presented data from key cancer studies at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany.
Recap of the Week's Most Important Stories
Merck & Bristol-Myers Announce Mixed Quarterly Results: Both Merck and Bristol-Myers' third-quarter results were mixed as the companies beat estimates for earnings but slightly missed the same for sales. Though Merck tightened its sales guidance for 2018, it was only due to less favorable currency impact owing to a strengthening dollar. It raised its expectations for adjusted earnings for the full year. Bristol-Myers also increased its adjusted earnings guidance for 2018 while raising sales growth expectations for the full year.
Earlier in the week, Merck announced that it received positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for label expansion of its PD-L1 inhibitor, Keytruda as an adjuvant therapy in patients with stage III melanoma who have undergone surgery.
Cancer Data at ESMO: Merck and partner AstraZeneca AZN presented data from a phase III SOLO-1 study, which showed that its key cancer drug Lynparza, as a maintenance therapy, cut the risk of disease progression or death by 70% in patients with newly-diagnosed, advanced BRCA-mutated ovarian cancer. Meanwhile, 60.4% of patients treated with Lynparza remained progression-free at 36 months compared with 26.9% of those in the placebo arm.
Merck also presented interim data from the KEYNOTE-057 study on Keytruda in patients with high-risk non-muscle invasive bladder cancer (NMIBC), which was unresponsive to standard of care. In the study, Keytruda led to a complete response rate of nearly 40%. Merck also presented interim data from the phase III KEYNOTE-048 study evaluating Keytruda, both as a monotherapy and in combination with chemotherapy, for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The data showed that Keytruda monotherapy improved overall survival by 39% and 22%, respectively in patients whose tumors expressed PD-L1 with CPS≥20 and CPS≥1. Meanwhile, as a combination regimen, it improved OS by 23% in the total patient population.
Novartis NVS presented data from a phase III study evaluating its investigational treatment BYL719 (alpelisib) plus fulvestrant for the treatment of patients with HR+ advanced breast cancer whose disease has progressed on or after an aromatase inhibitor with or without a CDK4/6 inhibitor versus fulvestrant alone. In the study, BYL719 plus fulvestrant demonstrated a median progression-free survival (PFS) of 11 months compared to 5.7 months for fulvestrant alone and reduced the risk of death or progression in those patients by an estimated 35% compared to fulvestrant alone. Novartis also presented positive data from a mid-stage study on its pipeline candidate, capmatinib in patients with MET mutated advanced non-squamous non-small cell lung cancer (NSCLC).
Roche presented data from pivotal mid-stage/early-stage studies, which showed that its investigational personalized medicine entrectinib shrank tumors in 57.4% of patients with NTRK fusion-positive solid tumour. Importantly, entrectinib shrank tumors irrespective of tumor type even those that had spread to the brain, thus demonstrating the candidate's potential to treat a range of difficult-to-treat and rare cancers.
Separately, Roche also presented data, which showed that its breast cancer treatment, Tecentriq in combination with Abraxane significantly improved progression-free survival compared with chemotherapy alone as a first-line treatment for patients with metastatic triple-negative breast cancer who had high levels of a protein known as PD-L1. Another phase III data on Tecentriq showed that the drug in combination chemotherapy, as an initial treatment, helped advanced NSCLC patients, live significantly longer compared to chemotherapy alone
Bristol-Myers also presented data from several cancer studies, which demonstrated survival benefits and encouraging response rates of the combination regimen of its drugs Opdivo plus Yervoy. Pfizer PFE presented detailed overall survival data from the phase III PALOMA-3 study evaluating a combination of its breast cancer drug, Ibrance and AstraZeneca's Faslodex in women with HR+, HER2- metastatic breast cancer whose disease progressed after prior endocrine therapy.
J&J Offers to Buy Out Japanese Cosmetics Company: J&J JNJ offered to buy the remaining stake in Japanese cosmetics and skin care products company, Ci:z Holdings Co., Ltd for approximately 230 billion Japanese yen ($2.05 billion). J&J already owns 19.9% stake in Ci:z since July 2016 when J&J's subsidiary, Cilag bought rights to distribute Ci:z' products outside Japan and also acquired the stake. The acquisition will add Ci:z' popular skincare brands like Dr.Ci:Labo, Labo Labo and Genomer to J&J's product portfolio. J&J will be able to strengthen its presence in Japan's skincare market by accessing Ci:z' large consumer base. (Read more: J&J Intends to Buy Residual Stake in Japanese Skincare Firm )
FDA Delays Approval Deadline of Bristol-Myers' Cancer Drug Combo: The FDA has delayed its decision on Bristol-Myers' regulatory application looking for the approval of a combination of its cancer drugs Opdivo plus Yervoy (low-dose) for the treatment of metastatic first-line non-small cell lung cancer. This is because Bristol Myers submitted additional information including overall survival data for a patient sub-group from the CheckMate 227 study to the FDA, which the latter categorized as a major amendment to the supplemental biologics license application (sBLA). As a result of the three-month delay, the FDA will now give its decision for the combination-drug treatment for lung cancer patients on May 20, 2019. (Read more: Bristol-Myers Declines, FDA Delays Review of Opdivo for NSCLC )
AstraZeneca to Buy Stake in Innate Pharma: AstraZeneca acquired full oncology rights to French drugmaker Innate Pharma's anti-NKG2A antibody, monalizumab as well as option rights to Innate's anti-CD39 monoclonal antibody, IPH5201 and four to-be-agreed preclinical molecules from its pipeline. In exchange, AstraZeneca will out-license U.S. and EU commercial rights to its recently FDA approved rare disease medicine, Lumoxiti (moxetumomab pasudotox) for hairy cell leukemia (HCL). In addition to making total payments of $170 million, AstraZeneca will acquire a newly issued 9.8% equity stake in Innate Pharma while the latter will make an upfront payment of $50 million to AstraZeneca for Lumoxiti.
AbbVie's JAK1 inhibitor Meets Endpoints in Ulcerative Colitis Study: AbbVie ABBV announced that a phase IIb/III dose-ranging study (U-ACHIEVE) evaluating its investigational JAK1 inhibitor, upadacitinib for moderately-to-severely active ulcerative colitis, met the primary endpoint of clinical remission and all ranked secondary endpoints including endoscopic improvement, clinical remission and clinical response. Based on data from this mid-stage study, phase III studies in ulcerative colitis have been initiated.
AbbVie also announced new patient-reported outcomes data from a late-stage rheumatoid arthritis study on upadacitinib. The data showed that treatment with upadacitinib monotherapy for 14 weeks led to significant improvement in physical function, pain and health-related quality of life in such patients compared to those receiving methotrexate.
Upadacitinib is one of the key candidates in AbbVie's immunology pipeline and is in being evaluated in late-stage studies for Crohn's disease, psoriatic arthritis and atopic dermatitis while a new drug application seeking approval for rheumatoid arthritis is expected to be filed soon.
AbbVie also announced that it is taking full commercial and development responsibility of all clinical/pre-clinical programs in cystic fibrosis products, which were originally discovered and developed jointly by AbbVie and Galapagos. AbbVie will now continue the development of the triple combination therapy for CF.
Pfizer/Lilly's Pain Drug Shows Promise in Late-Stage Study: Pfizer and Lilly announced detailed data from a phase III study evaluating their pipeline candidate, tanezumab (subcutaneous) for the treatment of osteoarthritis (OA) pain of the knee or hip.
Top-line data from the study was announced in July when the company said that treatment with tanezumab led to statistically significant improvement in pain, physical function and the patients' overall assessment of their OA - the three primary endpoints - compared to placebo at 16 weeks. In the latest data presentation, the companies informed that over half of the patients treated with tanezumab reported a 50% or greater reduction in osteoarthritis pain of the knee or hip.
A potential approval to the candidate will provide a safer pain medication for patients in the United States where opioid abuse is widespread. Moreover, the currently approved drugs are underserving patients who continue to suffer from pain. Tanezumab is also being evaluated for chronic low back pain (CLBP) and cancer pain (due to bone metastases).
Meanwhile, Pfizer announced the creation of a new biotech called Cerevel Therapeutics in partnership with private equity firm Bain Capital, LP, which will focus on developing drugs to treat central nervous system (CNS) disorders, including Parkinson's and Alzheimer's disease. Pfizer will have a 25% stake in Cerevel. (Read more: Pfizer Succeeds in Pain Study, Forms JV to Make CNS Drugs )
Roche Gets FDA Nod for New Flu Medicine: Roche announced that the FDA approved Xofluza (baloxavir marboxil), its single-dose oral medicine with a novel mechanism of action to treat influenza or flu. The approval was based on data from the phase III CAPSTONE-1 study, which showed that a single-dose of Xofluza significantly reduced the duration of flu symptoms compared to placebo.
The NYSE ARCA Pharmaceutical Index declined 2.8% in the last five trading sessions.
Large Cap Pharmaceuticals Industry 5YR % Return
Large Cap Pharmaceuticals Industry 5YR % Return
Here is how the seven major stocks performed in the last five trading sessions:
In the past six months, Lilly (LLY) has been the biggest gainer (30.4%) while Bristol-Myers declined the most (5.8%).
(See the last pharma stock roundup here: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal )
What's Next in the Pharma World?
Watch out for third-quarter earnings of several large drugmakers, including Pfizer and Allergan, and pipeline and regulatory updates next week.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Novartis AG (NVS): Free Stock Analysis Report
AstraZeneca PLC (AZN): Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie's JAK1 inhibitor Meets Endpoints in Ulcerative Colitis Study: AbbVie ABBV announced that a phase IIb/III dose-ranging study (U-ACHIEVE) evaluating its investigational JAK1 inhibitor, upadacitinib for moderately-to-severely active ulcerative colitis, met the primary endpoint of clinical remission and all ranked secondary endpoints including endoscopic improvement, clinical remission and clinical response. AbbVie also announced new patient-reported outcomes data from a late-stage rheumatoid arthritis study on upadacitinib. Upadacitinib is one of the key candidates in AbbVie's immunology pipeline and is in being evaluated in late-stage studies for Crohn's disease, psoriatic arthritis and atopic dermatitis while a new drug application seeking approval for rheumatoid arthritis is expected to be filed soon. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie's JAK1 inhibitor Meets Endpoints in Ulcerative Colitis Study: AbbVie ABBV announced that a phase IIb/III dose-ranging study (U-ACHIEVE) evaluating its investigational JAK1 inhibitor, upadacitinib for moderately-to-severely active ulcerative colitis, met the primary endpoint of clinical remission and all ranked secondary endpoints including endoscopic improvement, clinical remission and clinical response. AbbVie also announced new patient-reported outcomes data from a late-stage rheumatoid arthritis study on upadacitinib. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie's JAK1 inhibitor Meets Endpoints in Ulcerative Colitis Study: AbbVie ABBV announced that a phase IIb/III dose-ranging study (U-ACHIEVE) evaluating its investigational JAK1 inhibitor, upadacitinib for moderately-to-severely active ulcerative colitis, met the primary endpoint of clinical remission and all ranked secondary endpoints including endoscopic improvement, clinical remission and clinical response. AbbVie also announced new patient-reported outcomes data from a late-stage rheumatoid arthritis study on upadacitinib. | AbbVie's JAK1 inhibitor Meets Endpoints in Ulcerative Colitis Study: AbbVie ABBV announced that a phase IIb/III dose-ranging study (U-ACHIEVE) evaluating its investigational JAK1 inhibitor, upadacitinib for moderately-to-severely active ulcerative colitis, met the primary endpoint of clinical remission and all ranked secondary endpoints including endoscopic improvement, clinical remission and clinical response. AbbVie also announced new patient-reported outcomes data from a late-stage rheumatoid arthritis study on upadacitinib. Upadacitinib is one of the key candidates in AbbVie's immunology pipeline and is in being evaluated in late-stage studies for Crohn's disease, psoriatic arthritis and atopic dermatitis while a new drug application seeking approval for rheumatoid arthritis is expected to be filed soon. |
25294.0 | 2018-10-26 00:00:00 UTC | iShares Core Dividend Growth ETF Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/ishares-core-dividend-growth-etf-experiences-big-inflow-2018-10-26 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core Dividend Growth ETF (Symbol: DGRO) where we have detected an approximate $173.6 million dollar inflow -- that's a 4.1% increase week over week in outstanding units (from 122,650,000 to 127,650,000). Among the largest underlying components of DGRO, in trading today AbbVie Inc (Symbol: ABBV) is down about 2.2%, PepsiCo Inc (Symbol: PEP) is off about 1.6%, and Boeing Co. (Symbol: BA) is lower by about 1.7%. For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price performance of DGRO, versus its 200 day moving average:
Looking at the chart above, DGRO's low point in its 52 week range is $32.82 per share, with $37.93 as the 52 week high point - that compares with a last trade of $34.19. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of DGRO, in trading today AbbVie Inc (Symbol: ABBV) is down about 2.2%, PepsiCo Inc (Symbol: PEP) is off about 1.6%, and Boeing Co. (Symbol: BA) is lower by about 1.7%. For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price performance of DGRO, versus its 200 day moving average: Looking at the chart above, DGRO's low point in its 52 week range is $32.82 per share, with $37.93 as the 52 week high point - that compares with a last trade of $34.19. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of DGRO, in trading today AbbVie Inc (Symbol: ABBV) is down about 2.2%, PepsiCo Inc (Symbol: PEP) is off about 1.6%, and Boeing Co. (Symbol: BA) is lower by about 1.7%. For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price performance of DGRO, versus its 200 day moving average: Looking at the chart above, DGRO's low point in its 52 week range is $32.82 per share, with $37.93 as the 52 week high point - that compares with a last trade of $34.19. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of DGRO, in trading today AbbVie Inc (Symbol: ABBV) is down about 2.2%, PepsiCo Inc (Symbol: PEP) is off about 1.6%, and Boeing Co. (Symbol: BA) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core Dividend Growth ETF (Symbol: DGRO) where we have detected an approximate $173.6 million dollar inflow -- that's a 4.1% increase week over week in outstanding units (from 122,650,000 to 127,650,000). For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price performance of DGRO, versus its 200 day moving average: Looking at the chart above, DGRO's low point in its 52 week range is $32.82 per share, with $37.93 as the 52 week high point - that compares with a last trade of $34.19. | Among the largest underlying components of DGRO, in trading today AbbVie Inc (Symbol: ABBV) is down about 2.2%, PepsiCo Inc (Symbol: PEP) is off about 1.6%, and Boeing Co. (Symbol: BA) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core Dividend Growth ETF (Symbol: DGRO) where we have detected an approximate $173.6 million dollar inflow -- that's a 4.1% increase week over week in outstanding units (from 122,650,000 to 127,650,000). For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price performance of DGRO, versus its 200 day moving average: Looking at the chart above, DGRO's low point in its 52 week range is $32.82 per share, with $37.93 as the 52 week high point - that compares with a last trade of $34.19. |
25295.0 | 2018-10-26 00:00:00 UTC | AbbVie (ABBV) Q3 Earnings Preview: What's Shaping Up? | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q3-earnings-preview%3A-whats-shaping-up-2018-10-26 | nan | nan | The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on November 2. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on theearnings call it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus Estimate
This drugmaker is expected to post quarterly earnings of $2.01 per share in its upcoming report, which represents a year-over-year change of +42.6%.
Revenues are expected to be $8.26 billion, up 18.1% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0.43% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Price, Consensus and EPS Surprise
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is subject to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time , and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for AbbVie?
For AbbVie, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -1.16%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination makes it difficult to conclusively predict that AbbVie will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that AbbVie would post earnings of $1.98 per share when it actually produced earnings of $2, delivering a surprise of +1.01%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
AbbVie doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. | The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. | The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. | For the last reported quarter, it was expected that AbbVie would post earnings of $1.98 per share when it actually produced earnings of $2, delivering a surprise of +1.01%. The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2018. How Have the Numbers Shaped Up for AbbVie? |
25296.0 | 2018-10-24 00:00:00 UTC | Healthcare ETFs to Buy Ahead of Q3 Earnings | ABBV | https://www.nasdaq.com/articles/healthcare-etfs-buy-ahead-q3-earnings-2018-10-24 | nan | nan | Healthcare was the best performing sector in the third quarter. The dual tailwinds of encouraging industry fundamentals and the sector's defensive tilt led to the rally in the sector. The wave of mergers and acquisitions also added to its strength (read: Top Performing ETFs of the Third Quarter ).
Popular ETFs like Health Care Select Sector SPDR Fund XLV has gained 4.2%, while Vanguard Health Care ETF VHT , iShares U.S. Healthcare ETF IYH and Fidelity MSCI Health Care Index ETF FHLC are up at least 2.5% each over the past three months. The strength is likely to continue into the Q3 earnings season as some big names like Pfizer PFE , Merck MRK , Amgen AMGN , AbbVie ABBV , Gilead Sciences GILD and Bristol-Myers Squibb (BMY) are lined up to report this week and in the next. All these stocks collectively account for 25.1% share in XLV, 23.2% in IYH, 22% in FHLC and 21.4% in VHT.
Let's dig deeper into the earnings picture of these companies that will drive the performance of the abovementioned funds in the coming days:
According to our methodology, a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), when combined with a positive Earnings ESP increases our chances of predicting an earnings beat, while Zacks Rank #4 or 5 (Sell rated) stocks are best avoided. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Inside Our Surprise Prediction for These Stocks
Pfizer has a Zacks Rank #3 and an Earnings ESP of -0.79%, indicating a lower chance of beating estimates this quarter. The stock has witnessed positive earnings estimate revision of a penny for the to-be-reported quarter over the past seven days. It delivered an average positive earnings surprise of 6.46% for the past four quarters. Analysts raising estimates right before earnings - with the most up-to-date information possible - is a pretty good sign for the stock. Pfizer has a VGM Score of D. The company is scheduled to report earnings on Oct 30, before the opening bell.
Merck is expected to report results on Oct 25 before market opens. It has a Zacks Rank #3 and an Earnings ESP of -0.30%. The stock delivered a positive earnings surprise in the last four quarters, with an average beat of 5.25% and witnessed positive earnings estimate revision of a penny over the past seven days for the to-be-reported quarter. Merck has a VGM Score of B (read: Best ETFs & Stocks From the Top Sector of Q3 ).
Amgen carries a Zacks Rank #2 and has an Earnings ESP of +0.56%, indicating a higher chance of beating estimates this time around. The earnings surprise track over the past four quarters is strong, with an average positive surprise of 4.29%. Amgen has witnessed positive earnings estimate revision of a penny over the past 30 days for the quarter to be reported. The stock has a VGM Score of C. Amgen will report earnings on Oct 30 after market close.
AbbVie has a Zacks Rank #3 and an Earnings ESP of -0.20%. The company delivered a positive earnings surprise in the last four quarters, with an average beat of 2.28% and has seen no earnings estimate revision over the past seven days for the to-be-reported quarter. The stock has a solid VGM Score of A. The company is scheduled to report on Nov 2 before the opening bell.
Gilead is expected to release earnings on Oct 25 after market close. It has a Zacks Rank #1 and an Earnings ESP of -1.98%, indicating lower chance of beating estimates this quarter. Gilead delivered positive earnings surprise of 6.43% over the last four quarters and saw no earnings estimate revision over the past seven days for the to-be-reported quarter. It has a VGM Score of D.
Bristol-Myers will likely report earnings on Oct 25 before the opening bell. It has a Zacks Rank #2 and an Earnings ESP of -0.48%. The stock delivered an average positive earnings surprise of 6.39% over the past four quarter, and saw positive earnings estimate revision of a penny over the past seven days for the to-be-reported quarter. It flaunts a top VGM Score of A (read: Top-Ranked Healthcare ETFs for Long-Term Investors ).
Summing Up
With most of the healthcare companies witnessing positive earnings estimate revision lately, the sector is expected to witness earnings growth of 8.4% in the third quarter, suggesting continued outperformance for healthcare ETFs. In particular, all the four ETFs have a Zacks ETF Rank #2 (see: all the Healthcare ETFs here ).
Want key ETF info delivered straight to your inbox?
Zacks' free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
VIPERS-HLTH CR (VHT): ETF Research Reports
FID-H CARE (FHLC): ETF Research Reports
SPDR-HLTH CR (XLV): ETF Research Reports
ISHARS-US HLTHC (IYH): ETF Research Reports
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The strength is likely to continue into the Q3 earnings season as some big names like Pfizer PFE , Merck MRK , Amgen AMGN , AbbVie ABBV , Gilead Sciences GILD and Bristol-Myers Squibb (BMY) are lined up to report this week and in the next. AbbVie has a Zacks Rank #3 and an Earnings ESP of -0.20%. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report VIPERS-HLTH CR (VHT): ETF Research Reports FID-H CARE (FHLC): ETF Research Reports SPDR-HLTH CR (XLV): ETF Research Reports ISHARS-US HLTHC (IYH): ETF Research Reports Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. | The strength is likely to continue into the Q3 earnings season as some big names like Pfizer PFE , Merck MRK , Amgen AMGN , AbbVie ABBV , Gilead Sciences GILD and Bristol-Myers Squibb (BMY) are lined up to report this week and in the next. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report VIPERS-HLTH CR (VHT): ETF Research Reports FID-H CARE (FHLC): ETF Research Reports SPDR-HLTH CR (XLV): ETF Research Reports ISHARS-US HLTHC (IYH): ETF Research Reports Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie has a Zacks Rank #3 and an Earnings ESP of -0.20%. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report VIPERS-HLTH CR (VHT): ETF Research Reports FID-H CARE (FHLC): ETF Research Reports SPDR-HLTH CR (XLV): ETF Research Reports ISHARS-US HLTHC (IYH): ETF Research Reports Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The strength is likely to continue into the Q3 earnings season as some big names like Pfizer PFE , Merck MRK , Amgen AMGN , AbbVie ABBV , Gilead Sciences GILD and Bristol-Myers Squibb (BMY) are lined up to report this week and in the next. AbbVie has a Zacks Rank #3 and an Earnings ESP of -0.20%. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report VIPERS-HLTH CR (VHT): ETF Research Reports FID-H CARE (FHLC): ETF Research Reports SPDR-HLTH CR (XLV): ETF Research Reports ISHARS-US HLTHC (IYH): ETF Research Reports Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The strength is likely to continue into the Q3 earnings season as some big names like Pfizer PFE , Merck MRK , Amgen AMGN , AbbVie ABBV , Gilead Sciences GILD and Bristol-Myers Squibb (BMY) are lined up to report this week and in the next. AbbVie has a Zacks Rank #3 and an Earnings ESP of -0.20%. |
25297.0 | 2018-10-24 00:00:00 UTC | 3 Healthcare Stocks I'd Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-healthcare-stocks-id-buy-right-now-2018-10-24 | nan | nan | Warren Buffett once said, "When it's raining gold, reach for a bucket, not a thimble." Believe it or not, it's raining gold right now. And that's especially the case for several great healthcare stocks.
What I mean is that the stock market's pullback is causing quite a few stocks to trade at attractive prices. Whether you're looking for solid dividend stocks , value stocks, or high-growth stocks, there are plenty of buying opportunities. Three healthcare stocks I'd buy right now are AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , and Teladoc Health (NYSE: TDOC) .
1. AbbVie
I like dividends -- and AbbVie claims one of the best dividends in healthcare. The big pharma company's dividend currently yields over 4.5%. AbbVie has increased its dividend by 140% since being spun off from Abbott Labs in 2013.
AbbVie also looks like a bargain right now. Its shares trade at only 9.5 times expected earnings. The stock has come under pressure for several reasons this year. The overall market decline has dragged AbbVie down, of course. However, investors have also been concerned about how the company's top drug, Humira, will fare with healthcare changes being proposed by the Trump administration and with biosimilar competition in Europe starting this month.
Rick Gonzalez, AbbVie's CEO, stated in July that "there were probably more positives than there were negatives" for AbbVie with the Trump administration's proposed changes. I suspect that he's right. And while Amgen has begun to market its biosimilar to Humira in Europe, over two-thirds of the drug's revenue (and even more of its profits) are made in the U.S.
Meanwhile, sales continue to soar for AbbVie's cancer drug Imbruvica and hepatitis C drug Mavyret. The company has other drugs ready to step up, such as cancer drug Venclexta and endometriosis drug Orilissa. AbbVie's pipeline also appears to be very strong, with immunology candidates risankizumab and upadacitinib leading the way.
2. Celgene
Celgene doesn't pay a dividend, but it possesses another attribute that I really like -- a dirt-cheap valuation. The biotech stock trades at roughly 7.5 times expected earnings. But Celgene really shines when you factor in its growth prospects. Its price-to-earnings-to-growth (PEG) ratio is a super-low 0.47.
But is there a worrisome reason why Celgene is so cheap? And are the company's growth prospects relatively solid? At first glance, the answers to those questions might not give you a warm-and-fuzzy feeling about Celgene.
Investors have been worried that Celgene depends too much on revenue from one drug -- Revlimid -- and that the drug could lose its patent protection. They've also been concerned that Celgene's growth depends on its pipeline success -- and the biotech has had two major pipeline stumbles over the last year or so.
However, my view is that Celgene will reach settlements with drugmakers seeking to market generic versions of Revlimid, just as it has done before. I think that the drug should be safe from competition until 2022 and then only with limited volumes of generic version sales. I'm also impressed with Celgene's pipeline and expect the company will have several blockbusters on the way, including ozanimod, fedratinib, luspatercept, and liso-cel (also known as JCAR017).
3. Teladoc Health
There are two strikes against Teladoc Health. It doesn't pay a dividend. It isn't really a bargain. The company isn't even profitable yet but still claims a market cap of close to $5 billion. So why do I like Teladoc? Tremendous growth prospects. And it certainly helps that the stock is less expensive than it's been in a while.
Teladoc's revenue has skyrocketed by a compound annual growth rate (CAGR) of 75% since 2014. The company has rapidly established itself as the premier telehealth services provider. Roughly 40% of the Fortune 500 members steer their employees to Teladoc's services, which are available via phone, internet video, or mobile app.
I think that Teladoc can grow a lot more. Telehealth is more convenient for patients. Even better, though, it's less costly for payers. The company should have tremendous growth prospects as Americans' healthcare needs increase and payers -- including Medicare and Medicaid -- look for ways to control costs.
Teladoc also has significant growth opportunities in international markets. In the second quarter , nearly 16% of the company's total revenue came from international subscriptions. A year earlier, Teladoc had no subscription revenue from international markets.
Raining gold?
Is the stock market really "raining gold" right now? I think so. The key to seeing the opportunity is to have a long-term perspective.
Over the long run, AbbVie's current products (including Humira) and its pipeline candidates should allow the company to deliver solid total returns to investors. The same scenario should apply for Celgene as well. Teladoc stands to capture an even greater share of the growing telehealth market.
I'd buy any of these three healthcare stocks right now. Actually, I already owned two of them -- AbbVie and Celgene -- prior to the market pullback and scooped up shares of Teladoc recently. And like Buffett recommended, I put out a bucket instead of a thimble.
10 stocks we like better than Teladoc
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Teladoc wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Keith Speights owns shares of AbbVie, Celgene, and Teladoc. The Motley Fool owns shares of and recommends Celgene. The Motley Fool recommends Amgen and Teladoc. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Over the long run, AbbVie's current products (including Humira) and its pipeline candidates should allow the company to deliver solid total returns to investors. Three healthcare stocks I'd buy right now are AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , and Teladoc Health (NYSE: TDOC) . AbbVie I like dividends -- and AbbVie claims one of the best dividends in healthcare. | Three healthcare stocks I'd buy right now are AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , and Teladoc Health (NYSE: TDOC) . Over the long run, AbbVie's current products (including Humira) and its pipeline candidates should allow the company to deliver solid total returns to investors. AbbVie I like dividends -- and AbbVie claims one of the best dividends in healthcare. | Three healthcare stocks I'd buy right now are AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , and Teladoc Health (NYSE: TDOC) . *Stock Advisor returns as of August 6, 2018 Keith Speights owns shares of AbbVie, Celgene, and Teladoc. AbbVie I like dividends -- and AbbVie claims one of the best dividends in healthcare. | AbbVie I like dividends -- and AbbVie claims one of the best dividends in healthcare. Three healthcare stocks I'd buy right now are AbbVie (NYSE: ABBV) , Celgene (NASDAQ: CELG) , and Teladoc Health (NYSE: TDOC) . AbbVie has increased its dividend by 140% since being spun off from Abbott Labs in 2013. |
25298.0 | 2018-10-23 00:00:00 UTC | AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-dips-more-than-broader-markets%3A-what-you-should-know-2018-10-23 | nan | nan | AbbVie (ABBV) closed at $82.96 in the latest trading session, marking a -1.55% move from the prior day. This change lagged the S&P 500's daily loss of 0.55%. At the same time, the Dow lost 0.5%, and the tech-heavy Nasdaq lost 0.42%.
Coming into today, shares of the drugmaker had lost 9.79% in the past month. In that same time, the Medical sector lost 6.09%, while the S&P 500 lost 5.71%.
Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. This is expected to be November 2, 2018. The company is expected to report EPS of $2.01, up 42.55% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $8.26 billion, up 18.09% from the prior-year quarter.
ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.86 per share and revenue of $32.90 billion. These results would represent year-over-year changes of +40.36% and +16.61%, respectively.
Investors might also notice recent changes to analyst estimates for ABBV. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.03% lower. ABBV is currently sporting a Zacks Rank of #3 (Hold).
Digging into valuation, ABBV currently has a Forward P/E ratio of 10.72. This represents a discount compared to its industry's average Forward P/E of 15.85.
We can also see that ABBV currently has a PEG ratio of 0.83. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.05 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 107, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (ABBV) closed at $82.96 in the latest trading session, marking a -1.55% move from the prior day. ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.86 per share and revenue of $32.90 billion. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. | AbbVie (ABBV) closed at $82.96 in the latest trading session, marking a -1.55% move from the prior day. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.86 per share and revenue of $32.90 billion. | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.86 per share and revenue of $32.90 billion. AbbVie (ABBV) closed at $82.96 in the latest trading session, marking a -1.55% move from the prior day. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.86 per share and revenue of $32.90 billion. AbbVie (ABBV) closed at $82.96 in the latest trading session, marking a -1.55% move from the prior day. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. |
25299.0 | 2018-10-23 00:00:00 UTC | Validea Joel Greenblatt Strategy Daily Upgrade Report - 10/23/2018 | ABBV | https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-10232018-2018-10-23 | nan | nan | The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt . This value model looks for companies with high return on capital and earnings yields.
ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Joel Greenblatt changed from 70% to 80% based on the firm's underlying fundamentals and the stock's valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
Since its inception, Validea's strategy based on Joel Greenblatt has returned 103.01% vs. 117.84% for the S&P 500. For more details on this strategy, click here
About Joel Greenblatt : In his 2005 bestseller The Little Book That Beats The Market, hedge fund manager Joel Greenblatt laid out a stunningly simple way to beat the market using two -- and only two -- fundamental variables. The "Magic Formula," as he called it, produced back-tested returns of 30.8 percent per year from 1988 through 2004, more than doubling the S&P 500's 12.4 percent return during that time. Greenblatt also produced exceptional returns as managing partner at Gotham Capital, a New York City-based hedge fund he founded. The firm averaged a remarkable 40 percent annualized return over more than two decades.
About Validea : Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt . | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt . | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab). | Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt . |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.